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Childhood obesity is a nutrition-related disease with multiple underlying etiologies. The gut 
microbiota is thought to be a contributor in the development of obesity by fermentation of non-digestible 
polysaccharides to short chain fatty acids (SCFA), which increases host capacity for energy harvest and 
storage. Several genes encoding SCFA receptors and transporters, as well as other host responders to gut 
microbiota have been described. However, the collective impact of common genetic variations (single 
nucleotide polymorphisms [SNP]) in these genes on obesity phenotypes has yet to be examined in 
humans. Our hypothesis is that genetic variation in SCFA recognition pathways are related to excess 
weight gain and that the SCFA producing capacity of the fecal microbiota are associated with overweight 
and obesity in children. These studies provide a unique approach in studying the relationship between gut 
microbiota and child obesity through identification of gut microbe-host adiposity relationships measured 
by dual energy X-ray absorptiometry (DXA), assessment of the SCFA-producing capacity of fecal 
inoculates, and evaluation of associations between SNPs within genes with known interaction with SCFA 
and obesity-related phenotypes. 
Study 1 
Microbial dysbiosis is implicated in obesity in adults, but less in known about its association with 
childhood obesity. Herein, fecal microbiota, BMI and fat distribution were investigated in 4-7 year-old 
children to test the hypothesis that abundance of butyrate-producing bacteria is associated with 
overweight and obesity in children. RT-qPCR was conducted on fecal DNA for Clostridium cluster XIVa, 
Clostridium cluster IV, Lactobacillus spp., Bifidobacterium spp., Bacteroides-Prevotella group, 
Faecalibacterium prausnitzii, Roseburia intestinalis, and Eubacterium rectale. BMI was calculated from 
height and weight measures and percent body fat was measured by dual-energy x-ray absorptiometry 
(DXA). Associations between bacterial abundance and obesity phenotypes were tested using t-tests, 





compared to lean (n=12) (P = 0.03). Relationships between percent body fat and bacterial abundance 
were impacted by sex. In girls, Bifidobacterium spp. were negatively associated with trunk fat, while F. 
prausnitzii was negatively correlated with BMI. In boys, Clostridium cluster IV was positively correlated 
with both trunk and visceral fat (P < 0.05). These findings demonstrate associations between fecal 
bacterial composition and overweight in children. Gender-specific effects are apparent as early as 4-7 
years-of-age, and DXA measurements provide insight into the relationship between bacterial quantities 
and regional fat depots beyond BMI alone. 
Study 2 
 The majority of the current work in the gut microbiome and childhood obesity has focused on 
associations between the gut microbial composition and BMI, and little work to date has addressed the 
metabolic capacity of fecal microbiome from preschool age children. Building upon data from study 1, our 
goal was to further characterize the gut microbiome-host relationship by conducting an in vitro 
experiment to measure the SCFA-production of fecal inoculates from preschool age children. Fresh stool 
samples were collected and processed within 45 minutes of defecation (n = 6, female = 2) and were used 
to inoculate media containing inulin substrate. Fermentation was conducted and SCFA quantities 
including acetate, propionate, and butyrate were measured at 0 and 12 hours by gas chromatography. 
Dietary fiber intake was assessed with 24-hour recall and whole body fat was measured with DXA. 
Dichotomous groups were established based on high and low total fiber intake and whole body fat 
separated by the median. Differences in SCFA quantities were tested using Kruskal-Wallis for 
nonparametric data and T-test. Children in the high body fat group produced more acetate and total SCFAs 
than children in the low body fat group (1.591 v. 3.775 mmol/g feces, P = 0.0495; 2.926 v. 5.541 mmol/g 
feces, P = 0.0495 respectively). Children consuming high total fiber had higher butyrate production 
compared to those consuming low total fiber (0.417 v. 1.615 mmol/g feces, P = 0.0495). Propionate as a 





was a significant increase in acetate as a percent of the total from 0 to 12 hours (30.9% ± 10.4 v. 68.0% ± 
8.2, P = 0.0439). Current and past dietary exposures may play a role in SCFA production of the gut 
microbiome. Further analysis of the microbiome by sequencing will increase our understanding of the 
metabolic capabilities of the microbiome, which are shaped by dietary influences. 
Study 3 
This study investigated the cumulative association of single nucleotide polymorphisms (SNP) of 
genes involved in SCFA recognition and metabolism with obesity. Study participants were non-Hispanic 
White children (2-5 yrs.) from the STRONG Kids Illinois and Michigan cohorts (n=270). Height and weight 
were measured to calculate obesity-related phenotypes. Genomic DNA was extracted from saliva and 
genotyped using the Fluidigm® platform. Statistical analyses were performed in SAS 9.4. Ten SNP variables 
(PPARG, ANGPTL3/4, LPL, PYY, NPY2R, SLC5A8, SLC16A3, SLC16A1, and IL6) were dichotomized according 
to dominant or recessive inheritance models with the effect size of each SNP variable on BMI Z-score 
established using β-coefficients estimated from general linear models. A weighted genetic risk score (GRS) 
was generated by summing the β-coefficients. The GRS was significantly associated with BMI Z-score with 
the model explaining 12.4% of the variance using linear regression (R2 = 0.124, P <0.0001). Similarly, the 
GRS was associated with weight-for-age Z-score (R2 = 0.045, P = 0.002) but not with height-for-age Z-score. 
This initial analysis suggests the cumulative association of the genetic variants studied with early-onset 
obesity. Our data supports the concept that gut microbiota influences obesity development through key 
host genes interacting with SCFA, warranting further investigation into the mechanisms driving these 
associations. 
 Overall, these data demonstrate distinct genetic and metabolic relationships between the gut 
microbiome and adiposity of preschool age children. Study 1 and 2 present key methodological 





dietary intake, to stratify analysis by sex when considering regional body fat, and to collect and preserve 
fresh stool samples for in vitro experiments. Study 3 represents a novel approach to generating a 
cumulative genetic risk score from the selection of candidate genes and SNPs to the construction of the 
risk score. These findings provide avenues for new lines of research in genetic epidemiology and the gut 
microbiome. As both fields rapidly advance, the translation of this work to clinical and public health 
settings hinges on our ability to harness an understanding of the biological mechanisms underlying obesity 
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Chapter 1: Literature Review 
Introduction 
 
Obesity is a well-established nutrition-related disease and childhood obesity statistics in the 
United States (U.S.) provide evidence for concern. In 2010, 31.8% of children in the U.S. were considered 
overweight and 16.9% were considered obese.1 Children who remain obese in adolescence are at an 
increased risk of being obese as an adult.2,3 While one national report suggested a plateau in the obesity 
rates in US children and a decline amongst preschool age children, differences in the obesity rates across 
ethnic and economic divides reveal substantial disparities hidden by the overall statisitics.4,5 Data from 
the Early Childhood Longitudinal Study Kindergarten class (ECLS-K) indicated an overall increase in 
overweight and obesity when comparing two nationally representative cohorts measured between 1998-
1999 and 2010-2011. Obesity rates climbed from 11.6% to 13.9% between the two cohorts of this study. 
Furthermore, several disparities in obesity trends amongst kindergarten children have been observed. 
While obesity rates decreased in children of the highest quintile for socioeconomic state, obesity 
increased in the lowest quintile. Obesity rates also increased in non-Hispanic black children while 
remaining at similar rates for non-Hispanic white, Hispanic, and other ethnic groups.6 Obesity has been 
associated with several comorbidities including type 2 diabetes (T2DM), cardiovascular disease (CVD), 
sleep apnea, arthritis, and some cancers.7,8 There is evidence to suggest that comorbidities of adult obesity 
begin to manifest in childhood obesity and at the onset of overweight or obesity in preschool age 
children.9-11 A pro-inflammatory state has been detected in pre-pubertal obese children who have not yet 
developed the metabolic comorbidities associated with obesity.12 These related conditions provide 
further reason to investigate strategies of intervening and preventing the onset of obesity at an early 





  At the heart of the issue is the intersection of an obesogenic environment interacting with genetic 
and biological factors giving rise to early-onset obesity.15,16 Researchers, healthcare providers, and public 
officials have begun to collaborate in a concerted effort to develop novel strategies to combat obesity, as 
our understanding of the multiple factors contributing to the development of obesity in children 
increases. Recent interventions indicate that there is a window of opportunity to effectively impact the 
weight status of a child during preschool age and early childhood.17,18 Danielsson and colleagues have 
demonstrated that change in body mass index (BMI) was most malleable in the youngest age group of 
their study (6-9 years old).18 The Synergistic Theory and Research on Obesity and Nutrition Group 
(STRONG) Kids Program aims to tackle childhood obesity by developing our understanding of the factors 
that contribute to weight gain in children from the cell to the country.19 The STRONG Kids program is a 3-
year longitudinal study with a transdisciplinary approach to understanding the social, environmental, and 
biological determinants of obesity in children. STRONG Kids is built upon an ecological framework which 
includes the cell, child, clan, community, culture, and country.19 
 
Measuring obesity throughout childhood 
Studying obesity in children presents many challenges as factors contributing to growth may also 
function in excess adipose gain.20 There are critical points during growth that have been postulated to be 
important in obesity development including in utero effects (fetal programming through epigenetic 
modifications), infancy, adiposity rebound, and the onset of puberty.21 Excessive gestational weight gain 
in obese mothers has led to greater percent fat mass at birth (14.2%) in their infants compared to infants 
of normal weight (11.8%) and overweight mothers (13.7%).22 In the Fels Longitudinal Study, both paternal 
and maternal BMI status influenced birth weight and infant BMI; however, maternal influence was shown 
to be more significant.23 Adiposity rebound (AR) is classically defined as the rebound in BMI after it reaches 





for obesity (OR = 6.0, CI = 1.3-26.6) compared to those with late AR.3,24 In addition to predicting obesity 
later in life, early AR has been shown to increase the risk of developing T2DM and CVD.25 Koyama 
specifically found that early AR was associated with high triglycerides, apolipoprotein B, systolic blood 
pressure, and diastolic blood pressure in boys at the age of 12.26 In girls, early AR was associated with 
elevated apolipoprotein B. The authors of this work did note that pubertal status was not taken into 
consideration, which may have biased their results. Nonetheless, these results highlight not only the 
pressing need to prevent obesity at an early age, but also show clear differences in the relationship 
between adiposity and metabolic disease progression by sex. Differences in body composition between 
males and females are apparent as early as the first 6 months of life.27 In a cohort of 2,284 Serbian children, 
percent fat was more highly correlated with BMI in girls than in boys, a finding that was also shown in 
Japanese children.28,29 Results from these studies have since been replicated in National Health and 
Nutrition Examination Survey (NHANES) data and punctuate the need for more accurate measurements 
of body composition as BMI, particularly in boys, may not be the best indicator of adiposity.30 Additionally, 
children gain lean mass that is not proportional to their gain in height, and this phenomena is more 
apparent in boys.31 Differences in body composition between males and females becomes drastically 
apparent at the onset of puberty, though it is important to recognize that these differences are detectable 
in pre-pubertal children.32 
 BMI is the standard metric for assessing body composition due to its practical use in data 
collection in epidemiological and clinical settings, and its strong correlation with measurements of body 
adiposity.33 Age and sex specific reference growth curves have been established by the Centers for Disease 
Control (CDC) and the World Health Organization (WHO) to provide guidelines for nutritional status and 
to track growth at the population level. When comparing different BMI-derived measures, BMI Z-score 
(BMIZ) has been shown to correlate the strongest with percent body fat, though the utility of BMIZ in 





adiposity.30,34 Due to the limitations of BMI in differentiating between lean and fat mass, other 
measurements including percent body fat by dual energy X-ray absorptiometry (DXA) have been proposed 
to establish reference data for children.35 DXA has been shown to be a valid method for assessing body 
composition in children and has been adapted to assess visceral adiposity.36-38 For children between the 
ages of 8 and 19, Ogden and colleagues collated NHANES data from 1999 to 2004 to generate smooth 
reference curves for percent body fat.35,39 While it has been noted that an asymptotic trend at the upper 
limit of percent body fat (~60%) is an inherent limitation to the measurement, other metrics utilizing body 
composition data including the fat mass index (FMI) and lean mass index (LMI) have been developed to 
circumvent this shortcoming.31,40 These indices bear similarity to BMI in that fat mass and lean mass are 
divided by height squared to obtain FMI and LMI phenotypes. Magnetic resonance imaging (MRI) and 
computed tomography (CT) are also other methods used to assess whole body and regional adiposity, but 
are expensive and considered to be more invasive through increased radiation exposure compared to 
DXA.36 In particular, the establishment of non-biased reference data for body composition is argued to be 
critical for the assessment of clinical outcomes for obesity treatment.31 However, differences in body 
composition across ethnic groups due to genetic and environmental factors may preclude the 
development of a single reliable dataset in favor of population-specific growth curves on body 
composition in the future.31 Body composition phenotypes identified within ethnic groups, such as body 
shape and regional distribution of fat, have been attributed to genetics.41-44  
 
Genetic determinants of obesity 
 
Evolutionary perspective on the genetic origins of obesity 
The genetic basis of obesity has been traced back to the evolutionary history of mankind through 





developed to describe the rise in diabetes in the population and was adapted to the obesity epidemic. 
The thrifty genotype hypothesis posited that selective pressure throughout human evolution favored 
genetic variants more efficient in energy storage during times of feast and famine.45 Additionally, it was 
also postulated that the thrifty genotype conferred protection against infertility during times of famine.  
While a genetic profile favoring efficiency in energy storage at one point in time created an advantage for 
human ancestors, the thrifty genotype would not be considered advantageous in the current obesogenic 
environment of developed nations.46 The thrifty genotype has come under speculation as new ideas on 
the genetic and biological basis of obesity have been proposed. John Speakman presented a counter 
hypothesis called the drifty genotype, which asserted that the loss of selective pressure via predation led 
to a decrease in pressure for genetic variants favoring survival against predators, and genetic variants 
favoring energy storage were not removed, effectively drifting into the gene pool.47 Around the same time 
that the drifty genotype hypothesis emerged, Bouchard presented another explanation regarding the 
genetic determinants of obesity. His work proposed of five genotype classes including thrifty, hyperphagic, 
sedens, low lipid oxidation, and adipogenesis.48 In 2014, Sellayah and colleagues echoed many of the 
thoughts on the thrifty genotype shared by Bouchard and offered their own hypothesis, which 
incorporated the ethnic differences in genetic susceptibility to obesity.49 Both Bouchard and Sellayah were 
critical of the assumption the thrifty genotype made regarding the selective pressure from feast and 
famine events occurring over populations that distributed across the world approximately 20,000 years 
ago.50 Essentially, it is unreasonable to assume that different environments throughout the world 
provided the same selective pressures, but rather each climate likely produced its own pressures on gene 
selection within each population. Sellayah further postulated that the ethnic differences in obesity rates 







Genetic forms of obesity 
Despite the ongoing debate on the evolutionary origins of obesity susceptibility, there has been 
longstanding recognition of the genetic contributions to obesity with several twin studies, indicating a 
wide range of heritability for obesity (40 to 70%).51 Heritability is defined as the proportion of the total 
variation of a phenotype that is attributed to genetic factors.52,53 Although there are several ways to 
calculate heritability from data collected in related individuals, adding up the genetic effects is a common 
method to estimate a statistic known as narrow-sense heritability or h2.54  Fox et al. established heritability 
estimates of subcutaneous (SAT) and visceral (VAT) adipose tissue at 0.57 and 0.36 respectively within 
adults of the Framingham Heart Study, which has been replicated in the Southwest Ohio Study with similar 
findings (h2 of SAT=0.44 and h2 of VAT=0.36).55,56 Malis found the heritability of total and regional fat to 
range between 0.71 and 0.86 in young adults and elderly subjects.57 Hsu predicted the heritability of fat 
mass to be 0.71 and total fat mass to be 0.63.58 Obesity, from a genetic point of view, is categorized based 
on the number of gene variants involved in the development of the disease. Several classic monogenic 
forms of obesity manifest as the direct result of mutations leading to loss of function in key genes 
regulating energy homeostasis and appetite in the body. These include mutations in proopiomelanocortin 
(POMC), as well as deficiencies in leptin (LEP) and melanocortin 4 receptor (MC4R).59-61 Other examples 
of obesity arising from distinct genetic origins are due to genetic disorders with excessive weight gain as 
a secondary outcome termed pleiotropic syndromes (eg. Prader-Willi, Bardet-Biedl, and Down 
syndrome).61 However, the vast majority of obesity cases are considered polygenic, as they arise from 
multiple genetic factors each contributing small effects to the phenotype. 
The emphasis of the most recent work in understanding the genetic contributions to obesity has 
been on common variants known as single nucleotide polymorphisms (SNPs).52 SNPs are single base 
changes in the DNA sequence where the minor allele is represented in more than 1% of the population.62 





or pyrimidine to pyrimidine) and represent the majority of the SNPs in the human genome. Tranversions 
are point mutations in which the base changes from a purine to a pyrimidine or vice versa. While the 
majority of SNPs are dimorphic, tri- and tetramorphic variants can occur as well as insertions or deletions 
of sequences. Variation in genomic repeats through copy number variants (CNVs) and variable number 
tandem repeats (VNTRs) also provide additional sources of genomic variability. The convention for this 
manuscript for dimorphic polymorphisms will be A/a (eg. A/T) with the major allele listed first. 
 
Approaches in genetic association studies on obesity 
There are several types of genetic studies, including family-based studies, case-control studies, 
and population-based studies, which can use either hypothesis-free or hypothesis-driven approaches. In 
assessing the contributions of common genetic variants in obesity, careful considerations must be made 
in the design of the study including the sample population, phenotypes to be tested (use of continuous or 
categorical variables, selection of intermediate phenotypes), the selection of genetic markers to be tested 
with consideration of the minor allele frequencies (MAF), and the approach in the statistical analyses.63 
Hardy-Weinberg equilibrium (HWE) and linkage disequilibrium (LD) represent two fundamental concepts 
in genetic epidemiology that are commonly tested in genetic association studies. The former, HWE, 
employs a chi-squared test on the frequency of the genotype groups to ensure that assumptions regarding 
the sample population are met.63 The latter, LD, is an association among alleles at two or more loci and is 
a measure of co-segregation of these alleles in a population.64 Often times, genetic polymorphisms are 
found in close proximity to each other as SNP variants appear almost every 300 base pairs (bp).65 
Depending on their distance to each other and allele frequencies, their recombination frequency or LD 
can be calculated.66 There is an estimated total of 12.8 million SNPs in the human genome. Therefore, the 
selection of maximally informative or representative SNPs (tag SNPs) for a given genomic region allows 





Genome-wide association approach 
One approach that takes advantage of LD amongst SNP variants is genome-wide association study 
(GWAS) method, which has been used by large scale studies such as the Genetic Investigation of 
Anthropometric Traits (GIANT) consortium. The GIANT consortium has taken an unbiased approach to 
map out the regions of the genome most closely linked or associated with obesity.67-70 GWAS utilize high-
throughput SNP genotyping in combined cohorts and have revealed 190 loci within the human genome 
associated with obesity (predominantly by BMI) in adults69,71,72 and children.73,74 Some genetic loci had 
larger effect estimates in adolescents compared to adults.75 In the studies following the initial GWAS, 
meta-analyses combining many child cohorts have revealed important considerations on the genetic 
effect on obesity throughout childhood.76,77 One meta-regression analysis indicated that the genetic 
impact on BMI increased throughout childhood and peaked around the age of 20.76  Loci identified to be 
associated with a given phenotype in GWAS are typically interrogated for their functional role after the 
statistical relationship is established.78 
One such genomic region is the fat mass and obesity associated (FTO) gene. The initial finding that 
FTO variants repeatedly showed the strongest association with BMI in GWAS led to further work 
establishing the functional role of the FTO gene in obesity development.79,80 The 1st intronic region of the 
FTO gene was recently shown to serve as an enhancer for the IRX3 gene.81,82 Principally, FTO gene variants 
previously linked to obesity were associated with IXR3 expression rather than FTO expression.82,83 The 
FTO-IRX3 interaction was explored further and is described in Appendix C. This example underscores the 
limitations of using purely statistical approaches to understand the complex biological mechanisms 








Missing heritability of obesity 
Over the past few years, GWAS have steadily identified SNPs that are unequivocally associated 
with obesity.84 Despite advances in genetic epidemiology, large cohort studies have only been able to 
account for a small proportion (2-4%) of the total heritability of obesity.71,78 Using an in silico model, a 
recent report has estimated that 37% of the missing heritability can be accounted for when examining the 
additive effect of common SNPs which likely do not reach significance in GWAS statistical models.85 It has 
been postulated that the effect size of individual genes is often smaller than the detection limits to reach 
statistical significance.78,85 In order to address the missing heritability, the genetic risk score (GRS) 
approach has been employed to assess the cumulative association of common genetic variants on obesity. 
 
Genetic risk score approach 
The concept of assessing the cumulative association of several genetic markers on a phenotype 
was first suggested in an in silico model using simulated data from Janssens and co-authors.86 Just as 
GWAS were gaining ground, this early work provided the theoretical framework for the use of multiple 
gene variants in the prediction of disease risk. One of the key advantages of the GRS approach compared 
to GWAS was the reduction in type I error due to multiple testing and the need for correction using 
Bonferroni or the false discovery rate (FDR). Janssens showed that the use of several gene variants could 
be effective in disease prediction depending on some important characteristics of the model design. The 
predictive capacity or percent of the phenotype that can be explained by the genetic score was measured 
by the area under the curve (AUC), which was affected by the overall effect size of each individual genetic 
variant and their MAFs, the number of variants included, the sample size, and the disease prevalence in 
the population. Genetic variants with larger effect sizes could improve AUC and the number of gene 
variants tested was also able to increase predictive capacity up to a certain threshold (~100 genes) before 





of the AUC and the prevalence of the disease. For a disease such as obesity, a higher AUC is needed to 
increase the percent of the variance attributed to genetic factors. Indeed, the GRS approach became 
increasingly utilized following the initial GWAS discoveries, with both adult and child cohorts studied.87-91 
 
Cross-sectional GRS studies  
Over the past few years, several reports have surfaced that applied the concept of a cumulative 
risk score in children based on the results of GWAS and subsequent meta-analyses. The results and 
descriptions of these studies are summarized in Appendix A. GRS across most studies to date have not 
been shown to be strongly linked to birth weight. One report from the Hyperglycemia Adverse Pregnancy 
Outcomes Study did find an association between their GRS and large-for-gestational age at birth.92 In 
2009, Zhao et al. conducted one of the first GRS studies in a pediatric population of 6,078 children from 
the Children’s Hospital of Philadelphia (CHP). Their GRS of 15 GWAS SNPs from 13 susceptibility loci was 
significantly associated with BMIZ and explained 1.12% of the variation in the phenotype.93 Shortly after 
this, a report from the European Youth Heart Study (EYHS) emerged, which examined 17 GWAS-identified 
SNPs for their combined effect on BMI, skinfold thickness, and waist circumference in both pre-pubertal 
child and adolescent cohorts.94 The GRS was associated with all three obesity-related phenotypes, and 
individuals carrying 21 or more risk alleles had a BMI that was 0.51 standard deviations higher than those 
with 10 or fewer risk alleles. Notably, this was one of the first attempts at understanding the interaction 
between physical activity and an obesity GRS in children, though their GRS was not found to interact with 
their measure of physical activity. The genetic risk for obesity was also studied in the CHP cohort (2-18 
years old, n=7,225) using a GRS consisting of 8 adult obesity associated SNPs.95 When stratifying their data 
into BMI quantiles, Mitchell observed an increase in the strength of the association between the GRS and 
the phenotype groups from the 15th to the 85th percent quantiles. This trend did not continue beyond the 





more informative in high-risk children with susceptibility towards obesity assessed by their family history 
compared to individuals representative of the general pediatric population.89 While the genetic influence 
on obesity may be stronger in children who are overweight, obese, or at higher risk for obesity, this needs 
to be conducted in a larger sample size and diverse populations to confirm the observed relationships.  
 
GRS approach in the Avon Longitudinal study 
 The Avon Longitudinal Study (ALSPAC) has frequently utilized the GRS approach to describe the 
genetic contribution to obesity in their birth cohort.77,96-99 In their first report, 8 and 10 obesity-associated 
SNPs from GWAS were analyzed in separate GRS using a non-weighted additive model for their association 
with BMI-SDS (similar to BMIZ), weight, and height (n=7,146) 9-year old children.100 When comparing 
children with 4 or fewer risk alleles to those with 13 or more, weight, BMI, and height were 3.5 kg, 1.4 
kg/m2, and 2.0 cm higher in the highest genetic risk group, respectively. Elks and collaborators reported 
that the 8-SNP GRS accounted for 1.7% of the total variance in the BMI-SDS variable. This first study from 
ALSPAC also gave an indication that the GRS also was associated with early infancy weight and length gain, 
and a reduction in the odds of failure to thrive, which suggests that some genetic factors may be protective 
and promote survival early in life. Following the first report, Beyerlein and colleagues included two DXA 
measured phenotypes (FMI and LMI) in their evaluation of the same GRS in the ALSPAC cohort.96 They 
found that their GRS showed a stronger relationship with both BMI-SDS and FMI in the higher quantiles 
compared to the lower quantiles. In 2013, the ALSPAC GRS was expanded to include 32 SNPs and their 
analysis was replicated in children from the Western Australian Pregnancy Cohort (Raine) Study 
(n=1,460).99 This study was a longitudinal assessment of the genetic contributions to obesity throughout 
childhood and adolescence (from birth to 17 years). In analyses that were stratified by sex, the association 
of the 32-SNP GRS with BMI was detected by the first year of life, and was shown to be earlier in males 





and declined in the strength of the association by age thereafter. Importantly, this study demonstrated 
small but significant relationships between the GRS and BMI at critical time points in development 
including adiposity peak and AR, explaining <1% and 1-2% of the variance in BMI of each of these time 
points respectively. Other longitudinal studies have been conducted in some of the longstanding historical 
cohorts and are described in the next section.88,97,101 
 
GRS in retrospective analysis of historic longitudinal cohorts 
 One of the first GRS constructed on obesity in children was a retrospective analysis of the Dunedin 
Multidisciplinary Health and Development Study between 1972 and 1973 in New Zealand.88 Belsky and 
co-authors reported on the heritability of BMI and the association of their 29-SNP GRS with obesity from 
birth to 38 years. Their primary findings were that children in the highest GRS tertile were predicted to 
have a faster rate of growth throughout childhood and that these children also had a 1.61 to 2.41-fold 
increased risk for obesity in their second and fourth decades of life. An 11-SNP obesity risk score was 
examined in the 1946 British Birth Cohort for its long-term effects spanning over 53 years of life.97 The 
GRS peaked in its association with BMI-SDS at the age of 11 and 20 and explained 1.6% of the variance in 
BMI. This observation was further supported by investigating the longitudinal trajectories on weight, BMI, 
and height amongst the GRS groups when separated into tertiles. Children in the highest GRS tertile were 
at an increased risk for greater gains in all three phenotypes (2.7%, 4.9%, and 6.5%) throughout childhood 
and adolescence compared to the other two risk score tertiles. The relationship was observed to converge 
as the children aged into adulthood. The GRS was associated with a faster rate of growth by height in 
children between the ages of 2 and 7 before the onset of puberty, but not in the 7 to 20 year period. The 
longitudinal analysis presented here suggests the utility of a GRS in identifying a new at-risk group: 
children with rapid growth in height before puberty and slowed growth in height at adolescence. 





management and prevention of obesity in the clinical setting. A retrospective study from the Fels 
Longitudinal cohort used the same 32 SNPs from the Belsky report for their non-weighted GRS and 
measured its effect over 40 years of life.101 The percent of the BMI explained by the GRS ranged from 1 to 
3.3% with the highest values observed after the age of 30. From their data, Choh et al. contended that 
genes influencing BMI earlier in life may be different than those in adults. The Choh study adjusted for 
year of birth to control for potential generational or era effects, since their data were collected from 1934 
to 2011. For the Belsky report, this was not possible as birth year data were not available, and all 
participants of the 1946 British Birth cohort were born within two weeks of each other. The retrospective 
GRS analyses thus far have generated unique insight into the relationship between GRS and obesity 
development throughout life, but may be limited in providing the full picture as the environmental factors 
affecting obesity have changed drastically over the past nine decades.15   
 
Longitudinal GRS studies in contemporary cohorts 
Bridging the gap between historical cohorts and more recent population samples, Morandi 
examined the additive effect of 39 SNPs on BMI at the age of 6 and 17 in the Northern Finland Birth Cohort 
(n=4,032).102 Their work was cross-validated in two sample populations from Veneto, Italy (n=1,503) and 
Massachusetts (n=1,032). This study concluded that the current genetic markers identified from GWAS 
did not provide additional predictive value for clinical use when traditional clinical measures of risk were 
also considered (eg. sex, pre-pregnancy parental BMI). Principally, the AUC values of their GRS were 
relatively poor ranging from 0.56 to 0.59 compared to the AUC values obtained from traditional clinical 
measures, which ranged from 0.69 to 0.85. An AUC value of 0.5 is the equivalent of flipping a fair coin. 
Another study including data from a more contemporary cohort, the Twins Early Development Study 
(TEDS), demonstrated similar findings seen from the ALSPAC studies regarding the age affects in 





the association of their 28-SNP weighted GRS with BMI-SDS was more pronounced at the age of 10 than 
at the age of 4 with a difference of 2.4% (CI: 2.0-7.8%). Bootstrapping analysis was performed to provide 
the confidence interval for the difference in percent variance explained at the two ages. The Generation 
R Study developed and tested 2 GRS constructed from obesity phenotypes in adults, 29 for BMI and 14 
for waist-hip ratio (WHR) associated SNPs.104 The adult BMI GRS was associated with higher age at 
adiposity peak during infancy but the adult WHR GRS was not. Cross-sectional analyses were performed 
with both GRS when the children were 6 years old. While the adult BMI GRS was associated with higher 
BMI, total fat mass, android/gynoid ratio and preperitoneal fat area (2.4%, 1.4%, 1.2%, and 0.5% of the 
variance explained), the WHR GRS was associated with android/gynoid ratio and preperitoneal fat area. 
Overall, the results of the GRS studies in children on obesity in contemporary cohorts reflect the findings 
in the retrospective cohorts.  
 
Application of obesity GRS on other phenotypes 
Investigators of the genetic contributions to obesity in children have pursued new approaches by 
applying obesity GRS to other phenotypes beyond measures of adiposity. Genetic factors underlying 
appetite and satiety, insulin resistance, subclinical inflammation, dietary intake and physical activity have 
also been linked to obesity. One intermediate phenotype, satiety responsiveness, was analyzed for its 
relationship with a 28-SNP GRS previously shown to be associated with BMI-SDS in the TEDS cohort.105 
Satiety responsiveness was measured using the Child Eating Behavior Questionnaire. The risk score was 
negatively associated with satiety responsiveness and explained 0.4% of the variance. More importantly, 
this intermediate phenotype was found to be a mediator between the genetic score and obesity. The 
introduction of satiety responsiveness into the regression model attenuated the association between the 
GRS and BMI-SDS. The relationship between an obesity GRS and insulin resistance measured by HOMA-IR 





risk score was associated with the development of insulin resistance as children with 10 or more risk 
alleles were 1.47-fold (CI: 1.12-1.94) more likely to be in the upper 25th percentile for HOMA-IR than those 
carrying 5 or fewer risk alleles. However, the association was not upheld after including BMI in the model 
as a covariate and was only observed in pre-pubertal children when the analysis was separated by age 
group. This indicates that BMI and HOMA-IR were independently associated and also suggests that the 
SNPs selected for the GRS were perhaps guilty by association. Toemen and colleagues recently completed 
a cross-sectional examination of the association between a GRS, levels of C-reactive protein, and 
measures of adiposity by DXA and ultrasound in 6-year old children of the Generation R Study.107 The 
same 29-SNP GRS from their previous work was associated with elevated C-reactive protein levels (>23.0 
mg/l) in a dose-dependent manner. Though this finding was of borderline significance, each additional 
risk allele conferred 1.04-fold (CI: 1.00-1.07) greater risk of elevated C-reactive protein levels. Measures 
of adiposity including BMI, fat mass percent, android/gynoid fat mass ratio, and preperitoneal abdominal 
fat were independently associated with C-reactive protein levels in the children of this cohort. Analysis of 
2,346 children from ALSPAC revealed the impact of their 8-SNP GRS on obesity measures with 
environmental and dietary factors taken into consideration.98 Both maternal overweight and unsaturated 
fat intake were associated with the GRS. Consuming an adequate amount of unsaturated fat appeared to 
mask the effect of the GRS on FMI, as the GRS was not associated with FMI in the normal intake group. A 
limitation for this study was that the diet data were collected at the age of 7, which was 2 years prior to 
measurement of the obesity-related phenotypes. Though obesity GRS have been applied to different 
phenotypes in children with modest results, use of genetic variants with putative roles in those respective 








Primary themes from GRS on obesity in children 
Taken together, several themes have emerged from the cumulative work addressing GRS and 
obesity in children. From the current data, it is evident that the genetic contribution to obesity phenotypes 
is detectable early in life and tends to increase throughout childhood and adolescence. The results from 
the GRS approach summarized here and by meta-regression analyses of data from large consortia of 
individuals support the assertion that genetic influences on obesity are strongest during childhood. 
Retrospective longitudinal studies have provided important information regarding the prediction of 
overweight and obesity based on genetic risk, but the cohort or era effect is a confounding factor as the 
nutritional environment and psychosocial landscapes have changed significantly since the time those data 
were collected.15 Examining subgroups within the pediatric population has revealed additional 
relationships. Genetic influence may be stronger in children who are in the upper quantiles for BMI, are 
already overweight or obese, or are at higher risk for obesity as indicated by their family history.89,95 As 
described by Mitchell, individual genetic variants vary in their strength of association across the 
distribution of BMI.95 The effect of GRS separately on males and females appears to be driven by age as 
well. The genetic association with obesity appears to manifest earlier in males.104 Furthermore, the 
differences in lean mass and fat mass accrual between boys and girls become increasingly apparent 
throughout childhood especially at the onset of puberty, which indicates a need to account for this 
population stratification in GRS studies by separating the analysis by sex and using more precise 
measurements of adiposity.31,32 
 
Disparities in genetic risk for obesity by ethnicity 
Children of different ethnic backgrounds are disproportionately affected by obesity, and the 
application of GRS across these groups has not been well established. The issue of ethnicity in GRS studies 





European ancestry. Future studies in admixed populations and populations with a high degree of genetic 
heterogeneity will need to account for stratification within the dataset using ancestry informative markers 
(AIMs).108-111 Klimentidis investigated the association of a GRS in a pediatric cohort consisting of African-
American, Hispanic American, European American, and biracial individuals.112 When analyzing the entire 
cohort, population stratification by ethnicity was accounted for through a covariate generated using 
maximum likelihood estimation, which was established by integrating SNP data from 142 AIMs into a score 
ranging from 0 to 100. Their GRS was not associated with BMI, FMI, or LMI when all ethnic groups were 
considered, and the mean risk score was significantly different amongst the groups. Though this particular 
study may have been limited by their sample size (n=298), their data demonstrate the challenges 
confronting researchers in understanding the cumulative genetic effects on obesity in children of diverse 
cohorts. 
 
Standardization of the GRS approach 
While the current literature on GRS and obesity in children has provided depth in our 
understanding of the cumulative association of genetic variants across the lifespan, improved uniformity 
in the standard practice of this approach would yield greater consistency and allow for more comparisons 
across studies. Some studies have employed the use of a secondary dataset or cross-validation sample 
cohort to confirm the relationships observed in their sample, but this has not been consistent in all 
studies.89,94,99,102 The use of the additive model in constructing risk scores is currently common practice in 
the field. Genotype groups for each SNP are reassigned with the values 0, 1, and 2 to simulate an additive 
model of risk. Often times, GRS are not weighted for the effect size of each SNP on the phenotype. When 
GRS are weighted, adjustment for the effect size of each SNP is achieved using weighted values from 
previously generated odds ratios from publically available GWAS data. However, this approach raises 





inheritance may not always follow the additive model and the assigned risk allele may actually be different 
or not confer the same risk across different populations.113,114 In fact, Sellis and colleagues have argued 
that the heterozygote advantage may play a larger role in the maintenance of genetic variation than 
previously thought.115 The concept of balancing selection is postulated to occur during short periods of 
balancing states because the increased diversity provides a fitness advantage, despite the possibility that 
homozygote carriers may be at a selective disadvantage.115 
Genetic epidemiologists have recognized the limitation of not knowing the mode of inheritance a 
priori and have addressed this longstanding concern using several statistical methods. Traditionally, the 
Cochran-Armitage test (CATT) has been used to test the fit of the data with the additive model.116 Indeed, 
prediction of the mode of inheritance is an active area of research, and new methods including the 
maximum (MAX) test and maximum efficiency robust test (MERT) have been developed to maximize 
power while limiting type 1 error.117 
 
SNP inclusion in GRS 
Thus far, all of the SNPs selected in GRS studies in children have been taken from GWAS data 
either from adult or child studies, which has allowed for the use of previously established odds ratios or 
beta estimates to assign weight for each SNP within the GRS. However, this may not always be appropriate 
as the association of genetic markers with obesity phenotypes has clearly been shown to differ by age. 
Perhaps the safe approach for future studies would be to extract the SNPs and their effect size from GWAS 
conducted in children. SNPs taken from GWAS data have passed the gauntlet of statistical tests, but may 
not ultimately reflect the biological mechanisms driving early-onset obesity. Strictly form the standpoint 
of disease prediction for early intervention, the genetic markers that make up a cumulative risk score need 
not have biological significance. However, the limitation of using these genetic variants may be in their 





gene based methods. Other phenotypes including fat mass, android/gynoid ratio, and preperiotoneal fat 
as a proxy for VAT have been addressed, but the SNPs themselves and the genes closest in proximity to 
these SNPs may not play a role in the biological pathways intrinsic to obesity development in childhood 
(i.e. adipose tissue generation, remodeling, and differentiation). Questions surrounding the utility of GRS 
for not only prediction of obesity risk but also for contributing to the missing heritability paradigm have 
arisen. Indeed, the percent of variance explained by GRS in the obesity phenotypes studied thus far have 
been well below 5% (1-3.3%, Appendix A). Identification of putative genetic markers in a pathway-based 
approach may be a favorable approach to account for the missing heritability moving forward. 
Consideration of other factors including physical activity and diet as environmental components have 
been made, but gene-gene interactions have not been adequately addressed in the context of a 
GRS.88,93,98,118-120 Many current researchers in the field have pointed out the lack of data on mechanisms 
linking the GWAS reported SNPs with the propensity for excess adiposity. Recently, GWAS approaches 
have made strides in identifying new loci associated with WHR adjusting for BMI thus establishing the 
functional pathways that may be implicated through the SNPs discovered to be associated with WHR.121  
 
Summary and new directions for GRS approach 
Current GRS studies on obesity in children demonstrate modest but significant associations that 
vary throughout the lifespan and peak during childhood. The wealth of GWAS data has provided ample 
opportunity to explore additional avenues of analyses such as the GRS approach described here and 
others: linkage tests, gene-gene interactions122, gene-environment interactions123, and pathway-based 
methods.124-127 While this will aid in our understanding of the genetic contributions to obesity, the time 
has come to integrate these approaches with processes that identify variants in genes with putative roles 
in pathways directly related to nutrient metabolism, appetite regulation, adipogenesis and fat storage, 





testing single genetic markers for their association with a given phenotype but were limited in the 
reproducibility of the results.128 The candidate gene process could be applied to select SNPs to be included 
in a cumulative score. Coupled with the knowledge that genes work in a cooperative and interactive 
manner under physiological conditions, it may be more advantageous to identify gene variants within 
molecular pathways impacting metabolic activity, appetite regulation, inflammation, adipogenesis and fat 
storage to test for genetic effects on obesity.127,129,130 There are a number of studies that have used the 
candidate gene approach when selecting for genetic markers in various pathways involved in fat oxidation 
and hypothalamic regulation of appetite.125,126,131 However, the majority of these studies only investigated 
the effect of individual genetic markers on the phenotype and did not construct an overall genetic risk 
score (GRS). We have demonstrated the cumulative association of SNPs located in genes within the leptin-
melanocortin pathway on elevated BMI percentile in children of the STRONG Kids cohort.132 In addition 
to the leptin-melanocortin pathway and its involvement in the regulation of appetite and satiety, 
hormonal and neuronal signals from the gut act on elements of the brain including the 
hypothalamus.133,134 These signals are derived, in part, from microorganisms residing along the 
gastrointestinal tract. A budding new field of research has emerged over the past decade to understand 




The gut microbiota is a community of microorganisms inhabiting the gastrointestinal tract. Before 
the advent of molecular techniques, the gut microbiota within the colon was estimated to consist of 1010-
1011 bacteria per gram of luminal content and harbor 400 to 500 species of bacteria.135 Current culture-
independent techniques have provided researchers with the tools to characterize the intestinal microbial 
community using both molecular techniques as well as first and second generation sequencing.136 Using 





(1013 to 1014) and provide an estimated 150 times more genes than the human genome.137-139 With such 
diversity and significant genetic contributions to the intestinal environment, the gut microbiota has been 
implicated in having a role in many physiological processes including immunoregulatory responses, pro-
inflammatory states, fat storage, and fat metabolism.140,141 These effects ultimately contribute to disease 
outcomes, such as Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), colon cancer, 
diabetes, allergies, and obesity.140-146 As much of the early work focused on microbial composition, 
research in this field has now shifted towards gaining an understanding of the functional significance of 
the gut microbiota from the genes they carry (microbiome), to the genes they express (transcriptomics), 
and the metabolites they produce (metabolomics).147,148 The National Institute of Health initiated the 
Human Microbiome Project (HMP) with several goals including the characterization of the human 
microbiome and various sites of the body, its variation amongst the population, and its relationship to 
human disease.149,150 Indeed, the gut microbiota presents a plethora of opportunities for researchers to 
explore the complex interactions between diet, host genes, and microbes, and how these interactions 
impact human health.135  
 
Gut Microbial Composition 
Microbial life inhabits the human gut immediately following birth and continues to develop in the 
first two years of life.151 The density and type of bacteria varies depending on the region of gut. While 
these microbes are present throughout the gut, they most prominently reside in the proximal colon. In 
this region, the high prevalence of gut microbiota is due to the availability of substrate for bacterial 
consumption.152 The mode of delivery affects the microbial make-up in the infant gut. The gut microbiota 
has been shown to differ in time of colonization and composition when comparing infants delivered 
vaginally or via C-section.153-156 Colonization is marked by two key events: early feeding by either breast 





microbiota is changing and becoming increasingly dense in a variety of microbes.159,160 Bifidobacterium 
spp. predominate the infant gut microbiota, remain important members of the gut microbiota in children, 
and decline in abundance in adults.161-163 Human breast milk is considered by many as a natural prebiotic 
as it contains fermentable human milk oligosaccharides (HMOs). HMOs are the third most abundant solid 
component in breast milk behind lactose and lipids.164 These non-digestible polysaccharides exert a 
prebiotic effect in the infant gut by selectively promoting the growth of Bifidobacterium and Bacteroides 
spp., which are able to utilize a variety of HMO structures as their sole carbon source.165 A probiotic effect 
of breastfeeding is thought to occur through the vertical transmission of bacteria via the enteromammary 
pathway and other external sources.166 The protective effect of breastfeeding on childhood obesity have 
been shown through epidemiological data, though the results have not been consistent.167 Antibiotic 
administration has been implicated in risk for obesity, and the reason for this relationship is thought to 
be attributed to alterations in the gut microbiota especially during infancy and early childhood.168-170 
Longitudinal assessments of antibiotic use have indicated that infants in the U.S. will, on average, be 
exposed to three treatments by the age of 2 years.171 Azad and colleagues showed that antibiotic exposure 
increased the risk of overweight at the age of 9 and 12 in boys. The risk was found to be stronger in boys 
than in girls; however, increasing the number of exposures did not increase risk of overweight in a dose-
dependent manner.172 Other considerations for antibiotic use include the spectrum of the treatment 
administered (broad or narrow) and the age of exposure as these factors could impact the gut microbiota 
as it is established during infancy. 
While it has been suggested that the gut microbiota resembles that of an adult by the age of two, 
Bergstrom and Yatsunenko have shown additional shifts in microbial composition between the ages of 2 
and 3.160,173 It is generally recognized that the gut microbial composition stabilizes by the age of 3, and 
shifts toward an adult-like microbiota coincide with the introduction to solid foods.151 Some studies have 





composition in adulthood leading to old age.174,175 The adult gut microbiota appears to be more stable 
over time than in the infant gut microbiota.176 The composition of the gut microbiota is primarily from 
one of two bacterial phyla: Bacteroidetes and Firmicutes.159 Most of the Firmicutes belong to the Clostridia 
class while other phyla are present in much lower quantities and include Proteobacteria, Actinobacteria 
(eg. Bifidobacterium), Fusobacteria, and Verrucomicrobia.177 It has been suggested that there may be a 
core of microbial genes identifiable in humans, and that there may be gut microbiota “enterotypes” based 
on clustering independently of geographic location.178-180 Despite inter-individual differences in gut 
microbial composition, there appears to be functional redundancy in the microbial genes present 
reflecting a core microbiome rather than a core microbiota.150,181 
 
Dietary effects on gut microbiota 
Data from fecal samples collected across the world indicate differences in gut microbiota 
composition by geographical location.160,182 Some reports have even suggested a correlation between the 
relative abundance of the predominant gut microbial phyla and latitude.183 In children, the roles of 
geographical location and diet in shaping the gut microbiota have been examined in a comparison 
between cohorts from Europe and Burkina Faso. Children from Burkina Faso had a lower Firmicutes-to-
Bacteroidetes ratio, increased diversity and richness, and higher quantities of fecal propionate and 
butyrate than children from Europe. There were several bacterial genera that were only present in the 
samples from the Burkina Faso children. The differences in gut microbiota observed between two vastly 
different groups of children demonstrate how diet and geographical location can influence the microbial 
inhabitants of the gut.184 It appears that the diversity of microbes observed by geography can be 
attributed to three main components: true differences in microbial composition by geographical location, 
ethnic or genetic influences on microbial colonization, and the impact of dietary intake. Of these, diet 





of studies, dietary factors that affect the gut microbiota include caloric load, diet composition, and dietary 
fiber intake. Jumpertz and co-workers have shown that phylum-level changes in gut microbiota 
composition occur as a result of caloric restriction.187 The specific macronutrient composition plays a 
dominant role in shaping the gut microbiota. Comparison of gut microbiota across several mammalian 
species by diet type (herbivore, omnivore, and carnivore) has illustrated this point.188 Since then, dietary 
intervention studies have established important characteristics of the gut microbiota in response to 
alterations in dietary composition. 
 
Characteristics of the gut microbiota in response to dietary modification 
 The gut microbiome responds to changes in diet through rapid shifts in composition, 
demonstrating adaptability to substrate availability. The shifts in microbial composition in response to all-
plant and all-animal based diets in adult humans was studied by David and colleagues.189 The participants 
of the study consuming the animal-based diet experienced significant weight loss by the 3rd day of the 
dietary intervention, and those consuming the plant-based diet maintained their weight. Interestingly, 
this reduction in weight was not due to a difference in the total caloric intake between the diets. 
Compared to baseline intake for each participant, fiber intake was reduced dramatically when consuming 
the animal-based diet and increased when consuming the plant-based diet. Microbial shifts were more 
apparent when participants changed to the animal-based diet compared to the plant-based diet. 
Corresponding shifts in the microbial composition to adapt to amino acid fermentation was observed as 
Alistipes, Bilophila, and Bacteroides were increased in abundance and Roseburia, Eubacterium rectale, and 
Ruminococcus bromii decreased in abundance. This rapid and drastic shift in gut microbiota through 
dietary intervention observed by David et al. reflects the flexibility and adaptability of the microbiome. 





in response to dietary changes. In adult humans, rapid shifts in the gut microbiota were observed, but the 
enterotypes identified from their data persisted despite undergoing dietary modifications.190 Fava et al. 
showed how the gut microbiota was altered though 5 experimental diets each with different carbohydrate 
and fat loads.191 In an elegant design utilizing many mouse lines and experimental diets including low-fat 
high plant polysaccharide and high fat high sugar, Carmody et al. demonstrated the rapid shifts in 
composition seen previously, steady states as the gut microbiota adapted to the change in diet, and the 
reversibility of the composition once the dietary intervention was stopped.185 However, inter-individual 
variation plays a role in the ability of the gut microbiota to change with dietary modifications.192,193 
 
Microbial composition related to obesity 
The Firmicutes-to-Bacteroidetes ratio has been implicated in obesity in both the mice and 
humans.142 Phylogenetic analysis of the gut microbiota initially revealed a relationship between the 
Firmicutes-to-Bacteroidetes ratio and the weight status of the host. This concept arose from studies 
performed in mice where microbiota was taken from genetically obese (ob/ob) and lean mice and 
transplanted into germ-free mice. Comparison of the two inoculum revealed the ob/ob microbiota 
contained a higher abundance of Firmicutes relative to the lean microbiota. The mice receiving the ob/ob 
microbiota gained significantly more percent body fat than the mice receiving microbiota from the lean 
mice. It is important to note that the two groups of mice receiving transplanted microbiota did not differ 
in their intake of food over the two week period of measurement, suggesting that the different microbiota 
accounted for a difference in energy harvest.194 In addition, Samuel and Gordon investigated the impact 
of the predominant species of Archaea, Methanobrevibacter smithii, on the interactions between 
microorganisms within the gut and on the host’s ability to harvest energy from the diet. In both conditions, 
the co-colonization of M. smithii and B. thetaiotaomicron into germ-free mice led to increased density of 





triglyceride levels when compared to control mice only colonized with B. thetaiotaomicron.195 Inoculation 
of these two microbes into germ-free mice clearly demonstrated an interaction between B. 
thetaiotaomicron and M. smithii; however, it may be premature to apply these results directly to an 
environment containing hundreds of species of microbes with multiple potential interactions, of which, 
many have yet to be discovered. These studies do suggest that the composition of the gut microbiota may 
play a role in energy harvested from non-digestible polysaccharides, and that the interactions between 
microbes are also significant.194  
 
Early gut microbiota studies in adult humans and obesity 
The focus in gut microbiota research shifted from the germ-free mouse model towards 
investigation of gut microbial differences observed in different human populations. Ley and colleagues 
examined the Firmicutes-to-Bacteroidetes ratio in 12 obese subjects randomly assigned to either a fat-
restricted or carbohydrate restricted diet. Over the course of one year, both diet types correlated with an 
increase in Bacteriodetes when the individual lost at least 6% of body weight on the fat-restricted diet 
and 2% of body weight on the carbohydrate-restricted diet.142 In another study comparing obese, 
anorexic, and normal weight individuals, a significant decrease in the quantity of Bacteriodetes was found 
between obese and lean and obese and anorexic individuals.196 While these results support the Ley 
findings, results from a report by Schwiertz contradicts the previous findings. Schwiertz and co-workers 
found that the overweight and obese had a higher proportion of Bacteriodetes compared to their lean 
counterparts. Instead, these researchers suggested that the production of short chain fatty acids (SCFAs) 
may be the important factor influencing host weight status rather than the composition of microbes 
inhabiting the gut.197 Duncan et al. indicated that the proportion of Bacteriodetes did not differ between 





placed on weight loss diets.198 Weight loss was associated with a decrease in Roseburia and Eubacterium 
rectale as a percent of the total bacteria, but the authors attributed this to the change in the diet.  
 
Gut microbiota and obesity in children 
With the establishment of the gut microbiota’s relationship with obesity through animal models 
and adult humans, research efforts have increased in seeking to understand its effects in children 
(Appendix B). Both longitudinal and cross-sectional studies have been conducted in child cohorts in many 
populations globally. Though a diverse range of children have been examined, the variety of methods 
utilized to measure the gut microbiota across these studies presents challenges in comparing the results 
across studies. Furthermore, precise measurements of adiposity have only been used in a single study to 
date. 
One of the earliest studies suggested that gut microbial composition could be a predictor of 
overweight.199 Fecal Bifidobacterium amounts at infancy were higher in children that remained normal 
weight compared to children that became overweight at 7 years of age. A follow-up report on the same 
group of Finnish children observed a similar trend with Bifidobacterium abundance at age 10, but these 
results were not statistically significant.200 In a large sample of 909 infants from the KOALA birth cohort, 
B. fragilis colonization measured by quantitative PCR (qPCR) within the first 6 weeks of life was associated 
with BMIZ in an unadjusted model but not in the adjusted model, where self-reported BMI was provided 
at 7 time points between the age of 1 and 10. A subgroup of this cohort was reported to have lower BMIZ 
in response to B. fragilis colonization in both the unadjusted and adjusted models. C. difficile colonization 
was also associated with lower BMIZ at 8.6 ± 0.4 years of age.201 Taken together, two reports from the 
EVASYON study group showed several shifts in fecal microbial composition of Spanish adolescents in 
response to a 10-week weight loss intervention, which included caloric restriction (10-40%) and increased 





coccoides, Bifidobacterium longum, and Bifidobacterium adolescentis amounts were decreased as 
measured by qPCR. By FISH, they also observed reductions in Clostridium histolyticum and E. rectale-C. 
coccoides amounts. They also found that high responders to the intervention (>4 kg weight loss) 
experienced additional changes in microbial composition, including increased Bacteroides-Prevotella and 
Lactobacillus amounts and decreased C. lituseburense amounts.202,203 These reports demonstrated that 
the microbial composition could be used to predict how an individual would respond to a weight loss 
intervention, and this idea has recently been investigated further.204  
While some have looked at the longitudinal outcomes of gut microbial establishment, the majority 
of the reports investigating the association between gut microbiota and childhood obesity have been 
cross-sectional in design. Five studies assessed the relationship between obesity measures and the 
predominant bacterial phyla in children. Ferrer and Bervoets have reported that the Firmicutes-to-
Bacteroidetes ratio was elevated in obese and overweight compared to lean children, but Payne did not 
report any correlation between this ratio and BMI.205-207 In a cohort of Kazakh children (n=187), the 
Firmicutes-to-Bacteroidetes ratio was positively correlated while Bacteroides copy number was negatively 
correlated with BMI using qPCR.208 Obese girls also had elevated Firmicutes-to-Bacteroidetes in the 
Kazakh cohort. Firmicutes and Bacteroidetes were detected with PCR in in fecal samples from a cohort of 
Egyptian children and adults, but they did not quantify the bacterial phyla nor did they separate their 
analysis by age group.209 The inconsistencies in these findings may be partially attributed to the differing 
methods used by each study to assess bacterial composition. Bervoets utilized traditional culturing 
techniques and quantified by qPCR, Ferrer’s group used 454 pyrosequencing, and Payne performed 
terminal restriction fragment length polymorphism (T-RFLP). Using culture techniques, Sepp et al. found 
the relative abundance of Bifidobacteria and Eubacteria were positively correlated with BMI, and 





Several studies have used qPCR to compare the differences in bacterial quantities amongst obese, 
overweight, and normal weight children.211-213 A case and control cohort of 40 Swedish children showed 
family and genus level differences in bacterial abundance between overweight and normal weight 
children. They found Enterobacteriaceae to be higher and both Desulfovibrio and Akkermansia 
muciniphila-like bacteria to be lower in overweight compared to normal weight children.214 Gao et al. also 
utilized a case and control study design in 63 obese and 63 normal weight Chinese children.211 They found 
differences in the ratio of Bifidobacterium and E. coli between the obese and normal weight groups using 
qPCR, although the reason behind choosing 1 as the cutoff ratio value was not described in depth. In a 
large cohort of Mexican children (n=190), the relative abundance of Faecalibacterium, Roseburia, Blautia 
sp., Caprocaoccus sp., and Enterobacteriacae were higher in the overweight and obese individuals 
compared to the normal weight individuals.213 Succinivibrio sp., Erwinia sp., and Oscillospira sp. were 
lower in overweight and obese children than in normal weight children, though Oscillospira sp. abundance 
was lower in overweight children compared to the obese children.  
Indeed, microbial composition has been examined in a wide range of child cohorts, but BMI has 
been used as the primary metric in childhood obesity studies. In the SKOT birth cohort of 330 Danish 
children, Bergstrom and colleagues studied the relationship between gut microbiota and body 
composition measured by bioelectrical impedance (BIA) and DXA (n=101) at age 3.173 Body composition 
measurements including fat mass, fat-free mass, and resistance index (height2/resistance) were not 
associated with any of the bacterial quantities measure by qPCR at 9, 18, and 36 months of life. While this 
study was the first to use BIA and DXA in this manner and had the advantage of demonstrating longitudinal 
outcomes during infancy, they may have been limited as antibiotic administration throughout the study 
period was not recorded. Additionally, only three body composition measurements were considered, and 





abundance in the gut and regional depots of adiposity in the body as obesity develops due to the adverse 
metabolic consequences of visceral adiposity. 
 
Metabolic activity of the gut microbiota 
 
Short-Chain Fatty Acids 
The gut microbiota impacts many host functions including gastrointestinal development, motility, 
and nutrient metabolism. Metabolic functions include breaking down dietary toxins and carcinogens, 
fermenting indigestible foods, and assisting in absorbing electrolytes and minerals, and absorption of 
short chain fatty acids.215 One of the functional roles of the gut microbiota is the fermentation of non-
digestible polysaccharides to SCFAs. The three major SCFAs produced in the colon by gut microbes are: 
acetate, propionate, and butyrate. It is estimated that 95% of the SCFA produced by the gut microbiota 
will be absorbed by the host.216 Acetate is the principal SCFA produced and is transported to the liver and 
adipose to be converted to acetyl-CoA for energy and lipogenesis, with residual acetate directed to the 
muscle for energy. Propionate is transported to the liver, which leads to gluconeogenesis and possible 
decrease in hepatic cholesterol synthesis.217-219 Butyrate is the primary and preferred energy source for 
colonocytes and has been implicated in cell proliferation and differentiation, as well as gene expression 
at the level of histone modification.220,221 Bacterial fermentation has been shown to be a key contributor 
to caloric requirements for an adult human with an estimated 6 to 10% contribution from SCFAs.222,223 
This is of particular interest to researchers due to the possible contribution of the gut microbiota in fat 








Fecal SCFA quantities and obesity 
In general, studies in humans measuring fecal SCFA quantities have shown that overweight and 
obese subjects have higher levels relative to lean subjects. Schwiertz and colleagues have found that both 
propionate and overall fecal SCFA quantities were higher in overweight adults compared to lean adults.197 
Fernandes showed that overweight and obese adults had higher total SCFAs including acetate, 
propionate, and butyrate compared to lean adults.224 This report also demonstrated positive relationships 
between individual SCFAs and the Firmicutes-to-Bacteroidetes ratio regardless of BMI status and a 
negative relationship between SCFA quantities and the Bacteroidetes phylum measured by qPCR. In 
children, Payne found that fecal quantities of propionate and butyrate were higher in obese compared to 
normal weight children.207 Altered fecal SCFA quantities have been presented in overweight and obese 
Mexican children. Butyrate and propionate quantities were lower in obese children compared to normal 
weight children. Interestingly, propionate quantities were higher in the overweight group relative to the 
obese group of the same study.213 The primary limitation of analyzing the SCFA quantity of fecal samples 
has been that it only provides a snapshot of the host-microbe interaction. It is difficult to ascertain 
whether the elevated levels of SCFAs observed in fecal samples are the result of the increased 
fermentative capacity of gut microbiota from overweight individuals or an indication of reduced 
absorption by the host. Recent work from Rahat-Rozenbloom investigated the latter part by measuring 
the rectal absorption of SCFA in human participants.225 While rectal absorption may not be entirely 
representative of absorption in the proximal colon, this pilot study suggested that the higher quantities 
of total fecal SCFAs observed in overweight and normal weight individuals were not due to decreased 
absorption. However, they did find that increasing fecal SCFA concentration was positively associated with 
percent SCFA absorption in the rectum of overweight and obese participants. The cumulative data on 
SCFA and obesity thus far demonstrate a critical role for SCFA in mediating host metabolic responses to 





In vitro fermentation models 
An in vitro fermentation model provides an opportunity to quantify the metabolic capacity of gut 
microbes to ferment SCFAs over a specified time course. Since it is a closed system, production of SCFA, 
lactate and gasses can be accurately quantified. Several in vitro experiments have established the effects 
of a variety of substrates on microbial composition and SCFA production. While some226,227 reported on 
the prebiotic effect of several common dietary fibers, others228 have shown the potential for common 
food ingredients (eg. inulin, raftilose, galactooligosaccharides, maltisorb, maltisweet, maltidex, 
polydextrose) to alter microbial composition. Many of the studies to date have focused on the 
fermentation of human milk oligosaccharides (HMOs) using fecal inoculates from human infants.229-231 
Murine models have provided further evidence that the substrate type can alter the fermentative capacity 
of fecal inoculates both in vivo and in vitro. Haenen and colleagues have shown that the cecal and colonic 
contents from adult female pigs fed a diet high in resistant starch (RS) over two weeks contain higher SCFA 
than pigs fed a diet containing digestible starch over the same time period.232 Li et al. investigated the 
SCFA production of microbiota from the ascending colon contents of both formula-fed (FF) and sow-
reared (SR) piglets. Principally, they found that inoculum from FF piglets produced higher total SCFA and 
acetate than SR piglets while SR piglet inoculum produced more butyrate and lactate than FF piglets. 
Overall, the substrate lacto-N-neotetraose (LNnT) produced the highest amount of SCFA followed by 
HMOs and short-chain fructooligosaccharides.233    
While in vitro studies to date have advanced our understanding of the effect various substrates 
have on SCFA production and on microbial composition, very little work has investigated this relationship 
in children. Investigators from the Institute of Food, Nutrition and Health in Zurich have used fecal 
microbiota from children in their in vitro experiments, with the primary focus of developing an intestinal 
model mimicking in vivo settings.234,235 Furthermore, only a few studies have compared the SCFA-





colleagues were unable to differentiate the fermentative capacity of fecal inoculates of obese adults from 
that of their lean counterparts. However, these researchers only tested one substrate (α-gluco-
oligosaccharide) against an inulin control.237 Another study using frozen fecal inoculates from 10 obese 
and 9 normal weight adults did report that the microbiota from obese patients produced higher 
propionate levels than microbiota from normal weight patients. All measurements in this study were 
taken at baseline and after a single 12-hour fermentation period.238 Aguirre and co-authors compared the 
differences in microbial growth and SCFA production in the TIM-2 proximal colon model between pooled 
fecal inoculates from lean (n=4) and obese (n=4) human donors using a variety of substrates.236  Although 
they were unable to conduct any statistical analyses due to their sample size after pooling the inoculum 
in the obese and lean groups, metabolite production was different between the obese and lean groups 
and was dependent on the type of substrate provided. SCFA production was lower in the lean pool 
compared to the obese pool for galacto-oligosaccharides and lactulose. In summary, current in vitro 
experiments have characterized the SCFA-producing capacity of fecal microbiota with various substrates 
mostly in human adults and infants as well as some animal models, but more work needs to be done in 
samples collected from children. Because SCFAs are intermediaries between the gut microbes and their 
host, further investigation into the genes responsible in these interactions is warranted. 
 
Mechanisms implicating gut microbiota in obesity 
 
Pathway 1: SCFA absorption by monocarboxylate transporters 
 
There are several mechanisms by which gut microbes have been postulated to effect host 
metabolism, which provide insight into the complexity of the interaction between the gut microbiota and 
its host. The first proposed mechanism is the use of SCFAs as substrate for several metabolic processes. 





propionate may be substrate for lipogenesis and gluconeogenesis.239,240 While the majority of SCFAs 
diffuse passively, there are several genes that code for transporters that aid in SCFA absorption in the 
colon including monocarboxylate transporter 1 (MCT1), sodium-coupled monocarboxylate transporter 1 
(SMCT1), monocarboxylate transporter 4 (MCT4), and monocarboxylate transporter 5 (MCT5). These 
proteins are coded for by the genes, SLC16A1, SLC5A8, SLC16A3, and SLC16A4 respectively in humans.241 
MCT1 is a proton-coupled transporter and is a member of the monocarboxylate transporter 
family, containing 14 members from which MCT1-4 have been reported to transport monocarboxylates.242 
SLC16A1 is expressed in many tissue types including brain, heart, liver, kidney, intestine, and adipose 
tissue.243 While MCT1 is involved in lactate transport in hypothalamic and adipose tissue, there is special 
interest in its function as a transporter of the SCFAs, in particular butyrate, across human colonocytes at 
the apical membrane.244 Enteropathogenic Escherichia coli (EPEC) infection inhibits butyrate uptake 
through MCT1.245 Several primary culture studies have highlighted the importance of SCFAs in the 
expression of SLC16A1, which is regulated through a signal cascade involving protein kinase C and many 
transcription factors (NF-κB, AP2, SP1, and USF).246,247 The SLC16A1 promoter is TATA-less and its 
expression is at least in part, regulated by its substrate, butyrate.248 MCT4 and MCT5 have also been 
investigated for their role of SCFAs transport into portal circulation.241 Both transporters have been shown 
to localize to the basolateral membrane through antibody immunoblotting and are most abundantly 
expressed in the distal colon.241 The polarity of the MCTs have also been demonstrated in other cell types 
including kidney-derived MDCK cells.249 
 
Genetic variants of SLC16A1 
Current data are limited in describing specific genetic variants of the SLC16A1 gene. Mct1 -/- mice 
are not viable, and Mct1 +/- mice demonstrate a unique haploinsufficient phenotype characterized by 





of the Mct1 haploinsufficient phenotype include reduced food intake, decreased nutrient absorption, and 
reduced fat mass.250 Cupeiro described the relationship between rs1049434 (A/T polymorphism at 1470 
position) in the SLC16A1 gene and lactate accumulation through high intensity circuit training.251 In their 
pilot study (n=10), individuals that carried the rs1049434 T allele appeared to have impaired lactate 
transport capability. Reduced capacity for lactate transport may influence an individual’s propensity to 
engage in physical activity and to continue this lifestyle throughout life. Learning more about this genetic 
polymorphism could aid in our understanding of individual responses to exercise. In addition, this 
polymorphism may also be involved in the ability of SLC16A1 to transport SCFAs in the distal gut. The 
SLC16A1-rs1049434 variant has also been shown to be a common within many populations including the 
Chinese individuals studied by Lean and Lee.252 Another SNP in the promoter region of the SLC16A1 gene, 
rs60844753 (G/C/T), resides in one of the many SP1 binding sites and could potentially alter the 
transcription of the gene. Identification of additional genetic polymorphisms key to the regulation and 
expression of the SLC16A1 provide further insight into the relationship between MCT1 and nutrient 
sensing in the gut. 
 
Pathway 2: SCFA signaling through the fatty acid receptors and the gut-brain axis 
There is evidence to support the idea that the gut microbiota may impact host physiology and 
metabolism beyond simply improving energy harvest. SCFAs may be important mediators of appetite 
regulation by binding receptors within the intestine and inducing the expression of gut hormones. SCFAs 
including acetate, propionate, butyrate and other short chain carbon molecules are ligands for free fatty 
acid receptors 3 and 2 (FFAR3 and FFAR2 respectively). These receptors are part of a once-orphaned family 
of G protein-coupled receptors (GPCR) which include FFAR1, FFAR3, FFAR2, and GPR42.253,254 Many 





variety of cell types. FFAR1 has been shown to be expressed in pancreatic islet cells that produce insulin, 
while FFAR2 and FFAR3 are both expressed in enteroendocrine L cells.255,256 FFAR2 is also expressed in 
immune cells and adipocytes, though the expression of FFAR3 in adipose remains inconclusive.253,254,257-260 
These receptors serve as potential links between the byproducts of non-digestible polysaccharides by gut 
microbes and appetite regulating pathways as FFARs are associated with leptin (LEP), peptide-YY (PYY), 
and proglucagon (GCG) expression.254,256,261-263  
Cellular response to SCFAs through FFARs depends on the location of the signal. In the intestine, 
release of gut hormones including PYY and glucagon-like peptide-1 (GLP-1), which are co-expressed in 
enteroendocrine L cells, are altered in a SCFA-dependent manner.263,264 PYY is an enteroendocrine cell-
derived hormone that inhibits pancreatic secretion, reduces gut mobility, and is thought to be a key 
anorexigenic signal between the gut and brain.265 Greenway et al. have shown that serum PYY levels 
increase with increased fiber intake.261 In a study conducted by Samuel and colleagues, PYY expression 
was altered through colonization of germ-free mice with B. thetaiotaiomicron and M. smithii. Mice 
expressing Gpr41 and colonized by these microbes had increased PYY levels compared to germ-free 
controls, but their Gpr41 deficient littermates did not show this increase in PYY.195 These results suggest 
that both the presence of gut microbes and the availability of Gpr41 are important factors that influence 
PYY levels in mice. Gpr41 deficient mice also had increased gut motility compared to colonized Gpr41 
expressing littermates. The effect of the Gpr41 genotype on intestinal transit rate was dependent on 
microbiota as this trend was not found in their germ-free counterparts. GLP-1 is a peptide hormone with 
many functions including the stimulation of insulin secretion (incretin function), inhibition of gut motility, 
and regulation of appetite.266 Tolhurst showed that acetate and propionate stimulated the secretion of 
GLP-1 in murine primary cultures.263 Both Ffar2 and Ffar3 knockouts showed reduction in GLP-1 secretion, 
though the effect was more pronounced in Ffar2 deficient primary mouse colonic cultures. They further 





mice. Lin et al. have suggested that SCFA stimulated secretion of gut hormones may also be through FFAR-
independent mechanisms.267 One of their key findings was that the inhibition of diet-induced weight gain 
by dietary propionate and butyrate supplementation was the same in Ffar3 knockout and wild-type mice. 
They did also show that Ffar3 knockout mice had a blunted GLP-1 response after butyrate administration.  
In adipose tissue, leptin secretion appears to be stimulated by propionate through FFAR2. Xiong 
initially reported that leptin production in murine adipocytes was the result of activation of Gpr41.254 
However, several reports since then have not been able to detect Gpr41 expression in adipocytes and 
have instead supported the FFAR2 mechanism underlying leptin response to SCFA.257,258,260 Both 
propionate and acetate also decrease other adipocyte metabolic activities such as lipolytic activity and 
regulation of plasma free fatty acid levels in murine Gpr43 knockouts.268 The majority of the original 
studies establishing the connection between FFARs, SCFAs, and appetite regulation were conducted in 
mouse models and cell culture experiments. Chambers and colleagues were the first to demonstrate that 
propionate administration in humans increased PYY and GLP-1 release and resulted in lowered energy 
intake in a weight loss intervention.269 Other mechanisms of action by FFARs in regulating energy 
homeostasis have also been proposed. Kimura showed that sympathetic activity in sympathetic chain 
ganglion was decreased, and an increase in heart rate through propionate administration was abolished 
in in Gpr41 -/- mice.270 Another report supports the notion that FFAR3 may act through the periportal 
afferent neural system to drive intestinal gluconeogenesis.271 Gpr41 -/- mice from a study conducted by 
Bellahcene and colleagues had increased body fat compared to wild type, which they attributed to 
decreases in energy expenditure.257 Although the cumulative data do not all agree, these reports highlight 







Genetic variants of FFAR3, FFAR2, and GPR42 
As seven transmembrane receptors, considerable attention has been given to the potential to 
produce pharmaceutical agents targeting the FFARs.272-274 Before progress on this front can be made, 
there are several challenges to overcome regarding the effect of genetic variants in the regulatory and 
coding regions of the FFARs. The current genomic map of the FFAR region in chromosome 19 was the 
result of a duplication event.275 The occurrence of functional FFAR1 and FFAR3 genes (formerly GPR40 and 
GPR41), followed immediately by a GPR40 remnant and proposed GPR42 pseudogene provides further 
evidence of the duplication and can be seen when comparing and aligning the genomic region in humans 
and other animal species.276 Pseudogenes are defined as dysfunctional relatives or copies of functional 
genes.277 Liaw and Connolly studied the six sequence polymorphisms in the coding region of FFAR3 and 
GPR42. They postulated that many individuals may express functional GPR42 depending on the allele at 
the missense variant, rs424241 (C/T polymorphism at R174W amino acid position). This site has been 
implicated as the position in which GPR42 lost its function due to an amino acid change from arginine to 
tryptophan.275 However, it is important to note that the genomic region upstream of FFAR1 was recently 
shown to exhibit bicistronic characteristics.278 This implies that FFAR3 is under the transcriptional 
regulation of the FFAR1 promoter but also suggests that the GPR40 remnant and GPR42 pseudogene 
would likely not be actively transcribed. Another study has indicated differences in methylation status of 
an 87 base pair region upstream of FFAR3 in obese and type 2 diabetic patients compared to lean 
controls.279 While this report sheds new light on potential regulation at the FFAR3 promoter region, it 








Pathway 3: SCFA signaling in the regulation of fatty acid storage 
Beyond activation of FFARs, SCFAs also play a role in fat regulation including storage and 
adipogenesis. Angiopoetin-like protein 4 (ANGPTL4) codes for a circulating peptide that inhibits the 
activity of lipoprotein lipase (LPL) and is expressed in many tissue types including adipose, liver, skeletal 
muscle, and intestine.280,281 ANGPTL4 is produced by enteroendocrine L cells of the GI tract.282 Evidence 
from Backhed and colleagues revealed that upon conventionalization of normal mice, Fiaf expression (the 
mouse analog of ANGPTL4) was suppressed in the intestinal epithelium.140 Decreased Fiaf expression led 
to an increased propensity to store fat in germ-free mice receiving microbiota from conventionally-raised 
mice. Oral administration of the probiotic, Lactobacillus paracasei, led to increases in fat accrual and 
circulating Fiaf in mice.283 Transcriptional regulation by peroxisome proliferator-activated receptor 
gamma (PPARG) and glucocorticoid receptor further implicates ANGPTL4 in lipid metabolism.282,284 A PPAR 
response element has been identified in the third intron of ANGPTL4.285 The role of ANGPTL4 in mediating 
host response to gut microbiota is strengthened by a report indicating that SCFAs induced ANGPTL4 
expression in human colon adenocarcinoma cells.286 In particular, butyrate was shown to induce the 
expression of ANGPTL4 in HT-29 cells independent of PPARG.287  
 
Genetic variants of ANGPTL4 
Genetic studies have identified SNP variants in the ANGPTL4 gene locus associated with 
cardiovascular disease risk including blood lipid levels, arterial malformations, and body composition.288-
291 The non-synonymous variant, rs116843064 (A/G polymorphism at E40K amino acid position) was 
associated with lower plasma triglycerides and higher HDL cholesterol in a Caucasian cohort.290 This 
genetic variant was also found to be critical in the activity of ANGPTL4 in suppressing LPL.292 Mikhak 
reported that the A allele of rs11672433 (G/A/C), a synonymous variant at the 389 amino acid position, 





allele was reported to be associated with high percent fat and WHR in adolescents of the HELENA study.288 
Furthermore, Legry demonstrated a gene-gene interaction between ANGPTL4-rs4076317 and PPARG-
rs1805192. GG homozygotes for ANGPTL4-rs4076317 and carriers of the PPARG-rs1805192 G allele had 
the highest WHR compared to the other genotype groups.  
 
Pathway 4: Gut microbial products and immunological responses in the host 
A close relationship exists between the gut microbiota and the host immune system through 
several gene-mediated mechanisms. Gut-associated lymph tissue (GALT) are present throughout the GI 
tract representing 70% of the total immune system and are localized in Peyer’s patches. Gut microbes are 
necessary for the proper development of the immune system within the gut, and germ free mice exhibit 
developmental defects in adaptive immunity.293 A concerted effort is made by the host to subdue the 
immune response to commensal microbiota in a process known as peripheral tolerance. An in-depth 
review of this mechanism that is carried out through the newly discovered peripheral T regulatory cells is 
summarized elswhere.294 In addition to the utilization of SCFAs substrates and signaling molecules, SCFAs 
may also relay immunoregulatory signals to the host. Several immune cell types express Gpr43, the mouse 
analog of FFAR2, and Gpr43 knockouts have difficulty in resolving inflammation.295 Butyrate has a known 
function as a histone deacetylase inhibitor and through this mechanism, reduces the expression of nuclear 
factor kappa beta (NFKB).296,297 Nf-KB is a transcription factor that is a master regulator of immune 
response including the promotion of pro-inflammatory cytokine expression. Gut microbes may influence 
inflammatory tone in visceral fat due to increased gut permeability allowing lipopolysaccharide (LPS) to 
translocate into the circulation.298,299 In mice given subcutaneous injections of LPS, increases in visceral 
and subcutaneous adipose tissue mass, expression of inflammatory factors, and clinical markers of 





by strengthening the intestinal barrier and suppressing NFKB expression.301,302 LPS is a component of the 
cell wall of gram negative bacteria and activates toll-like receptor 4 (TLR4).303 Activated TLR4 leads to an 
intracellular signal cascade, which induces the expression of NFKB and pro-inflammatory cytokines 
including interleukin 6 (IL6) and tumor necrosis factor alpha (TNFA).304  
 
Genetic variants of TLR4 
A body of evidence has accumulated associating several TLR4 SNPs and a variety of phenotypes 
including metabolic syndrome (MetS), T2DM, obesity, and fatty liver.305-308 A meta-analysis consisting of 
six studies investigated the association between two TLR4 missense SNPs, rs4986790 (A/G polymorphism 
at D229G amino acid position) and rs4986791 (C/T polymorphism at T399I amino acid position) and MetS 
T2DM.305 They demonstrated that the AG and GG genotype groups for rs4986790 were at decreased risk 
for T2DM and MetS (OR = 0.566, CI: 0.347-0.925). These missense variants were also previously reported 
to be associated with endotoxin hyporesponsiveness.309 TLR4-rs11536889 (G/C polymorphism at +3725 
position) is a SNP in the 3’ UTR that was investigated for its association with obesity-related metabolic 
phenotypes in Argentinian men.307 CC homozygotes for rs11536889 were protected from overweight and 
had elevated adiponectin levels compared to carriers of the G allele. The protective effect of the CC 
genotype was strongest in non-smoking individuals. The +3725C variant of rs11536889 was then cloned 
into a luciferase reporter system in HeLa cells. The resultant mutant UTR decreased luciferase expression 










In summary, there is strong evidence to suggest that host genetic and gut microbial factors 
contribute to the development of obesity in children. Emerging reports associating gut microbial 
composition with obesity in children have focused on BMI as the primary metric. Due to the adverse health 
implications of regional distributions of adiposity and in particular, visceral fat, there is a need to 
investigate the relationship between gut microbiota and more precise measurements of body 
composition. Fecal SCFA quantities have been shown to be associated with obesity in adult and child 
cohorts, but the difference in the SCFA-producing capacity of fecal inoculates from normal weight and 
obese children has not been adequately addressed. The mechanisms by which the gut microbiota is 
implicated in obesity are broad from transport of metabolic byproducts (SCFAs) of fermentation and 
signaling of appetite and fat storage, to inflammatory responses from microbial components including 
LPS. GRS constructed from SNPs identified by GWAS clearly demonstrate small but significant associations 
with BMI and related obesity phenotypes early in life. However, the majority of the missing heritability of 
obesity remains unaccounted for. There is a need to utilize a biologically-driven approach to identify 
functional and regulatory variants in host genes with known interaction with the gut microbiota. These 
genes may serve as mediators between the gut microbiota and its effect on adipose storage and their 










Chapter 2: Stratification by sex in preschool age children reveals differential associations between 
common fecal bacterial abundance and regional fat distribution: a cross-sectional pilot study  
Abstract 
Microbial dysbiosis is implicated in obesity in adults, but less in known about its association with 
childhood obesity. Herein, fecal microbiota, BMI and fat distribution were investigated in 4-7 year-old 
children to test the hypothesis that abundance of butyrate-producing bacteria is associated with 
overweight and obesity in children. RT-qPCR was conducted on fecal DNA for Clostridium cluster XIVa, 
Clostridium cluster IV, Lactobacillus spp., Bifidobacterium spp., Bacteroides-Prevotella group, 
Faecalibacterium prausnitzii, Roseburia intestinalis, and Eubacterium rectale. BMI was calculated from 
height and weight measures and percent body fat was measured by dual energy X-ray absorptiometry. 
Associations between bacterial abundance and obesity phenotypes were tested using t-tests, 
correlations, and regressions. Overweight (n=6) children harbored lower Clostridium cluster IV abundance 
compared to lean (n=12) (P = 0.03). Relationships between percent body fat and bacterial abundance 
were impacted by sex. In girls, Bifidobacterium spp. were negatively associated with trunk fat, while F. 
prausnitzii and R. intestinalis were negatively correlated with BMI. In boys, Clostridium cluster IV was 
positively correlated with both trunk and visceral fat (P < 0.05). These findings demonstrate associations 
between fecal bacterial composition and overweight in children. Gender-specific effects are apparent as 
early as 4-7 years-of-age, and DXA measurements provide insight into the relationship between bacterial 








Nearly one in three children in the United States is overweight.1 Central adiposity has been 
implicated in the adverse metabolic consequences of obesity, and these deleterious effects have been 
shown to be present in children.3,14,310-313 Over the past decade, changes in the abundance and 
composition of the gut microbiota has been implicated as a risk factor for obesity development.142,239,240,314 
Gnotobiotic mice inoculated with feces from human twin pairs that were discordant for obesity 
experienced greater adiposity gain when receiving microbiota from the obese twin compared to the lean 
twin.315 However, most studies in children have relied upon BMI as the primary metric for 
obesity.199,205,207,208 In a birth cohort of 300 Danish children, Bergstrom and colleagues studied the 
relationship between gut microbiota and body composition measured by dual energy X-ray 
absorptiometry (DXA) and bioelectrical impedance at age 3. This study did not detect any associations 
between bacterial quantities and fat mass, but regional distributions of at were not considered.173 There 
is a need to investigate the relationship between the bacterial abundance in the gut and regional depots 
of adiposity in the body as obesity develops in early childhood due to the adverse metabolic consequences 
of visceral adiposity.55,316 Recent evidence also indicates that the relationship between gut microbiota and 
obesity may be different by sex.208,317,318 
 One mechanism through which gut microbiota influences host metabolism is the fermentation of 
non-digestible polysaccharides to short chain fatty acids (SCFA). One SCFA, butyrate, is utilized by 
colonocytes as an energy source, but is not observed in high quantities in portal circulation and does not 
appear to contribute to energy harvest and storage beyond the colon.223,319 Butyrate improves intestinal 
barrier function, increases insulin sensitivity, and inhibits histone deacetylase.301,320 Additionally, butyrate 






The objective of this study was to determine fecal microbial profiles associated with obesity 
phenotypes in 4 to 7-year-old children, including measurements of total body fat and regional adipose 
distribution using DXA and to characterize these relationships by sex. Due to the protective effects of 
butyrate on adiposity, we hypothesized that butyrate-producing bacteria would be associated with 





Eighteen non-Hispanic White children (female n=8) recruited from the Synergistic Theory and 
Research on Obesity and Nutrition Group (STRONG) Kids cohort from the east-central Illinois area. 12 lean 
children (BMI percentile < 85th, reference group) and 6 overweight children (BMI percentile ≥ 85th, study 
group) were studied. The STRONG Kids Program is a 3-yr longitudinal, cross-disciplinary study designed to 
identify risk factors for excessive weight gain and obesity development in preschool-age children.19 
Written informed consent was provided by the parents and assent was given from the child before data 
were collected. This study received approval from the Institutional Review Board at the University of 
Illinois. Children given antibiotic treatment within 14 days of stool collection were excluded. Dietary 
information on yogurt consumption and breastfeeding (BF) duration was obtained from the parents of 
the study participants. 
 
DXA and anthropometric measurements 
Height and weight were measured by trained researchers according to established training 
protocols from the Centers for Disease Control (CDC).324 Standing height was measured to the nearest 0.1 





digital scale (HealthOmeter, Model 349KLX, Jarden Consumer Solutions, Boca Raton, FL) to the nearest 
0.1 kg with participants wearing light clothing. Height and weight were used to calculate BMI and BMIPCT 
(BMI percentile for age.325 Body composition was measured by DXA (1-1.5% precision) using a Hologic 
QDR 4500A bone densitometer (Bedford, MA). Children were required to fast for 8 h prior to 
measurement, not wear any garments containing metal, and lay still for 2-3 min during the scan. Body 
composition measurements including whole body fat percent (WBPFAT), trunk percent fat (TRUNKPFAT), 
percent visceral adipose tissue (VATPFAT), percent subcutaneous adipose tissue in abdomen 
(SUBABPFAT), android percent fat (ANDPFAT), and gynoid percent fat (GYNPFAT) were obtained using 
Hologic software (version 13.4.2). VATPFAT was estimated by subtracting subcutaneous fat ring from total 
fat measured in the abdomen.38 SUBABPFAT was calculated by dividing subcutaneous fat mass by total 
fat mass in the abdomen and multiplying by 100. 
 
Stool sample collection and DNA extraction 
Freshly-voided stool samples were collected at home by parents using a stool collection 
commode. Stool samples were stored in home freezers (<1day) and were transported to the laboratory 
using nylon coolers containing frozen gel packs. The samples were stored at -20ᵒC until genomic DNA was 
extracted from 200 mg (wet weight) of stool using a commercial kit (QIAamp DNA Stool Mini Kit; Qiagen) 
following an established protocol using a bead-beating step (30 s at 30 Hz, 3-times).326 The quality of DNA 
was evaluated by Nanodrop 2000 (Wilmington, DE) and PCR using universal bacteria primers.  
 
Real-time quantitative PCR (qPCR) 
The primer sequences and annealing temperatures used to enumerate the quantities of fecal 





performed using the 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA). All PCR 
experiments were done in triplicate with a reaction volume of 10 µl. Each reaction contained 5 µl of 2 × 
Power SYBR Green PCR Master mix (Applied Biosystems), 1 µl BSA at 1 mg/ml, 0.5 µM of each primer, and 
10 ng of template DNA. The cycling conditions were 50°C for 2 min, 95°C for 10 min, followed by 40 cycles 
of 95°C for 15 s, primer-specific annealing temperature for 20 s and 72°C for 45 s. Following amplification, 
a dissociation step was included to analyze the melting profile of the amplified products. Standard curves 
(101–108 16S rRNA gene copies per reaction) were generated using purified 2.1 TOPO-TA plasmids or pMA-
T plasmids (Life Technologies) containing the 16S rRNA gene for Eubacterium hallii 27751 (Clostridium 
cluster XIVa), Clostridium leptum 29065 (Clostridium cluster IV), Bacteroides fragilis 25285 (Bacteroides-
Prevotella group), Lactobacillus rhamnosus 53103 (Lactobacillus spp.), Bifidobacterium longum 15707 
(Bifidobacterium spp.), F. prausnitzii, R. intestinalis, and E. rectale. 327-333 Data were processed with SDS 




Statistical analysis was performed with SAS 9.4 (SAS Institute, Cary, NC) and associations between 
abundance of bacteria and obesity phenotypes were tested using t-test, Kruskal-Wallis, Spearman 
correlation and stepwise regression. Relationships between percent body fat measurements and age were 
analyzed by linear regression. Pairwise comparisons were adjusted for multiple testing with Tukey-Kramer 
in the general linear model. All microbial values were analyzed after log transformation (per g wet feces). 
Duration of BF and frequency of yogurt consumption were tested as binary covariates in the associations 
between bacterial abundance and obesity phenotypes. Children were classified as either BF for less than 
six months (BF = 0) or greater than six months (BF = 1), according to the American Academy of Pediatrics 





14 days. Children consuming one or more servings of yogurt per week were considered frequent 
consumers and those consuming less than one serving per week were considered infrequent consumers. 
This categorization was in accordance to recent NHANES data on the frequency of yogurt consumption in 
children in the United States.335 Correlations between microbial abundance and BMI, WBPFAT, 
TRUNKPFAT, VATPFAT, SUBABPFAT, ANDPFAT, and GYNPFAT included BF, frequency of yogurt 
consumption, age, and sex as covariates. Correlations between microbial abundance and BMIPCT included 




 Overweight children had significantly higher BMI, BMIPCT, WBPFAT, TRUNKPFAT, VATPFAT, 
SUBABPFAT, ANDPFAT and GYNPFAT when compared to their lean counterparts (Table 2.1). Overweight 
children also had higher VATPFAT, but not SUBABPFAT compared to lean children. Additionally, 
descriptive data of the 18 participants are presented in supplemental Table N.1 (Table N.1). 
 Boys and girls did not differ in age, weight, height, BMI, BMIPCT or any of the microbial 
measurements. However, significant differences in WBPFAT, TRUNKPFAT, VATPFAT, SUBABPFAT, 
ANDPFAT and GYNPFAT between the sexes were observed (Table N.1). While percent body fat decreased 
in boys with age, this relationship was not observed in girls (P < 0.05, Figure 2.1). BMI did not correlate 
with any of the percent body fat measurements in boys, while TRUNKPFAT and GYNPFAT were correlated 
with BMI in girls (Table N.2). BF duration and frequency of yogurt consumption were evaluated 
independently for their association with both obesity measurements and fecal bacterial quantities. While 
BF duration was not associated with any of the measurements, frequent yogurt consumers had higher 





 Clostridium cluster IV quantities were positively correlated with both Clostridium cluster XIVa and 
Bifidobacterium spp. (r = 0.93, P < 0.0001; r = 0.56, P = 0.04). Additionally, Lactobacillus and Bacteroides-
Prevotella quantities were positively correlated (r = 0.53, P = 0.05). Microbial data (copy number g-1 feces) 
are presented in Table 2.2. Clostridium cluster IV levels were lower in overweight children (study group) 
compared to their lean counterparts (reference group) (P = 0.03). Clostridium cluster IV was negatively 
associated with BMI by stepwise regression (R2 = -0.38, P = 0.04) (Figure 2.2A). The abundance of F. 
prausnitzii was negatively associated with BMI and BMIPCT (R2 = -0.33, P = 0.01; R2 = -0.27, P = 0.02 
respectively) (Figure 2.2B). Although not statistically significant, R. intestinalis showed a negative trend 
with GYNPFAT (r = -0.52, P = 0.12). No other associations were found between other obesity phenotypes 
and microbial levels when the entire cohort was analyzed. 
Further analyses revealed differential relationships between obesity phenotypes and bacterial 
levels when stratifying by sex (Table 2.3 and Table 2.4). In boys, Clostridium cluster IV abundance was 
positively correlated with TRUNKPFAT, WBPFAT, ANDPFAT and VATPFAT (P = 0.008, P = 0.04, P = 0.03, and 
P = 0.05), while TRUNKPFAT correlated positively with Clostridium cluster XIVa abundance (P = 0.05). In 
girls, several negative correlations were observed between obesity measurements and bacterial 
abundance including Clostridium cluster XIVa with BMIPCT (P = 0.03), Bifidobacterium spp. with 
TRUNKPFAT (P = 0.02), F. prausnitzii with TRUNKPFAT (P = 0.02), E. rectale with WBPFAT (P = 0.05), and R. 
intestinalis with both BMI and ANDPFAT (P = 0.03 and P = 0.03). Neither Lactobacillus spp. nor the 
Bacteroides-Prevotella group correlated with obesity phenotypes. When duration of BF and frequency of 
yogurt consumption were excluded from the analyses, the majority of the relationships observed 









 The objective of this study was to investigate the relationship between the abundance of key 
constituents of the gut microbiota and obesity in children using more precise measurements of regional 
adiposity compared to weight or BMI. The data not only demonstrate differences in bacterial abundance 
between lean (reference group) and overweight (study group) children, but also show differential 
relationships between microbial abundance and regional adiposity by sex. 
 In accordance to our hypothesis, we observed a negative relationship between both Clostridium 
cluster IV and F. prausnitzii abundance and BMI. Results from previous studies have been mixed with 
nutritional status, diet, sex, and even ethnicity appearing to influence the effect of F. prausnitzii on 
obesity.207,318,336,337 Specific butyrate producing members of Clostridium clusters IV and XIVa (i.e. F. 
prausnitzii) have an important role in promoting gut health, and our data along with previous findings 
support the notion that butyrate-producing bacteria may be protective against obesity and related 
metabolic disorders.338,339 Gut microbes may influence inflammatory tone in visceral fat due to increased 
gut permeability allowing lipopolysaccharide (LPS) to translocate into the circulation.298,299 In mice given 
subcutaneous injections of LPS, increases in visceral and subcutaneous adipose tissue mass, expression of 
inflammatory factors, and clinical markers of diabetes were observed.300 Butyrate could mediate 
metabolic disease progression through this pathway by strengthening the intestinal barrier and 
suppressing nuclear factor-ᴋB expression.301 In vitro, butyrate treatment altered expression of several 
genes involved in lipid metabolism including angiopoietin-like protein 4, a known inhibitor of lipoprotein 
lipase.340 The current body of work highlights the need to directly measure colonic butyrate or the 
butyrate-producing capacity of the gut microbiota to better understand the underlying mechanisms by 
which butyrate influences host adiposity.  
 Correlations were observed between obesity phenotypes, including percent body fat by DXA and 





differences in the relationship between regional fat and BMI by sex could be contributing to our results. 
For example, the positive correlation between VATPFAT and Clostridium cluster IV in boys and the 
negative relationships between several of the bacterial quantities and obesity measures in girls indicate 
the possibility of this occurring within our dataset. Some differences in fecal microbial quantities between 
males and females have been noted in previous work, but differences were not detected in the present 
study. Instead, the association of specific bacterial quantities on measures of obesity by sex in children 
were observed, which only a few others have shown.208,318 The mechanism by which sex could mediate 
the effect of gut microbiota on the host is not well established and is an important consideration in future 
studies.  
 Differences in body composition and fat deposition were apparent amongst boys and girls aged 
4-7 years. Adiposity rebound is classically defined as the rebound in BMI after it reaches a nadir between 
the ages of 3 to 7, and children with early rebound (<5 years) are thought to be at higher risk for obesity.24 
The observed weight and BMI increase during this time are primarily due to increases in fat mass in girls 
and fat free mass in boys.341 BMI may not be the strongest indicator of adiposity as our data and others 
have indicated that percent body fat is not as strongly correlated with BMI in boys as it is in girls.28 
Differences in body composition between males and females, which begin as early as the first 6 months 
of life, will be important to consider in future gut microbiota-obesity studies using specific measurements 
of adiposity in this age group.27 
 Bifidobacterium spp. predominate the infant gut microbiota and remain important members of 
the gut microbiota in children.161-163,342 Our observation that Bifidobacterium spp. levels were negatively 
correlated with TRUNKPFAT in girls is consistent with previous reports in children and pregnant 
women.199,343 Bifidobacterium spp. also confer beneficial effects in the host, including immune 
development, metabolism of complex carbohydrates and iron, provision of vitamins, and protection 





report from Delzenne (2007) showed that the probiotic treatment with Bifidobacterium spp. in mice fed 
a high-fat diet to induce endotoxemia improved indicators of type 2 diabetes, including glucose tolerance, 
insulin secretion, and inflammatory state.349 Taken together, these data suggest that targeting 
Bifidobacterium spp. may be a strategy in the management of adiposity.350  
 Diet plays a significant role in gut microbial composition. During the first two years of life, the 
establishment of the gut microbiota is influenced by mode of feeding.351 BF has been shown to have 
protective effects against obesity.167 Previous work has indicated changes in body composition and 
decreases in fat mass through pre- and probiotic interventions in adults.352-354 BF and frequency of yogurt 
consumption were analyzed as covariates in this study, but the observed relationships remained 
consistent when these covariates were excluded from the model. We recognize that there is an inherent 
limitation to absolute quantification by the 16s rRNA gene as the copy number varies considerably, 
particularly for Bifidobacterium spp.355 Because antibiotic use was not recorded beyond 14 days prior to 
collection of the stool samples, we cannot rule out the possibility that this may have impacted the 
bacterial quantification. Indeed, early antibiotic exposure during infancy has been suggested to be a risk 
factor for child obesity through mechanisms likely involving the gut microbiota.172,356,357 This presents 
challenges for gut microbiome research in children as the pediatric population in the U.S. is estimated to 
be exposed to 10 antibiotic treatments by the age of 10, and these past exposures may have long-term 
consequences on the microbiome.168 When possible, future studies should request more specific 












In summary, the current study represents a unique approach in investigating the relationship 
between gut microbiota and obesity development in children by using DXA. The findings demonstrate that 
abundance of common bacterial genera and species were associated with BMI, and that distinct bacterial 
types were correlated with whole body and regional measurements of adiposity when stratifying by sex. 
Our report strengthens the accumulating evidence supporting the notion that the gut microbiota may be 
modifiable for the maintenance of health and prevention of early-onset obesity. 
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Table 2.1 Anthropometric and DXA differences of lean and overweight children in the STRONG Kids 
ORB cohort 





AGE (months) 72.4 ± 10.9 61.2 ± 10.0 45.0 – 88.0 
WEIGHT (kg) 22.1 ± 3.4 23.2 ± 4.9 15.9 – 31.9 
HEIGHT (cm) 118.4 ± 7.5 113.6 ± 10.7 99.0 – 132.5 
BMI (kg/m2)C 15.7 ± 1.2 17.8 ± 0.8 13.4 – 18.6 
BMIPCTB 55.6 ± 28.3 91.9 ± 4.6 1.1 – 97.6 
ANDPFATB 23.7 ± 5.9 32.8 ± 4.8 15.9 – 41.4 
VATPFATA 18.0 ± 5.1 26.0 ± 6.0 10.4 – 37.9 
GYNPFATA 35.4 ± 5.8 42.3 ± 4.0 28.2 – 47.5 
SUBABPFAT 6.2 ± 3.0 7.2 ± 2.0 2.8 – 10.4 
TRUNKPFATB 18.0 ± 4.2 25.7 ± 4.2 11.9 – 32.3 
WBPFATB 23.9 ± 4.7 31.3 ± 4.1 17.8 – 37.6 
Data are expressed as Mean ± SD. Abbreviations: BMI: body mass index, BMIPCT: BMI percentile, 
ANDPFAT: android percent fat, VATPFAT: percent visceral adipose tissue, GYNPFAT: gynoid percent fat, 
SUBABPFAT: percent subcutaneous adipose tissue in abdomen, TRUNKPFAT: trunk percent fat, WBPFAT: 
whole body percent fat. Superscripts represent significant p-values:  A (P < 0.05), B (P < 0.01), C (P < 0.001), 














Clostridium cluster XIVa¥ 10.5 ± 0.4 9.7 ± 0.9 
Clostridium cluster IVA,¥ 10.6 ± 0.3 9.9 ± 0.6 
Lactobacillus spp. 6.9 ± 0.3 6.9 ± 0.2 
Bifidobacterium spp.¥ 10.3 ± 0.4 9.1 ± 1.5 
Bacteriodes-Prevotella group 11.6 ± 0.2 11.5 ± 0.2 
Faecalibacterium prausnitzii 9.9 ± 1.0 8.9 ± 1.3 
Eubacterium rectale* 11.6 ± 1.2 11.1 ± 1.5 
Roseburia intestinalis* 8.6 ± 1.2 7.7 ± 1.8 
Data are expressed as Mean ± SD. Superscripts represent significant P-values:  A (P < 0.05) for Student’s t-
test and ¥ (P < 0.05) and £ (P < 0.01) for Krukal-Wallis Test. 





Table 2.3 Correlations between obesity phenotypes and bacterial abundance by sex 
Age, breastfeeding, and frequency of yogurt consumption included as partial covariates 
Superscripts represent significant P-values:  A (P < 0.05), B (P < 0.01) (Spearman correlation). Abbreviations: 
BMI: body mass index, BMIPCT: BMI percentile, ANDPFAT: android percent fat, VATPFAT: percent visceral 
adipose tissue, GYNPFAT: gynoid percent fat, SUBABPFAT: percent subcutaneous adipose tissue in 



















 Boys Girls Boys Girls Boys Girls Boys Girls Boys Girls 
BMI -0.23 -0.77 0.02 -0.73 0.35 -0.75 -0.38 0.10 -0.01 -0.44 
BMIPCT -0.25 -0.80A -0.03 -0.69 0.25 -0.75 -0.30 0.25 -0.02 -0.29 
ANDPFAT 0.70 -0.20 0.80A -0.23 -0.02 -0.38 -0.32 0.61 0.39 -0.30 
VATPFAT 0.66 -0.36 0.75A -0.41 -0.07 -0.34 -0.22 0.72 0.52 -0.53 
GYNPFAT 0.48 -0.29 0.58 -0.19 -0.25 -0.49 -0.32 0.00 0.39 -0.73 
SUBABPFAT 0.26 -0.67 0.31 -0.71 0.26 -0.09 0.51 0.22 0.36 -0.28 
TRUNKPFAT 0.72A -0.61 0.90B -0.76 0.08 -0.75 -0.17 -0.35 0.41 -0.68 





Table 2.4 Correlations between obesity phenotypes and bacterial species abundance by sex 
  Faecalibacterium 
prausnitzii 
Eubacterium rectale* Roseburia 
intestinalis* 
 Boys Girls Boys Girls Boys Girls 
BMI -0.45 -0.86A -0.23 -0.76 0.59 -0.99A 
BMIPCT -0.44 -0.86 0.69 -0.77 0.45 -0.82 
ANDPFAT 0.18 -0.21 0.25 -0.37 -0.26 -0.99A 
VATPFAT 0.05 -0.34 0.25 -0.33 -0.26 -0.97 
GYNPFAT -0.20 -0.40 0.19 -0.91 -0.43 -0.94 
SUBABPFAT 0.33 -0.58 0.25 0.25 0.02 0.52 
TRUNKPFAT 0.22 -0.93A 0.23 -0.89 -0.35 -0.94 
WBPFAT 0.06 -0.56 0.18 -0.95A -0.35 -0.74 
Age, breastfeeding, and frequency of yogurt consumption included as partial covariates 
Superscripts represent significant P-values:  A (P < 0.05) (Spearman correlation). Abbreviations: BMI: body 
mass index, BMIPCT: BMI percentile, ANDPFAT: android percent fat, VATPFAT: percent visceral adipose 
tissue, GYNPFAT: gynoid percent fat, SUBABPFAT: percent subcutaneous adipose tissue in abdomen, 
TRUNKPFAT: trunk percent fat, WBPFAT: whole body percent fat. 





































Percent body fat measurements were negatively associated with age in boys and no relationship was 
observed in girls. A) Whole body percent fat (WBPFAT) by age (R2 = 0.03, P = 0.70 in girls; R2 = 0.53, P = 
0.02 in boys). B) Trunk percent body fat (TRUNKPFAT) by age (R2 = 0.001, P = 0.95 in girls; R2 = 0.45, P = 
0.04 in boys). The trunk consists of the chest, abdomen, and pelvis. C) Percent visceral adipose tissue 
(VATPFAT) by age (R2 = 0.07, P = 0.26 in girls; R2 = 0.51, P = 0.01 in boys). All percent fat measurements 
were determined by DXA. Circles represent female children and triangles represent male children. Solid 


















Using stepwise regression, Clostridium cluster IV (panel A) and F. prausnitzii (panel B) levels were 
negatively associated with BMI. Clostridium cluster IV and F. prausnitzii were measured in copy number/g 
feces. Sex was the only covariate to reach significance in the models (R2 = -0.38, P = 0.04 and R2 = -0.30, P 






Chapter 3: In vitro quantification of SCFA-producing capacity of fecal inoculates from preschool 
age children demonstrates importance of dietary fiber intake in SCFA production and composition 
Abstract 
 
The gut microbiome is thought to be a contributor to host metabolism through the production of 
SCFAs from non-digestible polysaccharides. Although current work in the gut microbiome and childhood 
obesity have demonstrated ties between the gut microbial composition and fecal SCFA quantities and 
BMI, less is known about the metabolic capacity of fecal microbiome from preschool age children. The 
primary aim of this study was to further characterize the gut microbiome-host relationship by conducting 
an in vitro experiment to measure the SCFA-production of fecal inoculates from preschool age children. 
Fresh stool samples were collected and processed within 45 minutes of defecation (n = 6, female = 2) and 
were used to inoculate media containing inulin Orafti HP substrate. Fermentation was conducted and 
SCFA quantities including acetate, propionate, and butyrate were measured at 0 and 12 hours by gas 
chromatography. Dietary fiber intake was assessed with 24-hour recall and whole body fat was measured 
with DXA. Dichotomous groups were established based on high and low total fiber intake and whole body 
fat separated by the median. Differences in SCFA quantities were tested using Kruskal-Wallis for 
nonparametric data and T-test. Children in the high body fat group produced more acetate and total SCFAs 
than children in the low body fat group (1.591 v. 3.775 mmol/g feces, P = 0.0495; 2.926 v. 5.541 mmol/g 
feces, P = 0.0495 respectively). Children consuming high total fiber had higher butyrate production 
compared to those consuming low total fiber (0.417 v. 1.615 mmol/g feces, P = 0.0495). Propionate as a 
percent of total SCFAs was lower in all fermentation experiments. Within the low total fiber group, there 
was a significant increase in acetate as a percent of the total from 0 to 12 hours (30.9% ± 10.4 v. 68.0% ± 
8.2, P = 0.0439). Current and past dietary exposures may play a role in SCFA production of the gut 
microbiome. Further analysis of the microbiome by sequencing will increase our understanding of the 








While childhood obesity remains a chief health concern in the United States, recent studies in gut 
microbiome research have made strides in unraveling the complex etiology driving excess adiposity in 
children. Initial studies have revealed an intriguing relationship between the composition of gut 
microbiome and obesity, and fecal microbial composition has been associated with obesity in a range of 
mutli-ethnic cohorts in children.142,201,239,240,314,315 Because BMI has been used as the primary metric to 
assess obesity, the relationship between the gut microbiome and regional adipose depots remains 
unclear. Furthermore, diet has a significant role in shaping the composition of the gut microbiome185,189, 
and dietary intake has not been consistently addressed in studies in children. Much of the early work in 
gut microbiome research focused on microbial composition, and the field is shifting to metagenomic and 
metabolomic approaches to gain an understanding of the functional significance of the gut microbiome 
in obesity development.147 
One of primary the metabolic contributions of the gut microbiome is the production of short chain 
fatty acids (SCFAs) through the fermentation of non-digestible polysaccharides. It is estimated that 95% 
of the SCFA produced by the gut microbiome will be absorbed by the host, which may contribute ~6-10% 
of the total caloric needs of an adult.216 Extensive work has also established SCFAs as key signaling 
molecules within the host affecting a range of physiological function from appetite and satiety to adipose 
storage and lipogenesis.140,260-263,267,283 Studies examining fecal SCFA quantities have suggested several 
relationships with measures of obesity, 197,224,225 but only a limited number of studies have been conducted 
in children. Payne found that fecal quantities of propionate and butyrate were higher in obese compared 
to normal weight children, but the results from Murugesan and colleagues opposed these findings.207,213 





obese group of their study. Fecal SCFA quantification is limited as it only provides a snapshot of the host-
microbe interaction, and it is difficult to determine whether the elevated levels of SCFAs observed in fecal 
samples are the result of the increased fermentative capacity of gut microbiota from overweight 
individuals or an indication of reduced absorption by the host.  
The advantage of an in vitro fermentation model is the ability to accurately quantify the metabolic 
capacity of the gut microbiome to ferment SCFAs over a specified time course. Several in vitro studies 
have advanced our understanding of the effect of various substrates on SCFA production and on microbial 
composition, 226-228,230,231,238,358 but only a few studies have compared the SCFA-producing capacity of fecal 
microbiota from obese versus normal weight individuals. While Yang reported higher propionate 
production in obese patients than normal weight patients, Sarbini and colleagues were unable to 
differentiate the fermentative capacity of fecal inoculates of obese adults from that of their lean 
counterparts.237 One of the limitations of the former study was the use of frozen stool samples as 
inoculates.238 A recent study by Aguirre and co-authors used the TIM-2 proximal colon model to evaluate 
the differences in microbial growth and SCFA production between pooled fecal inoculates from lean (n = 
4) and obese (n = 4) human donors using a variety of substrates.236 Although statistical analyses were not 
conducted, the numerical quantity of SCFA production was lower in the lean pool compared to the obese 
pool for galacto-oligosaccharide and lactulose. Data collected for in vitro studies in children are even more 
limited. Investigators from the Institute of Food, Nutrition and Health in Zurich used fecal microbiota from 
one obese and one normal weight child in their in vitro experiments, with the primary focus of developing 
an intestinal model mimicking in vivo settings.234,235 Total SCFAs, particularly acetate and butyrate, 
increased due to a high energy nutrient load compared to lower nutrient loads regardless of donor.234 
Insofar, there is a paucity of data on obesity in in vitro models and children have been 
understudied. The overall goals of the present study were to strengthen the current body of work in 





fecal microbiome and regional distributions of adiposity with consideration of dietary intake, by 2) 
assessing differences in metabolic capacity of fecal inoculates to produce SCFAs in children of low and 
high total body fat, and by 3) establishing the association between gases in exhaled breath and fecal 
microbiome of preschool age children. Body composition was assessed by dual energy X-ray 
absorptiometry (DXA), which seldom has been used in microbiome research to date.173 Based on our 
previous findings (Chapter 2) and the current literature, we hypothesized that both the specific type and 
overall amount of SCFA produced in vitro would be different amongst children with low and high total 
body fat. Butyrate production was postulated to contribute a protective effect against obesity, and overall 





Study participants and body composition measurements 
 Preschool age children (2-5 yrs., n=19, female=7) were recruited from the Central Illinois area 
daycare centers. Height and weight were measured by trained researchers according to established 
training protocols from the Centers for Disease Control.324 Standing height was measured to the nearest 
0.1 cm with a portable stadiometer (Seca, Model 242, Hanover, MD). Body weight was measured using a 
digital scale (HealthOmeter, Model 349KLX, Jarden Consumer Solutions, Boca Raton, FL) to the nearest 
0.1 kg with participants wearing light clothing. Height and weight were used to calculate BMI and BMI 
percentile (BMIPCT). Body composition was measured by dual energy X-ray absorptiometry (DXA) at a 
precision level of 1-1.5% using a Hologic QDR 4500A bone densitometer (Bedford, MA). Children were 
required to fast for 8 h prior to measurement, not wear any garments containing metal, and lay still for 2-





region 1 percent fat (REG1PFAT), trunk percent fat (TRUNKPFAT), percent visceral adipose tissue 
(VATPFAT), android percent fat (ANDPFAT), and gynoid percent fat (GYNPFAT) were obtained using 
Hologic software (version 13.4.2). VATPFAT was estimated by subtracting subcutaneous fat ring from total 
fat measured in the abdomen.38 REG1PFAT is defined by the region of the body between L1 and L4 of the 
spine and has been used previously to describe central adiposity.359  
 
Survey data and dietary assessment 
 Parents of the child participants were asked to fill out a brief survey to obtain information on 
known factors affecting the gut microbiota including past nutritional (breastfeeding duration) and 
antibiotic exposure as well as mode of delivery at birth. Children were classified as either breastfed (BF) 
for less than six months (BF = 0) or greater than six months (BF = 1), according to the American Academy 
of Pediatrics recommendation.334 Children were not administered antibiotics at least one month prior to 
stool collection. Mode of delivery was converted into a dichotomous variable where children delivered by 
cesarean section were given the value 0 and children delivered vaginally were given the value 1.   
Multiple-pass 24-hour dietary recalls were conducted with the parents at the initial visit (n=19) 
and again for the day prior to the in vitro experiment in a subset of children (n=6). The recall process 
included a quick list of all food and beverage intake for the past 24 hours taken without interruption 
followed by a forgotten foods list of food categories commonly overlooked in the quick recall stage. Next, 
the dietary recall was supplemented with time and occasion of each intake for the day. To improve the 
accuracy of the list, the recall interviewer went through a detail cycle to determine amounts and 
descriptions of all food items. Lastly, the interviewer conducted a final review probe to ensure all foods 
were accounted for. All data obtained through the 24-hour recall were entered into the 2014 Nutrition 





total energy (kilocalories), total carbohydrates (g), total protein (g), total fat (g), total dietary fiber (g), 
soluble fiber (g) and insoluble fiber (g) were extracted from NDSR for statistical analysis. 
 
Breath and stool sample collection 
Breath samples were obtained from study participants following a protocol adapted for preschool 
age children described elsewhere (Appendix D).360 Breath samples were collected using the GaSampler™ 
kit and 20 mL of the sample was measured with the BreathAnalyzer SC instrument in duplicate in parts 
per million (ppm) for methane (CH4) and hydrogen (H2) and as a percent of total gas for carbon dioxide 
(CO2) (QuinTron, Milwaukee, WI, USA). Stool samples were collected on two separate occasions to 
establish the normal fecal microbiome (n = 19) and to provide inoculum for the in vitro experiment (n = 
6). For the first sample, freshly-voided stool was collected at home by the parent using a stool collection 
commode. Stool samples were stored in home freezers (<1 day) and were transported to the laboratory 
using nylon coolers containing frozen gel packs. The samples were stored at -80ᵒC in the laboratory.  
For the second sample, freshly-voided stool was collected within a 6-hour time period based on 
the viability of the growth media for the in vitro portion of the study. Parents were instructed to collect a 
fresh bowel movement from their child at home using a stool collection commode and transfer the sample 
using a sterile spoon into a sterile 50 ml conical tube. Next, the sample tube was placed into the GasPak™ 
EZ Anaerobe Pouch System (Becton, Dickinson, and Company, Franklin Lakes, NJ, USA) and the bag was 
sealed after pressing out any excess air. The sample bag was placed into a 20 oz. thermos container filled 
with hot tap water and the container was closed. Parents were asked to contact research personnel for 
immediate sample retrieval. All samples were collected and transported to the research facility within 45 
minutes of defecation. 





 The fermentation of fecal inoculates was performed following the protocol established by 
Bourquin.361 Briefly, fresh 0.3 g of fresh stool was used to inoculate a control media and experimental 
media containing inulin Orafti HP (Beneo, Morris Plains, NJ, USA) substrate in triplicate. Fermentations 
were performed separately for each child donor, and SCFA concentrations were measured at initial (0 
hours) and at final (12 hours) using gas chromatography. SCFA quantities were reported in ug/g DMB.  
 
DNA extraction and bacterial quantification  
Genomic DNA was extracted from 200 mg (wet weight) of stool using a commercial kit (QIAamp 
DNA Stool Mini Kit; Qiagen) following an established protocol using a bead-beating step (30 s at 30 Hz, 3-
times).326 The quality of DNA was evaluated by Nanodrop 2000 (Wilmington, DE) and PCR using universal 
bacteria primers. Real-time quantitative PCR was performed using the 7900HT Fast Real-Time PCR System 
(Applied Biosystems, Foster City, CA) for genera and species of bacteria (Appendix I.1) following a protocol 
described previously (see Methods for Ch. 2). Bacterial quantities were log transformed and are expressed 
as number of 16S rRNA gene copies g-1 feces (wet weight). 
 
Statistical analysis 
 Statistical analyses were performed in SAS 9.4 (SAS Institute, Cary, NC, USA). Variables for gas 
from exhaled breath, dietary composition, bacterial abundance and body composition were dichotomized 
by the median. Study participants were also grouped by BMIPCT with children between the 5th and the 
85th percentile categorized as normal weight (n = 11) and children at or above the 85th percentile 
categorized as overweight (n = 7). Associations between gas from exhaled breath, dietary composition, 
bacterial abundance and body composition were evaluated using the nonparametric Kruskal-Wallis test 
and Fisher’s exact test. Mode of delivery, breastfeeding duration, and sex were independently tested for 





between bacterial abundance and body composition were assessed using t-test, Spearman correlation, 
and linear regression. Age, sex, and total dietary fiber intake were included as covariates in the correlation 
and regression analyses. For the in vitro study, a subset of children (n = 6, female = 2) were categorized 
into two groups based on WBPFAT (low WBPFAT n = 3, high WBPFAT n = 3) and total dietary fiber intake 
(low TOTFIBER n = 3, high TOTFIBER n= 3). Differences in SCFA quantities amongst the in vitro experiment 
groups at baseline and at 12 hours of fermentation were determined using Kruskal-Wallis. The absolute 
quantity of SCFA values at baseline and at final (SCFAi and SCFAf) were included in the analyses as well as 
each SCFA as a percent of the total (SCFAPCTi and SCFAPCTf), and the change in quantity from baseline to 
final (ΔSCFA). Within group changes in SCFAPCT were evaluating using t-test. Statistical significance was 
set at P < 0.05, and pairwise comparisons were adjusted for multiple testing with Tukey-Kramer in the 




 Descriptive data of the 19 (female = 8) child participants are presented in Supplemental Table O.1 
(Table O.1). Overweight children had significantly higher BMI and BMIPCT compared to normal weight 
children; however, this was not observed for the percent body fat measurements. Additionally, there were 
no significant differences in body composition by mode of delivery, by breastfeeding duration, or by sex. 
Clostridium cluster IV and XIVa were higher in children delivered by cesarean section compared to those 
delivered vaginally (P < 0.05). 
Dietary data and differences in dietary components by sex and overweight status are presented 
in Supplemental Table O.2 (Table O.2). Girls consumed less total protein than boys (P = 0.005), but the 
percent of total calories from protein did not differ by sex. Overweight children consumed more total 





carbohydrate or total dietary fiber as a percent of total calories by overweight status. No other differences 
in body composition were observed by dietary composition (Tables O.6 and O.7). High protein consumers 
had lower R. intestinalis abundance than low protein consumers (P = 0.0124). Children in the high dietary 
fiber consumption group had higher Lactobacillus spp. abundance and lower R. intestinalis abundance 
than low dietary fiber consumers (P = 0.0433 and P = 0.0124) (Tables O.8 and O.9). 
 Average values for the gasses in exhaled breath are shown in Supplemental Table O.3 (Table O.3). 
Breath CH4 was detected in three of the participants measured. High CO2 producers had higher BMIPCT 
than low CO2 producers (P = 0.034). CH4 producers had higher quantities of Clostridium cluster IV than 
non-CH4 producers (P = 0.0438). A negative relationship was observed between R. intestinalis and CO2 
production (P = 0.0152).  
 
Relationships between bacterial abundance and body composition 
 Quantities of several bacterial genera and species including Bifidobacterium spp., Clostridium 
cluster IV, F. prausnitzii, and Clostridium cluster XIVa were higher in overweight children compared to 
normal weight children (Table 3.1). With the exception of Clostridium cluster XIVa, all pairwise 
relationships remained significant after adjusting for multiple testing (Figure 3.1). In the correlation 
analyses, Clostridium cluster XIVa was positively correlated with ANDPFAT and REG1PFAT (r = 0.66, P = 
0.0057; r = 0.65; P = 0.0060). R. intestinalis was also positively correlated with ANDPFAT (r = 0.56, P = 
0.0231) (Table 3.2). The results of the correlation analyses for the bacterial abundance and DXA 
measurements remained significant when adjusting for dietary fiber intake (Table O.10).  Stepwise 
regression analyses supported the observed relationships between Clostridium cluster XIVa and both 





Prevotella entered into the model, but when tested independently, only Clostridium cluster XIVa remained 
significant.  
 
Differences in SCFA production in vitro by body fat composition and dietary fiber consumption 
 At the initial time point, butyratei was higher and propionatei was lower in the high TOTFIBER 
group compared to the low TOTFIBER group (P = 0.0495, P = 0.0495). PropionatePCTi was also lower in 
the high TOTFIBER group (P = 0.0495). Butyratef and was higher in the high TOTFIBER group versus the 
low TOTFIBER group after the 12-hour fermentation (P = 0.0495), which was also reflected in the 
Δbutyrate comparison (Table O.11). Fecal inoculates from the high WBPFAT group produced more 
acetatef and total SCFAf than those from the low WBFAT group (P = 0.0495, P = 0.0495), which was 
reflected in the Δacetate and Δtotal SCFA comparisons. No differences in SCFAPCT production by WBPFAT 
group were observed. 
When examining within group changes in SCFA as a percent of the total resulting from the 
fermentation, similar relationships were found between the low TOTFIBER and high WBPFAT groups 
(Figures 3.3 and 3.4). In the low WBPFAT group, there was a significant reduction in propionatePCT from 
45.0% to 14.6% (P = 0.0379). Changes in acetatePCT and butyratePCT were not significant, though both 
showed compensatory increases following the fermentation. In the high WBPFAT group, a similar 
reduction in propionatePCT was observed, although the change was not statistically significant (P = 
0.0828). ButyratePCT remained relatively stable from initial to final (21.5% to 18.4%, P = 0.4139) while the 
compensatory shift in SCFA composition appeared to be from increases in acetatePCT (38.3% to 69.2%, P 
= 0.1120). Similarly, in the low TOTFIBER group, a significant reduction in propionatePCT was observed in 
conjunction with an increase in acetatePCT (56.8% to 17.8%, P = 0.0056; 30.9% to 68.0%, P = 0.0439 





= 0.0147), and the compensatory increases in SCFA mirrored the findings in the low WBPFAT group (Table 
3.4). R. intestinalis abundance was higher in the high WBPFAT group compared to the low WBPFAT group, 
while Bifidobacterium spp. was lower in the high TOTFIBER group compared to the low TOTFIBER group 
(P > 0.05). 
 
Discussion 
 Gut microbiome studies in children have employed many approaches to understand its functional 
role in host metabolic activity. In this study, our results contribute to the overall body of evidence linking 
the gut microbiome to host adiposity by specifically measuring regional fat distribution in children. Several 
bacterial genera and species were found to be associated with body composition measurements by DXA, 
particularly Clostridium cluster XIVa. Furthermore, we utilized an in vitro experimental technique to 
directly measure the SCFA-producing capacity of fecal inoculates. Our study demonstrates that overall 
SCFA production and changes in SCFA composition were affected by the total dietary fiber consumption 
and donor nutritional status reflected in total body fat, and these effects are likely mediated through 
modulation of the gut microbiome. The comprehensive analysis shown here also took into consideration 
dietary intake as an independent variable influencing fecal bacterial abundance, and analyzed the 
relationships between exhaled gas from breath and bacterial quantities. 
 As Clostridium cluster XIVa was positively associated with both ANDPFAT and REG1PFAT, this 
suggests a role for these bacteria in promoting regional fat storage. Several members of Clostridium 
cluster XIVa are SCFA producers, including R. intestinalis, which also was positively correlated with 
REG1PFAT.362-364 Overweight children of this study consumed more total dietary fiber than normal weight 
children and coupled with the previous information, the case could be made for a situation in which high 





primed for excess adipose storage. However, as the data from our in vitro study indicates, it is premature 
to make these statements without the context of SCFA production and information regarding the overall 
gut microbial community. The relationships between bacterial abundance and body composition 
measurements here share similarity with other reports,202,213,318,336 yet appear to show inconsistencies 
with previous findings from our research group (Chapter 2). Quantities of Bifidobacterium spp., 
Clostridium cluster IV, and F. prausnitzii were higher in overweight children compared to normal weight 
children in this cohort. Differences in the findings across studies could be attributed to the age difference 
as well as small differences in the stool sample collection and storage across the studies.365,366 The cross-
sectional nature of the analyses may also limit the scope in which many of the observed relationships are 
manifesting, which could suggest that overweight children indeed are experiencing perturbations in their 
gut microbiome.367,368 More longitudinal data are needed to better characterize shifts in microbial 
abundance coinciding with changes in adiposity throughout childhood in order to better describe our 
cumulative observations. Unlike the previous study, stratification of the analysis by sex was not required 
as the body composition values did not differ between boys and girls (Table 3.1). The main observed 
findings with the regional body fat measurements were found to be consistent between boys and girls 
with the direction of the relationships, though the magnitudes of the associations were greater in boys 
than in girls (Table O.12). However, the relationships between BMIPCT and both Clostridium clusters IV 
and XIVa appeared to be driven by the girls within this cohort, and there were differences in the 
relationship between bacterial abundance and body composition by sex, particularly with Lactobacillus 
spp. These observations highlight the need to evaluate sex as a potential independent variable in future 
gut microbiome work.369 
 The results of the in vitro study herein suggest that SCFA production is dependent on both host 
dietary intake and body fat composition. Inulin is found naturally in many vegetables including onions, 





substrate used was inulin Orafti HP, a synthetic chicory-derived oligofructose with varying chain length 
(3-60 carbons). Inulin did not select for the production of propionate and a reduction in propionatePCTf 
was observed in all donor fermentations. As a consequence, compensation for the reduction of 
propionate in the low TOTFIBER and high WBPFAT groups came mostly from acetate while butyrate 
production remained relatively stable. However, in the high TOTFIBER and low WBPFAT groups, 
contributions came from both butyrate and acetate. Two explanations arise from these findings: 1) an 
obesogenic gut microbiome in the high WBPFAT donors was prepared for acetate production and 2) high 
fiber intake primed the gut microbiome for both acetate and butyrate production, perhaps even utilization 
of acetate as substrate for butyrate production. Many prominent butyrate producers including R. 
intestinalis and F. prausnitzii utilize acetate to produce butyrate through the butyryl-CoA:acetate CoA-
transferase gene.372 R. intestinalis was higher in abundance in the high WBPFAT group and was positively 
correlated with acetate production. While this suggests that fecal inoculates from the high WBPFAT group 
would have greater capacity to produce butyrate from acetate, R. intestinalis does not ferment inulin and 
its initial growth in the experiment may have been hindered.363 Bifidobacterium spp. abundance was lower 
in the high TOTFIBER group compared to the low TOTFIBER group. This could provide an explanation for 
why both acetate and butyrate production compensated for the decrease in propionatePCTf in the high 
TOTFIBER group, and why only acetate compensated for the decrease in propionatePCTf in the low 
TOTFIBER group. One member of the Bifidobacterium spp. in particular, B. adolescentis, has been shown 
to ferment inulin and produce acetate.370 Taken together, the observed changes in SCFA production and 
composition within the dietary fiber and body fat groups indicate the need to better understand other 
members of the gut microbial community. 
 Interestingly, Clostridium cluster IV abundance was greater in the methane producers of our 
study. Many members of Clostridium cluster IV are prominent butyrate producers in the gut and this result 





fermentation.339 Although not statistically significant, H2 quantities were numerically greater in the 
methane producers (data not shown). Methanogenic archaea compete with sulfate-reducing bacteria for 
H2, and it will be important to investigate the presence and abundance of these microbes in subsequent 
analyses.373,374 Methane production was only observed in low quantities in three participants of our study, 
which is in line with previous reports indicating lower methane production in children compared to 
adults.375 Additionally, the amount of methane detected was low, which could be indicative of a gradual 
rise in methane production in children once methanogenic microbes are acquired. 
 There are some limitations to this study including a small sample size, cross-sectional study design, 
and the method used for dietary data collection. Ideally, a food frequency questionnaire or a 3-day food 
log would have better captured the dietary patterns of our child participants with respect to the first stool 
sample analyzed. At this time, the proposed mechanisms in describing the results of the in vitro 
experiment are speculative as the fecal material used for gut microbial analysis and for inoculation were 
from the same individual but not the same sample. Stool samples amongst individuals collected at 
different time points have been shown to vary, and the diet can rapidly alter the gut microbial 
composition.185,189,362 Although the in vitro model provided advantages of a controlled environment and 
equal treatment across donor inoculates, provision of a single substrate is not representative in the 
context of the in vivo lumen.  
         
Conclusion 
Overall, this study represents an advancement in the approach to quantify and characterize the 
gut microbiome’s relationship with host adiposity. Current data in preschool age children are limited and 
confined to use of BMI as the primary metric for obesity. The results of the in vitro experiment reveal that 





gut microbiome. However, data on the whole gut microbial profile are needed to more accurately depict 
the metabolic consequences of excess adiposity and dietary fiber consumption. Future studies evaluating 
the longitudinal changes in microbial composition in response to excess gains in adiposity during 






Table 3.1 Differences in bacterial genera and species abundance in normal weight vs. overweight 
children in the GHBC cohort 
Data are expressed as Mean ± SD. 
Superscripts represent significant P-values:  A (P < 0.05) and B (P < 0.01) for Student’s t-test. 
Abbreviations: GHBC: Gut Health and Body Composition Study   






F. prausnitzii 11.50 ± 0.36 11.88 ± 0.21 0.0105A 
Lactobacillus spp. 7.86 ± 0.91 7.87 ± 1.11 0.9863 
Bifidobacterium spp. 10.40 ± 0.26 10.75 ± 0.11 0.0008B 
R. intestinalis 10.85 ± 0.74 10.84 ± 0.46 0.9709 
Bacteroides-Prevotella group 11.04 ± 0.62 11.35 ± 0.38 0.1885 
Clostridium cluster IV 10.86 ± 0.32 11.17 ± 0.19 0.0183A 






















BMIPCT 0.48 0.07 0.55A 0.14 0.18 0.49A 0.50A 
ANDPFAT 0.21 -0.15 0.22 0.56A 0.27 0.14 0.66B 
GYNPFAT 0.28 0.01 0.16 0.27 0.13 0.08 0.28 
VATPFAT 0.07 -0.17 0.28 0.40 0.13 -0.04 0.40 
REG1PFAT 0.07 0.02 0.22 0.43 0.28 0.15 0.65B 
TRUNKPFAT 0.23 -0.03 0.27 0.40 0.22 0.05 0.42 
WBPFAT 0.28 -0.05 0.30 0.35 0.07 0.12 0.44 
Age and sex included as partial covariates 
Superscripts represent significant P-values: A (P < 0.05) and B (P < 0.01) for Spearman correlation 
Abbreviations: BMIPCT: BMI percentile, BMI: body mass index, ANDPFAT: android percent fat, VATPFAT: 
percent visceral adipose tissue, GYNPFAT: gynoid percent fat, REG1PFAT: region 1 percent fat, 






















Data presented as means amongst TOTFIBER and WBPFAT groups.  




























Mean Mean P-value Mean Mean P-value 
Acetatei  20.0 15.7 0.8273 13.7 22.2 0.1266 
Propionatei  20.1 15.2 0.5127 23.3 11.9 0.0495A 
Butyratei  5.8 8.2 0.2752 5.1 8.9 0.0495A 
Total SCFAi  46.0 39.2 0.1266 42.2 43.0 0.8273 
Acetatef 1591.4 3774.7 0.0495A 2133.8 3232.4 0.2752 
Propionatef  388.7 678.7 0.2752 529.2 538.2 0.8273 
Butyratef  945.3 1087.3 0.8273 417.4 1615.2 0.0495A 





Table 3.4 Comparisons of changes in SCFA composition within total body fat and dietary fiber groups 





(% total SCFA) 
Initial Final P-value Initial Final P-value 
AcetatePCT 42.8 ± 14.5 56.4 ± 15.0 0.4698 38.3 ± 19.0 69.2 ± 10.6 0.1120 
PropionatePCT 45.0 ± 20.8  14.6 ± 10.8  0.0379A 40.2 ± 16.9  12.4 ± 2.3  0.0828 
ButyratePCT 12.2 ± 6.3  28.9 ± 22.5  0.2206 21.5 ± 7.1 18.4 ± 10.3  0.4139 
 





(% total SCFA) 
Initial Final P-value Initial Final P-value 
AcetatePCT 30.9 ± 10.4  68.0 ± 8.2 0.0439A 50.2 ± 14.0 57.6 ± 17.7  0.6125 
PropionatePCT 56.8 ± 8.9  17.8 ± 7.2  0.0056B 28.5 ± 7.2   9.2 ± 4.2  0.0147A 
ButyratePCT 12.3 ± 6.6  14.2 ± 3.3 0.7662 21.3 ± 7.1  33.2 ± 20.4 0.4269 
Data are presented as mean SCFA values as a percent of total SCFA ± SD. 







Figure 3.1 Comparison of Bifidobacterium and Clostridium cluster IV abundances in overweight vs. 
















Data are expressed in means ± SD. Bifidobacterium spp. and Clostridium cluster IV were measured in copy 





















Using stepwise regression, Clostridium cluster XIVa quantities were positively associated with BMIPCT, android fat (ANDPFAT), and region 1 fat 





Figure 3.3 Within group comparisons of changes in SCFA composition in fermentation experiment for 


















Data are presented as percent of total SCFA at initial (time=0 hours) and final (time=12 hours). Red 
indicates acetate, blue indicates propionate, and white indicates butyrate. Superscripts represent 









Figure 3.4 Within group comparisons of changes in SCFA composition in fermentation experiment for 

















Data are presented as percent of total SCFA at initial (time=0 hours) and final (time=12 hours). Red 
indicates acetate, blue indicates propionate, and white indicates butyrate. Superscripts represent 










Chapter 4: A genetic risk score demonstrates the cumulative association of single nucleotide 




Background: Childhood obesity is a nutrition-related disease with multiple underlying etiologies. While 
genetic factors contribute to obesity, the gut microbiota has been implicated through fermentation of 
non-digestible polysaccharides to short chain fatty acids (SCFA). SCFA provide additional substrate for 
energy harvest and storage, and are postulated to be signaling molecules effecting expression of gut 
hormones. 
Methods: This study investigated the cumulative association of single nucleotide polymorphisms (SNP) of 
genes involved in SCFA recognition and metabolism with obesity. Study participants were non-Hispanic 
White children (2-5 yrs.) from the STRONG Kids Illinois and Michigan cohorts (n=270). Height and weight 
were measured to calculate obesity-related phenotypes. Genomic DNA was extracted from saliva and 
genotyped using the Fluidigm® platform. Statistical analyses were performed in SAS 9.4. Ten SNP variables 
(PPARG, ANGPTL3/4, LPL, PYY, NPY2R, SLC5A8, SLC16A3, SLC16A1, and IL6) were dichotomized according 
to dominant or recessive inheritance models with the effect size of each SNP variable on BMI Z-score 
established using β-coefficients estimated from general linear models. A weighted genetic risk score (GRS) 
was generated by summing the β-coefficients.   
Results: The GRS was significantly associated with BMI Z-score with the model explaining 12.4% of the 
variance using linear regression (R2 = 0.124, P < 0.0001). Similarly, the GRS was associated with weight-
for-age Z-score (R2 = 0.045, P = 0.002) but not with height-for-age Z-score.  
Conclusion: This preliminary analysis suggests the cumulative association of the genetic variants studied 





development through key host genes interacting with SCFA, warranting further investigation into the 




Childhood obesity is a nutrition-related disease with multiple underlying etiologies. Genetics play 
a significant role in the development of obesity, and twin studies indicate that the heritability of obesity 
ranges from 40 to 70%.376,377 The results from meta-regression analyses provide evidence that the genetic 
influences on obesity are greater during childhood than in adulthood.76 Genome-wide association studies 
(GWAS) have taken an unbiased approach and have revealed 190 loci within the human genome that are 
associated with obesity in adult and child cohorts.69,71-73 Building upon GWAS findings, the genetic risk 
score (GRS) approach has been employed to address concerns in statistical analyses over multiple testing 
and to account for the missing heritability of obesity.86 GRS constructed from GWAS-identified SNPs and 
tested across prospective and retrospective cohorts support the notion that the genetic effect on obesity-
related phenotypes is age dependent.88,99,101,103,104 Cross-sectional studies in children also demonstrate a 
relationship between GRS and measures of obesity.89,93-96,100  However, the percent of variance of BMI and 
other obesity-related phenotypes explained by the GRS in child studies remains small ranging from 1.0 to 
3.4%. In fact, Le Chatelier suggested that the current obesity susceptibility genetic variants identified from 
GWAS are less informative in distinguishing between lean and obese individuals than the microbiome 
within the gastrointestinal tract.378 
One possible explanation on how the gut microbiome contributes to obesity development 
includes the interaction between host genetics and short chain fatty acids (SCFA), the products of bacterial 
fermentation of non-digestible polysaccharides.379,380 In particular, butyrate promotes overall gut health 





lipogenesis and gluconeogenesis.239,240 Therefore, we identified key genes involved in the transport and 
signaling of SCFAs. From these genes, four main pathways were established: 
1. SCFA transport across the gut epithelium via monocarboxylate transporter 1 (SLC16A1) and 
sodium coupled monocarboxylate transporter 1 (SLC5A8) (apical membrane) and via 
monocarboxylate transporters 4 and 5 (SLC16A3 and SLC16A4) (basolateral membrane.241,244 
2. SCFA signaling through free fatty acid receptors 2 and 3 (FFAR2 and 3) bind SCFAs and effect 
downstream regulation of appetite through downstream effectors including peptide YY (PYY) and 
glucagon-like peptide 1 (GCG) in enteroendocrine L cells, and leptin (LEP) in adipocytes.254,262 
3. Alterations in adipose storage through angiopoietin-like 4 (ANGPTL4), an inhibitor of lipoprotein 
lipase (LPL).381 Both ANGPTL4 and LPL are under the transcriptional regulation of peroxisome 
proliferator-activated receptor gamma (PPARG). 
4. Immunological response to lipopolysaccharide (LPS) via toll-like receptor 4 (TLR4) and the 
inflammatory response by the expression of nuclear factor kappa beta (NFKB) leading to the 
release of cytokines interleukin 6 (IL6) and tumor necrosis factor alpha (TNFA).382  
 
 SCFA receptors and transporters and other host responders to gut microbiota have been 
described, but the collective impact of common functional and regulatory genetic variants in these genes 
on obesity-related phenotypes has not been studied in humans.129 The current study assessed the 
individual, interactive, and cumulative association of SNP variants within genes involved in gut microbiota 
and/or SCFA recognition and metabolism on obesity-related phenotypes in preschool-age children. We 
hypothesized that genetic variation in SCFA recognition pathways would be associated with obesity-
related phenotypes. GRS were constructed using both traditional (additive model) and non-traditional 
(non-additive models) methods taking into consideration the magnitude and directionality of the effect 







Study participants and anthropometric measurements 
Participants for this study were preschool age children (2-5 years) from the Synergistic Theory and 
Research on Obesity and Nutrition Group (STRONG) Kids Program (n = 475) with cohorts from the 
University of Illinois (Urbana, IL; n = 265) and the University of Michigan (Ann Arbor, MI; n = 210).19 Height 
and weight were measured to calculate BMI and related measures using a stadiometer (Peslter, USA) and 
electronic remote display scale (Jarden Consumer Solutions, USA) with a precision level of 0.1 cm and 0.1 
kg respectively. BMI, BMIPCT, BMI z-score for age (BMIZ), weight for age z-score (WAZ), and height for 
age z-score (HAZ) were calculated using the standard SAS program from the CDC. Z-scores express the 
standard deviation from the mean to indicate a child’s weight, height, and BMI status according to the sex 
and age-specific CDC growth charts from 2000.383 Additional data regarding age, sex and ethnicity were 
collected from a large panel survey completed by study participant parents. Children with BMIZ above or 
below 4 standard deviations and those with known metabolic disorders were excluded (n = 5).  
 
Candidate gene and SNP selection 
Candidate genes were identified after examination of the published literature regarding each 
gene’s known interaction with SCFAs and gut microbiota (FFAR2, FFAR3, ANGPTL4, CD36, SLC16A1, 
SLC16A3, SLC16A4, SLC5A8, and TLR4). Many of these genes have been described to be important in the 
recognition of gut microbiota and SCFAs.379,380 Additionally, downstream effector genes were also 
included in order to identify potential gene-gene interactions and to test the cumulative association of 
carrying risk alleles on the development of obesity early in life (LPL, PYY, GCG, LEP, LEPR, NPY, NPY2R, 
PPARG, NFKB, IL6, and TNFA).254,257,258,260,281,284,285,303,304,384     
Single nucleotide polymorphism (SNP) selection was performed using a systematic approach. 





regulatory potential. The Single Nucleotide Polymorphism Database (dbSNP) and Ensembl databases were 
searched for SNPs located in high priority regions including the 5’ and 3’ untranslated regions (UTR), exons 
(synonymous and non-synonymous variants), and the 10 base pair (bp) region within exon-intron 
boundaries.128 Several in silico tools were utilized to further assess the likelihood that the SNP would 
impact protein function or gene regulation. While minor allele frequencies (MAF) were taken into 
consideration, less common variants and in particular, non-synonymous SNPs, were included based on 
their Sorting Tolerant from Intolerant (SIFT) and PolyPhen scores.385,386 RegulomeDB and miRdSNP were 
used to identify SNPs likely to affect transcription factor and microRNA binding respectively.387,388 In the 
SNP selection process, tag SNPs for the genes of interest were also identified using Haploview version 4.2 
(Cambridge, MA) when functional or regulatory SNPs were not available.389 Appendix F.1 provides a 
summary of the 52 candidate SNPs and the justification for their selection. In addition, ancestry 
informative markers (AIMs) were used to generate an admixture score to allow for individuals from a 
variety of ethnicities including non-Hispanic White (NHW, n = 270), non-Hispanic Black (NHB, n = 113), 
Hispanic, Asian, and mixed ethnicity to be analyzed together.109  
 
DNA extraction and genotyping 
Genomic DNA (gDNA) was extracted and purified following the Oragene-DNA protocol for the 
manual purification of DNA from saliva samples (average yield = 9.8 µg, average OD 260/280 ratio = 1.9). 
Selected markers (48 total SNPs) were genotyped using either the Fluidigm® SNP genotyping platform or 
TaqMan genotyping assays. For the Fluidigm® protocol, the assay design was constructed on the Fluidigm® 
D3™ website. The Functional Genomic Unit of the W.M. Keck Center at the University of Illinois performed 
pre-amplification and genotyping using 250 ng of gDNA. Genotypes were called using Fluidigm® 
Genotyping Analysis software version 4.1.2 (San Francisco, CA) at a minimum of 85% confidence. The 





rs10423648 and FFAR1-rs10422744 and a custom assay for FFAR3-rs424241. Fluorescent signals were 
detected for VIC and FAM after PCR, and genotypes were assigned using the allelic discrimination program 
in the sequence detection systems (SDS) 2.4 software (Applied Biosystems, Carlsbad, CA, USA).   
 
Statistical analysis 
Minor allele frequencies (MAF), linkage disequilibrium (LD), and Hardy-Weinberg Equilibrium 
(HWE) were calculated using the SNP & Variation Suite (SVS) software version 8 (Golden Helix, Bozeman, 
MT). MAFs were calculated for the entire STRONG Kids cohort (ALLSKP, n = 466) and the following cohorts: 
NHW and NHB combined (NHW+NHB, n = 384), NHW, and NHB.  Both D’ and r2 statistics were computed 
for SNPs located within the same chromosome for the NHW and NHB cohorts using the composite 
haplotype method (CHM) in SVS. For genomic regions with multiple SNPs of interest in LD, the SNP with 
the strongest association with the phenotype was kept for GRS construction. Χ2 tests were used in the 
NHW and NHB cohorts to identify significant departures from HWE. SNPs were excluded from the analyses 
if the genotype call rate confidence was <95%, HWE P-value was <0.05, or the MAF was <0.05. The total 
number of SNPs analyzed for each cohort are as follows: 15 SNPs in ALLSKP and NHW+NHB, 47 SNPs in 
NHW, and 38 SNPs in NHB.  
Genetic risk for obesity was investigated from candidate SNPs selected from putative genes 
involved in gut microbiota recognition and SCFA metabolism after the inclusion criteria described above 
were met. Initially, individual genetic associations for each SNP were tested using the general linear model 
(GLM). Gene-gene interactions were evaluated in each pathway by using SNP-SNP interaction terms in 
the GLM. SNPs were included in the GRS based on their strength of association with BMIZ (P <0.3) using 
the GLM select procedure where the SNPs were grouped by pathway. GRS were constructed for the 
NHW+NHB, NHW, and NHB for BMIZ with 5, 10, and 9 SNPs used in the GRS for each cohort respectively. 





(GRS-non-NW), additive weighted (GRS-add-W), non-traditional weighted (GRS-non-W), and genotypic 
weighted (GRS-gen-W). 
To construct the GRS-add-NW, each genotype group for the selected SNPs was assigned the value 
0, 1, or 2 according to the additive model of risk and the values were summed. Construction of the GRS-
non-NW was performed by reassigning the genotype groups 0 or 1 according to the dominant or recessive 
models of risk and by summing the values. β-coefficients for each SNP were estimated in the GLM and 
were used to obtain the three weighted risk scores. Assigned values for the GRS-add-W were multiplied 
by their β-coefficients and summed to generate the GRS-add-W.  For the GRS-non-W, assigned values 
from the GRS-non-NW were multiplied by their β-coefficients and summed. The GRS-gen-W was 
constructed without assumption of genetic model; β-coefficients were summed without multiplication of 
an assigned value. The Cochran-Armitage exact test was conducted to predict the goodness of fit to the 
additive mode of inheritance. The β-coefficients used for the weighted scores and the P-values for the 
Armitage exact test are shown in Table P.4. 
Normality for the GRS variables was assessed by examining the skewness and kurtosis. The 
skewness values were >-1 and the kurtosis values were <1 for all constructed GRS. The cumulative 
associations between BMIZ and the five GRS were assessed using linear regression. Logistic regression 
was used to generate receiver operating characteristic (ROC) curves to assess the specificity and sensitivity 
of the each GRS to predict overweight status. The GRS for BMIZ were applied to the WAZ and HAZ 
phenotypes. All statistical analyses were performed with age and sex as covariates using SAS 9.4 (SAS 
Institute Inc., Cary, NC). An additional covariate for age (age2) was added to the models when age was 
independently associated with the phenotype. While P-values less than 0.05 were considered statistically 
significant, adjustment for multiple testing was conducted using Tukey-Kramer test in the GLM. 
Bootstrapping analyses were conducted at 10, 100, 500 and 1,000 replications to reevaluate the observed 





To account for ethnicity, principal component analysis of 64 AIMs was performed in SVS to 
generate continuous admixture scores.390 The 64 AIMs were established after removing 29 SNPs from the 
original 93 AIMs that demonstrated an independent relationship with the HAZ phenotype (P <0.2). The 
first three principal component scores for the 64 AIMs were included as covariates in the GLM for the 
individual genetic associations tests in ALLSKP and NHW+NHB as well as the models for GRS in NHW+NHB. 
Eigenvalues for the principal components generated are shown in Table P.3 and the stratification of the 




STRONG Kids cohort demographics and descriptive data for genetic markers 
 Descriptive data of the STRONG Kids cohort is presented in Table4.1. In ALLSKP, 73.7% were 
normal weight, 14.6% were overweight, and 7.4% were obese. No significant differences in age, height, 
BMI, or Z-scores were found between boys and girls. There were no differences in any of the 
anthropometric measurements or rates of overweight amongst the NHW and NHB cohorts. Although not 
statistically significant, children of the NHB cohort showed a trend towards lower BMIPCT and higher HAZ 
compared to children of the NHW cohort. MAFs and HWE values for each SNP and LD tables by cohort for 
the genes of interest are summarized in Tables P.1 and P.5 respectively.  
 
Individual genetic associations and gene-gene interactions 
 There were several significant associations between the candidate SNPs and obesity-related 
phenotypes. In NHW, LPL-rs13702 was associated with BMIZ using the genotypic and recessive models (P 
= 0.0008 and P = 0.0002), PPARG-rs12639162 was associated with BMIZ using the genotypic and dominant 





SLC16A4-rs12062656 was associated with BMIZ in both the genotypic and dominant models (P = 0.0087 
and P = 0.0062), and NPY-rs16145 was associated with HAZ with both the genotypic and recessive models 
(P = 0.0487 and P = 0.0141). CD36-rs10499859 was also associated with HAZ in NHB but only in the 
genotypic model (P = 0.0286). After adjustment with Tukey-Kramer, all SNPs remained associated with 
their respective obesity-related phenotype (Table 4.2). A summary of the individual genetic association 
tests is shown in Tables P.6-P.29. 
 The SNP-SNP model and interaction term P-values for BMIZ by pathway and by cohort (NHW and 
NHB separately) are shown in Figure P.1. Three significant interactions were observed in NHW: ANGPTL4-
rs1044250 and LPL-rs13702 (P = 0.0032), ANGPTL3-rs10889337 and PPARG-rs12639162 (P = 0.0222), and 
FFAR1-rs1042348 and BDNF-rs6265 (P = 0.0026). SNPs representing FFAR1-3 appeared interact with 
several SNPs for PYY, GHRL, LEP, NPY2R, and NPY in pathway 2 for both the NHW and NHB cohorts, though 
the model P-values did not reach significance. In NHB, an interaction between FFAR3-rs424241 and 
NPY2R-rs1047214 was observed (P = 0.0014). There were no other appreciable differences when 
comparing the SNP-SNP interactions between the NHW and NHB cohorts.  
 
 
Genetic Risk Scores 
 The SNPs selected for the construction of the GRS for each cohort are in Table 4.3. As described 
earlier, all SNPs included in the GRS demonstrated a relationship with BMIZ according to the genetic 
modes of inheritance listed. With the exception of the GRS-add-W in NHW+NHB, all GRS were associated 
with BMIZ. The R2 values and percent of variance explained increased as the GRS progressed from additive 
to non-additive and from non-weighted to weighted approaches in all three cohorts. GRS-non-W and GRS-
gen-W explained the largest percent of the variance in BMIZ (BMIZ%) and had the highest R2 values across 
and within the cohorts. GRS-gen-W explained 3.75%, 12.90%, and 26.70% of the variance in BMIZ in the 





Table 4.4 and comparisons of the non-weighted and weighted scores are shown in Figures 4.1 and 4.2. 
Bootstrapping at 10, 100, 500, and 1,000 replicates of the dataset yielded confirmed the associations 
between the constructed GRS and BMIZ (Table 4.6). 
 In general, analysis using logistic regression demonstrated similar results as observed when using 
linear regression. However, only the area under the curve (AUC) values for NHW improved when 
progressing from additive to non-additive and from non-weighted to weighted approaches (AUC range: 
0.57-0.64). The AUC values for the GRS in NHW+NHB and NHB remained relatively the same across GRS 
regardless of risk score construction method (Table 4.4 and Figure 4.3). While the AUC values in the NHB 
GRS were the highest, ranging from 0.72 to 0.78, the NHW+NHB GRS performed the poorest in predicting 
overweight with AUC values ranging between 0.55 and 0.57. The NHW+NHB GRS had the lowest BMIZ% 
and further analysis into the strength of association of the GRS within NHW and NHB separately revealed 
a differential relationship. Whereas the GRS for NHW+NHB was associated with BMIZ in NHW, these GRS 
were not associated with BMIZ in NHB (data not shown). 
 We next sought to determine if specific pathways were contributing more to the overall GRS than 
others by constructing scores by pathway within the NHW and NHB cohorts. In the NHW GRS, we observed 
that SNPs representing genes in the adipose storage pathway (ANGPTL4-rs1044250, LPL-rs13702, and 
PPARG-rs12639162) contributed to nearly half of the BMIZ% (R2 = 0.07, 6.44%). For NHB, both the 
transport and signaling pathways contributed approximately equal amounts to the overall GRS (R2 = 
0.1050, 12.21% and R2 = 0.0982, 11.27% respectively). Although the majority of the SNPs in the GRS for 
NHW and NHB were different, each shared IL6-rs1554606 and many of the same genes (PYY, SLC5A8, and 
NPY2R). The GRS for BMIZ were also applied to WAZ and HAZ in all three cohorts (Table 4.5). Though the 
percent of variance explained was reduced, all the GRS for BMIZ were associated with WAZ. The GRS for 








 The current study describes the cumulative relationship between gut microbiome-associated 
genes and obesity phenotypes in children. The results here demonstrate the benefit of integrating 
traditional and non-traditional methods of genetic analyses with a selection procedure of genetic variants 
rooted in the biological mechanisms underlying obesity. Specifically, we constructed genetic scores 
consisting of functional, regulatory, and tag SNPs in genes with known and proposed interactions with the 
gut microbiome. In a cohort of healthy preschool age children, the GRS consisting of variants with putative 
roles in SCFA recognition and transport demonstrated significant relationships with BMIZ and WAZ in 
NHW and NHB children. The pathway approach provides avenues for future research not only in the 
genetic determinants of early-onset obesity, but also the possibility of applying this method to other 
diseases of complex etiology including type 2 diabetes and cardiovascular disease.391  
Another advantage of the pathway-based approach is the ability to further investigate gene-gene 
interactions. Prior evidence obtained from in vitro and in vivo animal models provided the biological basis 
for these tests. Most notably, we showed an interaction between ANGPTL4-rs1044250 and LPL-rs13702 
in NHW, which is consistent with ANGPTL4’s known role as an inhibitor of LPL activity.381 The SNP-SNP 
interactions examined in the present study were limited to the four selected pathways. Though several of 
the interactions tested did not reach statistical significance in pathways 1-4, Figure P.2 provides insight 
into potential SNP-SNP relationships within and across pathways that could be further explored provided 
an adequate sample size to conduct multiple testing. Future studies should to continue to search for 
functional variants and to test for genetic interactions as more evidence of these relationships becomes 
available. Regarding the genetic architecture of complex diseases such as obesity, additive contributions 
of genetic variants that are independent of each other are assumed. However, Zuk has suggested that this 





taken into consideration and estimated heritability of a phenotype may be inflated.54 Adequate statistical 
models to address these interactions in the context of a GRS have not been established, and future work 
could address these concerns. Here, we present the possibility that certain pathways may be contributing 
more to the GRS than other pathways within the NHW and NHB cohorts. While SNPs in the adipose 
storage pathway appeared to be overrepresented in the NHW GRS, the NHB GRS appeared to be 
represented equally by both transport and signaling pathway SNPs. Although we currently are unable to 
interpret this as a biological phenomenon or as a result of bias arising from the initial SNP selection, the 
underlying mechanisms driving excess adipose accumulation may be different amongst NHW and NHB 
children.  
 Data are limited using the GRS approach in a multiethnic cohort of children. The Klimentidis study 
was the first to show that the mean GRS value was different amongst African American, Hispanic, 
European American, and biracial groups.112 Similarly, we found that the GRS constructed for the 
NHW+NHB cohort of our study was associated with BMIZ in NHW but not in NHB. Selection of genetic 
markers that could be studied in both groups was limited due to differences in the genotype frequencies 
of the initial candidate SNPs. Our data further demonstrated that, while similar genes were associated 
with obesity-related phenotypes in the NHW and NHB cohorts, the SNPs carrying those signals often 
differed between the groups. This presents a challenge for researchers in the future to find and establish 
shared genetic variants that can be used for association studies in multiethnic cohorts. We conducted PCA 
of AIMs to account for population stratification by ethnicity.108,392 The primary advantage of this method 
was the creation of several continuous variables that could more accurately characterize differences 
amongst and within ethnic groups than a single categorical variable. Use of this technique could be 
valuable in future work in the field of genetic epidemiology as admixed populations increase the likelihood 





There were several noteworthy trends from our analysis as a result of the statistical methods used 
to develop the GRS. Application of β-coefficients to estimate the effect size of each SNPs’ contribution to 
the phenotype improved the percent of variance explained by the GRS, which was anticipated based on 
simulation data from previous work.395 Few studies have used the weighted approach, and those that 
have apply values reported from GWAS.99,103-105,107 The application of weighted values to one dataset from 
a previously analyzed dataset removes potential bias within the sample set of interest, yet the reference 
population should share similarity by age and ethnicity for this to be appropriate. The findings here need 
to be cross-validated in an independent dataset, as our sample size was limited. The results of our 
bootstrapping analysis provide the initial evidence to validate our approach. Comparison of the GRS-add-
W to the GRS-gen-W suggests that a hypothesis-free approach to the genetic mode of inheritance is more 
representative of the genotype-phenotype relationship than assuming the inheritance model. The 
advantage of applying the additive, dominant or recessive models is an improvement in the power of the 
analysis.117 However, the genetic model is seldom known a priori and conforming SNPs to these models 
in our dataset presented concerns in calculating the GRS. New statistical methods including the MAX and 
MERT methods have been developed to better predict the mode of inheritance from the empirical data 
and could be used in follow-up analyses of the GRS herein.396 
The goal of the current study was to investigate the cumulative association between genes 
involved in the host-microbe interface and early-onset obesity. Past works have shown relationships 
between many of the same genes and other disease-related phenotypes including biomarkers of 
cardiovascular and metabolic disease, but this is the first report to our knowledge that combined their 
effects into a risk score.288,290,397-402 Several of the genes selected for this study including SLC16A1 and 
FFAR3 have expression in tissue beyond the gastrointestinal tract.243,270,271 While the premise of this work 
was based on the transport and signaling pathways of SCFAs produced by gut microbes in the distal 





through the proposed pathways. Nevertheless, the stage has been set to further elucidate the underlying 
genetic and microbial mechanisms of obesity development in children.  
   
Conclusion 
 
 In summary, the novel approach introduced in this study establishes a path by which basic 
research in molecular and genetic mechanisms of obesity can be utilized in population-level genetic 
analyses. There are several opportunities to build upon the genetic data presented here, setting the stage 
for longitudinal assessments of the GRS constructed on obesity as throughout child development. Past 
reports using GRS have demonstrated that their association with obesity-related phenotypes changes by 
age and could be particularly important at critical times of development including infant peak, adiposity 
rebound and puberty.88,97,99-101,103 While some aspects of this approach have been utilized in past studies, 
the methodology here represents a departure from the traditional ways of selecting genetic markers and 
constructing a GRS, which have often relied on GWAS-obtained data to inform on downstream analytical 
measures. 
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Table 4.1 Descriptive Characteristics of children in the STRONG Kids Cohort stratified by sex and 
ethnicity 
N=466, 238 males (51%), 228 females. Data are presented as means ± (SD). P-values for continuous 
variables were generated using Student’s T-test and Chi-square test for categorical variables.  
Abbreviations: BMI-Body mass index, BMIPCT-BMI percentile, BMIZ-BMI z-score, HAZ-Height-for-age Z-
















48.2 ± 10.5 47.8 ± 10.4 48.7 ± 10.7 0.35 47.8 ± 10.7 47.9 ± 10.2 0.93 
Height (cm) 102.6 ± 7.6 
 
102.7 ± 7.4 102.4 ± 7.9 0.66 102.2 ± 7.7 103.1 ± 7.4 0.27 
Weight (kg) 17.1 ± 3.0 
 





16.2 ± 1.5 16.3 ± 1.4 16.0 ± 1.6 0.07 16.2 ± 1.4 16.1 ± 1.6 0.56 
BMIPCT (%) 59.7 ± 27.5 60.2 + 27.0 58.8 ± 27.8 0.58 60.6 ± 27.9 56.5 ± 27.5 0.19 
BMIZ 0.32 ± 0.97 0.35 ± 0.95 0.28 ± 0.99 0.45 0.34 ± 0.93 0.22 ± 0.97 0.27 
HAZ 0.23 ± 1.02 0.21 ± 1.06 0.28 ± 0.96 0.45 0.22 ± 0.93 0.41 ± 1.3 0.14 
WAZ 0.32 ± 0.98 0.36 ± 1.04 0.27 ± 0.92 0.29 0.32 ± 0.90 0.37 ± 1.2 0.65 
Overweight 
(%) 
21.8 22.6 21.9 0.71 22.2 18.4 0.41 














Dominant and recessive models 
    P-value GLM P-value Tukey Adj. P-value 
Gene SNP Cohort Phenotype Model SNP 1v2 1v3 2v3 1v2 1v3 2v3 
LPL rs13702 NHW BMIZ 0.0033 0.0008 0.5301 0.0004 0.0002 0.8045 0.0012 0.0005 
PPARG rs12639162 NHW BMIZ 0.0340 0.0133 0.0034 0.4676 0.3401 0.0095 0.7475 0.6055 
SLC16A1 rs7169 NHW HAZ 0.0175 0.0038 0.0054 0.4192 0.0113 0.0149 0.6978 0.0302 
SLC16A4 rs12062656 NHB BMIZ 0.0354 0.0087 0.1558 0.6415 0.0032 0.3296 0.8869 0.0089 
CD36 rs10499859 NHB HAZ 0.0216 0.0286 0.0659 0.1863 0.0150 0.1560 0.3817 0.0395 
NPY rs16145 NHB HAZ 0.0291 0.0487 0.0183 0.0300 0.8567 0.0478 0.0759 0.9821 
Gene SNP Cohort Phenotype Mode of 
inheritance 
Model SNP Tukey  Adj. 
P-value 
LPL rs13702 NHW BMIZ Recessive 0.0015 0.0002 0.0002 
PPARG rs12639162 NHW BMIZ Dominant 0.0231 0.0054 0.0055 
SLC16A4 rs12062656 NHB BMIZ Dominant 0.0399 0.0062 0.0069 





Table 4.3 SNP inclusion in GRS for BMIZ by sub-cohort 
NHW+NHB      





PPARG rs12639162 A Dominant 0.0554 Intron variant, tagged SNP 
ANGPTL4 rs1044250 C Recessive 0.1859 Missense variant 
IL6 rs1554606 T Dominant 0.0139 Intron variant, tagged SNP 
SLC16A3 rs3176827 T Dominant 0.0723 Intron variant, possible splice variant 
PYY rs2070592 G Recessive 0.2038 5’ UTR variant, possible splice variant 
NHW only      
Gene SNP     
PPARG rs12639162 A Dominant 0.0103 Intron variant, tagged SNP 
ANGPTL4 rs1044250 C Recessive   0.2030* Missense variant 
ANGPTL3 rs10889337 G Dominant 0.0459 Intron variant 
LPL rs13702 A Recessive 0.0031 3’ UTR variant, -125 bp from hsa-miR-29a,b,c 
PYY rs2014257 A Dominant 0.1013 TBX5 TF binding motif 
NPY2R rs1047214 C Recessive 0.2346 Synonymous variant 
SLC5A8 rs7309172 G Dominant 0.0916 3’ UTR variant, -67 bp from hsa-miR-29a,b,c 
SLC16A3 rs3176827 T Dominant 0.1303 Intron variant, possible splice variant 
SLC16A1 rs9429505 G Dominant 0.0691 3’ UTR variant, tagged SNP 
IL6 rs1554606 T Dominant 0.1087 Intron variant, tagged SNP 
NHB only      
Gene SNP     
CD36 rs3173798 C Dominant 0.0676 Possible splice variant 
PYY rs2070592 G Recessive 0.0909 5’ UTR variant, possible splice variant 
NPY2R rs2880415 A Dominant 0.0181 Synonymous variant 
LEP rs11761556 C Dominant 0.2450 Upstream variant, Elk-1 TF binding motif 
SLC16A4 rs12062656 G Dominant 0.0436 Intron variant, tagged SNP 
SLC16A3 rs4789698 G Recessive 0.0328 Downstream variant, tagged SNP 
SLC5A8 rs1709189 C Dominant 0.0898 Missense variant 
TLR4 rs4986790 A Dominant 0.1146 Missense variant 
IL6 rs1554606 T Dominant 0.0275 Intron variant, tagged SNP 
Determination of SNPs to be included in GRSs for NHW+NHB was based on strength of association with 
BMIZ using GLM. SNP inclusion for NHW and NHB sub-cohort GRSs were based on GLM select procedure 










Table 4.4 Comparison of GRS by cohort for BMIZ using linear and logistic regression 
 GRS-add-NW GRS-add-W GRS-non-NW GRS-non-W GRS-gen-W 
NHW+NHB      
Adjusted R2 0.0265 0.0179 0.0388 0.0397 0.0404 
% variance 2.38 1.54 3.59 3.68 3.75 
Model P-value 0.0183 0.0578 0.0030 0.0026 0.0024 
GRS P-value 0.0027 0.0160 0.0002 0.0002 0.0002 
AUC (CI) 0.57 (0.50-0.64) 0.55 (0.48-0.62) 0.57 (0.51-0.64) 0.57 (0.50-0.65) 0.57 (0.50-0.65) 
OR (CI) 1.24 (1.03-1.48) 1.99 (0.67-5.87) 1.41 (1.07-1.85) 4.93 (1.30-18.67) 4.36 (1.24-15.39) 
NHW only      
Adjusted R2 0.0220 0.0657 0.0983 0.1242 0.1277 
% variance 2.45 6.77 10.00 12.55 12.90 
Model P-value 0.0319 <0.0001 <0.0001 <0.0001 <0.0001 
GRS P-value 0.0106 <0.0001 <0.0001 <0.0001 <0.0001 
AUC (CI) 0.57 (0.49-0.65) 0.60 (0.53-0.68) 0.63 (0.56-0.70) 0.64 (0.56-0.72) 0.64 (0.56-0.72) 
OR (CI) 1.16 (1.00-1.35) 1.74 (1.12-2.69) 1.40 (1.12-1.74) 3.95 (1.62-9.61) 3.69 (1.62-8.42) 
NHB only      
Adjusted R2 0.0987 0.1532 0.2278 0.2322 0.2567 
% variance 11.32 16.47 23.90 24.33 26.69 
Model P-value 0.0025 <0.0001 <0.0001 <0.0001 <0.0001 
GRS P-value 0.0003 <0.0001 <0.0001 <0.0001 <0.0001 
AUC (CI) 0.77 (0.64-0.90) 0.72 (0.62-0.82) 0.76 (0.64-0.88) 0.74 (0.62-0.87) 0.78 (0.68-0.88) 
OR (CI) 1.87 (1.32-2.65) 2.78 (1.40-5.55) 2.11 (1.43-3.12) 5.90 (2.21-15.70) 5.76 (2.23-14.87) 
Abbreviations: GRS: genetic risk score, GRS-add-NW: additive non-weighted, GRS-add-W: additive weighted, GRS-non-NW: non-traditional non-
weighted, GRS-non-W: non-traditional weighted, GRS-gen-W: genotypic weighted, AUC: area under the curve, OR: odds ratio, CI: confidence 
interval, NHW+NHB: combined non-Hispanic white and non-Hispanic black cohort. Statistical analysis conducted in both linear and logistic 





Table 4.5 Comparison of the weighted non-additive and genotypic GRSs for BMIZ in WAZ and HAZ 
 WAZ HAZ 
 GRS-non-W GRS-gen-W GRS-non-W GRS-gen-W 
NHW+NHB     
Adjusted R2 0.329 0.0304 -0.0024 -0.0022 
Model P-value 0.0072 0.0104 0.5302 0.5182 
GRS P-value 0.0230 0.0401 0.9522 0.7438 
NHW only     
Adjusted R2 0.0445 0.0343 -0.0080 -0.0051 
% variance 4.45 3.43 -0.80 -0.51 
Model P-value 0.0019 0.0070 0.8254 0.6464 
GRS P-value 0.0005 0.0020 0.8143 0.3683 
NHB only     
Adjusted R2 0.0943 0.1101 0.0179 0.0230 
% variance 9.43 11.01 1.79 2.30 
Model P-value  0.0033* 0.0013 0.1769 0.1647 
GRS P-value 0.0136 0.0046 0.6679 0.8365 







Table 4.6 Comparison of GRS after bootstrapping with 10, 100, and 1000 replications 
 10 replications 100 replication 1000 replications 
 GRS-non-W GRS-gen-W GRS-non-W GRS-gen-W GRS-non-W GRS-gen-W 
NHW+NHB       
Adjusted R2 0.0589 0.0564 0.0572 0.0573 0.0577 0.0582 
% variance 4.15 3.90 3.59 3.60 3.72 3.77 
Model P-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
GRS P-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
NHW only       
Adjusted R2 0.1437 0.1462 0.1341 0.1362 0.1334 0.1376 
% variance 13.40 13.65 12.69 12.90 12.52 12.94 
Model P-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
GRS P-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
NHB only       
Adjusted R2 0.2372 0.2748 0.2392 0.2686 0.2543 0.2772 
% variance 21.55 25.28 23.18 26.11 24.43 26.72 
Model P-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
GRS P-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
Odds ratios (OR), confidence limits (CL) and χ2 P-values were determined at 10, 100, and 1000 







Figure 4.1 Comparison of additive non-weighted GRS for BMIZ in NHW (top) and NHB (bottom) 
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Figure 4.2 Comparison of weighted GRS for BMIZ in NHW (top) and NHB (bottom) 
 






























Chapter 5: Future Directions 
 
Implications for genetic research in child obesity: basic science 
 We have established the individual and cumulative association of several SNPs within gut 
microbiome-associated genes and obesity-related phenotypes in children. The first logical next step would 
be to characterize these relationships in a larger independent cohort and to assess the longitudinal 
association of these genetic variants throughout childhood. Since we examined several genetic variants 
located in the regulatory domains and open reading frames of their respective genes, another avenue of 
research is to understand the functional consequences of these SNPs in vitro. Perhaps an upstream, 5’ 
UTR, or promoter genetic variant (PYY-rs2070592, PYY-rs2014257, LEP-rs11761556) can be inserted into 
a luciferase reporter system to observe mRNA expression level changes resulting from the SNP. Protein 
function as a result of a SNP variant (ANGPTL4-rs1044250, SLC5A8-rs1709189, TLR4-rs4986790) could be 
assessed. Several of the SNPs were also located near microRNA binding sites (LPL-rs13702, SLC5A8-
rs7309172) and transcription factor binding sites, and the effect of these SNPs on binding to the DNA 
could be further examined. We observed several significant SNP-SNP interactions in our analyses and the 
effect of the SNPs on gene interactions could be explored. At the physiological level, differences in 
circulating inflammatory cytokines or gut hormones could be measured and quantitatively compared by 
genotype group. Assessing the levels of these circulating factors by genotype group after a dietary or 
physical activity intervention could further our understanding of the functional consequences of genetic 
variation in adapting to environmental changes. Intermediate phenotypes to obesity such as satiety 
responsiveness and eating behaviors are important considerations as well because this could ultimately 
aid in our ability to utilize the basic science to make behavioral changes in an individual. When intronic or 
intergenic SNPs were used due to their tagged classification, the next step would be to characterize the 
association as a proxy for another signal within the same genomic region (LD) or establish the genetic 





Implications for genetic research in child obesity: approaches in genetic studies 
 In addition to the functional significance of the SNPs studied, the overall approach to the genetic 
analysis could be further developed to begin to account for the missing heritability of obesity. The search 
for candidate genes based on known interactions between host genes and gut microbiota and subsequent 
identification of potential functional or regulatory SNPs was the novel concept demonstrated here. 
Current publically available datasets that allow for the query of available genetic markers and estimates 
of their functional or regulatory potential were critical for the development of this approach, but still 
come with limitations. Most of the MAFs from HapMap project or 1000 genomes are small datasets, which 
presents challenges when making decisions on SNPs to include in a genetic study. Large-scale studies such 
as GWAS may be more reliable resources for MAF, yet even these are often limited in the ethnic diversity 
of their sample population. Population level differences in allele frequency (e.g. by ethnicity), 
demonstrate the need to find variants with similar frequencies across populations and to stratify analyses 
when appropriate (one size does not fit all).393 SNPs were chosen were based on the best available 
information from in silico tests (SIFT and PolyPhen scores, RegulomeDB and miRdSNP databases), which 
estimated the functional or regulatory potential of the genetic variants. These methods have only been 
recently developed, and candidate gene and SNP selection through this methodology will improve as 
these databases are updated and completed.  
For small datasets, utilization of the appropriate model of inheritance (additive, dominant, 
recessive) is important to reflect the observed genotype-phenotype relationship. Ideally, the true mode 
of inheritance could be identified a priori, and the MAX and MERT methods have been developed for this 
purpose. The present data could benefit from additional analysis with these programs. In instances where 
the heterozygote advantage is observed, the hypothesis-free approach to the genetic model becomes 
essential for this phenomenon to be reflected in could be truly reflected within a cumulative risk score. 





(additive, dominant or recessive). While evidence of the utility of this approach is suggested in our data 
where the genotype groups of each SNP in a cumulative score are summed according to their β-coefficient 
only, this would need to be further tested in an adequately-sized sample population. 
As described before, conventional methods in calculating heritability of a phenotype may inflate 
the value.62 Nonetheless, the current GWAS-identified SNPs only account for a small fraction of the 
estimated heritability. The advent of the GWAS approach held promise in identifying the genetic culprits 
of diseases such as obesity. Indeed, several loci within the genome have been mapped out, but genetic 
epidemiologists began to hint at the need to look at rare variants and other interactions (gene-gene and 
gene-environment) once it became clear that the cumulative effect of the strongest signals established 
by GWAS remained far from accounting for the heritability of obesity. Rare variants will require much 
larger sample sizes, and the use of simulation data to replicate datasets may assist in describing the role 
of rare variants in disease. It is assumed that rare variants will have more complete penetrance than 
common genetic variants. Evidence that the field is shifting to investigation of rare variants can be seen 
in whole exome sequencing.403 The most recent GWAS publications demonstrate that there is a concerted 
effort to describe the functional and mechanistic role of genes and SNPs investigated.77,121 Additionally, 
the data are becoming more refined as measurements of central adiposity including WHR, VAT, and waist 
circumference are being utilized at the large-scale. 
 
Clinical implications of genetic research 
There are clinical implications of the genetic data from the formulation of chemical agents 
targeting the biological pathways described to the development of a risk score to predict early-onset 
obesity risk. The receptors and transporters studied here are critical in the sensing and transport of SCFAs, 





mechanisms behind SCFA recognition and utilization, perhaps a strategy in obesity prevention for the 
future could be administration of a precise dose and type of dietary fiber that promotes the maintenance 
of resident microbes producing beneficial SCFAs.404  
While the existence of a genetic tool that could predict obesity risk in children has not yet been 
developed102, the utility of providing genetic information in the pediatric setting has also come into 
question. Tercyak and colleagues investigated the factors that are associated with parent perceptions of 
the risks and benefits of pediatric genetic testing and the willingness of the parents to have their child 
tested.405 They reported that parents viewed the benefits of pediatric genetic testing outweighed its risks 
and they were interested in learning about the genetic testing. The authors indicated this as having a 
positive decisional balance. Positive decisional balance was associated with parents that wanted to know 
more about the gene-health associations in their child, were not anticipating having trouble 
understanding genetic information, and having a positive emotional reaction when learning about their 
child’s decreased risk of diseases. Parents who were more willing to undergo genetic testing were more 
typically mothers, perceived their child to be at greater risk, wanted to know more about gene-health 
relationships, anticipated that learning about genetic testing would not be difficult, and were likely to 
have positive emotional reactions to learning about their child’s decreased risks. They concluded that 
pediatricians should be aware that parents may have increased interest in genetic testing in their children 
and should help these parents make informed decisions about these tests. Their results also suggest that 
parents may not be prepared to anticipate the full range of possibilities from the genetic testing. The 
parents that were most willing to have their children tested also anticipated having positive emotional 
responses to decreased health risks in their children. This is important as clinicians should be prepared to 
counsel parents to adequately prepare them for the wide range of results that can come from the genetic 
tests. Parents tend to seek out reassuring information regarding the health of their children. In the case 





clinicians can be better equipped in counseling parents regarding this issue with the results from the 
study. 
The social impact must be taken into consideration in evaluating the clinical application of obesity 
research. More studies similar to the one conducted by Tercyak et al. are needed to further evaluate the 
integration of genetic information in the clinical setting. Even with the best available evidence for clinical 
practice derived from rigorous and extensive scientific testing, the whole patient must be taken into 
consideration for the applicability of research. Is the patient willing to make the recommended changes 
in behavior, dietary modifications, take the prescribed medication? What are the barriers to these 
changes? Would genetic testing and the information gained change the outcome or would it be perceived 
as an inevitable outcome that is beyond their control? Are clinicians prepared to mediate the feelings of 
shame or guilt parents may have in response to genetic testing, that they may feel somehow responsible 
for their child’s health trajectory? How can studies examining the patient-provider relationship inform on 
future clinical practices that integrate genetic testing into medical diagnoses? 
 
Implications for gut microbiome research in child obesity 
The current data collected should inform on a future microbiome and genome research. Host 
genotype has been proposed to have an effect on the microbial composition within the gut, but this 
relationship is not well understood in humans. This is an emerging topic in gut microbiome research with 
early work in murine models showing evidence of an interaction. Use of murine models to test this 
hypothesis allows for control over several factors including maternal genetic effects and environmental 
influences on shaping the gut microbiota. Benson et al established that several genetic loci were linked to 
the relative abundance of microbial taxa in an intercrossed line of mice.406 Initial human studies in 





suggested to be small.407 Carmody suggested that the role of host genetics was minimal compared to the 
role of diet in the gut microbiota composition.185 However, the influence of host genetics on the initial 
colonization of the GI tract has been suggested by Faith, but has not been fully addressed.408 Furthermore, 
are individual genetic variations in host genes associated with the metatranscriptomic profile of gut 
microbiome?  
For future studies, our findings emphasize the need to use more precise measurements of 
adiposity, dietary intake, and antibiotic use, as well as the standardization of sample collection and data 
analysis. In just the past 10 years, the composition and metabolic activity of the gut microbiota have been 
connected to metabolic surgery and even autism. The initial associative observations that linked gut 
microbial composition to obesity have not been consistently replicated across studies. These 
inconsistencies were due, in part, to differences in sample collection, primer bias, and the various 
methods to quantify the gut microbiome (i.e. absolute vs. relative abundance). Recent emphasis on the 
standardization of how to conduct a gut microbiome study should ensure that new data emerging from 
the field will have greater consistency to solidify past findings and direct new lines of research for the 
future.366 Furthermore, characterization of the functional capacity of the gut microbiome should 
strengthen our understanding of its impact on host metabolism. The results in Chapters 2 and 3 
demonstrate how the data collection process improved through advancements within the field of gut 
microbiome research. For example, inclusion of dietary data, mode of delivery, and antibiotic use as well 
as sample storage (from -20°C to -80°C) in Chapter 3 improved our ability to account for variation in the 
sample set relative to what was presented in Chapter 2. 
Many environmental factors influence gut microbial composition; antibiotic use, infection, and 
dietary changes can lead to short term aberrations in adults and children. In children, especially in the first 





practices from breastfeeding or formula to the introduction of solid foods, and antibiotic use. Controlling 
for these past exposures and current dietary intake is critical in understanding the true relationship 
between gut microbiota and host adiposity, which many of the current studies in pediatric obesity and 
gut microbiota did not take into consideration.  
SCFA impact the physiology of the host gut, maintaining the intestinal barrier, providing an energy 
source for colonocytes, and developing the immune system early in life. Our in vitro study showed that 
both dietary fiber consumption and total body fat play a role in the quantity and composition of SCFA 
produced. These data are novel as this is the first study to investigate the SCFA-producing capacity of fecal 
inoculates of children of high and low total body fat. In vitro studies are expensive, difficult to coordinate 
with participants, particularly children, but provide a unique perspective and are feasible. Sample 
collection, as we have performed, preserves the microbial communities in the stool, which will hopefully 
be employed in future research in the field. Use of frozen samples in the past may have limited the growth 
of key bacterial populations with high metabolic activity. Allowing parents or participants to collect 
samples from home is less invasive to the normal activity of the family. Current publications in the field 
have low sample sizes and will even pool data across individuals. This may not be advantageous, given the 
high degree of inter-individual variation of the gut microbiome. Increasing sample sizes of gut microbiome 
studies and examining multiple substrates are important considerations for the future. Recently, Rahat-
Rozenbloom investigated rectal absorption rates of SCFA in human adults.225 Is the extrapolation of this 
data appropriate for the proximal colon, where the majority of the microbiome of the GI resides? What 
about the application of this method in the pediatric population, would it be met with resistance from 
parents as far as willingness to participate? New fermentation models have gained traction in the past 






Clinical implications of gut microbiome research 
Several therapeutic strategies have been proposed, each with the aim of targeting and 
modulating the gut microbiome to confer a health benefit to the host. Some of the concepts are more 
radical while others are dietary strategies that have been more extensively studied. Starting at birth, new 
experiments are now studying the effect of inoculating neonates delivered by cesarean section with 
maternal vaginal microbiota. In cases where the cesarean section procedure is clinically advised, this 
method serves as a way to preserve the inoculation process that occurs during natural child birth. Another 
innovative strategy in gut microbiome manipulation has gained ground in the treatment of C. difficile 
infection, which is a significant issue during prolonged hospital stays. Stool transplantation therapy has 
been shown to resolve recurrent C. difficile infection when antibiotic treatment was ineffective. This 
therapy has great potential as it serves as a mechanism to restore the gut microbiome after exposure to 
antibiotic treatment or an infection. This is a cautionary tale, however, as metabolic phenotypes have 
been shown to be transferred through fecal transplantation and there is the risk of virulence or 
pathogenicity in donor samples. In response to these concerns, Petrof and colleagues have been 
developing a stool substitute therapy derived from intestinal bacteria of a single healthy female adult 
donor, which was purified and isolated in culture.409 The 33 isolates constituting repopulate are 
considered a bare bones representation of commensal microbiome and was used to effectively treat two 
patients with recurrent C. difficile infection. 
There are specific components of the diet that can directly or indirectly modify the gut microbiota, 
which can be taken (as part of yogurt or as a supplement). Probiotics are defined by the WHO as “live 
microorganisms that, when administered in adequate amounts, confer a health benefit to the host.”410 
Species of Bifidobacterium and Lactobacillus are the most extensively studied, and have been described 
to be beneficial in the treatment and prevention of gastrointestinal diseases.410,411 In particular, body 





in adult humans.352-354 For the sustainability of the changes observed in probiotic therapies, it remains to 
be seen if the probiotic would need to be consumed for a long period of time to continue to be effective.  
Prebiotics are defined as “a selectively fermented ingredient that results in specific changes in the 
composition and/or activity of the gastrointestinal microbiota, thus conferring benefit(s) upon host 
health” by the International Scientific Association for Probiotics and Prebiotics (ISAPP) in 2010. Both pre- 
and probiotics have been evaluated for their clinical relevance in the treatment of a variety of 
gastrointestinal disorders and allergies.412 Besides breast milk, data are presently lacking on the effects of 
pre- and probiotics on gut microbiota and obesity measures in children. One randomized control trial 
investigated the effect of oligofructose supplementation on body weight of 7 to 18 year-old overweight 
and obese children over a 12-week period.413 The age-dependent dose (8 g/day for children 7 to 11 year- 
olds and 15 g/day for 12 to 18 year-olds) did not affect BMIZ over the course of the intervention.  
The new frontiers of gut microbiome therapies have generated excitement in the possibilities of 
the future, yet the basic research in establishing guidelines for dietary fiber intake in children has 
remained poorly characterized. Insofar, the benefits of dietary fiber have been extrapolated from human 
data in adults, but the consideration of the establishment of the early gut microbiome and the change in 
need based on growth must be evaluated.414 Current recommendations are conflicting with three 
different ones available. Daily recommended intake of dietary fiber for children from the Institute of 
Medicine are 19 g/d for 1 to 3 year-olds and 25 g/d for 4 to 8 year-olds, which are based on 14 g fiber 
consumption per 1000 kcal.415 The American Heart Foundation has recommended fiber consumption in 
children to follow a simple calculation whereby age in years is added to 5 g beginning at the age of 2.416 
The American Academy of Pediatrics has recommended dietary fiber consumption at 0.5 g per kg of body 
weight.417 With such differing guidelines, it will be essential to synthesize these recommendations into 
one guideline supported by data collected in children. Indeed, an investment into these recommendations 





promote long term health in children. It is a modifiable risk factor in child nutrition that lacks the media 
and research attention, but could have the greatest immediate impact. 
 
Closing Remarks 
The genetic and microbial findings presented herein offer insight into opportunities for further 
investigation. Additionally, there are several avenues in which these data provide the framework for the 
clinical management and prevention of childhood obesity in the upcoming years. Currently, the growing 
wealth of knowledge in the basic sciences unraveling the mechanisms of early-onset obesity holds great 
promise. Irrespective of the novelty of the present findings and the emerging lines of research in the fields 
of genetic epidemiology and the gut microbiome, several underlying currents in the practical application 
of this research remain. How readily will society accept the innovative strategies and adopt the 
recommendations emerging from the current research? Have our methods in evaluating potential obesity 
treatments and therapies adequately encompassed the multitude of factors that affect a child’s 
susceptibility to excess adiposity? Regarding patient readiness for change, how will clinicians integrate 
new evidence into their everyday practice? Another fundamental question persists: will we bear the fruits 
of our labor in developing evidence-based practices that treat and prevent pediatric obesity in the future? 
The goals of the national initiatives to end childhood obesity may yet be achievable through a concerted 
effort to utilize innovative strategies and to develop practical guidelines that are both evidence-based and 
implementable in the general public. It is the responsibility of the scientist not only to test and retest, to 
imagine and reimagine, but also to direct their efforts to make a positive impact on the health trajectories 








Appendix A: Summary of literature on genetic risk scores and obesity in children 
Author Sample Population Metrics for Obesity % variance by GRS 
GRS SNPs and 
type  Findings 
Zhao et al., 
2009 
Cross-sectional 
Children’s Hospital of 
Philadelphia (CHOP) 
N=6,078 





GRS associated with BMIZ 
(P=2.53x10-16) 
den Hoed 
et al., 2010 
Cross-sectional 
European Heart Study: 
Denmark, Estonia, Norway, 
Portugal 
N=1,252 children (9.7±0.4 yrs.) 
N=790 adolescents (15.5±0.5 
yrs.) 
Standardized BMI (BMI-
SDS), sum of skinfolds 








GRS associated with BMI-SDS, 






HAPO Study: Afro-Caribbean, 
Northern European, Mexican 
American, Thai 
N= 3,991 newborns 
Birth weight, SSF Not Reported 
25 SNPs for birth 
weight 
23 SNPs for SSF 
Additive, 
weighted 
GRS from pool of 40 SNPs 
within 12 loci associated with 





ALSPAC: South-west England 
N=2,346 Children 
Age: 9.8±0.3 yrs. 









-Increase of GRS effect size on 
FMI by quantile 
-GRS interaction with 
maternal overweight at 90th 
FMI quantile 
-In children consuming low 
mono and polyunsaturated 
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% variance 
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GRS SNPs and 
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Beyerlein 
et al., 2011 
Cross-sectional 
ALSPAC: South-west England 
N=4,837 
Age: 9 yrs. 




Stronger effect of GRS on BMI-
SDS and FMI in higher 
quantiles 
Mitchell  et 
al., 2012 
Cross-sectional 
Children’s Hospital of 
Philadelphia (CHOP) 
N=7,225 






GRS gained in strength of 
association from 15 to 85th 
percentiles for BMIZ 
González 
et al., 2013 
Cross-sectional,  Case-control 
INMA Birth cohort: Spain 
N=218 (Experimental group) 
N=190 (Control group) 
Two Birth Cohorts N= 653 
Children (Validation group) 
Age: 3.5-5 yrs. 
Obese and normal weight 









6 SNPs (selected 




-Each additional risk allele 
conferred 1.69 times risk of 
obesity (CI: 1.46-1.97) 
-1.23 increased risk in 
validation sample (CI: 1.03-
1.48) 




Dunedin Study: New Zealand 
N=1,037 
Age: birth-38 yrs. 
BMI, SSF (7 and 9 yrs.), 










Children with high GRS had 
1.61-2.41 increased likelihood 
of obesity in 2nd, 3rd, and 4th 
decades of life 
Elks et al., 
2012 
Longitudinal (Retrospective) 
1946 British Birth Cohort Study 
N=2,537 
Age: birth-53 yrs. 
Weight-SDS, Height-SDS, 
BMI-SDS 
1.6% (at age 
11 for 
Weight-SDS) 
11 SNPs, 9 SNPs 
(exclude FTO and 
MC4R), and 8 
SNPs (from 
ALSPAC) 
GRS peaked in association 
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% variance 
by GRS 
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Findings 
Choh et al., 
2014 
Longitudinal (Retrospective) 
Fels Longitudinal Study: 
Dayton, Ohio, U.S. 
N=1,176 





% of BMI-SDS variance ranges 
between 1-3.3% across age 
with peaks in adolescence and 
mid-adulthood 
Vogelezang 
et al., 2015 
Longitudinal, prospective 
Generation R Study: 
Netherlands 
N=4,151 
Age: 0-6 yrs. 
Birth weight, BMI, total 
fat mass, android/gynoid 
fat ratio, preperitoneal fat 
2.4%, 1.4%, 
1.2%, 0.5% 
29 SNPs for BMI 
14 SNPs for WHR 
Additive, 
weighted 
GRS for BMI associated with 
BMI, total body fat, 
android/gynoid fat ratio, and 
preperitoneal fat, and higher 




Northern Finland Birth Cohort 
of 1986 
N=4,032 
Age: 7 and 16 yrs. 
Validation samples: Italian 
children (N=1,503, 4-12 yrs.), 
U.S. children (N=1,032, 7 yrs.) 
 
Overweight/obesity using 














-GRS predicts 6 measured 
outcomes with poor 
discriminatory accuracy (AUC 
range: 0.56 to 0.59) 
-Addition of GRS to traditional 
risk score did not improve 
discrimination >1% 
Elks et al., 
2010 
Longitudinal (Contemporary) 
ALSPAC: South-west England 
N=7,146 
Age: 0-42 mo., 7-11 yrs. 
BMI-SDS, FMI and fat free 
mass index (FFMI), weight 
and length/height 





GRS strongest association with 
early infant weight and length 
gains (0.119 SDS/allele/year 









Appendix A: Summary of literature on genetic risk scores and obesity in children cont’d 
Author Sample Population Metrics for Obesity 
% variance 
by GRS 
GRS SNPs and 
type  Findings 
Llewellyn 
et al., 2014 
Longitudinal (Contemporary) 
Twins Early Development 
Study (TEDS): England 
N=2,556 
Age: 4 and 10 yrs. 





GRS was associated with BMI-
SDS at age 4 and 10 with a 
stronger association at 10 yrs. 
(R2 difference of 0.024, CI: 
0.002-0.078) 
Warrington 
et al., 2013 
Longitudinal (Contemporary) 
ALSPAC: South-west England 
(N=7,868) 
Raine birth cohort: Western 
Australia (N=1,460) 
Age: birth-17 yrs. 
BMI at adiposity peak 
(AP), at adiposity rebound 










-Strength of association 
between GRS and BMI 
increased to age 10, then 
declined 
-GRS associated with BMI at 
AP and AR 
Xi et al., 
2014 
Cross-sectional 
Beijing Child and Adolescent 
Metabolic Syndrome study: 
China 
N=3,468 
Age: 6-18 yrs. 










-Children with 10 or more risk 
alleles had 1.47 (CI: 1.12-1.94)  
fold higher risk to be in upper 
25th percentile for HOMA-IR 
compared to those with 5 or 
fewer risk alleles 
-Did not remain significant 
after adjusting for BMI 
Klimentidis 
et al., 2011 
Cross-sectional 
African-American, Hispanic 
American, European American, 
biracial 
N=298 
Age: 7-12 yrs. 










Mean GRS value significantly 
different by ethnic group, but 
GRS not associated with BMI, 
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et al., 2014 
Cross-sectional 
TEDS Study: England 
N=2,258 
Age: 9.9±0.8 yrs. 
Satiety sensitivity using 







-GRS negatively associated 
with satiety responsiveness 
-Association between GRS and 





Generation R Study: 
Netherlands 
N=4,338 
Age: 6 yrs. 
 
BMI, android and gynoid 










protein: 18 SNPs 
Additive, 
weighted 
GRS-BMI associated with 
increased risk of elevated C-
reactive protein (OR: 1.04, CI: 
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et al.  
Longitudinal intervention 
study based on both a 
caloric-restricted diet and 
increased physical activity 
for 10 weeks. 
N=39 overweight and 
obese adolescents  
BMI mean: 33.1 
Age mean: 14.8 
BMI, BMI z-scores and plasma 
biochemical parameters were 






Reductions in Clostridium histolyticum 
and E. rectale-C. coccoides proportions 







et al.  
Cross-sectional 
N=51 Estonian children (23 
male and 23 female) 
Body weight, height, BMI, All 
children were delivered vaginally 
without birth complications 
Culturing -BMI values were positively correlated 
with a relative share of anaerobic 
gram-positive bacteria. 
-Bacteroides showed a negative 





et al.  
Cross-sectional BMI  16s rDNA 
sequencing 
-Higher Firmicutes vs. Bacteroidetes in 
obese compared to lean. The lean gut 
showed a shift towards Bacteroidetes. -
-Combinations of species from different 
phyla could have overlapping and/or 




Bervoets et al.  
Cross-sectional 
N=26 overweight/obese 
(mean BMI: 28.7) 
N=27 lean (mean BMI: 
16.5) 
Age: 6-16 yrs. 




-Obese children had elevated 
Firmicutes-to-Bacteroidetes ratio 
compared to lean children. Low B. 
vulgatus and high Lactobacillus were 
observed in the obese microbiota. 
-Staphylococcus spp. positively 
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N=25 overweight and 
obese 
N=24 normal weight  
Age: birth, 3, 6, 12, 18, and 
24 mo., 4 and 7 yrs. 
BMI FISH and 
qPCR 
(Measured 
at 6 and 12 
mo.) 
-Bifidobacterium spp. at infancy higher 
in children remaining normal weight 
compared to overweight children at 
age 7 
-Overweight associated with greater 
abundance of fecal S. aureus at infancy 
Obesity (2012) 
Authors: 
Karsslon et al.  
Cross-sectional, Sweden 
N=20 overweight or obese 
children 
N=20 normal weight 
Age: 4-5 yrs.  
BMI, BMI-SDS, age, and gender  qPCR -Enterobacteriaceae was significantly 
higher in the obese children 
-Bifidobacterium inversely correlated to 




Authors: Xu et 
al.  
Cross-sectional 
N=175 Kazakh children 
Age: 7-13 yrs. 
BMI and hip circumference were 
measured and insulin resistance 
(HOMA-IR) calculated for the 175 
participants who fit the 
requirements 
qPCR -Bacteroides and Bacteroidetes-to-
Firmicutes ratio were significantly 
lower in the obese compared to normal 
weight children in girls  
JPGN (2011) 
Authors: Luoto 
et al.  




N=15 normal weight  
Matched for probiotic 
intervention with L. 
rhamnous 
Age: 0-10 yrs.  
BMI FISH  -Trend toward higher Bifidobacterium 
levels at 3 months in normal weight 





Appendix C: FTO and IRX3 genes interact to influence risk of overweight in preschool age children 
Abstract 
Objective: We investigated the relationship between FTO and IRX3 through gene-gene interaction and 
haplotype construction in non-Hispanic white children (2-5 yrs.) of the STRONG Kids Program (n = 270).  
Methods: Height and weight were measured to calculate BMI and related anthropometrics. FTO-
rs8057044 (intron 1 variant) and IRX3-rs3751723 (5’-UTR promoter variant) were genotyped by TaqMan 
assays and fluorescence polarization. 
Results: An interaction between rs8057044 and rs3751723 was positively associated with BMI Z-score (P 
= 0.02). Several differences in the risk of overweight amongst FTO-IRX3 haplotype groups were observed. 
Children with rs3751723-GG and rs8057044-AA genotypes (12.4% of total) were 9.8-times more likely to 
be overweight than individuals with rs3751723-GG and rs8057044-GG genotypes (13.5% of total) (OR = 
9.80, CI = 1.99-48.24). Replication of the dataset by bootstrap modeling (10, 50, 100, and 1000 
permutations) supported our findings. 
Conclusion: These data suggest a role for FTO in obesity beyond its own expression and highlight the need 
to integrate biological mechanisms with statistically generated relationships. 










In 2012, the rate of overweight and obesity was 20.9% amongst 2-5 year old children in the United 
States.1 Childhood obesity has serious health implications, as such novel strategies to identify those at 
early risk for obesity are needed to improve long-term health outcomes. Genome wide association studies 
(GWAS) have identified a cluster of single nucleotide polymorphisms (SNPs) within the fat mass and 
obesity associated (FTO) gene that are significantly associated with body mass index (BMI) and other 
obesity-related traits.79,80 These obesity-associated variants are located within a 47-kb region spanning 
FTO intron 1 and 2. FTO is a member of the non-heme dioxygenase superfamily, encodes a 2-oxoglutarate-
dependent nucleic acid demethylase, and is expressed in several components of the central nervous 
system, including the hypothalamic nuclei, brainstem, and extended amygdala.418 FTO contains numerous 
conserved noncoding elements in its introns and is located in chromosome 16 adjacent to a gene desert 
(long region of DNA devoid of any known protein-coding genes) and ~500-kb from the Iroquois homeobox 
3 (IRX3) gene, a transcriptional regulator expressed in the kidney, notochord (during development), 
forebrain, and hypothalamus.81  
While FTO has been investigated for its functional role in obesity development419-421, Smemo and 
Ragvin pioneered the concept that the obesity-associated region of FTO is an enhancer for IRX3 
expression.81,82 FTO has been shown to physically interact with the IRX3 promoter through DNA looping 
in adult mouse brain tissue.81 Furthermore, expression quantitative trait loci data showed that FTO SNPs 
were associated with IRX3 expression, but not with FTO expression in the cerebellum.82 Based on these 
findings, there is likely a mechanism by which FTO regulates IRX3 expression, which, in turn, provides the 
basis for the observed contribution of FTO to genetic predisposition to obesity.422 Building upon current 
data, the objective of this study was to determine the relationship between obesity-associated FTO-




obesity.423,424 Individual genetic associations, gene-gene interactions, and haplotype block construction 




Study participants included non-Hispanic white children (47.8 ± 10.7 months, n = 270) from the 
Synergistic Theory and Research on Obesity and Nutrition Group (STRONG) Kids Illinois and Michigan 
cohorts. Standing height was measured to the nearest 0.1 cm with a portable stadiometer (Peslter, USA). 
Weight was measured on a digital scale to the nearest 0.1 kg (Health o meter, Jarden Consumer Solutions, 
USA). Children with known metabolic disorders and BMIZ ± 3 SD were excluded from the analysis. 
DNA Extraction and Genotyping 
Saliva samples were collected and genomic DNA was extracted following the Oragene-DNA 
protocol for the manual purification of DNA (DNA Genotek Inc., Canada). Selected SNPs were genotyped 
by TaqMan assays or fluorescence polarization (FP) using 5 ng of dry genomic DNA as template for 
polymerase chain reaction (PCR). The TaqMan procedure was performed in the 7900 Real-Time machine 
using assays predesigned for rs8057044 (G/A) and rs3751723 (C/A reverse strand) (Applied Biosystems, 
Carlsbad, CA, USA). Fluorescent signals were detected for VIC and FAM after PCR, and genotypes were 
assigned using the allelic discrimination program in the sequence detection systems (SDS) 2.4 software. 






Anthropometric Measurements and Statistical Analyses 
Anthropometric measures including BMI and BMI percentile (BMIPCT), height-for-age Z-score 
(HAZ), weight-for-age Z-score (WAZ), and BMI Z-score (BMIZ) were calculated using a publicly available 
macro for SAS from the Centers for Disease Control and Prevention (CDC, 2010). Minor allele frequency 
(MAF), linkage disequilibrium (LD), and Hardy-Weinberg equilibrium (HWE) were determined with the SNP 
& Variation Suite software v8 (Golden Helix, Bozeman, MT). Both D’ and r2 statistics were calculated using 
the expectation-maximization method. All statistical analyses were conducted in SAS 9.4 (Cary, NC) with 
age and sex as covariates. The relationship between rs8057044 and rs3751723 was studied by adding an 
interaction term in the general linear model. Bootstrapping was conducted to reevaluate the observed 
associations. 
Haplotypes were analyzed using logistic regression for the dichotomous variable, BMI category 
(<85th BMI percentile and ≥85th BMI percentile). For the rs8057044-rs3751723 (FTO-IRX3) haplotype block, 
haplotypes were grouped by genotype combinations in the following manner: group 1: rs3751723-CC and 
rs8057044-AA; group 2: rs3751723-CC and rs8057044-AG; group 3 (reference group): rs3751723-CC and 
rs8057044-GG; group 4: rs3751723-AC and rs8057044-AA; group 5: rs3751723-AC and rs8057044-AG; 
group 6: rs3751723-AC and rs8057044-GG; and group 7: individuals with the rs3751723-AA genotype.   
 
Results 
Table C.1 contains basic descriptive information about the STRONG Kids cohort. The MAF for 
rs8057044 and rs3751723 were 0.48 (A) and 0.29 (A), respectively. Both SNPs were found to be in HWE 




Gene-gene interactions and haplotype association 
 FTO-rs8057044 and IRX3-rs3751723 were independently tested for their association with BMIZ, 
HAZ, and WAZ, and were not found to be associated with these phenotypes. However, a significant FTO-
IRX3 interaction was observed for BMIZ (P = 0.02). At 10, 50, and 100 permutations of the dataset, 
rs8057044, rs3751723, and the rs8057044-rs3751723 interaction were significant for BMIZ (P = <0.0001). 
Haplotype construction revealed several differences in the risk of overweight amongst FTO-IRX3 
haplotype groups (χ2 P = 0.04, Table C.3). Individuals in haplotype group 1 were 9.8-fold more likely to be 
overweight than individuals in the reference group 7 (OR = 9.79, CI = 1.98-48.24). Children in haplotype 
group 5 had a 4.7-fold greater risk of overweight (OR = 4.72, CI = 1.02-21.82), while group 6 had a 6-fold 
greater risk than the reference group (OR = 6.01, CI = 1.09-33.12). Children in group 7 were 7.3-fold more 
likely to be overweight and haplotype group 2 had a 5.7-fold greater risk than the reference group (OR = 
7.29, CI = 1.23-43.04; OR = 5.74, CI = 1.22-26.95). All remaining comparisons between haplotype groups 
are summarized Table C.4. These relationships were significant at 10, 50, and 100 replications (Figure C.1 
and Table C.5). 
 
Discussion 
The goal of this study was to explore the genetic interaction between FTO and IRX3 and to 
determine the association with obesity in preschool age children. As anticipated, FTO-rs8057044 and IRX3-
rs3751723 were not in LD (>500-kb distance apart), and traditional statistical genetic methods may not 
have investigated the interaction further. However, recent evidence that intron 1 of FTO physically 
interacts with IRX3 to enhance its expression led us to test the interaction and construct a haplotype.81,82 




were observed suggesting that the combination of the two variants has a greater influence than either of 
the SNPs independently. These data demonstrate the need for studies that will identify combinations of 
FTO-IRX3 variants affecting IRX3 expression. Along with many other HOX-domain genes, IRX3 may play a 
role in adipose tissue function as its expression is upregulated in subcutaneous adipose tissue after 
bariatric weight loss and overexpressed in subcutaneous adipose from cardiac bypass surgery 
patients.426,427 The role of the FTO-IRX3 interaction on IRX3 expression in specific adipose depots remains 
to be elucidated. 
While several studies have shown FTO-rs8057044 to be associated with obesity-related 
phenotypes, IRX3-rs3751723 has not been established as an obesity marker. Located in the IRX3 
promoter, rs3751723 is 63-bp from an 11-bp deletion (rs3833834). Upon reviewing publically available 
ENCODE data, rs3751723 was found to be in proximity of a transcription factor binding site (MSN2) and 
has been identified to be within a DNase1 region. This information provides an in silico theoretical 
explanation that rs3751723 may be a marker of IRX3 regulation at the transcriptional level. However, it is 
important to consider the evidence demonstrating a functional role for FTO in obesity development 
independent of its interaction with IRX3.419-421  
 
Conclusion 
The present findings support previous work implicating the obesity-associated FTO region in long 
distance enhancer mechanisms with neighboring genes, including IRX3. The discovery of the FTO-IRX3 
relationship shows the importance of following up large-scale statistical genome analyses in the context 
of biological processes where genes not only have independent actions but interact with each other and 




associated with obesity-related phenotypes could allow for the identification of children at a higher risk 
for obesity, thus prompting prevention and intervention strategies that could protect these individuals 
from weight-related disorders throughout life.  
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Study Importance Questions: 
• Genome wide association studies (GWAS) have identified a cluster of single nucleotide 
polymorphisms (SNPs) within the fat mass and obesity-associated (FTO) gene showing strong 
associations with obesity-related traits. 
• SNPs within intron 1 of FTO appear to indirectly affect obesity through an enhancer mechanism 
regulating the expression of the Iroquois homeobox 3 (IRX3) gene, located 500-kb downstream 
FTO on chromosome 16. 
• This study demonstrates the genetic interaction between FTO and IRX3 and its association with 
obesity by evaluating the risk of overweight amongst haplotype groups for FTO-rs8057044 and 


















Table C.1: Basic descriptive data for STRONG Kids cohort 
Variable All STRONG Kids (n 
=270) 
Boys 
(n = 126) 
Girls 
(n = 144) 
 
P-value 
Age (months) 47.8 ± 10.7 47.0 ± 10.1 48.5 ± 11.2 0.24 
Height (cm) 102.2 ±7.7 102.2 ±7.4 102.2 ± 8.0 0.97 
Weight (kg) 17.0 ± 2.9 17.0 ± 2.5 16.9 ± 3.2 0.64 
WAZ 0.32 ± 0.90 0.37 ± 0.87 0.27 ± 0.93 0.39 
HAZ 0.22 ± 0.93 0.18 ± 0.92 0.26 ± 0.94 0.48 
BMIZ 0.34 ± 0.93 0.37 ± 0.88 0.31 ± 0.98 0.59 
Data are expressed as Mean ± SD Abbreviations: BMI: body mass index, WAZ: weight-for-age Z-score, 








Table C.2: Linkage disequilibrium for Non-Hispanic White children of the STRONG Kids cohort 
 rs8057044 rs3751723 D’ 
rs8057044  0.032 
rs3751723 0.000  
r2 











CL (lower – upper) χ2 P-value 
1 v. 2 0.54 -0.39 – 1.46 0.2561 
1 v.4 1.27 -0.16 – 2.70 0.0812 
1 v. 5 0.73 -0.17 – 1.63 0.1117 
1 v. 6 0.49 -0.68 – 1.66 0.4137 
1 v. 7 0.30 -0.97 – 1.56 0.6476 
2 v. 4 0.74 -0.63 – 2.10 0.2913 
2 v. 5 0.20 -0.61 – 1.00 0.6336 
2 v. 6 -0.05 -1.15 – 1.05 0.9353 
2 v. 7 -0.24 -1.44 – 0.96 0.6955 
4 v. 5 -0.54 -1.90 – 0.82 0.4363 
4 v. 6 -0.78 -2.33 – 0.77 0.3242 
4 v. 7 -0.98 -2.59 – 0.64 0.2352 
5 v. 6 -0.24 -1.33 – 0.84 0.6620 
5 v. 7 -0.44 -1.62 – 0.75 0.4717 
6 v. 7 -0.19 -1.60 – 1.21 0.7866 
Haplotype groups for FTO-IRX3 haplotype were compared based on risk for overweight phenotype. Odds 





















The value in the gray-shaded boxes indicates the total number of individuals, and those the non-shaded 
boxes represent the number of normal weight (NW) and overweight (OW) children in each haplotype 
group. Haplotypes were grouped by genotype combinations in the following manner: group 1: rs3751723-
CC and rs8057044-AA; group 2: rs3751723-CC and rs8057044-AG; group 3 (reference group): rs3751723-
CC and rs8057044-GG; group 4: rs3751723-AC and rs8057044-AA; group 5: rs3751723-AC and rs8057044-




NW / OW AA AG GG 
rs3751723 
CC 
33 60 36 
21 / 12 45 / 15 34 / 2 
AC 
23 74 23 
20 / 3 58 / 16 17 / 6 
AA 
3 8 6 




Table C.5: Odds ratio for overweight risk: haplotype group comparisons with reference group at 0, 10, 
50, 100, and 1000 replications 
 
Contrast OR CL (lower - upper) χ2 P-value 
0 replications 
1 v. 3 9.80 1.99 – 48.24 0.0043 
7 v. 3 7.29 1.23 – 43.04 0.0284 
6 v. 3 6.01 1.09 – 33.11 0.0396 
2 v. 3 5.74 1.22 – 26.95 0.0269 
5 v. 3 4.72 1.02 – 21.82 0.0473 
4 v. 3 2.75 0.41 – 18.32 0.2963 
10 replications 
1 v. 3 10.5 6.30 – 17.34 <0.0001 
7 v. 3 8.76 5.00 – 15.33 <0.0001 
6 v. 3 6.78 3.98 – 11.56 <0.0001 
2 v. 3 6.31 3.87 – 10.28 <0.0001 
5 v. 3 5.59 3.45 – 9.05 <0.0001 
4 v. 3 2.59 1.41 – 4.78 0.0022 
50 replications 
1 v. 3 9.32 7.46 – 11.64 <0.0001 
7 v. 3 7.24 5.65 – 9.27 <0.0001 
6 v. 3 6.08 4.81 – 7.70 <0.0001 
2 v. 3 5.68 4.58 – 7.05 <0.0001 
5 v. 3 4.62 3.74 – 5.72 <0.0001 
4 v. 3 2.61 2.00 – 3.41 <0.0001 
100 replications 
1 v. 3 9.51 8.12 – 11.13 <0.0001 
7 v. 3 7.34 6.16 – 8.74 <0.0001 
6 v. 3 5.71 4.83 – 6.76 <0.0001 
2 v. 3 5.76 4.95 – 6.72 <0.0001 
5 v. 3 4.64 3.99 – 5.39 <0.0001 
4 v. 3 2.72 2.26 – 3.29 <0.0001 
1000 replications 
1 v. 3 9.46 9.00 – 9.95 <0.0001 
7 v. 3 7.23 6.84 – 7.65 <0.0001 
6 v. 3 6.14 5.82 – 6.48 <0.0001 
2 v. 3 5.69 5.42 – 5.97 <0.0001 
5 v. 3 4.63 4.41 – 4.86 <0.0001 
4 v. 3 2.68 2.52 – 2.84 <0.0001 
Haplotype groups 1-7 for FTO-IRX3 haplotype were compared based on risk for overweight phenotype 




χ2 P-values were determined for each contrast. Haplotype groups are not listed sequentially, but 





Figure C.1: Odds ratios for overweight risk: haplotype comparisons within FTO-IRX3 haplotype at 10 






Appendix D: Breath sample collection method for preschool age children 
 
Technical Report: An improved method for collecting breath from 3-7 year old children1 
 
Abstract 
Breath sampling and analysis provides healthcare professionals with a practical, non-invasive 
diagnostic measurement for children with a variety of gastrointestinal (GI) disorders. New biomarkers 
found in human breath have been investigated and provide the opportunity to diagnose bacterial 
overgrowth and other underlying causes to GI dysfunction.431,432 While several protocols have been 
described previously regarding breath sampling, few have demonstrated the feasibility of collection in 
young children.433 This communication introduces a simple game which allows for 3 to 7 year old children 
to practice breath exhalation in order to give a proper breath sample under a relaxed and comfortable 
environment. The technique described offers clinicians a creative approach for obtaining breath samples 
from a child by reducing the apprehension and anxiety associated with the research and clinical 
environment. 
 
Clinical Relevance Statement 
It is essential that the child is accepting of and comfortable with the diagnostic tool. Young 
children can feel fear and anxiety in clinical settings, which may lead to reclusive or obstinate behavior. 
Play has been identified as a leading coping mechanism used by children ages 4-6 to alleviate physician-
office fear.434 Therefore, by engaging children in an activity that is perceived as fun, healthcare 
practitioners can encourage cooperation during breath collection. This technical note describes a creative, 
cost-effective, time-saving activity for collecting breath from children ages 3 to 7.  
1(Publication: Wang, A.A., Paige, K.N., Gaskins, H.R. & Teran-Garcia, M. An improved method for collecting breath 
from 3- to 7-year-old children. JPEN J Parenter Enteral Nutr 38, 507-9 (2014). This work has been previously 





Breath analysis is commonly used in healthcare settings as a diagnostic tool. Breath analysis in 
children has been used to diagnose lactose and fructose intolerance, asthma and bacterial overgrowth in 
the small intestine.435,436 Breath measurement has advantages in the clinical setting not only due to the 
ability to measure metabolites relating to colonic health but also because of the noninvasive nature of 
collection. Bacterial fermentation products including the gases hydrogen (H2), carbon dioxide (CO2) and 
methane (CH4) can be measured in exhaled breath. In particular, exhaled methane has been shown to be 
associated with a variety of GI dysfunction such as constipation and encopresis as well as GI disorders 
including cystic fibrosis and diverticulosis.374,435,437 Exhaled hydrogen has been utilized in patients 
experiencing pancreatic insufficiency.10 It is also thought that exhaled gases are a reflection of overall 
colonic health with respect to the intestinal commensal microbiota. 
 The type of air collected during breath analysis is of critical importance. However, techniques for 
proper collection have not been described thoroughly in young children. An innovative approach for 
collecting breath samples from young children is needed as previous techniques have not yielded suitable 
alveolar samples for analysis.433 Alveolar air is that which has had the opportunity to exchange with gases 
in the blood. This type of air is desired because it is a true reflection of the colonic environment. The 
unwanted air is referred to as “dead space”. This is the air which is inhaled at the end of each breath. This 
portion of air is found in the mouth, trachea and bronchioles after inhalation and is the first to be exhaled. 
It has not yet had the opportunity to exchange with gases in the blood, therefore it is only a reflection of 
the surrounding environment and not useful for breath analysis.438 Instruction on proper exhalation 







Materials and Methods 
Materials needed for the “Ready, Set, Blow!” breath sampling preparation game include: drinking 
straws, large alphabet beads, laminated sheets or page protectors and a sheet of paper. Special attention 
was paid to ensure that all materials could be obtained from any general store for a minimal cost, were 
either disposable or reusable, and able to be maintained with proper cleaning solutions. The game 
materials are also easily transportable allowing for collection in multiple settings. GaSamplerTM collection 
systems and storage bags were obtained from QuinTron Instrument Company (Milwaukee, WI) and 
utilized for breath sample collection. The breath collection kit was assembled according to manufacturer’s 
directions prior to collection. This process includes adjusting the plastic collection bag based on the child’s 
weight, which allows the dead air to be separated from the desired alveolar air. Participants for this 
technical test (n=10) were recruited from the Synergistic Theory and Research on Obesity and Nutrition 
Group (STRONG) Kids project. The STRONG Kids project seeks to investigate multidisciplinary causes and 
consequences of childhood obesity.19 The sample collection was approved by the Institutional Review 
Board with informed consent from the parents of the children and assent from the child. 
 Once the child has been introduced to the researchers or clinicians and has verbally assented to 
participating, they are introduced to the “Ready, Set, Blow!” game. The child is shown the race track which 
is constructed from a piece of paper and enclosed in plastic or laminated. The paper includes a simple 
race track as shown in Figure 1. The examiner orients the track so the start line is closest to the child 
(bottom of the paper) and the far side of the paper is the finish line. The race track should be at least 10 
inches in length. The child is then given a drinking straw to practice breathing through. Instruct the child 
to close their mouth completely around the straw and blow through it. The child may have a better 
understanding if they are told to blow through the straw onto their own hand. This way the child will be 




 Once this concept is understood, the child may be instructed to use the same technique to move 
a game piece (a large alphabet bead, a race car or a Styrofoam ball) from the start to the finish line. 
Initially, the child may use multiple breaths to move the game piece from one side of the paper to the 
other. Once the child has mastered how to aim the straw and move the piece, the examiner may 
encourage the participant to try to move from start to finish in one continuous breath. It is helpful to have 
two racetracks so that the skill may be demonstrated by the researcher, clinician or a family member for 
improved patient compliance. 
 After the child is comfortable with the skills performed during the game, they may be shown the 
GaSamplerTM collection system. Referring to the kit as the “balloons” is helpful to encourage interest and 
compliance. First, the examiner may demonstrate how to inflate a separate sample collection system. Be 
sure to inhale and exhale slowly, filling both the initial plastic collection bag and then the aluminized-
mylar collection bag. Ask the child to repeat what they have seen, using the same breathing technique 
used during the game. At this point it is also important for the child to use a singular breath. If the child 
gets excited and exhales multiple times into the container, the sample must be released from the sample 
collection bag and collected again.  
Following collection, breath samples were analyzed in the BreathTracker instrument. This breath 
collection and analysis device has been used successfully in previous research of this nature.439 To ensure 
accuracy, the BreathAnalyzer SC was first calibrated with a reference gas provided by the manufacturer 
then was half-calibrated with equal parts reference gas and room air. This procedure was always 
completed prior to measurement of breath samples.  
 
Results 
Preliminary analysis of breath samples collected from 10 Caucasian children (7 males, age 6.2 ± 0.8 year 




BreathTracker SC. Table 1 displays measured hydrogen and methane levels adjusted for the percent of 
carbon dioxide present in the sample against the reference amount (5.5%). Utilization of a correction 
factor in breath sampling is commonly practiced and is described elsewhere. Furthermore, it appears that 
samples provided using this method can differentiate inter-individual variation in methane production.  
 
Conclusion 
Breath testing may be utilized for the diagnosis of multiple conditions including lactose and fructose 
intolerance, asthma and bacterial overgrowth in the small intestine.435,436 However, participants in this 
technical testing were healthy, therefore efficacy in non-healthy children cannot be concluded from our 
data. 
In our practice, 3-7 year old children find the game to be appealing and typically master the proper 
breathing technique within three minutes. Additionally, this technique was used to successfully collect 
breath from children as young as 3 years old; however, these data are not included in this report 
(unpublished data). Although data on parent perception was not collected, the game was generally well 
received and, observationally, a few parents and siblings even played along. 
Although the GaSamplerTM has been used successfully in our breath collection, QuinTron also 
offers a KidSamplerTM collection system specifically designed for the pediatric population. For research 
proposes, one advantage of using the GaSamplerTM system is the ability to store samples for up to two 
weeks in holding bags allowing for mobility in sample collection and flexibility in sample analysis. 
Concurrent research in the STRONG Kids cohort is recruiting more individuals and will test whether the 
associations described between elevated breath methane and obesity in adults could be detected in 
young children.13 
“Ready, Set, Blow!” is a simple and effective tool designed to create a comfortable environment 




child compliance in sample collection while obtaining a quality sample useful for diagnostics. This basic 
concept can be applied in other sampling procedures involving children to reduce the anxiety and fear 





Table D.1 Preliminary Breath Analysis using “Ready, Set, Blow!” Collection Method 
Patient H2 CH4 CO2 Correction factor 
1 4.7 0 3.6 1.5 
2 1.7 0.3 3.8 1.4 
3 12.3 3.3 3.7 1.5 
4 4.3 0 2.6 2.2 
5 3.3 0 3.1 1.8 
6 31.7 10 3.6 1.6 
7 4.3 1.7 3.7 1.5 
8 2 0 3.2 1.7 
9 45.3 7.3 4.1 1.3 
10 5.3 2 3.2 1.7 
11 11.5 2.5 3.5 1.6 
























A. Child practices blowing technique while playing “Ready, Set, Blow” (left). Child then blows into the 




Appendix E: Saliva collection from children and DNA extraction from saliva protocol 
 
1. Incubate saliva sample at 50 ⁰C for 1 hour and cool to room temperature. Transfer 500 µl to 
fresh 1.5 ml tube. Aliquot remaining sample into 2nd and 3rd repeats to be stored at -80°C. 
2. Add 1/25th (4%) volume of Oragene-DNA Purifier (Reagent 1) and mix by vortexing for a few 
seconds. For example: 






3. Incubate on ice for 10 min, then centrifuge at 13,500 rpm (Eppendorf) for 20 min. 
4. Transfer majority of supernatant (90-95%) with a pipette to a fresh 1.5ml tube without 
disturbing the pellet. 
5. Add an equal volume of room temperature 100% EtOH, mix gently by inversion 10 times, and 
incubate sample at room temperature for 10 min. 
6. Centrifuge sample at 15,000 rpm (Eppendorf) for 20 min. 
7. Remove supernatant and add 1 ml of 70% EtOH. Gently scrape DNA from sides of tube wall and 
mix with gentle pipetting to remove excess salt from DNA pellet. 
8. Centrifuge sample at 15,000 rpm (Eppendorf) for 20 min and repeat cleaning of DNA pellet and 
centrifugation once. 
9. Remove supernatant and allow sample to dry under hood for 30-40 min to ensure no residual 
alcohol remains.  
10. Rehydrate DNA with 50-150 µl TE buffer (DNA hydration solution) depending on estimated 
pellet size. Use vortexing and wide orifice pipet tip to dissolve DNA into solution. 
11. Incubate at 50⁰C for 1 hour, and place on rotator overnight at room temperature. 
12. On the next day, quantify sample using Nanodrop 2000 blanking with TE buffer. Sample can be 





Appendix F: Genotyping methods 
Fluorescence Polarization 
1. Primer design 
Gene SNP F/R/SBE Annealing 
Temp 
Sequence 
SLC16A1 rs4839273 F 60 GCTTTAGTTTCCTCGCCAGA 
  R  CCACCCACCGTGTTTCTATT 
  SBE  GAACACTTTCCAAGTTTTACCAATTACTTC 
FTO rs8057044 F 60 CTTGTGGAACCTTTGCCAAT 
  R  CCTGGGCTAACAGCAATCTC 
  SBE  GGCTAAGTGAGGCAACCT 
LEP rs7799039 F 60 AAAGGCCTGGAGGAATCAAT 
  R  TTCCTGCAACATCTCAGCAC 
  SBE  TTGTTTTGCGACAGGGTTGC 
 
2. PCR reaction 
Reagent Concentration Volume per reaction (µl) 
Qiagen PCR buffer (10X, 15mM MgCl2) 1X 0.6 
MgCl2 (25mM) 3.5mM total 0.48 
dNTPs (5mM each) 100µM each 0.24 
F-primer (10µM) 120nM 0.072 
R-primer (10µM) 120nM 0.072 
Taq (5U/µl)  0.024 
mH2O  4.512 
Total  6 
3. Add 6µl of PCR mix to 5µl gDNA at 1ng/µl (dried overnight)  
PCR conditions (temp. and cycles):    
                95°C                    2 min 
   35         95°C                    30 sec 
 cycles     60°C                    30 sec   
                72°C                   1.5 min  
            Repeat 34 cycles 
    72°C                    5 min 






4. Shrimp alkaline phosphatase clean up 




Add 5 µl SAP mix for clean up 
5. Single base pair extension (SBE) 
Reagent Volume per reaction (µl) 
Single Base Extension Buffer 2 
Primer 0.5 




Add 10 µl SBE mix and extend using 5-45 cycles 



















Taqman Genotyping Assays 
1. Assay design 
Gene SNP Assay name 
ANGPTL4 rs4076317 C__27520304_10 
IRX3 rs3751723 C__27476879_10 
FFAR1 rs10423648 C__30492467_10 
FFAR3 rs10422744 C__29609180_10 
FFAR3 rs424241 Custom assay 
 
2. PCR reaction 
Reagent Volume per reaction (µl) 
Universal Master Mix 2.5 
20x probe 0.25 
mH2O 2.25 
Total 5 
Add 5µl of PCR mix to 5µl gDNA at 1ng/µl (dried overnight)  
PCR conditions (temp. and cycles):    
                     50°C                    2 min 
                     95°C                   10 min 
 40                95°C                   15 sec                                                                                                                                 
cycles          60°C                    1 min  
3. Use allelic discrimination to measure fluorescence for VIC and FAM in Sequence Detection 






1. Assay designed in Fluidigm D3 website for the following SNPs: 
 
Table F.1 Candidate SNPs for GRS 
Ch. Gene SNP Alleles Minor 
allele 
GMAF Selection Criteria 
19 ANGPTL4 rs1044250 C/T T 0.254 Missense variant, T/M (Thr to Met) 
19 ANGPTL4 rs2278236 G/A A 0.410 Intron variant, Tagged SNP 
19 ANGPTL4 rs7255436 C/A A 0.463 Intron variant, cited in literature for association 
with HDL 
1 ANGPTL3 rs10889337 G/A A 0.360 Intron variant, cited in literature for association 
with TGs 
7 CD36 rs3173798 C/T C 0.240 Intron variant, possible splice variant 
7 CD36 rs10499859 A/G G 0.350 Intron variant 
7 CD36 rs1527483 G/A A 0.100 Intron variant 
19 FFAR1 rs10423648 A/G G 0.150 Upstream variant, transcriptional regulation 
19 FFAR2 rs2074056 C/T T 0.237 Upstream variant,  RFX TF binding motif 
19 FFAR3* rs423385 C/T T 0.480 Missense variant 
19 FFAR3* rs424241 C/T T 0.180 Missense variant, W/R (Trp to Arg) 
19 FFAR3 rs10422744 C/T T 0.450 Intergenic SNP 
2 GCG rs6717659 C/A A 0.146 Downstream variant, Tagged SNP 
3 GHRL rs27647 C/T C 0.251 5’ UTR variant 
3 GHRL rs696217 G/T T 0.090 Missense variant, L/M (Leu to Met) 
7 IL6 rs1554606 G/T T 0.270 Intron variant, Tagged SNP 
7 LEP rs11761556 A/G G 0.485 Upstream variant, Elk-1 TF binding motif 
7 LEP rs1349419 C/A A 0.478 3’ UTR variant, 399 bp from hsa-miR-331  
7 LEP rs7799039 G/A A 0.350 5’ UTR variant, AP-4 TF binding motif 
1 LEPR rs1137101 A/G A 0.410 Missense variant Q/R (Gln to Arg) 
8 LPL rs12678919 A/G G 0.100 Intergenic region, cited in literature for association 
with CVD 
8 LPL rs13702 T/C C 0.332 3’ UTR variant, -125 bp from hsa-miR-29a,b,c 
8 LPL rs1800590 T/G G 0.106 5’ UTR variant, Sp1 TF binding motif 
8 LPL rs328 C/G G 0.100 Stop-gain, loss of function 
4 NFkB rs230531 G/A G 0.330 Intron variant, Tagged SNP 
4 NFkB rs6834596 G/C C 0.130 5' UTR variant, AP-2 TF binding motif 
7 NPY rs2189495 A/G A 0.433 Downstream variant, Tagged SNP 
7 NPY rs16145 G/T G 0.447 Upstream gene variant, NPY affected gene(SUZ12) 
4 NPY2R rs1047214 C/T C 0.308 Synonymous variant, I/I (Ile to Ile) 
4 NPY2R rs13120088 A/G A 0.500 Downstream variant, Tagged SNP 
4 NPY2R rs2880415 C/T C 0.340 Synonymous variant, I/I (Ile to Ile) 
3 PPARG rs12639162 A/G G 0.270 Intron variant, Tagged SNP 
3 PPARG rs1801282 C/G G 0.070 Missense variant, P/A (Pro to Ala) 
4 PPARG rs2279525 T/C C 0.300 3’ UTR variant, 0 bp from hsa-miR-323 
17 PYY rs2070592 C/T C 0.457 5’ UTR variant, possible splice variant 
17 PYY rs2014257 T/A A 0.285 Upstream variant, TBX5 TF binding motif 
17 PYY rs228771 C/G G 0.209 Upstream variant, Sp1 TF binding motif 
2 SLC11A1 rs2695343 A/G A 0.437 Intron variant, Illumina data association with 
BMIPCT 
1 SLC16A1 rs7169 G/A G 0.343 3’ UTR variant, -231 bp from hsa-miR-320 
1 SLC16A1 rs9429505 A/G G 0.252 3’ UTR variant, Tagged SNP 




Table F.1 cont’d 
Ch. Gene SNP Alleles Minor 
allele 
GMAF Selection Criteria 
17 SLC16A3 rs4789698 C/T C 0.325 Downstream variant, Tagged SNP 
17 SLC16A3 rs3176827 A/G A 0.190 Intron variant, possible splice variant 
1 SLC16A4 rs12062656 G/C C 0.100 Intron variant, Tagged SNP 
1 SLC16A4 rs3738750 C/T T 0.174 Missense variant 
11 SLC1A2 rs1570226 T/G G 0.258 Intron variant, Illumina data associated with 
BMIPCT 
12 SLC5A8 rs1709189 C/T T 0.292 Missense variant, S/L (Ser to Leu) 
12 SLC5A8 rs7309172 G/T T 0.202 3’ UTR variant, -67 bp from hsa-miR-29a,b,c 
12 SLC5A8 rs844016 T/C T 0.490 Intron variant, Tagged SNP 
9 TLR4 rs11536889 G/C C 0.147 3’ UTR variant, 0 bp from hsa-miR-1208 
9 TLR4 rs4986790 A/G G 0.044 Missense variant, D/G (Asp to Gly) 
6 TNFA rs1800683 G/A A 0.399 Upstream variant, NFKB TF binding motif 
 
MAF represents global minor allele frequency as reported by the 1000 genomes project. 
*Minor allele frequency only available for Caucasian population. 
 
2. Prepare 250-300 ng of gDNA for Fluidigm pre-amplification and genotyping. Approximately 5 µl 
at 40-60 ng/µl was sent to the Functional Genomic Unit of the W.M. Keck Center for genotyping. 






Appendix G: In silico SNP selection procedure 
After conducting a thorough candidate gene selection process, the following steps outline how genetic 
variants within the chosen genes are selected.  
I. Create pool of candidate SNPs using large online databases and tools in silico.  
a. Query SNP databases (eg. dbSNP, Ensembl) for SNPs located near or within each gene of 
interest. Generate an excel file from csv files exported from Ensembl with lists of SNPs for 
the regions of the gene described below:   
i. Regions near or within the gene of interest with low priority include: 
1. 5kb upstream, 5kb downstream, deep intronic, intergenic regions 
2. Minor allele frequency (MAF) ≥0.15 for low priority SNPs 
ii. Regions near or within the gene of interest with high priority include: 
1. 5’ UTR, 3’ UTR, exonic (synonymous and non-synonymous), SNPs within 
10 bp of intron-exon boundary (splice site). 
2. MAF ≥0.05 for high priority SNPs 
iii. Note 1: MAF and minor allele may differ between populations (CEU, YRI, MEX 
etc.). Global MAF (GMAF) reflects MAF obtained from 1000 genomes. 
iv. Note 2: genes will often have several transcript variants. Knowledge of the amino 
acid chain length will help to determine which transcript variants to include in this 
initial step of pooling candidate SNPs. 
II. Clean up list of candidate SNPs  
a. Refine candidate SNP list for each gene by sorting by MAF, transcript variant, inclusion in 
HapMap or 1000 genomes, and current citations. Remove variants that are not SNPs (such 
as deletions, indels, or other sequence variants) or dimorphic SNPs. 
III. Use in silico web tools to test for the potential of candidate gene to affect protein function or 
regulation of gene expression. SNPs in this part of the selection process should still be common 
variants with MAF of at least 0.10 to be included. 
a. For missense variants, sort by MAF, SIFT score, and PolyPhen score. Variants with a SIFT 
score ≤0.05 are likely to be deleterious to the protein product. These values are included 
in the Ensembl database.   
b. For variants that may potential play a role in the regulation of gene expression, the 
SNPinfo web tool can be used to obtain values that approximate the likelihood of the SNP 
having a regulatory effect. SNPs in the promoter region of a gene may alter gene 
expression if they are located within a transcription factor (TF) binding site or response 
element. If the SNPinfo web tool does not contain the SNP of interest, other web tools 
such as regulomeDB can be used to obtain data on the potential of the SNP to be located 
in a regulatory domain. Include 5kb upstream and 5’ UTR in regulomeDB searches. SNPs 
returning a regulome DB score of 2 or less are likely to affect binding of a TF.   
IV. Use in silico web tools to test for potential of gene variants to post-transcriptionally affect gene 
expression (miRNA-binding site in 5’ or 3’ UTR) (splice-site variants within 10bp of exon-intron 
boundary). SNPs in this part of the selection process should still be common variants with MAF of 
at least 0.10 to be included. 
a. Use the miRdSNP web tool and microRNA database to search for potential SNPs within 
the 3’ UTR of your genes of interest that may affect microRNA binding. A search for your 




database. Indicate the name of the microRNA and the position of the SNP relative to the 
binding site. 
b. For intronic variants, conduct search in the SNPinfo SNP function prediction web tool and 
make sure the Splicing Regulation box is checked. If the SNP is near a splicing site, the 
Splicing (site) or Splicing (ESE or ESS) box in the SNPinfo output will contain a Y with a 
hyperlink for data on the splice variant.   
V. Create list of Tag SNPs based on linkage disequilibrium (LD) results obtained from Haploview 
software. 
a. For SNPs located in low priority regions, perform linkage test in Haploview to establish 
(LD) of the SNP of interest with other SNPs within or near the gene. This test can be 
conducted using data from HapMap or importing data from 1000 genomes into 
Haploview. Other online tools including SNPinfo, SNP Annotation and Proxy Search 
(SNAP), and the 1000 genomes web browser can be used to test for TagSNPs.  
i. Upload data from HapMap into Haploview by selecting the chromosome of 
interest, starting and ending kb, the population of interest, and the most recent 
HapMap build (version 3, release 27).  
ii. After creating an LD plot, run the Tagger function in Haploview to generate a list 
of SNPs that capture the largest number of alleles within the region of interest. 
For large genetic regions, several TagSNPs may be needed to cover the entire 






Appendix H: Stool sample collection and DNA extraction 
STOOL COLLECTION FOR STRONG KIDS STUDY 
Parents’ Instructions 
1. Collect your child’s stool specimen after the first bowel movement of that day. 
2. The stool specimen should be passed into a clean dry container such as a “potty chair” or the 
white plastic toilet insert given to you by the research group. If your child is not toilet-trained, you 
may collect the first bowel movement from diapers or training pants (e.g. “Pull-ups”). 
3. Your stool collection kit should contain all of the following: Nylon cooler, gloves, 3 collection 
containers, 3 sterile spoons, 3 collection tubes, and frozen gel packs 
4. Please wear the gloves supplied in the collection kit. After the sample is collected in one of the 
collection containers provided, you may call to have it picked up. If the sample is not able to be 
picked up that day, you may store it in your freezer in the nylon cooler until it is picked up. This 
procedure will be repeated two more times on separate days for the 2nd and 3rd samples.    
5. Alternatively, use one of the collection spoons to transfer a portion of the 1st specimen from the 
collection container to one of the collection tubes provided, filling the tube to the red line. Tightly 
secure the screw cap and store the sample in your freezer. This procedure will be repeated two 
more times on separate days for the 2nd and 3rd samples. Please store the samples in your freezer 
in the nylon cooler provided. You may discard the white collection containers after each use. Bring 
all 3 tubes to your scheduled visit. 
6. On the day of your visit to our facility, bring any remaining samples stored in the nylon cooler. 
 
Parents’ Instructions for follow-up sample collection 
1. Ask parent to review video on how to collect stool sample 
2. Collect your child’s stool specimen after the first bowel movement of that day. Sample collection 
should be done in the morning.   
3. The stool specimen should be passed into a clean dry container such as a “potty chair” or the 
white plastic toilet insert given to you by the research group. If your child is not toilet-trained, you 
may collect the first bowel movement from diapers or training pants (e.g. “Pull-ups”). 
4. Your stool collection kit should contain all of the following: Gloves, white plastic toilet insert, 
sterile spoon, sample bag A, bag B, aluminum bag C, nylon cooler 
5. The container is labeled with your child’s participation code in order to protect his or her privacy. 
6. Put on gloves to transfer the specimen into sample bag A, press out the air, and seal the zip top. 
Place sample bag A into bag B. 
7. Next, open aluminum bag C, take out the pouch, and place into bag B. Seal bag B. 
8. Place bag B with the sample and pouch into the nylon cooler and call immediately for a researcher 







Stool sample processing protocol 
ID Denaturing sol 
tube wt (g) 
Denaturing sol 
tube wt with 
sample (g) 
Oragene (check) Remaining sample 
(check) 
     
 
1. Once sample is processed by the Fahey group, the remaining sample will be further processed. 
2. First, use the autoclaved metal spatula to transfer ~20g of stool from the collection tube to the 
tube containing 20 ml of the denaturing solution. Fill this tube until the total volume reaches ~40 
ml. Close lid and vortex on high to homogenize the sample. This sample will be stored in the -80°C 
freezer. 
3. Next, transfer some of the sample to the Oragene tube using the plastic spatula provided and fill 
to the indicated line. Follow the instructions given in the kit. Please make sure to label the tube 
with the appropriate sample ID. Store this sample at room temperature (15-25°C). 
4. Two store stool sample for SCFA quantification, add equal amounts of stool and 2N HCl into 
Nalgene container (minimum 1g stool and 1 ml acid). Vortex to homogenize and store in -20°C for 
up to 1 month. Within 1 week of sample collection, measure out wet weight of portion of sample, 
dry at 50°C for 12 hours and record dry matter.  
5. Finally, store the original collection tube in the -80°C freezer. Complete all of the procedures 






DNA Extraction from Stool Protocol (2.5-3 hrs.) 
1. Partially thaw frozen stool samples on ice 
2. Use sterile spoon and column w/ beads (weigh and zero on scale before) 
3. Add ~200 mg (0.200g) stool into column w/ beads using plastic spoon 
4. After weighing samples, place on ice 
ID Whole Sample Bead Tube Sample Taken 
    
 
5. Add 1 mL ASL Buffer, vortex (super mixer at ~5.5) to homogenize (Use pipette tip to break down 
solids).  
6. Bead-beating step: place holder above tube caps to hold in place. Set to 6.0 m/s for 30 sec  
7. Incubate water bath 5 min at 95°C  (increases chance to lyse gram positive bacteria) 
8. Centrifuge for 1 min. at highest speed (13,000 rpm) 
9. Transfer 800 ul of supernatant to a new 2.0 mL tube, and discard bead tube 
10. Add 400 ul ASL solution, vortex briefly 
11. Add 1 inhibit Ex tablet, vortex to dissolve. Incubate at room temp for 1 min. once table dissolved 
12. Centrifuge for 3 min. at highest speed  
13. Transfer ~400 ul of supernatant to new 1.7 tube 
14. Centrifuge for 3 min. at full speed 
15. Into new 1.7 tube add 15 µl proteinase K, transfer ~200 ul of supernatant (avoid pellet), add 200 
µl AL buffer, vortex to mix. Extra supernatant can be frozen at -20°C 
16. Incubate at 70°C for 10 min.  
17. Add 200 µl 100% EtOH and vortex 
18. Transfer all liquid (~650 µl) to QIAamp spin column 
19. Centrifuge for 1 min, discard liquid and keep filter/column 
20. Wash by adding 500 µl AW1 buffer and centrifuging for 1 min, discard liquid again (tap on paper 
towel) 
21. Wash by adding 500 µl AW2 buffer and centrifuging for 3 min 
22. Move column to new 1.7 tube, centrifuge for 1 additional min.  
23. Move column to new 1.7 tube, add 100 µl AE buffer, and incubate at room temp for 1 min 
24. Centrifuge for 1 min, DNA is in AE buffer 
25. Quantify sample using Nanodrop 2000 blanking with AE buffer. Sample can be placed at -20°C for 






Appendix I: Plasmid design and isolation and qPCR procedure 
1. Custom plasmids were designed using GeneArt service after identifying 16s rRNA sequence, 
primer sequences, and annealing temperatures from the published literature. This information 
is summarized below: 
 
Table I.1 Real-time quantitative PCR primers used to determine density of fecal microbiota 
















Bifidobacterium spp. Bif164F- GGGTGGTAATGCCGGATG 
Bif662R- CCACCGTTACACCGGGAA 
60 Kok34 
Lactobacillus spp. LacF- AGCAGTAGGGAATCTTCCA 
LacR- CACCGCTACACATGGAG 
58 Rinttila36 




R. intestinalis F- GCATGACCTGGTGTGAA 
R- TTGGGCCGTGTCTCA 
56 Larsen38 
E. rectale F- CGGTACCTGACTAAGAAGC   
R- AGTTTYATTCTTGCGAACG 
61 Larsen38 
* Number indicates phylogenetic cluster of Clostridium as defined by Collins.37 
 
2. Plasmids were constructed with ampicillin resistance to allow for selective growth of heat-shock 
transformed E. coli in LB media overnight. 
3. Cloned plasmids were extracted using Oragene plasmid mini-prep 
4. Plasmid standards were quantified using Nanodrop 2000 and diluted to a stock concentration of 










1. qPCR reaction 
Reagent Volume per reaction (µl) 
Sybr green 5 
Bovine serum albumin (BSA) 1 
F primer 0.5 
R primer 0.5 
mH2O 1 
Total 8 
2. 2 µl of DNA from stool diluted to 5 ng/µl added in triplicate 
3. 2 µl of each standard (5E8, 5E7, 5E6) added in triplicate 
4. qPCR reaction temperature settings: 
                     50°C                    2 min 
                     95°C                   10 min 
 40                95°C                   15 sec                                                                                                                                 
cycles           60°C                    20 sec         
        72°C       45 sec         
  
5. Dissociation curve temperature settings: 
      95°C      15 sec 
     60°C                     15 sec                   
     95°C                     15 sec        
6. Samples quantified in SDS v2.4 software  




Appendix J: In vitro fermentation and SCFA quantification by Gas Chromatography 
 
1. The in vitro experiment was carried out following the protocol detailed in Bourquin.361 
2. Reagents for media: mineral solution A (330 ml), mineral solution B (330 ml), trace mineral 
solution (10 ml), resazurin solution (1 ml), yeast extract (0.5 g), trypticase (0.5 g), sodium 
carbonate monohydrate (4 g), dd water (296 ml), cysteine HCl monohydrate (0.5 g) 
3. In an autoclavable flask, reduce mixture above for 30 min. with copper dried carbon dioxide, seal 
and autoclave for 20 min. 
4. Add short chain fatty acid mix, filtered and sterilized water soluble vitamin solution (20 ml), 
folate:biotin solution (5 ml), riboflavin solution (5 ml), and hemin solution (2.5 ml). 
5. Mineral solution 1, mineral solution 2, sodium bicarbonate solution, anaerobic diluting solution 
6. Place Whatman 541 filter paper in a 105°C oven overnight and weight next day 
7. Weigh 0.3 g of sample, in triplicate, into 50 ml centrifuge tubes. Three blank tubes also needed 
8. Dispense 26 ml of medium into each tube. Stopper immediately with a rubber stopper containing 
a Bunsen valve. Allow substrate to hydrate at 4°C for 12-16 hrs. before inoculation 
9. Collect fresh feces in 50 ml tubes. Remove excess air in secondary container and maintain sample 
temperature at 37°C.  
10. Dilute feces 1:10 anaerobic diluting solution by blending it for 15 sec in Waring blender under 
carbon dioxide. Filter blended, dilute feces through 4 layers cheesecloth into serum bottles under 
carbon dioxide and seal. 
11. Warm tubes at 39°C for 45 min. Inoculate tubes with 4 ml 
12. Incubate tubes at 37°C with periodic mixing. 
13. After inoculation, transfer contents of tubes to 400 ml Berzelius beakers. Add 120 ml 95% ethanol 
and precipitate for 1 hr.  
14. For SCFA analysis, take 2 ml subsample and precipitate remaining 28 ml with 112 ml 95% ethanol. 
15. Filter precipitated sample tared with Whatman 541 filter paper. Rinse three 10 ml portions of 78% 






Appendix K: Body composition assessment 
Dual energy X-ray absorptiometry procedure 
1. Arrive 10-15 minutes before the start of the first scheduled appointment to prepare room for 
participant visit. 
2. Set-up stadiometer, calibrate scale, place disposable tissue over exam table, prepare breakfast 
table, and arrange participant information (consent, assent, survey) to be filled out by parent. 
3. QC machine using Phantom: Turn on computer and select QDR in the start-up menu (computer 
should automatically load APEX software). Select Daily QC, place phantom spine on table (need 
to align red X with white circle), click continue, and allow for scan to run. When the scan is 
complete, click review analysis and check total BMD value (should be between 0.972 and 1.002). 
Record this value in the log book and fill out other required information. Click OK.  
4. Take height and weight measurement of child while parent signs consent form and fills out the 
survey.  
5. Assent from child should be given before taking any measurement (refer to assent scripts if 
needed) Height and weight should be taken according to STRONG Kids protocol already 
established by following the instructions on ORB Project Height and Weight Measurement Form. 
6. Ask parents to read through and sign Consent Form. Inform parent of any modifications to the 
procedure described differently in the consent. Ask parents to fill out survey to the best of their 
knowledge. 
7. Once height and weight measurements have been taken, acquire assent from child to begin DXA 
scan. To perform scan, follow directions below: 
8. Make sure child is not wearing any clothes or garments containing metal (zippers, buttons, etc). 
If child is wearing metal containing clothing, ask child to remove that garment (if a coat) or to 
change into clothing provided. 
9. In the APEX software, click on perform scan and enter new patient. Follow instructions given in 
the SKP ORB Project Biological Information – Body Composition Testing VISIT 1 form. De-select 
default box and select whole body in the scan options. Ask child to lay flat on their back on the 
exam table with head facing towards computer. The child must be positioned within the black 
lines drawn on the exam table. Position rope on child’s feet to have toes point inward. Instruct 
child to be very still for the next two minutes and indicate that the table will move throughout the 
scan. Click start scan. When scan is complete, review scan and click on exit exam if scan results 
are satisfactory.  
10. If the child moves and the scan must be repeated, allow for scan to complete and inform child 
that the scan must be done again. Repeat procedure starting at step 9. 
11. Use of the machine must be logged into the log book provided. Additionally, all scans must be 
archived onto two back-up CDs. To archive, click on archive scan in the main menu and proceed 
in copying the new scans to the primary and secondary archive CDs. 
12. DXA scans were analyzed for regional fat distribution using anatomical features separating the 
upper and lower extremities from the head, trunk, hip, and abdominal regions of the body. Central 
adiposity was assessed using a region defined between L1 and L4 of the spine (red box). 
13. Regional fat measurements including android, gynoid, and visceral fat were calculating using the 










Appendix L: Survey data 
Recent Illness and Pre-, Pro- and Antibiotic Use Survey – Food Intake 
 
Please answer the first 2 questions by placing a Y in the boxes to indicate YES. For the 3rd question, please place a 
number under each column telling us how often your child has eaten any of the foods listed. Please indicate the 
mode of delivery for your child at birth and circle the appropriate duration of breastfeeding during infancy. 






Amoxicillin?     
Ciprofloxacin?     
Clindamycin?     
Erythromycin?     
Cefoperazone?     
If other, please specify:     
When was the last time your child received antibiotics? Date: (mm/dd/yyyy):  
Has your child had the following symptoms? Today In the last 7 days In the last 14 days 
Diarrhea?    
Constipation?    
Flu or flu-like symptoms?    
Ear infection?    
Has your child been diagnosed with Inflammatory Bowel Disease?    
Has your child been diagnosed with any type of colitis?    
Other disease, please specify:    
Please list the number of times your child has eaten the following 
foods 
Today In the last 7 days In the last 14 days 
Yogurt with live and active cultures (Yoplait, Dannon, Prairie Farms)    
Yogurt with probiotics such as Activia or Yo-plus    
Yogurt with probiotics and prebiotics such as Stoneyfield's YoBaby    
Soy products    
Oatmeal    
Rice    
Corn    
How was your child delivered?(cesarean section or vaginally)  
Was your child ever breastfed? Never Yes, <6 months Yes, >6 months 
 
Please record all food consumed by your child in the last 24hrs before the BREATH test is taken. 
Note food item and approximate quantity (example: Breakfast: ½ banana, milk (how many ounces) 
BREAKFAST 
LUNCH  




Appendix M: Dietary Assessment 
Interview protocol for multiple pass 24-hour dietary recall 
1. Ask parent to take a list of foods their child consumed throughout the day prior to data collection 
2. Review a quick list of all food and beverage intake of their child for the past 24 hours taken without 
interruption 
3. Follow the quick list with a forgotten foods list of food categories commonly overlooked in the 
quick recall stage 
4. Next, ask the parent the time and occasion of each intake 
5. For accuracy of the list, conduct a detail cycle to determine amounts and descriptions of all food 
items 
6. Lastly, conduct a final review probe to ensure all foods are accounted for 
7. For missing information on foods consumed at daycare, follow up can be conducted with daycare 
for day of intake 
8. Input dietary data into the 2014 Nutrition Data System for Research (NDSR, Nutrition Coordinating 
Center, Minneapolis, MN, USA) 






















Sample Dietary recall sheet 
Patient ID           
Date of 
Recall    Date of Intake   
 Recall 







lean, etc.)  
Quantity Unit Where Intake Occurred 
            




Items Specifics Quantity Unit 
Where Intake 
Occurred 
            
            
Additional 




Appendix N: Supplemental Tables and Figures for Chapter 2 
Supplemental Table N.1 Descriptive statistics of STRONG Kids ORB cohort and anthropometric and DXA differences of children in the STRONG 
Kids ORB cohort by sex (n=18) 
Variable ORB cohort (n=18) Boys (n=10) Girls (n=8) 
AGE (months) 68.7 ± 11.7 70.5 ± 13.9 66.4 ± 8.5 
WEIGHT (kg) 22.4 ± 3.8 21.9 ± 2.9 23.1 ± 5.0 
HEIGHT (cm) 116.8 ± 8.7 117.6 ± 7.2 115.8 ± 10.8 
BMI (kg/m2) 16.4 ± 1.5 15.9 ± 1.6 17.0 ± 1.1 
BMIPCT 67.7 ± 28.9 56.8 ± 33.6 81.9 ± 13.8 
ANDPFATC 26.7 ± 7.0 22.5 ± 5.0 32.1 ± 5.4 
VATPFATB 20.7 ±  6.5 17.2 ± 4.6 25.1 ± 6.1 
GYNPFATD 37.7 ± 6.1 33.4 ± 4.5 43.1 ± 2.5 
SUBABPFATB 6.6 ± 2.7 5.0 ± 2.6 8.5 ± 1.0 
TRUNKPFATD 20.6 ± 5.5 16.8 ± 3.6 25.3 ± 3.5 
WBPFATD 26.4 ± 5.7 22.5 ± 3.8 31.2 ± 3.2 
Abbreviations: ORB: Obesity-Risk Biomarkers, BMI: body mass index, BMIPCT: BMI percentile, ANDPFAT: android percent fat, VATPFAT: percent 

























Supplemental Table N.2 Relationship of obesity measures by Spearman correlation in girls (top, n=8) and boys (bottom, n=10) 
  BMI BMIPCT ANDPFAT VATPFAT GYNPFAT SUBABPFAT TRUNKPFAT WBPFAT 
BMI - 0.98D 0.43 0.55 0.79A 0.21 0.82A 0.80A 
BMIPCT  - 0.39 0.49 0.74 0.13 0.74 0.78A 
ANDPFAT   - 0.96C 0.40 -0.13 0.62 0.39 
VATPFAT      - 0.49 0.03 0.67 0.40A 
GYNPFAT     - -0.24 0.53 0.88B 
SUBABPFAT      - 0.40 -0.29 
TRUNKPFAT       - 0.64 
WBPFAT        - 
 
  BMI BMIPCT ANDPFAT VATPFAT GYNPFAT SUBABPFAT TRUNKPFAT WBPFAT 
BMI - 1.00D 0.51 0.53 0.48 -0.19 0.29 0.50 
BMIPCT  - 0.51 0.53 0.48 -0.19 0.29 0.50 
ANDPFAT   - 0.98D 0.85B 0.08 0.93C 0.96D 
VATPFAT    - 0.89B 0.09 0.89B 0.94C 
GYNPFAT     - -0.18 0.79 0.85B 
SUBABPFAT      - 0.28 0.22 
TRUNKPFAT       - 0.97D 
WBPFAT        - 
Abbreviations: ORB: Obesity-Risk Biomarkers, BMI: body mass index, BMIPCT: BMI percentile, ANDPFAT: android percent fat, VATPFAT: percent 
visceral adipose tissue, GYNPFAT: gynoid percent fat, SUBABPFAT: percent subcutaneous adipose tissue in abdomen, TRUNKPFAT: trunk percent 
fat, WBPFAT: whole body percent fat. Superscripts represent significant P-values:  A (P < 0.05), B (P < 0.01), C (P < 0.001), D (P < 0.0001) (Student’s 





Appendix O: Supplemental Tables and Figures for Chapter 3 
Supplemental Table O.1 Descriptive Characteristics of children in the GHBC Cohort stratified by sex and overweight status 
 











Age (months) 52.0 ± 9.9 52.7 ± 11.5 51.0 ± 7.8 0.7011 49.8 ± 8.7 55.9 ± 11.3 0.2443 
Height (cm) 105.7 ± 7.4 105.5 ± 8.2 106.0 ± 6.6 0.8680 104.2 ± 6.9 108.4 ± 7.9 0.2684 
Weight (kg) 18.5 ± 3.4 18.7 ± 3.6 18.3 ± 3.4 0.8454 17.1 ± 15.3 21.0 ± 18.2 0.0168 
BMI (kg/m
2
) 16.4 ± 1.3 16.6 ± 1.1 16.2 ± 1.5 0.5245 15.6 ± 0.8 17.8 ± 0.5 <0.0001 
BMIPCT (%) 68 ± 27.3 70.5 ± 27.7 64.5 ± 28.1 0.6474 53.4 ± 24.1 93.0 ± 2.7 <0.0001 
ANDPFAT 27.7 ± 5.6 26.2 ± 3.6 30.2 ± 7.6 0.2268 27.1 ± 5.1 28.7 ± 6.7 0.6112 
VATPFAT 21.1 ± 5.5 19.5 ± 3.7 23.5 ± 7.1 0.2071 20.1 ± 4.9 22.6 ± 6.4 0.4027 
GYNPFAT 42 ± 6.7 41.0 ± 5.7 43.7 ± 8.2 0.4564 42.6 ± 7.7 41.1 ± 5.0 0.6048 
REG1PFAT 25.5 ± 5.1 24.2 ± 3.1 27.5 ± 7.1 0.2844 25.1 ± 4.4 26.2 ± 6.3 0.6742 
TRUNKPFAT 25.4 ± 4.7 24.3 ± 2.9 27.2 ± 6.4 0.2906 24.6 ± 3.9 26.8 ± 5.7 0.3805 




Data presented as means ± SD. Significant P-values are in boldface. Data tested using Student’s T-test. Abbreviations: GHBC: Gut Health and 
Body Composition Study, BMI: body mass index, BMIPCT: BMI percentile, ANDPFAT: android percent fat, VATPFAT: percent visceral adipose 






Supplemental Table O.2 Descriptive Characteristics of dietary data by overweight status 

















Energy (kcal) 1515.4 ± 584.2 1685.10 ± 621.9 1273.0 ± 461.8 0.1432 1364.0 ± 618.3 1792.97 ± 429.5 0.0875 
Total Fat (g) 59.5 ± 34.1 67.3 ± 40.9 48.5 ± 31.2 0.3798 55.0 ± 37.7 68.0 ± 27.4 0.1594 
Total Carb (g) 203.3 ± 86.5 220.3 ± 96.1 179.2 ± 70.5 0.3291 178.5 ± 86.0 248.9 ± 73.0 0.0348 
Total Protein 
(g) 
49.2 ± 16.9 58.3 ± 14.2 36.2 ± 10.9 0.0047 45.8 ± 18.2 55.5 ± 13.2 0.1914 
Total Dietary 
Fiber (g) 
14.5 ± 9.5 17.1 ± 10.8 10.8 ± 6.15 0.1184 12.9 ± 10.8 17.4 ± 6.3 0.0444 
Soluble Fiber 
(g) 
4.0 ± 2.4 4.7 ± 2.5 3.1 ± 2.1 0.0790 3.6 ± 2.6 4.9 ± 2.0 0.1594 
Insoluble 
Fiber (g) 
10.4 ± 7.2 12.3 ± 8.3 7.7 ± 4.4 0.1432 9.3 ± 8.2 12.6 ± 4.7 0.0562 
Fat (% of total 
kcal) 
33.5 ± 9.6 33.3 ± 12.0 33.7 ± 28.8 0.6256 33.7 ± 10.5 32.9 ± 8.5 0.9199 
Carb (% of 
total kcal) 
52.8 ± 9.6 51.4 ± 11.3 54.7 ± 6.7 0.6963 51.9 ± 10.4 54.4 ± 8.6 0.6153 
Protein (% of 
total kcal) 




Supplemental Table O.3 Frequency of breastfeeding, mode of delivery, and exhaled gas from breath 
Variable Mean ± SD 0 1 
Mode of delivery NA 4 13 
Duration of breastfeeding NA 6 11 
Breath hydrogen (H2 in ppm) 7.6 ± 6.1 8 9 
Breath carbon dioxide (CO2 in %) 3.4 ± 0.7 8 9 
Breath methane (CH4 in ppm) 0.4 ± 1.0 14 3 
Data are presented as either means ± SD or number of observations for each category. Breath hydrogen and methane gas expressed in ppm. 
Breath carbon dioxide expressed as percent of total gas measured. Mode of delivery: 0=delivered by cesarean section, 1=delivered vaginally; 





Supplemental Table O.4 Comparison of body composition by exhaled gas in breath category 
 Hydrogen (H2 in ppm) Carbon dioxide (CO2 in ppm) Breath methane (CH4 in ppm) 
 Low H2 High H2 P-value Low CO2 High 
CO2 
P-value Low CH4 High 
CH4 
P-value 
BMI 16.22 16.69 0.5006 15.76 17.11 0.0343 16.26 17.46 0.1306 
BMIPCT 63.90 72.24 0.5006 52.06 82.76 0.0343 65.45 81.69 0.1658 
ANDPFAT 26.25 28.97 0.1722 26.44 28.78 1.000 27.36 28.69 0.9464 
GYNPFAT 39.67 43.85 0.2076 43.42 40.10 0.248 42.08 40.40 0.5449 
VATPFAT 19.60 22.87 0.2076 19.74 22.73 0.7527 21.04 22.08 0.7366 
REG1PFAT 23.16 27.28 0.1722 24.56 25.88 0.8336 24.88 26.68 0.7366 
TRUNKPFAT 24.13 26.74 0.3446 24.79 26.07 0.8336 25.02 27.24 0.7366 
WBPFAT 30.74 33.91 0.0929 32.58 32.09 0.5286 32.28 32.50 0.6377 
Data expressed as mean value for body composition measurement for groups categorized by low and high exhaled gas production. Significant P-





Supplemental Table O.5 Comparison of bacterial abundance by exhaled gas in breath category 
 Hydrogen (H2 in ppm) Carbon dioxide (CO2 in %) Breath methane (CH4 in ppm) 
 Low High P-value Low High P-value Low High P-value 
F. prausnitzii 11.63 11.64 0.3359 11.47 11.78 0.179 11.59 11.90 0.1658 
Lactobacillus spp. 7.89 8.02 0.7003 7.65 8.23 0.1779 7.98 7.84 1.000 
Bifidobacterium spp. 10.45 10.65 0.211 10.49 10.61 0.3359 10.54 10.61 0.7055 
R. intestinalis 10.70 10.82 0.6304 10.88 10.66 0.211 10.82 10.50 0.3778 
Bacteroides-Prevotella 
group 
11.12 11.12 0.9233 10.99 11.24 0.211 11.03 11.54 0.2077 
Clostridium cluster IV 10.96 10.96 0.6304 10.81 11.09 0.0833 10.90 11.25 0.0438 
Clostridium  cluster XIVa 11.09 11.14 0.2482 11.04 11.18 0.1779 11.10 11.18 0.6143 
Data expressed as mean value for log copies of 16s rRNA gene for groups categorized by low and high exhaled gas production. Significant P-






Supplemental Table O.6 Comparison of body composition by total energy and macronutrient category 
 Total Energy Total Fat Total Carbohydrate Total Protein 
 Low High P-value Low High P-value Low High P-value Low High P-value 
BMI 16.12 16.69 0.3359 16.22 16.60 0.7003 15.98 16.81 0.1489 16.02 16.78 0.3359 
BMIPCT 63.13 70.41 0.3359 61.87 71.52 0.5637 56.44 76.35 0.1237 62.47 71.00 0.2898 
ANDPFAT 30.08 25.64 0.2235 27.35 27.77 0.7913 27.97 27.29 0.7913 30.40 25.40 0.6400 
GYNPFAT 45.54 39.76 0.1530 42.38 42.21 0.9578 44.70 40.41 0.2235 45.69 39.64 0.1248 
VATPFAT 22.32 19.91 0.4914 19.71 21.93 0.2235 20.66 21.19 0.7913 23.08 19.31 0.2235 
REG1PFAT 28.08 23.38 0.0640 25.55 25.34 0.9578 26.75 24.4 0.4273 27.60 23.75 0.1530 
TRUNKPFAT 27.23 24.11 0.4914 25.98 25.08 0.9578 26.29 24.84 0.7913 27.90 23.58 0.0807 
WBPFAT 34.77 30.41 0.1530 32.29 32.34 0.9578 33.65 31.28 0.3683 34.80 30.39 0.1530 
Data expressed as mean value for body composition measurements for groups categorized by low and high dietary composition values. 






Supplemental Table O.7 Comparison of body composition by dietary fiber category 
 Total Dietary Fiber Soluble Fiber Insoluble Fiber 
 Low High P-value Low High P-value Low High P-value 
BMI 15.95 16.84 0.1779 16.26 16.57 0.5006 16.08 16.73 0.2482 
BMIPCT 61.08 72.23 0.1779 64.95 68.79 0.5637 62.88 70.63 0.2482 
ANDPFAT 28.01 27.26 0.5604 29.03 26.46 0.7110 27.39 27.74 0.8738 
GYNPFAT 44.47 40.59 0.4273 46.00 39.40 0.807 44.67 40.43 0.3146 
VATPFAT 20.87 21.03 0.7110 22.61 19.68 0.3146 19.80 21.86 0.4914 
REG1PFAT 25.48 25.40 0.5604 26.85 24.34 0.7110 25.47 25.41 0.6338 
TRUNKPFAT 25.55 25.41 0.6338 27.14 24.18 0.3683 25.02 25.83 0.7913 
WBPFAT 33.38 31.49 0.4914 34.88 30.32 0.1009 33.44 31.44 0.3683 
Data expressed as mean value for body composition measurements for groups categorized by low and high dietary fiber values. Significant P-






Supplemental Table O.8 Comparison of bacterial abundance by total energy and macronutrient category 
 Total Energy Total Fat Total Carbohydrate Total Protein 
 Low High P-value Low High P-value Low High P-value Low High P-value 
F. prausnitzii 11.66 11.70 0.5637 11.66 11.70 0.5006 11.53 11.81 0.0833 11.73 11.64 0.6304 
Lactobacillus spp. 8.00 8.00 0.9233 8.34 7.70 0.1779 8.01 7.99 0.7728 7.97 8.03 0.8474 
Bifidobacterium spp. 10.52 10.51 0.8474 10.50 10.53 0.8474 10.56 10.48 0.5637 10.41 10.61 0.2110 
R. intestinalis 11.04 10.57 0.1779 11.02 10.59 0.1237 10.91 10.69 0.5637 11.17 10.46 0.0124 
Bacteroides-Prevotella 
group 
11.32 11.14 0.7728 11.32 11.14 0.7728 11.15 11.29 0.3359 11.38 11.09 0.2898 
Clostridium cluster IV 11.04 11.00 0.8474 11.01 11.03 0.9233 10.96 11.07 0.3865 11.02 11.02 0.9233 
Clostridium  cluster 
XIVa 
11.18 11.07 0.3359 11.16 11.09 0.7003 11.11 11.14 0.8474 11.15 11.10 0.5637 
Data expressed as mean value for log copies of 16s rRNA gene for groups categorized by low and high dietary composition values. Significant P-






Supplemental Table O.9 Comparison of bacterial abundance by dietary fiber category 
 Total Dietary Fiber Soluble Fiber Insoluble Fiber 
 Low High P-value Low High P-value Low High P-value 
F. prausnitzii 11.64 11.71 0.3865 11.60 11.75 0.6304 11.62 11.74 0.2898 
Lactobacillus spp. 7.52 8.43 0.0433 7.78 8.19 0.5637 7.79 8.18 0.4414 
Bifidobacterium spp. 10.41 10.61 0.1489 10.54 10.49 0.7003 10.49 10.53 0.7728 
R. intestinalis 11.18 10.45 0.0124 10.84 10.75 0.5637 11.05 10.56 0.1489 
Bacteroides-Prevotella 
group 
11.28 11.18 0.8474 11.24 11.21 0.9233 11.22 11.23 0.4414 
Clostridium cluster IV 10.99 11.05 0.5006 11.00 11.04 0.8474 11.00 11.03 0.6304 
Clostridium  cluster 
XIVa 
11.10 11.14 0.5637 11.10 11.14 0.7728 11.14 11.11 0.9233 
Data expressed as mean value for log copies of 16s rRNA gene for groups categorized by low and high dietary fiber values. Significant P-values in 






Supplemental Table O.10 Correlations between obesity phenotypes and bacterial abundance for the GHBC cohort 











BMIPCT 0.39 0.11 0.46 0.23 0.15 0.45 0.47 
ANDPFAT 0.18 0.07 0.21 0.58A 0.43 0.21 0.62A 
GYNPFAT 0.16 0.02 0.23 0.33 0.05 -0.02 0.26 
VATPFAT -0.04 0.02 0.24 0.32 0.27 -0.02 0.32 
REG1PFAT 0.17 0.19 0.34 0.47 0.40 0.28 0.67A 
TRUNKPFAT 0.13 0.09 0.25 0.44 0.26 0.00 0.37 
WBPFAT 0.38 0.09 0.36 0.40 0.18 0.23 0.43 
Age, sex, and dietary fiber category included as covariates.  






Supplemental Table O.11 Change in SCFA quantity from fermentation initial to final by total body fat and dietary fiber consumption 
Data presented as mean difference in SCFA from initial to final time points. 
Significant P-values in boldface. Data tested using Kruskal-Wallis. 
  











Mean Mean P-value Mean Mean P-value 
Δacetate 94353.7 225729.0 0.0495 127311.0 192772.0 0.5127 
ΔPropionate 27308.1 49152.8 0.2752 37477.2 38983.7 0.8273 
ΔButyrate  82784.7 95076.4 0.8273 36325.3 141536.0 0.0495 




Supplemental Table O.12 Correlations between body composition and bacterial abundance by sex 
  
  











 Boys Girls Boys Girls Boys Girls Boys Girls Boys Girls Boys Girls Boys Girls 
BMIPCT 0.45 0.90 0.18 0.46 0.39 0.10 0.08 -0.77 -0.09 0.19 0.02 0.90 -0.13 0.73 
ANDPFAT 0.21 0.33 0.00 0.86 0.16 0.16 0.45 0.65 0.57 0.72 0.32 0.37 0.78 0.51 
GYNPFAT 0.22 0.47 0.13 0.93 0.19 0.19 0.12 0.53 0.10 0.74 0.22 0.52 0.56 0.61 
VATPFAT -0.09 0.33 -0.47 0.86 0.08 0.16 -0.06 0.65 0.19 0.72 -0.01 0.37 0.28 0.51 
REG1PFAT 0.11 0.33 0.26 0.86 0.43 0.16 0.29 0.65 0.32 0.72 0.37 0.37 0.82 0.51 
TRUNKPFAT 0.24 0.33 -0.06 0.86 0.21 0.16 0.21 0.65 0.28 0.72 0.09 0.37 0.43 0.51 
WBPFAT 0.39 0.65 0.04 0.99 0.24 0.18 0.20 0.31 0.09 0.76 0.32 0.70 0.50 0.76 
Age and dietary fiber category included as covariates.  


















Data presented as mean value as a percent of total SCFA at initial and final time points. 


















(% total SCFA) 
Mean Mean P-value Mean Mean ± SD P-value 
AcetatePCTi  36.9 32.6 0.8273 26.1 43.4 0.1266 
PropionatePCTi  47.58 41.2 0.8273 58.8 29.9 0.0495 
ButyratePCTi  15.5 26.2 0.2752 15.1 26.6 0.1266 
AcetatePCTf  49.0 62.4 0.2752 61.5 49.9 0.5127 
PropionatePCTf  15.9 13.8 0.8273 19.8 9.9 0.0495 




Supplemental Table O.14 Differences in dietary composition by total body fat and dietary fiber intake for in vitro study 
Data presented as means ± SD 
Significant P-values in boldface. Data tested using Kruskal-Wallis test. 
  












Energy (kcal) 1559.9 ± 535.7 1661.0 ± 697.0 1458.7 ± 448.4 0.8273 1247.7 ± 442.1 1872.0 ± 479.3 0.1266 
Total Fat (g) 61.0 ± 25.3 65.4 ± 34.8 56.5 ± 18.1 0.5127 52.2 ± 35.0 69.8 ± 12.0 0.5127 
Total Carb (g) 215.2 ± 85.2 219.3 ± 116.1 211.0 ± 67.8 0.8273 154.3 ± 16.2 276.0 ± 82.2 0.0495 
Total Protein 
(g) 
46.2 ± 12.4 53.7 ± 12.2 38.8 ± 8.6 0.1266 43.6 ± 15.1 48.9 ± 11.7 0.5127 
Total Dietary 
Fiber (g) 
16.5 ± 6.2 15.7 ± 7.6 17.2 ± 6.0 0.8273 11.3 ± 3.0 21.6 ± 2.4 0.0495 
Soluble Fiber 
(g) 
4.1 ± 1.3 4.2 ± 1.6 4.0 ± 1.3 0.8273 3.1 ± 0.3 5.1 ± 1.1 0.0495 
Insoluble Fiber 
(g) 
12.3 ± 5.0 11.3 ± 5.8 13.2 ± 5.0 0.5127 8.2 ± 3.0 16.3 ± 2.2 0.0495 
Fat (% of total 
kcal) 
33.9 ± 7.4 33.9 ± 11.4 33.9 ± 2.4 0.5127 34.4 ± 11.2 33.4 ± 3.2 0.8273 
Carb (% of 
total kcal) 
54.0 ± 7.6 52.2 ± 11.4 55.8 ± 2.0 0.5127 51.5 ± 10.8 56.5 ± 2.9 0.8273 
Protein (% of 
total kcal) 




Appendix P: Supplemental Tables and Figures for Chapter 4 
Supplemental Table P.1 Allele Frequencies, Hardy Weinberg Equilibrium and genotype frequency comparison of candidate SNPs in the 
STRONG Kids Cohort 























ANGPTL4 rs1044250 C/T T T 0.30 T 0.33 0.66 T 0.23 0.21 0.0230 
ANGPTL4 rs2278236 G/A A C 0.49 C 0.45 0.96 T 0.47 0.57 0.1415 
ANGPTL4 rs7255436 C/A A C 0.44 C 0.44 0.96 C 0.36 0.97 0.0777 
ANGPTL3 rs10889337 G/A A A 0.37 A 0.31 0.66 G 0.49 0.73 <0.0001 
CD36 rs3173798 T/C C C 0.12 C 0.07 0.66 C 0.17 0.45 0.0015 
CD36 rs10499859 A/G G G 0.48 A 0.46 0.31 G 0.32 0.53 <0.0001 
CD36 rs1527483 C/T T T 0.07 T 0.09 0.53 T 0.02 0.82  
FFAR1 rs10423648 A/G G G 0.1 G 0.06 <0.01 G 0.16 0.63  
FFAR2 rs2074056 C/T T T 0.22 T 0.19 0.45 T 0.32 0.84 0.0014 
FFAR3* rs423385 C/T T T 0.15 T 0.2 0.80 T 0.03 0.93 0.0003 
FFAR3* rs424241 C/T T T 0.01 T 0.02 0.11 T 0.01 0.74  
FFAR3 rs10422744 C/T T T 0.43 T 0.42 0.01 T 0.47 0.97  
GCG rs6717659 C/A A A 0.09 A 0.03 0.22 A 0.15 0.12  
GHRL rs27647 C/T C C 0.34 C 0.42 0.71 C 0.21 0.07 <0.0001 
GHRL rs696217 G/T T T 0.07 T 0.09 0.96 T 0.02 0.82  
IL6 rs1554606 G/T T T 0.41 T 0.47 0.91 T 0.38 0.57 0.1488 
LEP rs11761556 A/G G A 0.47 C 0.46 0.29 A 0.26 0.02 <0.0001 
LEP rs1349419 C/A A G 0.46 A 0.46 0.77 G 0.2 0.01 <0.0001 
LEP rs7799039 G/A A A 0.4 A 0.44 0.23 A 0.21 0.01  
LEPR rs1137101 A/G A A 0.5 G 0.46 0.30 A 0.49 0.41 0.5312 
LPL rs12678919 A/G G G 0.10 G 0.09 0.76 G 0.13 0.10  
LPL rs13702 T/C C G 0.32 G 0.26 0.68 G 0.47 0.82  
LPL rs1800590 T/G G G 0.11 G 0.02 0.71 G 0.33 0.11  
LPL rs328 C/G G G 0.09 G 0.10 0.67 G 0.10 0.85  
NFkB rs230531 G/A G C 0.29 C 0.35 0.82 C 0.13 0.07 <0.0001 
NFkB rs6834596 G/C C C 0.01 - 0 1.0 C 0.05 0.00  
NPY rs2189495 A/G A C 0.49 C 0.49 0.31 C 0.46 0.25 0.3724 
NPY rs16145 G/T G A 0.47 A 0.49 0.27 A 0.39 0.76 0.0445 
NPY2R rs1047214 C/T C C 0.38 C 0.47 0.03 C 0.15 0.77 <0.0001 
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NPY2R rs2880415 C/T C G 0.41 G 0.47 0.04 G 0.24 0.51 <0.0001 
PPARG rs12639162 A/G G G 0.24 G 0.25 0.04 G 0.22 0.51 0.6070 
PPARG rs1801282 C/G G G 0.1 G 0.13 0.28 G 0.03 0.67  
PPARG rs2279525 T/C C C 0.34 C 0.31 0.56 C 0.42 0.68 0.0157 
PYY rs2070592 C/T C G 0.36 G 0.32 0.77 G 0.43 0.98 0.0283 
PYY rs2014257 T/A A T 0.12 T 0.1 0.53 T 0.07 0.08  
PYY rs228771 C/G G C 0.32 C 0.41 0.37 C 0.12 0.47 <0.0001 
SLC11A1 rs2695343 A/G A A 0.5 A 0.39 0.47 G 0.27 <0.01  
SLC16A1 rs7169 G/A G C 0.34 C 0.41 0.63 C 0.18 0.46 <0.0001 
SLC16A1 rs9429505 A/G G G 0.29 G 0.22 0.54 A 0.48 0.47 <0.0001 
SLC16A3 rs4550503 T/C T T 0.29 T 0.3 0.87 T 0.32 0.74 0.9306 
SLC16A3 rs4789698 C/T C G 0.46 A 0.44 0.26 G 0.3 0.72 <0.0001 
SLC16A3 rs3176827 A/G A T 0.26 T 0.29 0.91 T 0.22 0.72 0.1110 
SLC16A4 rs12062656 G/C C C 0.09 C 0.07 0.11 C 0.14 0.86 0.0136 
SLC16A4 rs3738750 C/T T T 0.16 T 0.2 0.25 T 0.07 0.74 <0.0001 
SLC1A2 rs1570226 T/G G G 0.25 G 0.32 0.15 G 0.1 0.19 <0.0001 
SLC5A8 rs1709189 C/T T T 0.21 T 0.22 0.89 T 0.16 0.85 0.1451 
SLC5A8 rs7309172 G/T T T 0.23 T 0.18 0.79 T 0.36 0.66 0.0014 
SLC5A8 rs844016 T/C T C 0.48 C 0.44 0.39 T 0.45 0.11 0.0077 
TLR4 rs11536889 G/C C C 0.12 C 0.15 0.21 C 0.04 0.57  
TLR4 rs4986790 A/G G G 0.06 G 0.06 0.07 G 0.05 0.24 0.8241 





Supplemental Table P.2 List of Ancestry Informative Markers and MAF Comparisons 
Ch. Gene SNP P-value for HAZ Excluded from 64 
AIMs PCA 
NHW MAF NHB MAF 
4 LIMCH1 rs10007810 0.9255  0.24 0.29 
8 CSMD1 rs10108270 0.0156 1 0.28 0.24 
7 Intergenic rs10236187 0.9976  0.06 0.44 
6 CDYL rs1040045 0.0266 1 0.24 0.31 
1 TIPRL rs1040404 0.3419  0.28 0.32 
2 Intergenic rs10496971 0.3430  0.08 0.08 
3 CNTN4 rs10510228 0.2641  0.08 0.08 
17 Intergenic rs10512572 0.9021  0.11 0.20 
9 ASTN2 rs10513300 0.0871 1 0.4 0.03 
11 OR5P3 rs10839880 0.2296  0.37 0.25 
11 FBXL11 rs11227699 0.1570  0.34 0.42 
17 Intergenic rs11652805 0.0000 1 0.18 0.27 
1 USP24 rs12130799 0.0344 1 0.07 0.05 
15 Intergenic rs12439433 0.5012  0.02 0.07 
8 Intergenic rs12544346 0.7489  0.36 0.20 
3 Intergenic rs12629908 0.0179 1 0.05 0.07 
5 CMYA5 rs12657828 0.8621  0.12 0.25 
1 HIVEP3 rs1325502 0.1545  0.14 0.37 
2 CTNNA2 rs13400937 0.8020  0.29 0.30 
4 ADAMTS3 rs1369093 0.5582  0.04 0.26 
9 Intergenic rs1408801 0.8218  0.08 0.43 
8 KIF13B rs1471939 0.8903  0.28 0.30 
3 LPP rs1513181 0.4941  0.15 0.18 
14 PARP2,RPPH1 rs1760921 0.0312 1 0.04 0.48 
11 Intergenic rs1837606 0.9207  0.32 0.40 
6 Intergenic rs1871428 0.1777  0.34 0.20 
14 Intergenic rs1950993 0.4250  0.36 0.25 
14 Intergenic rs200354 0.3067  0.13 0.47 
3 Intergenic rs2030763 0.4057  0.19 0.06 
9 GTF3C5,CEL rs2073821 0.5130  0.13 0.02 
17 UNK,H3F3B rs2125345 0.0522 1 0.33 0.20 
12 Intergenic rs214678 0.8230  0.11 0.07 
9 SYK rs2306040 0.5192  0.06 0.05 
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Ch. Gene SNP P-value for HAZ Excluded from 64 
AIMs PCA 
NHW MAF NHB MAF 
14 Intergenic rs2357442 0.0987 1 0.13 0.17 
6 PKHD1 rs2397060 0.0399 1 0.14 0.34 
12 Intergenic rs2416791 0.0459 1 0.13 0.31 
6 Intergenic rs2504853 0.8542  0.35 0.37 
2 EDAR rs260690 0.6532  0.06 0.49 
2 TTN rs2627037 0.0347 1 0.09 0.36 
4 Intergenic rs2702414 0.9869  0.11 0.11 
11 Intergenic rs2946788 0.0014 1 0.29 0.32 
1 PLEKHG5 rs2986742 0.0149 1 0.11 0.43 
1 Intergenic rs3118378 0.9439  0.33 0.37 
5 Intergenic rs316598 0.0493 1 0.27 0.23 
1 PLD5 rs316873 0.5077  0.11 0.11 
7 Intergenic rs32314 0.2494  0.26 0.27 
19 ZNF528 rs3745099 0.0008 1 0.13 0.38 
14 BRF1 rs3784230 0.0277 1 0.42 0.19 
4 Intergenic rs385194 0.1321  0.27 0.24 
20 Intergenic rs3907047 0.0474 1 0.04 0.02 
8 DLC1 rs3943253 0.2124  0.08 0.26 
6 UTRN rs4463276 0.8172  0.25 0.23 
2 ALK rs4666200 0.1056 1 0.29 0.30 
2 Intergenic rs4670767 0.1302 1 0.10 0.09 
7 ELN rs4717865 0.4423  0.08 0.04 
10 USP54 rs4746136 0.0040 1 0.15 0.08 
16 CIITA rs4781011 0.4320  0.40 0.42 
22 Intergenic rs4821004 0.2953  0.41 0.28 
18 RTTN rs4891825 0.3512  0.08 0.31 
1 FGR,AHDC1 rs4908343 0.2158  0.19 0.24 
10 HABP2 rs4918842 0.6098  0.16 0.12 
16 FBXL16,STUB1,LOC33
9123,WDR24 
rs4984913 0.7888  0.27 0.33 
22 Intergenic rs5768007 0.1505  0.14 0.06 
5 COL23A1 rs6422347 0.2587  0.08 0.33 
5 NNT rs6451722 0.0040 1 0.21 0.32 




Supplemental Table P.2 cont’d 
Ch. Gene SNP P-value for HAZ Excluded from 64 
AIMs PCA 
NHW MAF NHB MAF 
1 Intergenic rs647325 0.5554  0.22 0.46 
3 ROBO1 rs6548616 0.9295  0.47 0.27 
7 Intergenic rs705308 0.6674  0.47 0.18 
18 Intergenic rs7238445 0.8462  0.26 0.26 
7 SCIN rs731257 0.6170  0.14 0.08 
3 Intergenic rs734873 0.9717  0.13 0.05 
2 Intergenic rs7421394 0.3606  0.34 0.23 
1 
TNFAIP8L2,LYSMD1,S
EMA6C rs7554936 0.3527  
0.34 0.21 
4 Intergenic rs7657799 0.1271 1 0.03 0.45 
12 CIP29 rs772262 0.0309 1 0.09 0.38 
6 FLJ22536 rs7745461 0.2045  0.14 0.28 
7 FLJ43663 rs7803075 0.3224  0.26 0.28 
8 Intergenic rs7844723 0.2250  0.42 0.16 
2 Intergenic rs798443 0.0670 1 0.23 0.34 
13 Intergenic rs7997709 0.4016  0.07 0.20 
15 Intergenic rs8035124 0.1438  0.16 0.38 
19 WDR88 rs8113143 0.0079 1 0.36 0.24 
16 LOC283867 rs818386 0.1697  0.17 0.09 
5 Intergenic rs870347 0.9698  0.07 0.07 
18 Intergenic rs874299 0.4052  0.29 0.22 
13 Intergenic rs9319336 0.1686  0.06 0.15 
11 GRIK4 rs948028 0.2863  0.19 0.42 
13 ARHGEF7 rs9522149 0.7450  0.22 0.23 
13 TBC1D4 rs9530435 0.0122 1 0.18 0.35 
3 
TTC21A,WDR48,GOR
ASP1 rs9809104 0.0092 1 
0.24 0.28 
3 MSL2L1 rs9845457 0.6524  0.41 0.19 
All reported minor allele frequencies (MAF) reported from Ensembl database. 
29 SNPs excluded from 64 AIMs principal component analysis (P-value<0.13 for HAZ). 





Supplemental Table P.3 Eigenvalues for 93 and 64 AIMs in ALLSKP and NHW+NHB 
 93 AIMs in 
ALLSKP 
93 AIMs in 
NHW+NHB 
64 AIMs in 
ALLSKP 




Eigenvalue Eigenvalue Eigenvalue Eigenvalue 
1 79.4788 72.6315 66.7533 60.2186 
2 20.2368 7.83741 25.0730 10.4372 
3 9.0141 7.65776 11.6200 10.1478 
4 8.2869 7.35049 11.2251 10.0349 
5 8.1953 7.28038 10.8846 9.88714 
6 7.8690 6.91781 10.7179 9.13931 
7 7.7249 6.66713 10.2445 8.68369 
8 7.6656 6.62216 10.0833 8.46627 
9 7.4133 6.37146 9.81836 8.39415 
10 7.2493 6.25242 9.41693 8.19162 






Supplemental Table P.4 β-coefficients for weighted GRS in NHW+NHB, NHW, and NHB for BMIZ 
NHW+NHB β-coefficient additive* β-coefficient dominant β-coefficient recessive Armitage Exact 
Test P-value 
Gene SNP 0 1 2 0 1 0 1 
PPARG rs12639162 0 0.2158 0.2240 0 0.1881 -- -- 0.2293 
ANGPTL4 rs1044250 0 -0.1160 0.0932 -- -- 0 0.2202 0.5244 
IL6 rs1554606 -0.3110 -0.0772 0 -0.2558 0 -- -- 0.2652 
SLC16A3 rs3176827 -0.1003 0.0885 0 -0.1733 0 -- -- 0.3388 
PYY rs2070592 -0.1588 -0.2159 0 -- -- -0.1882 0 0.0940 
NHW only         
Gene SNP         
PPARG rs12639162 0 -0.2128 0.1542 0 0.3244 -- -- 0.2874 
ANGPTL4 rs1044250 0 0.2442 0.1962 -- -- 0 0.2206 0.2968 
ANGPTL3 rs10889337 0 0.9003 0.8336 0 0.2276 -- -- 0.0882 
LPL rs13702 -0.2604 -0.2201 0 -- -- 0 0.8615 0.3432 
PYY rs2014257 -0.2186 -0.4552 0 0 0.2009 -- -- 1.0000 
NPY2R rs1047214 0 -0.0060 0.2319 -- -- -0.2360 0 0.3247 
SLC5A8 rs7309172 0 0.1900 0.4145 0 0.2464 -- -- 0.3141 
SLC16A3 rs3176827 -0.0692 0.1627 0 -0.2027 0 -- -- 0.2849 
SLC16A1 rs9429505 0 0.2914 0.0581 -0.2036 0 -- -- 0.2524 
IL6 rs1554606 -0.2314 -0.0914 0 -0.1686 0 -- -- 0.4727 
NHB only         
Gene SNP         
CD36 rs3173798 0 0.3616 0.5260 -0.3713 0 -- -- 0.1044 
PYY rs2070592 -0.2756 -0.5309 0 -- -- -0.4266 0 0.0290 
NPY2R rs2880415 0 -0.2364 0.2494 0 0.4396 -- -- 0.6685 
LEP rs11761556 -0.1159 -0.3343 0 -0.2808 0 -- -- 0.0619 
SLC16A4 rs12062656 0 -0.5493 0.4210 0 0.4800 -- -- 0.4409 
SLC16A3 rs4789698 0 0.3616 0.5260 -- -- 0 0.3283 0.0182 
SLC5A8 rs1709189 0 0.6737 0.8889 0 0.2784 -- -- 0.0370 
TLR4 rs4986790 0 -0.2582 0.2827 0 0.5175 -- -- 0.3816 




Supplemental Table P.5 Linkage Disequilibrium (D’ and R2) by CHM for genes in pathways 1-4 in NHW (left) and NHB (right) 
Pathway 1 
Gene SNP rs328 rs13702 rs12678919 Gene SNP rs328 rs13702 rs12678919 
LPL 
rs328 - 1.0000 0.9996 
LPL 
rs328 - 0.8912 0.9549 
rs13702  0.3297 - 1.0000 rs13702  0.0958 - 0.8891 
rs12678919  0.9583  0.3224 - rs12678919 0.6820  0.1275 - 
Gene SNP rs1044250 rs2278236 rs7255436 Gene SNP rs1044250 rs2278236 rs7255436 
ANGPTL4 
rs1044250 - 0.9562 0.9653 
ANGPTL4 
rs1044250 - 1.0000 1.0000 
rs2278236  0.3745 - 0.9999 rs2278236 0.3535 - 1.0000 
rs7255436  0.3734 0.9784  - rs7255436 0.1976  0.5032 - 
Gene SNP rs1527483 rs3173798 rs10499859 Gene SNP rs1527483 rs3173798 rs10499859 
CD36 
rs1527483 - 0.7129 0.6923 
CD36 
rs1527483 - 0.3493 0.2428 
rs3173798  0.4187 - 0.9991 rs3173798  0.0134 - 0.9493 
rs10499859  0.0552 0.0947  - rs10499859  0.0028 0.0830  - 
Gene SNP rs12639162 rs1801282  Gene SNP rs12639162 rs1801282  
PPARG rs12639162 - 0.9809  PPARG rs12639162 - 0.7213  
  rs1801282 0.4448 -    rs1801282 0.0587 -  







Supplemental Table P.5 cont’d 
Pathway 2 
Gene SNP rs10423648 rs10422744 rs424241 rs2074056 Gene SNP rs10423648 rs10422744 rs424241 rs2074056 
FFAR rs10423648 - 0.0290 0.1927 0.0958 FFAR rs10423648 - 0.8844 0.5886 0.2081 
  rs10422744 0.0000 - 0.0084 0.0034   rs10422744 0.1785 - 0.1515 0.1310 
  rs424241 0.0050 0.0000 - 0.1835   rs424241 0.0155 0.0045 - 0.5146 
  rs2074056 0.0001 0.0000 0.0037 -   rs2074056 0.0200 0.0074 0.0258 - 
Gene SNP rs2070592 rs2014257 rs228771  Gene SNP rs2070592 rs2014257 rs228771  
PYY 
rs2070592 - 0.4769 0.2634  
PYY 
rs2070592 - 0.2133 0.1276  
rs2014257 0.0571 - 1.0000  rs2014257 0.0023 - 1.0000  
rs228771 0.0468 0.1318 -  rs228771 0.0030 0.0160 -  
Gene SNP rs1047214 rs13120088 rs2880415  Gene SNP rs1047214 rs13120088 rs2880415  
NPY2R 
rs1047214 - 0.3415 0.9989  
NPY2R 
rs1047214 - 0.6592 1.0000  
rs13120088 0.0562 - 0.3381  rs13120088 0.1149 - 0.2500  
rs2880415 0.9837 0.0560 -  rs2880415 0.6042 0.0289 -  
Gene SNP rs7799039 rs11761556 rs1349419  Gene SNP rs7799039 rs11761556 rs1349419  
LEP 
rs7799039 - 0.8999 0.9741  
LEP 
rs7799039 - 0.8101 0.9352  
rs11761556 0.5551 - 0.9164  rs11761556 0.4892 - 0.9076  
rs1349419 0.6313 0.8159 -  rs1349419 0.8288 0.5994 -  
Gene SNP rs2189495 rs16145   Gene SNP rs2189495 rs16145   
NPY rs2189495 - 0.9935   NPY rs2189495 - 0.9643   
  rs16145 0.9799 -     rs16145 0.7208 -   
Gene SNP rs696217 rs27647   Gene SNP rs696217 rs27647   
GHRL rs696217 - 0.7560   GHRL rs696217 - 1.0000   






Supplemental Table P.5 cont’d 
Pathway 3 
Gene SNP rs4789698 rs3176827 rs4550503 Gene SNP rs4789698 rs3176827 rs4550503 
SLC16A3 
rs4789698 - 0.9596 0.9845 
SLC16A3 
rs4789698 - 0.4984 0.0269 
rs3176827 0.3004 - 0.9649 rs3176827 0.1632 - 0.3781 
rs4550503 0.3272 0.8997 - rs4550503 0.0006 0.0864 - 
Gene SNP rs7309172 rs844016 rs1709189 Gene SNP rs7309172 rs844016 rs1709189 
SLC5A8 
rs7309172 - 1.0000 0.8353 
SLC5A8 
rs7309172 - 0.4496 0.6625 
rs844016 0.3049 - 0.9719 rs844016 0.0942 - 0.9690 
rs1709189 0.0441 0.3274 - rs1709189 0.0460 0.1438 - 
Gene SNP rs3738750 rs12062656  Gene SNP rs3738750 rs12062656  
SLC16A4 rs3738750 - 1.0000  SLC16A4 rs3738750 - 0.3246  
  rs12062656 0.0535 -    rs12062656 0.0014 -  
Gene SNP rs7169 rs9429505  Gene SNP rs7169 rs9429505  
SLC16A1 rs7169 - 1.000  SLC16A1 rs7169 - 1.000  
  rs9429505 0.2309 -    rs9429505 0.2473 -  
 
Pathway 4 
Gene SNP rs11536889 rs4986790 Gene SNP rs11536889 rs4986790 
TLR4 rs11536889 - 0.6487 TLR4 rs11536889 - 0.0801 
  rs4986790 0.0051 -   rs4986790 0.0000 - 






Supplemental Table P.6 Individual Genetic Associations between candidate SNPs and BMIZ in ALLSKP (genotypic model) 
  P-value Least Square Means by genotype group GLM P-value Tukey adj. P-value 
Gene SNP Model SNP 1 2 3 1v2 1v3 2v3 1v2 1v3 2v3 
IL6 rs1554606 0.3328 0.1212 0.1946±0.0759 0.3391±0.0640 0.4562±0.1092 0.1466 0.0515 0.3554 0.3142 0.1255 0.6246 
SLC16A3 rs3176827 0.4787 0.1794 0.2402±0.0601 0.4188±0.0743 0.3467±0.1621 0.0654 0.5393 0.6856 0.1555 0.8123 0.9135 
PPARG rs12639162 0.3823 0.1498 0.3709±0.0577 0.1826±0.0770 0.3256±0.1694 0.0518 0.8000 0.4441 0.1262 0.9652 0.7241 
LPL rs12678919 0.7148 0.6733 0.3164±0.0497 0.2971±0.1057 -0.0662±0.4311 0.8693 0.3785 0.4135 0.9852 0.6532 0.6917 
LPL rs328 0.6224 0.4615 0.3132±0.0493 0.3176±0.1080 -0.2869±0.4808 0.9707 0.2151 0.2207 0.9993 0.4294 0.4382 
SLC16A3 rs4550503 0.3318 0.1417 0.2472±0.0624 0.4133±0.0712 0.1710±0.1529 0.0821 0.6459 0.1511 0.1907 0.8901 0.3222 
ANGPTL4 rs7255436 0.7790 0.9220 0.2826±0.0806 0.3237±0.0648 0.3166±0.1013 0.6919 0.7950 0.9527 0.9170 0.9634 0.9981 
NPY rs2189495 0.7825 0.8949 0.2980±0.0910 0.3296±0.0643 0.2808±0.0869 0.7771 0.8918 0.6529 0.9567 0.9898 0.8944 
TLR4 rs4986790 0.6986 0.6299 0.3180±0.0472 0.1931±0.1467 0.5299±0.4299 0.4185 0.6254 0.4586 0.6972 0.8762 0.7388 
SLC5A8 rs1709189 0.7101 0.6520 0.3195±0.0564 0.2654±0.0793 0.4536±0.2015 0.5794 0.5225 0.3845 0.8441 0.7981 0.6592 
NPY rs16145 0.7503 0.8513 0.2950±0.0925 0.3326±0.0659 0.2744±0.0830 0.7408 0.8697 0.5840 0.9414 0.9853 0.8476 
PYY rs2070592 0.2282 0.0735 0.3117±0.0689 0.2238±0.0687 0.5326±0.1158 0.3674 0.1034 0.0225 0.6392 0.2333 0.0583 
ANGPTL4 rs1044250 0.5849 0.3991 0.3086±0.0649 0.3440±0.0687 0.1197±0.1506 0.7100 0.2508 0.1756 0.9265 0.4840 0.3684 
PPARG rs2279525 0.1934 0.0472 0.3975±0.1312 0.4153±0.0682 0.1867±0.0665 0.9045 0.1547 0.0175 0.9921 0.3287 0.0460 






Supplemental Table P.7 Individual Genetic Associations between candidate SNPs and BMIZ in ALLSKP (dominant and recessive) 
  P-value LS Means P-value LS Means 
Gene SNP Model SNP Tukey adj. 0 1 Model SNP 
Tukey 
adj. 0 1 
IL6 rs1554606 0.3076 0.0664 0.0664 0.1955±0.0759 0.3690±0.0552 0.4364 0.1460 0.1460 0.2790±0.0489 0.4541±0.1093 
SLC16A3 rs3176827 0.3821 0.0703 0.0703 0.2402±0.0600 0.4064±0.0676 0.7935 0.8492 0.8492 0.3112±0.0463 0.3434±0.1625 
PPARG rs12639162 0.3320 0.0730 0.0730 0.3706±0.0577 0.2074±0.0698 0.7224 0.9107 0.9107 0.3030±0.0461 0.3227±0.1699 
LPL rs12678919 0.6929 0.7272 0.7272 0.3163±0.0497 0.2764±0.1026 0.6058 0.3819 0.3819 0.3128±0.0448 -0.0662±0.4306 
LPL rs328 0.7033 0.8319 0.8319 0.3131±0.0493 0.2884±0.1054 0.5043 0.2136 0.2136 0.3139±0.0447 -0.2869±0.4803 
SLC16A3 rs4550503 0.4300 0.1742 0.1742 0.2469±0.0625 0.3703±0.0647 0.5474 0.3473 0.3473 0.3196±0.0467 0.1686±0.1532 
ANGPTL4 rs7255436 0.6757 0.6900 0.6900 0.2825±0.0805 0.3217±0.0546 0.6966 0.9423 0.9423 0.3075±0.0502 0.3158±0.1012 
NPY rs2189495 0.6902 0.7064 0.7064 0.2806±0.0868 0.3191±0.0524 0.7068 0.8888 0.8888 0.3123±0.0514 0.2976±0.0909 
TLR4 rs4986790 0.6585 0.5403 0.5403 0.3181±0.0471 0.2281±0.1388 0.6728 0.6037 0.6037 0.3062±0.0448 0.5307±0.4297 
SLC5A8 rs1709189 0.6995 0.7537 0.7537 0.3197±0.0563 0.2904±0.0739 0.6384 0.4590 0.4590 0.3013±0.0458 0.4544±0.2103 
NPY rs16145 0.6569 0.6447 0.6447 0.2741±0.0829 0.3199±0.0536 0.6828 0.8822 0.8822 0.3101±0.0514 0.2943±0.0924 
PYY rs2070592 0.6608 0.9245 0.9245 0.3131±0.0692 0.3044±0.0593 0.2008 0.0357 0.0357 0.2676±0.0486 0.5332±0.1158 
ANGPTL4 rs1044250 0.7069 0.9738 0.9738 0.3085±0.0650 0.3055±0.0626 0.4832 0.1922 0.1922 0.3253±0.0469 0.1193±0.1505 
PPARG rs2279525 0.1284 0.0135 0.0135 0.1866±0.0664 0.4115±0.0606 0.6446 0.4986 0.4986 0.2980±0.0476 0.3931±0.1318 





Supplemental Table P.8 Individual Genetic Associations between candidate SNPs and WAZ in ALLSKP (genotypic model) 
  P-value Least Square Means by genotype group GLM P-value Tukey adj. P-value 
Gene SNP Model SNP 1 2 3 1v2 1v3 2v3 1v2 1v3 2v3 
IL6 rs1554606 0.3467 0.2767 0.2080±0.0775 0.3525±0.0653 0.3853±0.1115 0.1552 0.1955 0.7992 0.3294 0.3979 0.9649 
SLC16A3 rs3176827 0.3690 0.2998 0.2473±0.0617 0.3697±0.0763 0.4621±0.1665 0.2181 0.2283 0.6132 0.4342 0.4500 0.8685 
PPARG rs12639162 0.4552 0.6220 0.3369±0.0587 0.2411±0.0784 0.2997±0.1725 0.3302 0.8382 0.7577 0.5932 0.9773 0.9488 
LPL rs12678919 0.5468 0.7126 0.2986±0.0506 0.3653±0.1077 0.0439±0.4392 0.5762 0.5650 0.4777 0.8417 0.8331 0.7573 
LPL rs328 0.4883 0.5531 0.2984±0.0502 0.3747±0.1101 -0.1258±0.4901 0.5293 0.3896 0.3196 0.8040 0.6651 0.5795 
SLC16A3 rs4550503 0.2443 0.1927 0.2249±0.0637 0.3973±0.0727 0.3696±0.1561 0.0772 0.3930 0.8722 0.1805 0.6690 0.9585 
ANGPTL4 rs7255436 0.6637 0.9445 0.2880±0.0821 0.3193±0.0659 0.2888±0.1032 0.7674 0.9956 0.8027 0.9529 1.0000 0.9961 
NPY rs2189495 0.5802 0.8200 0.2668±0.0927 0.3062±0.0655 0.3479±0.0885 0.7287 0.5294 0.7055 0.9358 0.8041 0.9242 
TLR4 rs4986790 0.5595 0.7519 0.3196±0.0481 0.2071±0.1495 0.2017±0.4381 0.4745 0.7893 0.9970 0.7543 0.9614 0.9999 
SLC5A8 rs1709189 0.3457 0.2253 0.2939±0.0573 0.2871±0.0806 0.6544±0.2047 0.9455 0.0911 0.0951 0.9974 0.2088 0.2170 
NPY rs16145 0.4877 0.6030 0.3217±0.0942 0.3087±0.0671 0.3599±0.0845 0.5063 0.3158 0.6395 0.7839 0.5746 0.8837 
PYY rs2070592 0.3330 0.2638 0.3025±0.704 0.2467±0.0702 0.4719±0.1183 0.5747 0.2214 0.1028 0.8406 0.4393 0.2321 
ANGPTL4 rs1044250 0.5479 0.7553 0.3231±0.0662 0.3099±0.0700 0.1980±0.1537 0.8920 0.4562 0.5075 0.9899 0.7364 0.7849 
PPARG rs2279525 0.2867 0.1936 0.4858±0.1341 0.3430±0.0698 0.2290±0.0680 0.3341 0.0902 0.3453 0.6108 0.2070 0.4758 







Supplemental Table P.9 Individual Genetic Associations between candidate SNPs and WAZ in ALLSKP (dominant and recessive) 
  Dominant Model Recessive Model 
  P-value LS Means P-value LS Means 
Gene SNP Model SNP Tukey adj. 0 1 Model SNP 
Tukey 
adj. 0 1 
IL6 rs1554606 0.2542 0.1133 0.1133 0.2083±0.0774 0.3609±0.0563 0.4442 0.4593 0.4593 0.2924±0.0499 0.3833±0.1116 
SLC16A3 rs3176827 0.2895 0.1420 0.1420 0.2472±0.0617 0.3856±0.0695 0.4141 0.3450 0.3450 0.2960±0.0474 0.4599±0.1665 
PPARG rs12639162 0.3531 0.3551 0.3551 0.3368±0.0587 0.2512±0.0711 0.4455 0.9819 0.9819 0.3023±0.0468 0.2983±0.1724 
LPL rs12678919 0.4889 0.6773 0.6773 0.2985±0.0506 0.3470±0.1045 0.4657 0.5455 0.5455 0.3107±0.0457 0.0437±0.4389 
LPL rs328 0.4865 0.6606 0.6606 0.2984±0.0502 0.3506±0.1074 0.4167 0.3744 0.3744 0.3116±0.0456 -0.1258±0.4897 
SLC16A3 rs4550503 0.1680 0.0705 0.0705 0.2248±0.0637 0.3923±0.0659 0.4253 0.6823 0.6823 0.3000±0.0477 0.3671±0.1565 
ANGPTL4 rs7255436 0.5552 0.8200 0.8200 0.2877±0.0820 0.3105±0.0556 0.5584 0.8702 0.8702 0.3070±0.0511 0.2881±0.1303 
NPY rs2189495 0.4763 0.5989 0.5989 0.3478±0.0884 0.2931±0.0534 0.4790 0.6141 0.6141 0.3210±0.0524 0.2671±0.0926 
TLR4 rs4986790 0.4415 0.4499 0.4499 0.3196±0.0480 0.2066±0.1414 0.5031 0.8090 0.8090 0.3090±0.0457 0.2025±0.4379 
SLC5A8 rs1709189 0.5367 0.6610 0.6610 0.2943±0.0574 0.3360±0.0752 0.2487 0.0844 0.0844 0.2916±0.0466 0.6545±0.2045 
NPY rs16145 0.4213 0.4501 0.4501 0.3593±0.0845 0.2828±0.0546 0.3972 0.3746 0.3746 0.3285±0.0524 0.2323±0.0941 
PYY rs2070592 0.5032 0.9837 0.9837 0.3035±0.0705 0.3054±0.0604 0.2619 0.1251 0.1251 0.2745±0.0497 0.4722±0.1182 
ANGPTL4 rs1044250 0.4840 0.7271 0.7271 0.3230±0.0662 0.2907±0.0638 0.4341 0.4610 0.4610 0.3168±0.0479 0.1981±0.1535 
PPARG rs2279525 0.2644 0.1221 0.1221 0.2295±0.0680 0.3732±0.0620 0.3029 0.1642 0.1642 0.2845±0.0484 0.4836±0.1341 






Supplemental Table P.10 Individual Genetic Associations between candidate SNPs and HAZ in ALLSKP (genotypic model) 
  P-value Least Square Means by genotype group GLM P-value Tukey adj. P-value 
Gene SNP Model SNP 1 2 3 1v2 1v3 2v3 1v2 1v3 2v3 
IL6 rs1554606 0.8930 0.6507 0.1797±0.0811 0.2781±0.0684 0.2370±0.1166 0.3542 0.6888 0.7612 0.6233 0.9153 0.9503 
SLC16A3 rs3176827 0.8772 0.5238 0.2187±0.0644 0.2188±0.0797 0.4246±0.1783 0.9997 0.2689 0.2811 1.0000 0.5102 0.5275 
PPARG rs12639162 0.9326 0.9053 0.2238±0.0613 0.2538±0.0818 0.1714±0.1799 0.7695 0.7829 0.6778 0.9537 0.9590 0.9091 
LPL rs12678919 0.9186 0.7563 0.2217±0.0529 0.3111±0.1125 0.1409±0.4587 0.4736 0.8611 0.7188 0.7534 0.9833 0.9310 
LPL rs328 0.9311 0.8202 0.2254±0.0525 0.2986±0.1151 0.1101±0.5122 0.5632 0.8229 0.7196 0.8317 0.9727 0.9314 
SLC16A3 rs4550503 0.6591 0.2271 0.1731±0.0667 0.2680±0.0760 0.4640±0.1633 0.3519 0.1011 0.2766 0.6204 0.2287 0.5212 
ANGPTL4 rs7255436 0.9561 0.9061 0.2337±0.0854 0.2454±0.0686 0.1891±0.1074 0.9155 0.7482 0.6584 0.9938 0.9447 0.8978 
NPY rs2189495 0.8462 0.5118 0.1987±0.0967 0.2057±0.0683 0.3286±0.0923 0.9472 0.3317 0.5868 0.9976 0.5952 0.5335 
TLR4 rs4986790 0.8915 0.6453 0.2437±0.0502 0.2214±0.1561 -0.1847±0.4574 0.8919 0.3524 0.4009 0.9899 0.6211 0.6779 
SLC5A8 rs1709189 0.4858 0.1063 0.2070±0.0597 0.2350±0.0839 0.6775±0.2133 0.7864 0.0344 0.0537 0.9603 0.0867 0.1304 
NPY rs16145 0.6770 0.2450 0.1550±0.0982 0.1987±0.0699 0.3576±0.0881 0.7175 0.1288 0.1596 0.9303 0.2816 0.3372 
PYY rs2070592 0.9384 0.8971 0.2141±0.0736 0.2312±0.0734 0.2815±0.1237 0.8694 0.6414 0.7271 0.9852 0.8872 0.9350 
ANGPTL4 rs1044250 0.9439 0.8752 0.2608±0.0692 0.2085±0.0732 0.2348±0.1606 0.6058 0.8823 0.8814 0.8634 0.9880 0.9878 
PPARG rs2279525 0.7306 0.3057 0.4279±0.1401 0.1849±0.0729 0.2354±0.0710 0.1239 0.2240 0.6219 0.2725 0.4433 0.8744 






Supplemental Table P.11 Individual Genetic Associations between candidate SNPs and HAZ in ALLSKP (dominant and recessive) 
  Dominant Model Recessive Model 
  P-value LS Means P-value LS Means 
Gene SNP Model SNP Tukey 
adj. 
0 1 Model SNP Tukey 
adj. 
0 1 
IL6 rs1554606 0.8308 0.3809 0.3809 0.1794±0.0810 0.2676±0.0589 0.9150 0.9902 0.9902 0.2372±0.0522 0.2356±0.1166 
SLC16A3 rs3176827 0.9273 0.7181 0.7181 0.2186±0.0644 0.2542±0.0726 0.7980 0.2552 0.2552 0.2187±0.494 0.4246±0.1736 
PPARG rs12639162 0.8949 0.8713 0.8713 0.2239±0.0612 0.2396±0.0741 0.8857 0.7365 0.7365 0.2346±0.0488 0.1719±0.1797 
LPL rs12678919 0.8705 0.5123 0.5123 0.2217±0.0528 0.3014±0.1091 0.9108 0.8330 0.8330 0.2380±0.0477 0.1407±0.4585 
LPL rs328 0.8881 0.6049 0.6049 0.2254±0.0524 0.2895±0.1122 0.9091 0.8036 0.8036 0.2380±0.0477 0.1101±0.5118 
SLC16A3 rs4550503 0.7010 0.1819 0.1819 0.1734±0.0667 0.3028±0.0690 0.6578 0.1473 0.1473 0.2144±0.0498 0.4627±0.1633 
ANGPTL4 rs7255436 0.9311 0.9693 0.9693 0.2331±0.0854 0.2291±0.0579 0.9143 0.6662 0.6662 0.2408±0.0532 0.1889±0.1073 
NPY rs2189495 0.7580 0.2476 0.2476 0.3286±0.0922 0.2031±0.0557 0.8948 0.6513 0.6513 0.2493±0.0547 0.1988±0.0967 
TLR4 rs4986790 0.8938 0.6802 0.6802 0.2437±0.0502 0.1792±0.1477 0.8196 0.3542 0.3542 0.2416±0.0477 -0.1846±0.4569 
SLC5A8 rs1709189 0.8419 0.3836 0.3836 0.2075±0.0598 0.2938±0.0785 0.3794 0.0356 0.0356 0.2164±0.0485 0.6771±0.2130 
NPY rs16145 0.5784 0.1013 0.1013 0.3572±0.0881 0.1840±0.0569 0.8247 0.3612 0.3612 0.2601±0.0547 0.1568±0.0983 
PYY rs2070592 0.8980 0.7575 0.7575 0.2143±0.0735 0.2443±0.0630 0.8881 0.6626 0.6626 0.2227±0.0519 0.2814±0.1236 
ANGPTL4 rs1044250 0.8962 0.6209 0.6209 0.2608±0.0691 0.2130±0.0666 0.9201 0.9963 0.9963 0.2361±0.0500 0.2353±0.1604 
PPARG rs2279525 0.9163 0.9993 0.9993 0.2362±0.0711 0.2363±0.0649 0.6527 0.1445 0.1445 0.2108±0.0505 0.4289±0.1400 





Supplemental Table P.12 Individual Genetic Associations between candidate SNPs and BMIZ in NHW+NHB (genotypic model) 
  P-value Least Square Means by genotype group GLM P-value Tukey adj. P-value 
Gene SNP Model SNP 1 2 3 1v2 1v3 2v3 1v2 1v3 2v3 
IL6 rs1554606 0.1044 0.0452 0.1294±0.0864 0.3636±0.0689 0.4379±0.1106 0.0348 0.0294 0.5690 0.0875 0.0748 0.8362 
SLC16A3 rs3176827 0.3498 0.2669 0.2379±0.0662 0.4065±0.0786 0.3391±0.1765 0.1060 0.5928 0.7360 0.2382 0.8540 0.9366 
PPARG rs12639162 0.1645 0.0917 0.3816±0.0625 0.1509±0.0842 0.2967±0.1780 0.0289 0.6530 0.4601 0.0737 0.8944 0.7402 
LPL rs12678919 0.3695 0.3799 0.3263±0.0546 0.2461±0.1105 -0.2831±0.4771 0.5171 0.2054 0.2800 0.7934 0.4140 0.5259 
LPL rs328 0.2745 0.2191 0.3232±0.0541 0.2613±0.1123 -0.6112±0.5482 0.6208 0.0907 0.1195 0.8737 0.2081 0.2643 
SLC16A3 rs4550503 0.3210 0.2911 0.2511±0.0699 0.3904±0.0744 0.1814±0.1650 0.1742 0.6988 0.2493 0.3624 0.9207 0.4816 
ANGPTL4 rs7255436 0.4986 0.7785 0.2898±0.0842 0.2877±0.0707 0.3804±0.1175 0.9842 0.5342 0.4995 0.9998 0.8080 0.7776 
NPY rs2189495 0.5544 0.8934 0.2637±0.1003 0.3218±0.0711 0.3088±0.0918 0.6379 0.7408 0.9112 0.8850 0.9414 0.9932 
TLR4 rs4986790 0.5028 0.7159 0.3116±0.0516 0.2135±0.1527 0.5625±0.4763 0.5435 0.6009 0.4855 0.8158 0.8598 0.7647 
SLC5A8 rs1709189 0.4886 0.6753 0.3343±0.0607 0.2398±0.0878 0.3235±0.2391 0.3781 0.9652 0.7426 0.6518 0.9989 0.9422 
NPY rs16145 0.4822 0.8218 0.2568±0.1018 0.3328±0.0733 0.2891±0.0876 0.5461 0.8107 0.7035 0.8179 0.9688 0.9232 
PYY rs2070592 0.2881 0.3192 0.2995±0.0757 0.2548±0.0727 0.4929±0.1395 0.6711 0.2252 0.1313 0.9053 0.4452 0.2862 
ANGPTL4 rs1044250 0.3525 0.3540 0.3373±0.0704 0.3103±0.0761 0.0867±0.1592 0.7955 0.1520 0.2058 0.9636 0.3238 0.4146 
PPARG rs2279525 0.3951 0.4377 0.3459±0.1402 0.3670±0.0752 0.2350±0.0731 0.8946 0.4859 0.2117 0.9904 0.7650 0.4239 






Supplemental Table P.13 Individual Genetic Associations between candidate SNPs and BMIZ in NHW+NHB (dominant and recessive) 
  P-value LS Means P-value LS Means 
Gene SNP Model SNP Tukey adj. 0 1 Model SNP 
Tukey 
adj. 0 1 
IL6 rs1554606 0.0722 0.0153 0.0153 0.1298±0.0863 0.3843±0.0583 0.2850 0.1875 0.1875 0.2726±0.0541 0.4363±0.1112 
SLC16A3 rs3176827 0.2610 0.1119 0.1119 0.2378±0.0662 0.3946±0.0718 0.5209 0.8783 0.8783 0.3077±0.0504 0.3370±0.1769 
PPARG rs12639162 0.1283 0.0395 0.0395 0.3814±0.0625 0.1778±0.0760 0.4638 0.9812 0.9812 0.2995±0.0503 0.2951±0.1789 
LPL rs12678919 0.3769 0.3809 0.3809 0.3262±0.0546 0.2198±0.1078 0.3042 0.2180 0.2180 0.3104±0.0487 -0.2810±0.4768 
LPL rs328 0.3935 0.4344 0.4344 0.3231±0.0542 0.2267±0.1103 0.2057 0.0945 0.0945 0.3114±0.0486 -0.6101±0.5476 
SLC16A3 rs4550503 0.3393 0.2855 0.2855 0.2503±0.0700 0.3550±0.0678 0.3925 0.4309 0.4309 0.3164±0.0509 0.1797±0.1652 
ANGPTL4 rs7255436 0.4338 0.8337 0.8337 0.2905±0.0841 0.3124±0.0605 0.3834 0.4791 0.4791 0.2886±0.0540 0.3804±0.1173 
NPY rs2189495 0.4624 0.9511 0.9511 0.3090±0.0917 0.3023±0.0577 0.4387 0.6442 0.6442 0.3169±0.0558 0.2637±0.1002 
TLR4 rs4986790 0.4415 0.6702 0.6702 0.3116±0.0516 0.2458±0.1454 0.4280 0.5844 0.5844 0.3015±0.0488 0.5634±0.4759 
SLC5A8 rs1709189 0.3855 0.4103 0.4103 0.3343±0.0606 0.2497±0.0824 0.4610 0.9320 0.9320 0.3037±0.0498 0.3245±0.2391 
NPY rs16145 0.4071 0.8675 0.8675 0.2890±0.0875 0.3067±0.0592 0.3833 0.6185 0.6185 0.3148±0.0559 0.2566±0.1017 
PYY rs2070592 0.3964 0.9551 0.9551 0.3001±0.0758 0.3057±0.0645 0.2128 0.1467 0.1467 0.2762±0.0523 0.4932±0.1394 
ANGPTL4 rs1044250 0.4040 0.4907 0.4907 0.3371±0.0704 0.2688±0.0687 0.2592 0.1560 0.1560 0.32480.0513 0.0870±0.1590 
PPARG rs2279525 0.2919 0.2008 0.2008 0.2350±0.0730 0.3623±0.0661 0.4497 0.7683 0.7683 0.2292±0.0521 0.3443±0.1403 





Supplemental Table P.14 Individual Genetic Associations between candidate SNPs and WAZ in NHW+NHB (genotypic model) 
  P-value Least Square Means by genotype group GLM P-value Tukey adj. P-value 
Gene SNP Model SNP 1 2 3 1v2 1v3 2v3 1v2 1v3 2v3 
IL6 rs1554606 0.0485 0.2093 0.2011±0.0897 0.4020±0.0715 0.3606±0.1148 0.0808 0.2768 0.7602 0.1879 0.5213 0.9499 
SLC16A3 rs3176827 0.0963 0.5617 0.2844±0.0692 0.3733±0.0821 0.4555±0.1844 0.4118 0.3868 0.6836 0.6898 0.6618 0.9124 
PPARG rs12639162 0.0747 0.6035 0.3652±0.0647 0.2590±0.0871 0.2823±0.1841 0.3294 0.6709 0.9090 0.5921 0.9052 0.9928 
LPL rs12678919 0.1130 0.7297 0.3309±0.0565 0.3503±0.1144 -0.0520±0.4941 0.8799 0.4420 0.4276 0.9875 0.7219 0.7068 
LPL rs328 0.0955 0.6008 0.3313±0.0561 0.3516±0.1164 -0.2337±0.5682 0.8758 0.3231 0.3132 0.9866 0.5839 0.5711 
SLC16A3 rs4550503 0.0818 0.4472 0.2653±0.0724 0.3981±0.0770 0.3646±0.1708 0.2104 0.5944 0.8580 0.4219 0.8552 0.9825 
ANGPTL4 rs7255436 0.2193 0.9931 0.3217±0.0871 0.3234±0.0732 0.3384±0.1216 0.9886 0.9120 0.9157 0.9999 0.9933 0.9938 
NPY rs2189495 0.0858 0.4803 0.2379±0.1035 0.3307±0.0734 0.4083±0.0948 0.4667 0.2262 0.5205 0.7466 0.4466 0.7963 
TLR4 rs4986790 0.1017 0.6213 0.3480±0.0533 0.1872±0.1578 0.2751±0.4922 0.3351 0.8544 0.8924 0.5994 0.9816 0.9899 
SLC5A8 rs1709189 0.0861 0.3576 0.3312±0.0626 0.2911±0.0906 0.6686±0.2467 0.7167 0.1864 0.1515 0.9299 0.3828 0.3228 
NPY rs16145 0.0522 0.3235 0.1990±0.1050 0.3403±0.0756 0.4061±0.0903 0.2770 0.1375 0.5788 0.5217 0.2976 0.8437 
PYY rs2070592 0.0895 0.6619 0.3158±0.0784 0.3039±0.0752 0.4490±0.1445 0.9128 0.4195 0.3737 0.9934 0.6982 0.6466 
ANGPTL4 rs1044250 0.1146 0.7788 0.3429±0.0729 0.3385±0.0788 0.2182±0.1649 0.9673 0.4910 0.5110 0.9991 0.7698 0.7880 
PPARG rs2279525 0.0961 0.5613 0.4649±0.1450 0.3365±0.0778 0.2887±0.0756 0.4356 0.2844 0.6616 0.7152 0.5321 0.8997 







Supplemental Table P.15 Individual Genetic Associations between candidate SNPs and WAZ in NHW+NHB (dominant and recessive) 
  Dominant Model Recessive Model 
  P-value LS Means P-value LS Means 
Gene SNP Model SNP Tukey adj. 0 1 Model SNP 
Tukey 
adj. 0 1 
IL6 rs1554606 0.0288 0.0813 0.0813 0.2009±0.0896 0.3904±0.0605 0.0854 0.7835 0.7835 0.3239±0.0560 0.3592±0.1152 
SLC16A3 rs3176827 0.0624 0.3201 0.3201 0.2845±0.0691 0.3868±0.0750 0.0749 0.4886 0.4886 0.3214±0.0525 0.4544±0.1843 
PPARG rs12639162 0.0446 0.3177 0.3177 0.3652±0.0646 0.2633±0.0785 0.0630 0.8106 0.8106 0.3274±0.0518 0.2815±0.1841 
LPL rs12678919 0.0877 0.9963 0.9963 0.3309±0.0565 0.3303±0.1156 0.0707 0.4354 0.4354 0.3348±0.0504 -0.0525±0.4935 
LPL rs328 0.0877 0.9817 0.9817 0.3313±0.0561 0.3284±0.1141 0.0614 0.3183 0.3183 0.3352±0.0503 -0.2341±0.5674 
SLC16A3 rs4550503 0.0496 0.2088 0.2088 0.2651±0.0723 0.3924±0.0701 0.0865 0.5437 0.5437 0.3276±0.0527 0.3630±0.1709 
ANGPTL4 rs7255436 0.1477 0.9591 0.9591 0.3218±0.0870 0.3274±0.0626 0.1472 0.9070 0.9070 0.3227±0.0559 0.3384±0.1215 
NPY rs2189495 0.0628 0.3329 0.3329 0.4086±0.0947 0.2996±0.0596 0.0601 0.3044 0.3044 0.3599±0.0576 0.2377±0.1034 
TLR4 rs4986790 0.0628 0.3336 0.3336 0.3480±0.0532 0.1937±0.1502 0.0871 0.8831 0.8831 0.3315±0.0505 0.2587±0.4921 
SLC5A8 rs1709189 0.1084 0.9680 0.9680 0.3315±0.0627 0.3357±0.0852 0.0545 0.1645 0.1645 0.3182±0.0513 0.6690±0.2464 
NPY rs16145 0.0497 0.2998 0.2998 0.4059±0.0903 0.2919±0.0612 0.0359 0.1624 0.1624 0.3675±0.0576 0.1992±0.1049 
PYY rs2070592 0.0722 0.8560 0.8560 0.3161±0.0783 0.3349±0.0667 0.0544 0.3668 0.3668 0.3096±0.0541 0.4491±0.1443 
ANGPTL4 rs1044250 0.0831 0.7950 0.7950 0.3428±0.0728 0.3161±0.0711 0.0712 0.4799 0.4799 0.3408±0.0532 0.2183±0.1647 
PPARG rs2279525 0.0731 0.4595 0.4595 0.2890±0.0756 0.3651±0.0685 0.0629 0.3260 0.3260 0.3119±0.0538 0.4643±0.1449 





Supplemental Table P.16 Individual Genetic Associations between candidate SNPs and HAZ in NHW+NHB (genotypic model) 
  P-value Least Square Means by genotype group GLM P-value Tukey adj. P-value 
Gene SNP Model SNP 1 2 3 1v2 1v3 2v3 1v2 1v3 2v3 
IL6 rs1554606 0.4934 0.6249 0.2329±0.0957 0.3256±0.0762 0.2073±0.1225 0.4492 0.8703 0.4135 0.7292 0.9854 0.6917 
SLC16A3 rs3176827 0.5678 0.6997 0.2725±0.0736 0.2386±0.0873 0.4198±0.1960 0.7683 0.4836 0.3988 0.9532 0.7629 0.6754 
PPARG rs12639162 0.5000 0.8000 0.2548±0.0687 0.3066±0.0926 0.1721±0.1956 0.6540 0.6903 0.5354 0.8951 0.9161 0.8090 
LPL rs12678919 0.5642 0.8471 0.2593±0.0601 0.3352±0.1218 0.1980±0.5258 0.5780 0.9079 0.7993 0.8430 0.9926 0.9649 
LPL rs328 0.5872 0.9321 0.2640±0.0597 0.3154±0.1240 0.2499±0.6051 0.7095 0.9816 0.9156 0.9263 0.9997 0.9938 
SLC16A3 rs4550503 0.4506 0.5150 0.2268±0.0770 0.2899±0.0820 0.4493±0.1817 0.5754 0.2624 0.4248 0.8410 0.5008 0.7039 
ANGPTL4 rs7255436 0.7920 0.8333 0.2816±0.0925 0.2811±0.0777 0.1952±0.1291 0.9973 0.5893 0.5687 1.0000 0.8515 0.8359 
NPY rs2189495 0.3873 0.3789 0.1923±0.1100 0.2457±0.0780 0.2877±0.1007 0.6973 0.1917 0.2686 0.9179 0.3916 0.5098 
TLR4 rs4986790 0.4889 0.6125 0.2891±0.0567 0.1791±0.1678 -0.1298±0.5235 0.5353 0.4269 0.5742 0.8090 0.7061 0.8402 
SLC5A8 rs1709189 0.1994 0.0993 0.2447±0.0663 0.2682±0.0960 0.8258±0.2613 0.8408 0.0320 0.0457 0.9780 0.0809 0.1125 
NPY rs16145 0.2538 0.1863 0.1484±0.1116 0.2401±0.0804 0.4087±0.0960 0.5068 0.0793 0.1812 0.7842 0.1848 0.3741 
PYY rs2070592 0.5130 0.9201 0.2415±0.0833 0.2860±0.0800 0.2870±0.1536 0.7001 0.7951 0.9956 0.9214 0.9635 1.0000 
ANGPTL4 rs1044250 0.6034 0.9741 0.2610±0.0776 0.2811±0.0839 0.2979±0.1756 0.8614 0.8484 0.9314 0.9833 0.9800 0.9959 
PPARG rs2279525 0.4276 0.4642 0.4417±0.1542 0.2247±0.0827 0.2719±0.0804 0.2157 0.3322 0.6841 0.4303 0.5956 0.9127 






Supplemental Table P.17 Individual Genetic Associations between candidate SNPs and HAZ in NHW+NHB (dominant and recessive) 
  Dominant Model Recessive Model 
  P-value LS Means P-value LS Means 
Gene SNP Model SNP Tukey adj. 0 1 Model SNP 
Tukey 
adj. 0 1 
IL6 rs1554606 0.4532 0.6027 0.6027 0.2322±0.0956 0.2925±0.0646 0.4419 0.5446 0.5446 0.2896±0.0596 0.2067±0.1225 
SLC16A3 rs3176827 0.5372 0.9698 0.9698 0.2727±0.0735 0.2685±0.0798 0.4597 0.4280 0.4280 0.2584±0.0558 0.4202±0.1958 
PPARG rs12639162 0.4270 0.8037 0.8037 0.2549±0.0687 0.2819±0.0835 0.4064 0.6202 0.6202 0.2732±0.0550 0.1725±0.1954 
LPL rs12678919 0.4536 0.6050 0.6050 0.2593±0.0601 0.3284±0.1186 0.4830 0.8822 0.8822 0.2744±0.0537 0.1960±0.5253 
LPL rs328 0.4700 0.7189 0.7189 0.2640±0.0596 0.3128±0.1214 0.4855 0.9675 0.9675 0.2737±0.0536 0.2490±0.6044 
SLC16A3 rs4550503 0.4055 0.4060 0.4060 0.2274±0.0770 0.3170±0.0746 0.3710 0.3138 0.3138 0.2564±0.0560 0.4486±0.1815 
ANGPTL4 rs7255436 0.7346 0.8427 0.8427 0.2810±0.0924 0.2583±0.0665 0.6905 0.5457 0.5457 0.2813±0.0593 0.1952±0.1289 
NPY rs2189495 0.2970 0.1812 0.1812 0.3879±0.1006 0.2278±0.0633 0.4026 0.3972 0.3972 0.2991±0.0613 0.1920±0.1101 
TLR4 rs4986790 0.4083 0.4147 0.4147 0.2891±0.0567 0.1505±0.1598 0.4159 0.4400 0.4400 0.2778±0.0536 -0.1287±0.5231 
SLC5A8 rs1709189 0.4462 0.4301 0.4301 0.2451±0.0666 0.3341±0.0905 0.1339 0.0323 0.0323 0.2523±0.0543 0.8255±0.2610 
NPY rs16145 0.2004 0.0873 0.0873 0.4085±0.0959 0.2087±0.0650 0.3035 0.2099 0.2099 0.3097±0.0614 0.1488±0.1117 
PYY rs2070592 0.3969 0.6830 0.6830 0.2415±0.0832 0.2862±0.0708 0.4132 0.8931 0.8931 0.2647±0.0575 0.2867±0.1534 
ANGPTL4 rs1044250 0.4857 0.8318 0.8318 0.2611±0.0775 0.2842±0.0756 0.4885 0.8821 0.8821 0.2703±0.0566 0.2977±0.1754 
PPARG rs2279525 0.4845 0.9953 0.9953 0.2725±0.0804 0.2732±0.0729 0.3345 0.2416 0.2416 0.2490±0.0572 0.4423±0.1540 






Supplemental Table P.18 Individual Genetic Associations between candidate SNPs and BMIZ in NHW (genotypic model) 
  P-value Least Square Means by genotype group GLM P-value Tukey adj. P-value 
Gene SNP Model SNP 1 2 3 1v2 1v3 2v3 1v2 1v3 2v3 
ANGPLT4 rs1044250 0.5261 0.4154 0.3426±0.0866 0.3865±0.0855 0.1246±0.1780 0.7179 0.2725 0.1868 0.9305 0.5152 0.3833 
ANGPTL4 rs2278236 0.8423 0.9748 0.3655±0.1280 0.3381±0.0813 0.3288±0.1040 0.8566 0.8242 0.9438 0.9821 0.9731 0.9973 
ANGPTL4 rs7255436 0.8490 0.9939 0.3370±0.1027 0.3379±0.0817 0.3540±0.1292 0.9945 0.9183 0.9165 1.0000 0.9942 0.9939 
ANGPTL3 rs10889337 0.2162 0.1106 0.1989±0.1829 0.2321±0.0877 0.4638±0.0818 0.8700 0.1865 0.0549 0.9853 0.3829 0.1327 
CD36 rs10499859 0.8062 0.8808 0.3488±0.1203 0.3120±0.0834 0.3797±0.1042 0.8016 0.8468 0.6118 0.9657 0.9796 0.8675 
CD36 rs1527483 0.1581 0.0732 0.3119±0.0623 0.4282±0.1421 1.7759±0.6625 0.4550 0.0286 0.0480 0.7350 0.0727 0.1175 
CD36 rs3173798 0.1191 0.0509 1.2767±0.9347 0.6528±0.1511 0.2851±0.0614 0.5103 0.2906 0.0252 0.7872 0.5405 0.0647 
FFAR2 rs2074056 0.8228 0.9224 0.3244±0.0709 0.3677±0.1047 0.4018±0.2723 0.7331 0.7835 0.9068 0.9378 0.9592 0.9925 
GHRL rs27647 0.6686 0.6056 0.2599±0.1328 0.3973±0.0823 0.3037±0.0991 0.3795 0.7914 0.4681 0.6532 0.9621 0.7479 
GHRL rs696217 0.8468 0.9876 0.3417±0.0627 0.3311±0.1437 0.4343±0.6691 0.9461 0.8906 0.8805 0.9975 0.9896 0.9876 
IL6 rs1554606 0.3894 0.2523 0.2106±0.1061 0.3588±0.0815 0.4749±0.1225 0.2696 0.1062 0.4296 0.5109 0.2385 0.7088 
LEP rs11761556 0.7789 0.8173 0.3557±0.1047 0.3643±0.0833 0.2723±0.1203 0.9485 0.6021 0.5299 0.9977 0.8607 0.8043 
LEP rs1349419 0.8437 0.9788 0.3415±0.1234 0.3509±0.0817 0.3233±0.1060 0.9494 0.9110 0.8365 0.9978 0.9931 0.9768 
LEP rs7799039 0.7537 0.9215 0.2872±0.1275 0.3365±0.0844 0.3500±0.1006 0.7465 0.6997 0.9185 0.8501 0.9268 0.9840 
LEPR rs1137101 0.7455 0.7463 0.3362±0.1035 0.3796±0.0841 0.2674±0.1197 0.7457 0.6629 0.4450 0.9436 0.9004 0.7248 
LPL rs12678919 0.2115 0.1074 0.3852±0.0628 0.1764±0.1352 -0.7123±0.6611 0.1624 0.0995 0.1884 0.3418 0.2255 0.3860 
LPL rs13702 0.0033 0.0008 0.3649±0.0754 0.4382±0.0890 -0.4732±0.2218 0.5301 0.0004 0.0002 0.8045 0.0012 0.0005 
LPL rs328 0.2529 0.1367 0.3812±0.0632 0.2025±0.1327 -0.7114±0.6617 0.2252 0.1014 0.1763 0.4450 0.2291 0.3657 
NFkB rs230531 0.5376 0.4157 0.1753±0.1606 0.4074±0.0848 0.3186±0.0881 0.2024 0.4346 0.4686 0.4088 0.7141 0.7484 
NPY rs16145 0.7304 0.7165 0.2631±0.1116 0.3660±0.0860 0.3732±0.1070 0.4675 0.4766 0.9579 0.7474 0.7561 0.9985 
NPY rs2189495 0.8150 0.9026 0.3030±0.1132 0.3415±0.0852 0.3735±0.1071 0.7862 0.6512 0.8160 0.9602 0.8933 0.9705 
NPY2R rs1047214 0.4595 0.2485 0.5441±0.1283 0.3014±0.0755 0.3109±0.1121 0.1045 0.1711 0.9436 0.2353 0.3569 0.9972 
NPY2R rs13120088 0.7239 0.7041 0.3467±0.0907 0.3081±0.0813 0.4720±0.1765 0.7520 0.5279 0.4008 0.9463 0.8026 0.6776 
NPY2R rs2880415 0.4617 0.3263 0.2825±0.1147 0.3056±0.0767 0.5120±0.1279 0.8671 0.1809 0.1680 0.9847 0.3735 0.3515 
PPARG rs12639162 0.0340 0.0133 0.4639±0.0728 0.1027±0.0983 0.3120±0.1957 0.0034 0.4676 0.3401 0.0095 0.7475 0.6055 
PPARG rs1801282 0.4864 0.3541 0.3690±0.0651 0.1998±0.1255 0.6228±0.3541 0.2320 0.4815 0.2618 0.4554 0.7609 0.4997 




Supplemental Table P.18 cont’d 
  P-value Least Square Means by genotype group GLM P-value Tukey adj. P-value 
Gene SNP Model SNP 1 2 3 1v2 1v3 2v3 1v2 1v3 2v3 
PYY rs2014257 0.3764 0.2400 0.3783±0.0632 0.1419±0.1363 0.6307±0.4684 0.1167 0.5937 0.3171 0.2588 0.8546 0.5761 
PYY rs2070592 0.8136 0.8822 0.3145±0.0855 0.3591±0.0873 0.4047±0.1818 0.7152 0.6542 0.8212 0.9291 0.8951 0.9722 
PYY rs228771 0.7566 0.7693 0.3474±0.1328 0.2993±0.0837 0.3931±0.0971 0.7595 0.7815 0.4644 0.9496 0.9584 0.7443 
SLC11A1 rs2695343 0.2233 0.1451 0.6226±0.1498 0.3110±0.0800 0.2920±0.0960 0.0676 0.0636 0.8792 0.1603 0.1516 0.9873 
SLC16A1 rs7169 0.4822 0.4221 0.2381±0.1445 0.2948±0.0801 0.4346±0.0972 0.7314 0.2604 0.2685 0.9370 0.4977 0.5094 
SLC16A1 rs9429505 0.2220 0.1146 0.2567±0.0734 0.4970±0.0947 0.1956±0.2811 0.0461 0.8334 0.3105 0.1132 0.9759 0.5674 
SLC16A3 rs3176827 0.2880 0.1637 0.2441±0.0803 0.4730±0.0897 0.2913±0.1914 0.0592 0.8207 0.3895 0.1421 0.9720 0.6648 
SLC16A3 rs4550503 0.2879 0.1636 0.2575±0.0816 0.4687±0.0882 0.2054±0.1879 0.0808 0.8001 0.2038 0.1877 0.9652 0.4112 
SLC16A3 rs4789698 0.5124 0.3846 0.1860±0.1258 0.3777±0.0836 0.3874±0.1003 0.2058 0.2137 0.9405 0.4144 0.4270 0.9969 
SLC16A4 rs12062656 0.7308 0.7172 0.0884±0.5423 0.2381±0.1693 0.3573±0.0611 0.7926 0.6226 0.5077 0.9625 0.8748 0.7849 
SLC16A4 rs3738750 0.7719 0.8019 0.3644±0.0724 0.3118±0.0976 0.1646±0.3578 0.6654 0.5852 0.6923 0.9019 0.8484 0.9172 
SLC1A2 rs1570226 0.8174 0.9088 0.3355±0.1669 0.3718±0.0911 0.3169±0.0826 0.8481 0.9212 0.6566 0.9799 0.9946 0.8966 
SLC5A8 rs1709189 0.6670 0.5938 0.3456±0.0733 0.2985±0.0988 0.5863±0.2619 0.7024 0.3765 0.3061 0.9225 0.6497 0.5614 
SLC5A8 rs7309172 0.2122 0.1079 0.4218±0.0690 0.1896±0.1063 0.0286±0.2955 0.0679 0.1961 0.6091 0.1609 0.3987 0.8656 
SLC5A8 rs844016 0.5340 0.4111 0.2103±0.1242 0.3419±0.0840 0.4257±0.1007 0.3820 0.1789 0.5237 0.6562 0.3702 0.7990 
TLR4 rs11536889 0.7675 0.7924 0.3162±0.3135 0.2735±0.1167 0.3645±0.0673 0.8984 0.8804 0.5009 0.9910 0.9876 0.7788 
TLR4 rs4986790 0.7382 0.7319 0.3305±0.0609 0.3860±0.1748 0.7381±0.5422 0.7641 0.4556 0.5367 0.9515 0.7356 0.8101 





Supplemental Table P.19 Individual Genetic Associations between candidate SNPs and BMIZ in NHW (dominant and recessive) 
  Dominant Model Recessive Model 
  P-value LS Means P-value LS Means 
Gene SNP Model SNP Tukey adj. 0 1 Model SNP 
Tukey 
adj. 0 1 
ANGPLT4 rs1044250 0.6979 0.9718 0.9656 0.3421±0.0867 0.3371±0.0770 0.3825 0.2028 0.2030 0.3648±0.0608 0.1246±0.1777 
ANGPTL4 rs2278236 0.7094 0.8851 0.8907 0.3289±0.1038 0.3460±0.0684 0.7038 0.8322 0.8289 0.3346± 0.0640 0.3655±0.1278 
ANGPTL4 rs7255436 0.7138 0.9592 0.9648 0.3370±0.1025 0.3425±0.0688 0.7115 0.9126 0.9095 0.3375±0.0639 0.3539±0.1290 
ANGPTL3 rs10889337 0.1237 0.0363 0.0372 0.4639±0.0817 0.2259±0.0789 0.5644 0.4118 0.4131 0.3559±0.0600 0.1975±0.1839 
CD36 rs10499859 0.6691 0.6594 0.6539 0.3798±0.1040 0.3240±0.0684 0.7131 0.9424 0.9388 0.3384±0.0651 0.3489±0.1201 
CD36 rs1527483 0.4401 0.2482 0.2459 0.3107±0.0626 0.4889±0.1396 0.1085 0.0304 0.0300 0.3308±0.0569 1.7800±0.6619 
CD36 rs3173798 0.0746 0.0187 0.0183 0.2849±0.0613 0.6684±0.1491 0.5058 0.3249 0.3231 0.3376±0.0571 1.2714±0.9418 
FFAR2 rs2074056 0.6797 0.7002 0.6940 0.3244±0.0707 0.3720±0.0978 0.7025 0.8227 0.8199 0.3380±0.0584 0.4013±0.2718 
GHRL rs27647 0.6643 0.6428 0.6473 0.3037±0.0991 0.3593±0.0699 0.6093 0.4968 0.4995 0.3592±0.0633 0.2598±0.1327 
GHRL rs696217 0.7139 0.9655 0.9692 0.3418± 0.0626 0.3359±0.1400 0.7097 0.8883 0.8887 0.3400±0.0574 0.0574±0.6678 
IL6 rs1554606 0.3257 0.1481 0.1491 0.2114±0.1060 0.3943±0.0679 0.4056 0.2142 0.2231 0.3038±0.0646 0.4732±0.1225 
LEP rs11761556 0.7082 0.8716 0.8670 0.3555±0.1045 0.3345±0.0684 0.6228 0.5270 0.5170 0.3610±0.0650 0.2724±0.1201 
LEP rs1349419 0.7047 0.8396 0.8440 0.3233±0.1058 0.3480± 0.0680 0.7142 0.9798 0.9952 0.3406±0.0646 0.3414±0.1231 
LEP rs7799039 0.6147 0.8078 0.8174 0.3499±0.1005 0.3216±0.0704 0.5949 0.6979 0.7008 0.3421±0.0645 0.2873±0.1273 
LEPR rs1137101 0.7142 0.9762 0.9653 0.3370±0.1034 0.3424±0.0686 0.6033 0.4841 0.4876 0.3623±0.0650 0.2678±0.1195 
LPL rs12678919 0.2498 0.0980 0.0986 0.3854±0.0629 0.1419±0.1328 0.2754 0.1137 0.1134 0.3481±0.0571 -0.7071±0.6623 
LPL rs13702 0.6667 0.6508 0.6433 03649±0.0773 0.3375±0.0824 0.0015 0.0002 0.0002 0.3955±0.0575 -0.4731±0.2216 
LPL rs328 0.3175 0.1421 0.1429 0.3814±0.0633 0.1683±0.1304 0.2754 0.1137 0.1134 0.3481±0.0571 0.0571±0.6623 
NFkB rs230531 0.6878 0.7364 0.7420 0.3186±0.0882 0.3568±0.0750 0.4605 0.2701 0.2709 0.3647±0.0610 0.1753±0.1604 
NPY rs16145 0.6846 0.7213 0.7169 0.3736±0.1069 0.3275±0.0678 0.5660 0.4144 0.4171 0.3688±0.0667 0.2631±0.1114 
NPY rs2189495 0.6846 0.7213 0.7169 0.3736±0.1069 0.3275±0.0678 0.6781 0.6937 0.6976 0.3540±0.0664 0.3029±0.1130 
NPY2R rs1047214 0.7995 0.6731 0.6777 0.3098±0.1125 0.3639±0.0653 0.3049 0.0951 0.0935 0.3043±0.0625 0.5440±0.1281 
NPY2R rs13120088 0.7131 0.9414 0.9353 0.3465±0.0906 0.3370±0.0736 0.5781 0.4356 0.4330 0.3253±0.0604 0.4717±0.1762 
NPY2R rs2880415 0.6310 0.5468 0.5505 0.2812±0.1149 0.3603±0.0658 0.3099 0.1368 0.1348 0.2985±0.0635 0.5122±0.1277 
PPARG rs12639162 0.0231 0.0054 0.0055 0.4640±0.0728 0.1449±0.0878 0.6243 0.9065 0.9084 0.3360±0.0594 0.3121±0.1985 




Supplemental Table P.19 cont’d 
  Dominant Model Recessive Model 
  P-value LS Means P-value LS Means 
Gene SNP Model SNP Gene SNP Model SNP Gene SNP Model SNP 
PPARG rs2279525 0.5733 0.4203 0.4259 0.2948±0.0821 0.3861±0.0799 0.6671 0.6378 0.6646 0.3330±0.0606 0.4146±0.1776 
PYY rs2014257 0.3577 0.1727 0.1737 0.3782±0.0632 0.1799±0.1310 0.6266 0.5361 0.5345 0.3365±0.0575 0.6308±0.4697 
PYY rs2070592 0.6765 0.6547 0.6477 0.3146±0.0854 0.3677±0.0786 0.6941 0.7246 0.7222 0.3363±0.0610 0.4046±0.1815 
PYY rs228771 0.6150 0.5093 0.5041 0.3931±0.0969 0.3113±0.0706 0.7138 0.9598 0.9560 0.3393±0.0634 0.3474±0.1326 
SLC11A1 rs2695343 0.5022 0.4659 0.4572 0.2912±0.0964 0.3802±0.0709 0.1281 0.0498 0.0488 0.3032±0.0613 0.6227±0.1495 
SLC16A1 rs7169 0.3399 0.2050 0.2024 0.4346±0.0970 0.2815±0.0701 0.5191 0.4706 0.4733 0.3514±0.0618 0.2385±0.1446 
SLC16A1 rs9429505 0.1982 0.0698 0.0722 0.2569±0.0734 0.4662±0.0898 0.6513 0.6017 0.6027 0.3470±0.0583 0.1965±0.2826 
SLC16A3 rs3176827 0.2296 0.0864 0.0878 0.2437±0.0803 0.4405±0.0814 0.6980 0.7922 0.7719 0.3460±0.0599 0.2875±0.1923 
SLC16A3 rs4550503 0.3291 0.1506 0.1526 0.2569±0.0817 0.4219±0.0803 0.5843 0.4469 0.4362 0.3549±0.0599 0.2006±0.1886 
SLC16A3 rs4789698 0.6411 0.5730 0.5827 0.3862±0.1004 0.3189±0.0697 0.3509 0.1673 0.1677 0.3817±0.0641 0.1861±0.1251 
SLC16A4 rs12062656 0.5804 0.4397 0.4416 0.3573±0.0610 0.2246±0.1612 0.6629 0.6381 0.6382 0.3437±0.0575 0.0872±0.5417 
SLC16A4 rs3738750 0.6479 0.5919 0.5969 0.3642±0.0722 0.3014±0.0939 0.6568 0.6184 0.6177 0.3457±0.0580 0.1645±0.3573 
SLC1A2 rs1570226 0.6782 0.6939 0.6860 0.3167±0.0825 0.3635±0.0802 0.7139 0.9625 0.9656 0.3417±0.0610 0.3340±0.1666 
SLC5A8 rs1709189 0.7202 0.9391 0.9295 0.3453±0.0733 0.3349±0.0922 0.5237 0.3409 0.3394 0.3889±0.0587 0.5855±0.2615 
SLC5A8 rs7309172 0.1340 0.0404 0.0394 0.4218±0.0689 0.1709±0.0998 0.4709 0.2820 0.2816 0.3530±0.0581 0.0265±0.2968 
SLC5A8 rs844016 0.4941 0.3099 0.3064 0.4258±0.1007 0.3005±0.0693 0.4332 0.2411 0.2359 0.3763±0.0644 0.2010±0.1241 
TLR4 rs11536889 0.6118 0.5022 0.5048 0.3644±0.0672 0.2787±0.1092 0.7127 0.9339 0.9355 0.3416±0.058 0.3158±0.3132 
TLR4 rs4986790 0.6577 0.6212 0.6176 0.3304±0.0608 0.4189±0.1663 0.5930 0.4634 0.4616 0.3364±0.0574 0.7376±0.5413 





Supplemental Table P.20 Individual Genetic Associations between candidate SNPs and WAZ in NHW (genotypic model) 
  P-value Least Square Means by genotype group GLM P-value Tukey adj. P-value 
Gene SNP Model SNP 1 2 3 1v2 1v3 2v3 1v2 1v3 2v3 
ANGPLT4 rs1044250 0.5712 0.6061 0.2893±0.0836 0.3717±0.0826 0.1953±0.1719 0.4833 0.6240 0.3568 0.7625 0.8757 0.6262 
ANGPTL4 rs2278236 0.6867 0.7924 0.2419±0.12134 0.3376±0.0783 0.3377±0.1003 0.5132 0.5481 0.9999 0.7898 0.8195 1.0000 
ANGPTL4 rs7255436 0.6579 0.7321 0.3289±0.0990 0.3472±0.0786 0.2300±0.1245 0.8846 0.5353 0.4275 0.9884 0.8089 0.7066 
ANGPTL3 rs10889337 0.3819 0.3052 0.1404±0.177 0.2655±0.0849 0.3997±0.0792 0.5250 0.1819 0.2498 0.8001 0.3752 0.4822 
CD36 rs10499859 0.6208 0.6600 0.3814±0.1160 0.2679±0.0804 0.3495±0.1004 0.4223 0.8355 0.5258 0.7011 0.9765 0.8008 
CD36 rs1527483 0.2787 0.1947 0.2909±0.0603 0.4158±0.1377 1.341±0.6417 0.4070 0.1042 0.1603 0.6853 0.2347 0.3382 
CD36 rs3173798 0.1166 0.0617 0.9033±0.9027 0.6240±0.1459 0.2651±0.0592 0.7601 0.4810 0.0237 0.9498 0.7604 0.0612 
FFAR2 rs2074056 0.6152 0.6496 0.2824±0.0683 0.3807±0.1009 0.4278±0.2624 0.4217 0.5923 0.8669 0.7004 0.8536 0.9846 
GHRL rs27647 0.4142 0.3444 0.2111±0.1279 0.4014±0.0792 0.2573±0.0954 0.2066 0.7723 0.2460 0.4156 0.9548 0.4766 
GHRL rs696217 0.5655 0.5627 0.2994±0.0604 0.3893±0.1384 0.8855±0.6443 0.5516 0.3661 0.4530 0.8223 0.6373 0.7329 
IL6 rs1554606 0.2821 0.198 0.1701±0.1023 0.3512±0.0785 0.4435±0.1180 0.1617 0.0830 0.5145 0.3407 0.1922 0.7909 
LEP rs11761556 0.2345 0.2765 0.3358±0.1004 0.3965±0.0799 0.1331±0.1154 0.6367 0.1873 0.0618 0.8841 0.3841 0.1478 
LEP rs1349419 0.3796 0.3025 0.1622±0.1186 0.3676±0.0785 0.3511±0.1018 0.1500 0.2285 0.8981 0.3200 0.4501 0.9910 
LEP rs7799039 0.4644 0.5848 0.2935±0.1213 0.3608±0.0803 0.2366±0.0958 0.6434 0.7132 0.3213 0.8884 0.9281 0.5815 
LEPR rs1137101 0.6865 0.7919 0.2931±0.0999 0.3574±0.0812 0.2722±0.1156 0.6185 0.8911 0.5477 0.8721 0.9897 0.8191 
LPL rs12678919 0.6187 0.6562 0.3344±0.0611 0.2640±0.1313 0.1905±0.6423 0.6273 0.4165 0.4881 0.8780 0.6948 0.7670 
LPL rs13702 0.1523 0.0869 0.2995±0.0741 0.4129±0.0875 0.1058±0.2179 0.3231 0.0793 0.0280 0.5839 0.1846 0.0714 
LPL rs328 0.6053 0.6316 0.3367±0.0613 0.2567±0.1287 0.1906±0.6422 0.5754 0.4143 0.4946 0.8410 0.6924 0.7731 
NFkB rs230531 0.513 0.4798 0.1455±0.1550 0.3601±0.0818 0.3253±0.0851 0.2219 0.3103 0.7680 0.4399 0.5670 0.9531 
NPY rs16145 0.4631 0.4083 0.2714±0.1074 0.2718±0.0828 0.4339±0.1030 0.9978 0.2756 0.2222 1.0000 0.5195 0.4403 
NPY rs2189495 0.4366 0.3729 0.3067±0.1089 0.2517±0.0820 0.4341±0.1030 0.6873 0.3961 0.1680 0.9144 0.6723 0.3516 
NPY2R rs1047214 0.7879 0.8405 0.3829±0.1255 0.3007±0.0739 0.3319±0.1097 0.5736 0.7596 0.8137 0.8396 0.9496 0.9698 
NPY2R rs13120088 0.3393 0.2570 0.3312±0.0872 0.2564±0.0781 0.5609±0.1697 0.5233 0.2290 0.1049 0.7986 0.4509 0.2359 
NPY2R rs2880415 0.7462 0.9312 0.3137±0.1111 0.3063±0.0743 0.3578±0.1239 0.9563 0.7901 0.7221 0.9983 0.9616 0.9325 
PPARG rs12639162 0.3666 0.4047 0.3705±0.0706 0.2129±0.0953 0.2491±0.1898 0.1847 0.5494 0.8647 0.3799 0.8205 0.9841 
PPARG rs1801282 0.6665 0.7497 0.31082±0.0630 0.2875±0.1214 0.5643±0.3427 0.8225 0.4807 0.4476 0.9726 0.7600 0.7275 




Supplemental Table P.20 cont’d 
  P-value Least Square Means by genotype group GLM P-value Tukey adj. P-value 
Gene SNP Model SNP 1 2 3 1v2 1v3 2v3 1v2 1v3 2v3 
PYY rs2014257 0.7538 0.9506 0.3123±0.0613 0.3519±0.1322 0.2508±0.4543 0.7863 0.8932 0.8309 0.9602 0.9901 0.9751 
PYY rs2070592 0.7483 0.9247 0.2944±0.0825 0.3309±0.0842 0.3507±0.1753 0.7565 0.7722 0.9196 0.9483 0.9548 0.9944 
PYY rs228771 0.2998 0.2156 0.2840±0.1275 0.2368±0.0803 0.447±0.0932 0.7545 0.3038 0.0888 0.9474 0.5584 0.2041 
SLC11A1 rs2695343 0.1308 0.0783 0.6184±0.1450 0.2911±0.0774 0.2437±0.0930 0.0476 0.0301 0.6956 0.1165 0.0764 0.9189 
SLC16A1 rs7169 0.0568 0.0357 0.4086±0.1371 0.1726±0.0760 0.4651±0.0922 0.1329 0.7324 0.0151 0.2890 0.9375 0.0400 
SLC16A1 rs9429505 0.4685 0.4157 0.2572±0.0711 0.4122±0.0918 0.3869±0.2724 0.1836 0.6453 0.9301 0.3780 0.8896 0.9958 
SLC16A3 rs3176827 0.4266 0.3601 0.2386±0.0777 0.3991±0.0868 0.4052±0.1852 0.1710 0.4092 0.9764 0.3566 0.6868 0.9995 
SLC16A3 rs4550503 0.491 0.4475 0.2456±0.0790 0.3907±0.0854 0.3791±0.120 0.2151 0.5031 0.9542 0.4291 0.7808 0.9982 
SLC16A3 rs4789698 0.3706 0.2921 0.1601±0.1212 0.3272±0.0806 0.4073±0.0966 0.2523 0.1135 0.5239 0.4859 0.2527 0.7992 
SLC16A4 rs12062656 0.3562 0.2757 0.3826±0.5213 0.0700±0.1628 0.3496±0.0588 0.5680 0.9499 0.1070 0.8353 0.9978 0.2400 
SLC16A4 rs3738750 0.7186 0.8641 0.3235±0.0698 0.3235±0.0942 0.1340±0.3453 0.9999 0.5917 0.5976 1.0000 0.8532 0.8574 
SLC1A2 rs1570226 0.7354 0.9043 0.3808±0.1610 0.2989±0.0879 0.3188±0.0797 0.6540 0.7318 0.8676 0.8950 0.9372 0.9848 
SLC5A8 rs1709189 0.2517 0.1523 0.3262±0.0702 0.2488±0.0947 0.7682±0.2511 0.5120 0.0909 0.0545 0.7888 0.2082 0.1320 
SLC5A8 rs7309172 0.0690 0.0321 0.4044±0.0663 0.0952±0.1022 0.4643±0.2840 0.0117 0.8374 0.2230 0.0312 0.9770 0.4415 
SLC5A8 rs844016 0.2854 0.2013 0.2994±0.1195 0.2313±0.0808 0.4568±0.0970 0.6384 0.3073 0.0753 0.8852 0.5631 0.1764 
TLR4 rs11536889 0.3903 0.3152 0.2437±0.3014 0.1735±0.1122 0.3703±0.0647 0.8273 0.6815 0.1308 0.9741 0.9112 0.2852 
TLR4 rs4986790 0.7707 0.9953 0.3193±0.05880 0.3063±0.1689 0.3554±0.5238 0.9421 0.9454 0.9289 0.9971 0.9974 0.9956 





Supplemental Table P.21 Individual Genetic Associations between candidate SNPs and WAZ in NHW (dominant and recessive) 
  Dominant Model Recessive Model 
  P-value LS Means P-value LS Means 
Gene SNP Model SNP Tukey 
adj. 
0 1 Model SNP Tukey 
adj. 
0 1 
ANGPLT4 rs1044250 0.5526 0.6738 0.6587 0.2890±0.0836 0.3384±0.0743 0.482 0.4617 0.4576 0.3311±0.0588 0.1955±0.1717 
ANGPTL4 rs2278236 0.6012 0.8064 0.8205 0.3373±0.1002 0.3101±0.0660 0.5181 0.4949 0.4881 0.3376±0.0617 0.2419±0.1232 
ANGPTL4 rs7255436 0.6098 0.8870 0.9011 0.3285±0.0989 0.3137±0.0664 0.4908 0.435 0.4287 0.3402±0.0616 0.2300±0.1243 
ANGPTL3 rs10889337 0.2856 0.1599 0.1528 0.4000±0.0792 0.2421±0.0765 0.4064 0.2947 0.2898 0.3373±0.0579 0.1396±0.1773 
CD36 rs10499859 0.5810 0.6941 0.7076 0.3498±0.1003 0.3048±0.0660 0.5318 0.5291 0.5360 0.2997±0.0628 0.3815±0.1158 
CD36 rs1527483 0.3762 0.2554 0.2589 0.2901±0.0604 0.4574±0.1347 0.2223 0.1084 0.1092 0.3112±0.0551 1.3453±0.6413 
CD36 rs3173798 0.0627 0.0192 0.0196 0.2650±0.0591 0.6309±0.1439 0.5286 0.521 0.5236 0.3163±0.0552 0.8983±0.9097 
FFAR2 rs2074056 0.4502 0.3607 0.3715 0.2824±0.0682 0.3867±0.0942 0.5747 0.6671 0.6726 0.3134±0.0564 0.4268±0.2622 
GHRL rs27647 0.4958 0.4452 0.4347 0.2573±0.0955 0.3487±0.0674 0.4503 0.361 0.3536 0.3427±0.0610 0.2110±0.1280 
GHRL rs696217 0.4934 0.4403 0.4471 0.2997±0.0603 0.4121±0.1349 0.4596 0.3766 0.3748 0.3138±0.0553 0.8883±0.6435 
IL6 rs1554606 0.1970 0.0906 0.0877 0.1707±0.1021 0.3794±0.0654 0.3776 0.2572 0.2406 0.2840±0.0623 0.4414±0.1182 
LEP rs11761556 0.6043 0.8314 0.8423 0.3352±0.1009 0.3111±0.0660 0.1483 0.0604 0.0686 0.3730±0.0624 0.1330±0.1153 
LEP rs1349419 0.5814 0.6959 0.7066 0.3507±0.1020 0.3050±0.0656 0.2415 0.123 0.1375 0.3614±0.0621 0.1622±0.1183 
LEP rs7799039 0.3364 0.3533 0.3749 0.2365±0.0956 0.3404±0.0670 0.4701 0.9141 0.9026 0.3095±0.0615 0.2929±0.1213 
LEPR rs1137101 0.5905 0.7402 0.7672 0.2937±0.0998 0.3292±0.0662 0.5742 0.6652 0.6534 0.3318±0.0627 0.2728±0.1154 
LPL rs12678919 0.5377 0.5452 0.5365 0.3345±0.0610 0.2464±0.1287 0.489 0.4313 0.4281 0.3219±0.0553 -0.1888±0.6413 
LPL rs13702 0.5882 0.7283 0.7083 0.2995±0.0746 0.3409±0.0818 0.1225 0.0464 0.0453 0.3468±0.0566 -0.1058±0.2179 
LPL rs328 0.5199 0.4992 0.4909 0.3368±0.0613 0.2400±0.1263 0.489 0.4313 0.4281 0.3219±0.0553 -0.1888±0.6413 
NFkB rs230531 0.6107 0.8998 0.9151 0.3253±0.0851 0.3133±0.0724 0.361 0.2373 0.2332 0.3434±0.0589 0.1455±0.1547 
NPY rs16145 0.3074 0.1804 0.1845 0.4339±0.1028 0.2717±0.0652 0.5611 0.6166 0.6062 0.3355±0.0644 0.2707±0.1075 
NPY rs2189495 0.3074 0.1804 0.1845 0.4339±0.1028 0.2717±0.0652 0.6114 0.9093 0.8979 0.3225±0.0641 0.3063±0.1091 
NPY2R rs1047214 0.7107 0.9266 0.9390 0.3316±0.1095 0.3219±0.0636 0.6476 0.5955 0.6047 0.3105±0.0611 0.3827±0.1253 
NPY2R rs13120088 0.6052 0.8384 0.8534 0.3309±0.0875 0.3101±0.0710 0.2514 0.1308 0.1323 0.2897±0.0581 0.5604±0.1695 
NPY2R rs2880415 0.6139 0.9713 0.9587 0.3134±0.1109 0.3200±0.0635 0.5848 0.7114 0.7219 0.3086±0.0616 0.3578±0.1237 





Supplemental Table P.21 cont’d 
  Dominant Model Recessive Model 
  P-value LS Means P-value LS Means 
Gene SNP Model SNP Tukey 
adj. 
0 1 Model SNP Tukey 
adj. 
0 1 
PPARG rs1801282 0.6141 0.9864 0.9979 0.3183±0.0629 0.3186±0.1143 0.5052 0.4654 0.4673 0.3117±0.0559 0.5641±0.3420 
PPARG rs2279525 0.5861 0.7095 0.6914 0.2958±0.0793 0.3397±0.0772 0.3438 0.2166 0.1965 0.2938±0.0584 0.5277±0.1709 
PYY rs2014257 0.6021 0.8130 0.8222 0.3124±0.0612 0.3440±0.1268 0.6095 0.8837 0.8808 0.3193±0.0556 0.2508±4535 
PYY rs2070592 0.5880 0.7014 0.7196 0.2944±0.0823 0.3346±0.0758 0.6099 0.8317 0.8365 0.3123±0.0588 0.3504±0.1750 
PYY rs228771 0.1890 0.0853 0.0887 0.4468±0.0931 0.2502±0.0678 0.5965 0.775 0.7657 0.3262±0.0612 0.2839±0.1280 
SLC11A1 rs2695343 0.3687 0.2814 0.2976 0.2428±0.0935 0.3638±0.0678 0.0743 0.0266 0.0273 0.2716±0.0594 0.6187±0.1448 
SLC16A1 rs7169 0.0770 0.0373 0.0386 0.4651±0.0924 0.2279±0.0667 0.3712 0.4232 0.4312 0.2910±0.0591 0.4096±0.1384 
SLC16A1 rs9429505 0.3127 0.1855 0.1756 0.2573±0.0710 0.4096±0.0868 0.5991 0.7918 0.7958 0.3154±0.0563 0.3875±0.2728 
SLC16A3 rs3176827 0.2774 0.1526 0.1467 0.2386±0.0776 0.4002±0.0786 0.5793 0.6867 0.6348 0.3101±0.0578 0.4025±0.1855 
SLC16A3 rs4550503 0.3332 0.2064 0.1991 0.2456±0.0788 0.3886±0.0775 0.5996 0.795 0.7407 0.3125±0.0579 0.3759±0.1822 
SLC16A3 rs4789698 0.3983 0.2837 0.2696 0.4062±0.0967 0.2759±0.0671 0.2718 0.1478 0.1448 0.3600±0.0619 0.1606±0.1211 
SLC16A4 rs12062656 0.2542 0.1331 0.1298 0.3497±0.0587 0.0981±0.1550 0.611 0.9043 0.9060 0.3176±0.0555 0.3798±0.5229 
SLC16A4 rs3738750 0.6122 0.9241 0.9089 0.3232±0.0697 0.3101±0.0906 0.5526 0.5888 0.5884 0.3235±0.0560 0.1340±0.3447 
SLC1A2 rs1570226 0.6142 0.9902 0.9878 0.3192±0.0796 0.3175±0.0774 0.5753 0.6697 0.6766 0.3098±0.0588 0.3814±0.1607 
SLC5A8 rs1709189 0.6573 0.8962 0.9207 0.3257±0.0706 0.3144±0.0888 0.1796 0.0697 0.0698 0.2987±0.0563 0.7669±0.2508 
SLC5A8 rs7309172 0.0666 0.0207 0.0232 0.4044±0.0664 0.1379±0.0961 0.5591 0.6099 0.6113 0.3128±0.0562 0.4616±0.2869 
SLC5A8 rs844016 0.1828 0.0813 0.0839 0.4567±0.0968 0.2527±0.0666 0.6017 0.8105 0.8518 0.3238±0.0623 0.2984±0.1200 
TLR4 rs11536889 0.2533 0.1323 0.1287 0.3702±0.0646 0.1820±0.1050 0.6009 0.8041 0.7997 0.3209±0.0561 0.2429±0.3021 
TLR4 rs4986790 0.6139 0.9698 0.9608 0.3193±0.0587 0.3109±0.1606 0.613 0.94 0.9430 0.3179±0.0555 0.3555±0.5228 





Supplemental Table P.22 Individual Genetic Associations between candidate SNPs and HAZ in NHW (genotypic model) 
  P-value Least Square Means by genotype group GLM P-value Tukey adj. P-value 
Gene SNP Model SNP 1 2 3 1v2 1v3 2v3 1v2 1v3 2v3 
ANGPLT4 rs1044250 0.7936 0.7583 0.1644±0.0864 0.2563±0.0864 0.2474±0.1776 0.4495 0.6752 0.9640 0.7294 0.9076 0.9989 
ANGPTL4 rs2278236 0.6094 0.4798 0.0787±0.1271 0.2430±0.0867 0.2656±0.1033 0.2766 0.2558 0.8630 0.5210 0.4910 0.9837 
ANGPTL4 rs7255436 0.5912 0.4555 0.2449±0.1019 0.2579±0.0811 0.0704±0.1283 0.9201 0.2885 0.2181 0.9945 0.5376 0.4339 
ANGPTL3 rs10889337 0.8651 0.9737 0.1737±0.1836 0.2176±0.0880 0.2245±0.0821 0.8295 0.8002 0.9539 0.9747 0.9652 0.9982 
CD36 rs10499859 0.6491 0.5364 0.3144±0.1196 0.1599±0.0829 0.2316±0.1035 0.2892 0.6014 0.5882 0.5386 0.8601 0.8506 
CD36 rs1527483 0.8156 0.8453 0.2032±0.0626 0.2897±0.1428 0.1312±0.6659 0.5806 0.9143 0.8163 0.8449 0.9936 0.9706 
CD36 rs3173798 0.5283 0.3777 0.0420±0.9379 0.4079±0.1516 0.1859±0.0616 0.6360 0.8085 0.1770 0.8837 0.9681 0.3668 
FFAR2 rs2074056 0.5923 0.4568 0.17078±0.0704 0.2859±0.1040 0.4304±0.2704 0.3616 0.3537 0.6176 0.6320 0.6224 0.8715 
GHRL rs27647 0.5345 0.3850 0.1139±0.1320 0.2996±0.0817 0.1537±0.0985 0.2326 0.8095 0.2552 0.4564 0.9684 0.4902 
GHRL rs696217 0.3565 0.2072 0.1876±0.0621 0.3187±0.1422 1.2410±0.6623 0.3983 0.1147 0.1755 0.6747 0.2550 0.3644 
IL6 rs1554606 0.6123 0.4838 0.1071±0.1059 0.2533±0.0813 0.2819±0.1222 0.2749 0.2836 0.8453 0.5186 0.5307 0.9792 
LEP rs11761556 0.1448 0.0611 0.2149±0.1033 0.3247±0.0822 0.0049±0.1187 0.4065 0.1646 0.0233 0.6838 0.3458 0.0602 
LEP rs1349419 0.1417 0.0594 0.0281±0.1217 0.2955±0.0805 0.2653±0.1045 0.0275 0.0688 0.8192 0.0701 0.1627 0.9715 
LEP rs7799039 0.4631 0.2513 0.2077±0.1252 0.2884±0.0829 0.0827±0.0989 0.5905 0.4329 0.1113 0.8523 0.7123 0.2483 
LEPR rs1137101 0.833 0.8876 0.1926±0.1031 0.2445±0.0838 0.1923±0.1193 0.6976 0.9985 0.7215 0.9200 1.0000 0.9322 
LPL rs12678919 0.7764 0.7588 01981±0.0630 0.2945±0.1356 0.4282±0.6632 0.5178 0.7300 0.8439 0.7939 0.9364 0.9788 
LPL rs13702 0.7009 0.6183 0.1700±0.0770 0.2573±0.0909 0.3694±0.2265 0.4640 0.4052 0.6464 03744 0.6824 0.8903 
LPL rs328 0.8322 0.8856 0.2057±0.0634 0.2573±0.1330 0.4270±0.6636 0.7263 0.7401 0.8020 0.9346 0.9410 0.9659 
NFkB rs230531 0.7626 0.7310 0.0962±0.1602 0.2409±0.0846 0.2269±0.0879 0.4249 0.4751 0.9083 0.7039 0.7547 0.9927 
NPY rs16145 0.3034 0.1646 0.2350±0.1105 0.1111±0.0852 0.3640±0.1060 0.3770 0.4002 0.0647 0.6503 0.6769 0.1540 
NPY rs2189495 0.2761 0.1443 0.2487±0.1120 0.1056±0.0843 0.3639±0.1059 0.3094 0.4549 0.0580 0.5659 0.7349 0.1395 
NPY2R rs1047214 0.8144 0.8718 0.1687±0.1303 0.2164±0.0767 0.2583±0.1139 0.7529 0.6036 0.7600 0.9467 0.8617 0.9498 
NPY2R rs13120088 0.2137 0.1018 0.2217±0.0897 0.1418±0.0803 0.5497±0.1745 0.5075 0.0954 0.0350 0.7847 0.2172 0.0879 
NPY2R rs2880415 0.7955 0.7995 0.2611±0.1146 0.2219±0.0766 0.1468±0.1278 0.7766 0.5044 0.6151 0.9565 0.7820 0.8697 
PPARG rs12639162 0.7745 0.6075 0.1822±0.0827 0.2775±0.0982 0.0964±0.1955 0.4360 0.6812 0.4086 0.7156 0.9110 0.6862 
PPARG rs1801282 0.7151 0.6426 0.1892±0.0650 0.3182±0.1252 0.2256±0.3534 0.3607 0.9193 0.8050 0.6309 0.9944 0.9670 




Supplemental Table P.22 cont’d 
  P-value Least Square Means by genotype group GLM P-value Tukey adj. P-value 
Gene SNP Model SNP 1 2 3 1v2 1v3 2v3 1v2 1v3 2v3 
PYY rs2014257 0.326 0.1822 0.1702±0.0629 0.4419±0.1357 0.1148±0.4659 0.0702 0.9062 0.5007 0.1656 0.9924 0.7786 
PYY rs2070592 0.8553 0.9403 0.1910±0.0848 0.2273±0.0866 0.2208±0.1803 0.7647 0.8813 0.9742 0.9517 0.9878 0.9994 
PYY rs228771 0.2826 0.1490 0.1373±0.1314 0.1377±0.0828 0.3658±0.0960 0.9976 0.1614 0.0729 1.0000 0.3402 0.1713 
SLC11A1 rs2695343 0.3451 0.2030 0.4544±0.1502 0.1903±0.0802 0.1515±0.0963 0.1222 0.0900 0.7570 0.2691 0.2064 0.9485 
SLC16A1 rs7169 0.0175 0.0038 04783±01399 0.033±0.0776 0.3419±0.0940 0.0054 0.4192 0.0113 0.0149 0.6978 0.0302 
SLC16A1 rs9429505 0.7754 0.7569 0.2127±0.0736 0.2011±0.0950 0.4153±0.2818 0.9230 0.4870 0.4720 0.9949 0.7660 0.7517 
SLC16A3 rs3176827 0.7907 0.7891 0.2050±0.0804 0.1985±0.0899 0.3661±0.1916 0.9573 0.4403 0.4280 0.9984 0.7200 0.7072 
SLC16A3 rs4550503 0.6823 0.5878 0.2007±0.0816 0.1905±0.0882 0.4222±0.1879 0.9330 0.2820 0.2633 0.9961 0.5286 0.5019 
SLC16A3 rs4789698 0.7085 0.6312 0.1303±0.1254 0.2047±0.0834 0.2896±0.0100 0.6222 0.3238 0.5140 0.8746 0.5848 0.7906 
SLC16A4 rs12062656 0.3384 0.1922 0.523±0.5372 0.0629±0.1678 0.2489±0.0605 0.2992 0.6124 0.0812 0.5522 0.8679 0.1886 
SLC16A4 rs3738750 0.858 0.9536 0.2160±0.0721 0.2260±0.0973 0.1166±0.3565 0.9344 0.7853 0.7679 0.9963 0.9598 0.9530 
SLC1A2 rs1570226 0.7187 0.6490 0.3234±0.1659 0.1529±0.0905 0.2375±0.0822 0.3825 0.6452 0.5216 0.6567 0.8895 0.7972 
SLC5A8 rs1709189 0.1451 0.0688 0.2238±0.0722 0.1356±0.0973 0.7711±0.2580 0.4675 0.0419 0.0223 0.7473 0.1037 0.0577 
SLC5A8 rs7309172 0.0824 0.0300 0.2759±0.0684 0.0169±0.1054 0.6735±0.2930 0.0402 0.1875 0.0362 0.0998 0.3845 0.0906 
SLC5A8 rs844016 0.1067 0.0414 0.3422±0.1226 0.0600±0.0829 0.3600±0.0994 0.0584 0.9097 0.0213 0.1404 0.9929 0.0552 
TLR4 rs11536889 0.4958 0.3411 0.2192±0.3111 0.0667±0.1158 0.2668±0.668 0.6469 0.8811 0.1371 0.8906 0.9877 0.2968 
TLR4 rs4986790 0.7678 0.7414 0.2265±0.0606 0.1758±0.1740 0.1798±0.5399 0.7829 0.4551 0.5309 0.9589 0.7351 0.8052 





Supplemental Table P.23 Individual Genetic Associations between candidate SNPs and HAZ in NHW (dominant and recessive) 
  Dominant Model Recessive Model 
  P-value LS Means P-value LS Means 
Gene SNP Model SNP Tukey adj. 0 1 Model SNP 
Tukey 
adj. 0 1 
ANGPLT4 rs1044250 0.6398 0.4567 0.4348 0.1644±0.0862 0.2547±0.0766 0.7592 0.8358 0.8457 0.2110±0.0607 0.2476±0.1775 
ANGPTL4 rs2278236 0.6640 0.5534 0.5759 0.2650±0.1033 0.1958±0.0681 0.4473 0.2324 0.2252 0.2515±0.0636 0.0788±0.1269 
ANGPTL4 rs7255436 0.7160 0.7206 0.7451 0.2443±0.1020 0.2043±0.0685 0.4227 0.2099 0.2033 0.2529±0.0634 0.0704±0.1280 
ANGPTL3 rs10889337 0.7446 0.9289 0.8935 0.2246±0.0820 0.2093±0.0792 0.7338 0.8177 0.8048 0.2213±0.0598 0.1736±0.1833 
CD36 rs10499859 0.7358 0.8326 0.8588 0.2321±0.1036 0.2101±0.0681 0.5454 0.3422 0.3524 0.1879±0.0647 0.3146±0.1194 
CD36 rs1527483 0.6790 0.5927 0.6048 0.2034±0.0625 0.2826±0.1393 0.7434 0.9096 0.9010 0.2173±0.0571 0.1343±0.6650 
CD36 rs3173798 0.3969 0.1881 0.1945 0.1860±0.0615 0.3967±0.1495 0.7291 0.7872 0.7802 0.2176±0.0570 -0.0452±0.9393 
FFAR2 rs2074056 0.4667 0.2513 0.2675 0.1707±0.0703 0.3043±0.0971 0.5941 0.4140 0.4221 0.2070±0.0581 0.4292±0.2703 
GHRL rs27647 0.6163 0.4524 0.4340 0.1536±0.0986 0.2482±0.0696 0.5868 0.4022 0.3887 0.2401±0.0630 0.1138±0.1321 
GHRL rs696217 0.4629 0.2475 0.2565 0.1880±0.0622 0.3610±0.1390 0.3037 0.1214 0.1203 0.2085±0.0569 1.2446±0.6620 
IL6 rs1554606 0.4449 0.2301 0.2205 0.1073±0.1057 0.2620±0.0677 0.6860 0.6130 0.5580 0.1990±0.0644 0.2802±0.1222 
LEP rs11761556 0.7465 0.9963 0.9759 0.2141±0.1041 0.2179±0.0681 0.1048 0.0269 0.0344 0.2821±0.0643 -0.0052±0.1187 
LEP rs1349419 0.6706 0.5700 0.5883 0.2647±0.1053 0.1969±0.0676 0.0768 0.0179 0.0236 0.2843±0.0637 -0.0281±0.1215 
LEP rs7799039 0.3455 0.1154 0.1331 0.0821±0.0987 0.2639±0.0692 0.8426 0.9613 0.9812 0.2033±0.0637 0.2066±0.1256 
LEPR rs1137101 0.7189 0.7335 0.7823 0.1930±0.1029 0.2272±0.0683 0.7370 0.8416 0.8190 0.2238±0.0647 0.1928±0.1191 
LPL rs12678919 0.6277 0.4740 0.4880 0.1980±0.0629 0.3001±0.1328 0.7215 0.7461 0.7517 0.2153±0.0571 0.4258±0.6625 
LPL rs13702 0.5812 0.3936 0.3676 0.1700±0.0769 0.2729±0.0843 0.6301 0.4787 0.4863 0.2065±0.0588 0.3694±0.2263 
LPL rs328 0.7041 0.6727 0.6892 0.2057±0.0633 0.2637±0.1304 0.7215 0.7461 0.7517 0.2153±0.0571 0.4258±0.6625 
NFkB rs230531 0.7382 0.8519 0.8796 0.2269±0.0879 0.2094±0.0747 0.6037 0.4301 0.4206 0.2342±0.0608 0.0962±0.1599 
NPY rs16145 0.2623 0.0970 0.1020 0.3636±0.1059 0.1574±0.0672 0.7363 0.8367 0.8571 0.2105±0.0665 0.2339±0.1110 
NPY rs2189495 0.2623 0.0970 0.1020 0.3636±0.1059 0.1574±0.0672 0.7178 0.7285 0.7481 0.2059±0.0661 0.2479±0.1125 
NPY2R rs1047214 0.6838 0.6576 0.6784 0.2586±0.1137 0.2041±0.0660 0.6929 0.6918 0.6733 0.2295±0.0635 0.1684±0.1301 
NPY2R rs13120088 0.7441 0.9202 0.9480 0.2213±0.0903 0.2137±0.0733 0.1498 0.0435 0.0448 0.1774±0.0598 0.5491±0.1743 
NPY2R rs2880415 0.6919 0.6312 0.6506 0.2616±0.1144 0.2021±0.0655 0.6654 0.5569 0.5395 0.2340±0.0635 0.1465±0.1276 
PPARG rs12639162 0.7766 0.5772 0.6056 0.1822±0.0727 0.2410±0.0877 0.7725 0.5670 0.5581 0.2159±0.0584 0.0964±0.1954 




Supplemental Table P.23 cont’d 
  Dominant Model Recessive Model 
  P-value LS Means P-value LS Means 
Gene SNP Model SNP Tukey adj. 0 1 Model SNP 
Tukey 
adj. 0 1 
PPARG rs2279525 0.7442 0.8465 0.8816 0.2244±0.0818 0.2074±0.0797 0.3531 0.1518 0.1219 0.1853±0.0601 0.4742±0.1761 
PYY rs2014257 0.2410 0.0855 0.0894 0.1703±0.0628 0.4164±0.1301 0.7356 0.8313 0.8263 0.2182±0.0573 0.1147±0.4679 
PYY rs2070592 0.7204 0.7268 0.7607 0.1910±0.0846 0.2261±0.0779 0.7482 0.9408 0.9501 0.2088±0.0605 0.2207±0.1800 
PYY rs228771 0.1679 0.0509 0.0553 0.3658±0.0959 0.1376±0.0699 0.6492 0.5187 0.5047 0.2349±0.0631 0.1372±0.1320 
SLC11A1 rs2695343 0.5592 0.3766 0.4128 0.1508±0.0965 0.2490±0.0709 0.2264 0.0805 0.0847 0.1744±0.0615 0.4546±0.1499 
SLC16A1 rs7169 0.2657 0.0755 0.0804 0.3418±0.0953 0.1353±0.0688 0.1515 0.0342 0.0364 0.1564±0.0604 0.4794±0.1413 
SLC16A1 rs9429505 0.7463 0.9755 0.9290 0.2126±0.0736 0.2229±0.0899 0.6234 0.4658 0.4717 0.2083±0.0581 0.4153±0.2813 
SLC16A3 rs3176827 0.7401 0.8698 0.8407 0.2053±0.0804 0.2285±0.0815 0.6367 0.4919 0.4137 0.2021±0.0596 0.3662±0.1912 
SLC16A3 rs4550503 0.7340 0.8191 0.7910 0.2012±0.0816 0.2317±0.0802 0.5145 0.3036 0.2507 0.1960±0.0596 0.4225±0.1875 
SLC16A3 rs4789698 0.5926 0.4116 0.3788 0.2891±0.0998 0.1818±0.0693 0.6162 0.4522 0.4421 0.2394±0.0641 0.1308±0.1253 
SLC16A4 rs12062656 0.3256 0.1356 0.1303 0.2490±0.0606 -0.0103±0.1600 0.6704 0.5696 0.5722 0.2132±0.0572 0.5200±0.5393 
SLC16A4 rs3738750 0.7458 0.9561 0.9837 0.2158±0.0720 0.2182±0.0935 0.7271 0.7757 0.7759 0.2195±0.0578 0.1166±0.3558 
SLC1A2 rs1570226 0.7226 0.7516 0.7142 0.2384±0.0821 0.1962±0.0798 0.6278 0.4741 0.4851 0.2020±0.0607 0.3255±0.1657 
SLC5A8 rs1709189 0.6884 0.9057 0.9503 0.2233±0.0728 0.2160±0.0915 0.1017 0.0295 0.0299 0.1925±0.0579 0.7696±0.2578 
SLC5A8 rs7309172 0.2925 0.1146 0.1318 0.2758±0.0689 0.0928±0.0997 0.2958 0.1165 0.1174 0.1991±0.0578 0.6712±0.2948 
SLC5A8 rs844016 0.2268 0.0781 0.0832 0.3599±0.0999 0.1489±0.0688 0.5090 0.2971 0.2590 0.1831±0.0641 0.3408±0.1236 
TLR4 rs11536889 0.3652 0.1634 0.1565 0.2666±0.0667 0.0855±0.1084 0.7465 0.9881 0.9957 0.2167±0.0579 0.2184±0.3118 
TLR4 rs4986790 0.6973 0.6487 0.6339 0.2266±0.0605 0.1426±0.1656 0.6231 0.4651 0.4605 0.2211±0.0572 -0.1794±0.5389 





Supplemental Table P.24 Individual Genetic Associations between candidate SNPs and BMIZ in NHB (genotypic model) 
  P-value Least Square Means by genotype group GLM P-value Tukey adj. P-value 
Gene SNP Model SNP 1 2 3 1v2 1v3 2v3 1v2 1v3 2v3 
ANGPLT4 rs1044250 0.7339 0.5304 0.3051±0.1204 0.1076±0.1600 -0.0045±0.3504 0.3259 0.4055 0.7712 0.5868 0.6822 0.9542 
ANGPTL4 rs2278236 0.7785 0.6025 0.3532±0.1804 0.2102±0.1268 0.0812±0.2013 0.5180 0.3153 0.5890 0.7936 0.5728 0.8508 
ANGPTL4 rs7255436 0.7814 0.6273 0.2147±0.1473 0.1599±0.1398 0.4597±0.2680 0.7890 0.4249 0.3223 0.9611 0.7032 0.5820 
ANGPTL3 rs10889337 0.7787 0.6027 0.1347±0.1754 0.1864±0.1354 0.3863±0.1860 0.8177 0.3279 0.3851 0.9710 0.5893 0.6591 
CD36 rs10499859 0.7833 0.6104 0.1970±0.1349 0.1789±0.1426 0.4907±0.2836 0.9271 0.3522 0.3276 0.9954 0.6198 0.5890 
CD36 rs3173798 0.3728 0.1758 0.6754±0.6928 0.4746±0.1720 0.1092±0.1086 0.7786 0.4208 0.0748 0.9572 0.6989 0.1748 
FFAR2 rs2074056 0.6329 0.4055 0.1895±0.1350 0.3247±0.1385 -0.1127±0.2963 0.4862 0.3538 0.1842 0.7647 0.6218 0.3728 
GHRL rs27647 0.7333 0.5905 0.3265±0.6963 0.1049±0.1539 0.2974±0.1192 0.7562 0.9673 0.3280 0.9480 0.9991 0.5894 
IL6 rs1554606 0.2739 0.1137 -0.0367±0.1495 0.3664±0.1291 0.3843±0.2430 0.0435 0.1423 0.9481 0.1071 0.3055 0.9977 
LEP rs11761556 0.4632 0.2433 0.2023±0.2823 0.0033±0.1611 0.3457±0.1210 0.5406 0.6422 0.0919 0.8128 0.8873 0.2096 
LEP rs1349419 0.8054 0.6484 0.2581±0.1146 0.0971±0.1807 0.3289±0.3295 0.4562 0.8391 0.5387 0.7356 0.9774 0.8113 
LEPR rs1137101 0.9260 0.9237 0.2165±0.1851 0.2465±0.1366 0.1681±0.1785 0.8968 0.8517 0.7273 0.9907 0.9808 0.9349 
LPL rs12678919 0.8720 0.7834 0.1807±0.1077 0.3418±0.1898 0.2400±0.6992 0.4633 0.9333 0.8887 0.7426 0.9961 0.9892 
LPL rs13702 0.9450 0.9969 0.2082±0.1921 0.2192±0.1267 0.2362±0.1939 0.9619 0.9179 0.9417 0.9987 0.9941 0.9970 
LPL rs328 0.7957 0.6313 0.1843±0.1034 0.3884±0.2096 -0.2375±0.9869 0.3845 0.6713 0.5364 0.6584 0.9051 0.8093 
NFkB rs230531 0.9255 0.9287 0.0504±0.5773 0.2719±0.2104 0.2140±0.1055 0.7194 0.7818 0.8062 0.9310 0.9584 0.9672 
NPY rs16145 0.8655 0.8977 0.2620±0.2330 0.2329±0.1385 0.1582±0.1523 0.9146 0.7097 0.7178 0.9937 0.9262 0.9303 
NPY rs2189495 0.9198 0.9109 0.1510±0.2105 0.2478±0.1274 0.2170±0.1758 0.6954 0.8101 0.8875 0.9181 0.9685 0.9890 
NPY2R rs1047214 0.7601 0.5732 0.0920±0.5678 0.0663±0.1833 0.2795±0.1087 0.9659 0.7464 0.3187 0.9990 0.9437 0.5774 
NPY2R rs13120088 0.5225 0.2940 -0.0893±0.2402 0.2100±0.1300 0.3624±0.1549 0.2756 0.1158 0.4546 0.5188 0.2564 0.7340 
NPY2R rs2880415 0.1440 0.0485 0.3944±0.1166 -0.0885±0.1604 0.1530±0.3243 0.0161 0.4860 0.5104 0.0423 0.7645 0.7869 
PPARG rs12639162 0.9004 0.8548 0.1787±0.1187 0.3004±0.1629 0.2027±0.4053 0.5510 0.9545 0.8244 0.8214 0.9982 0.9731 
PPARG rs2279525 0.8558 0.7471 0.1961±0.2182 0.3015±0.1372 0.1259±0.1588 0.6839 0.7961 0.4106 0.9123 0.9637 0.6877 
PYY rs2070592 0.1458 0.0580 0.3048±0.1567 0.0149±0.1301 0.6013±0.2184 0.1593 0.2681 0.0239 0.3356 0.5081 0.0612 
PYY rs228771 0.5280 0.2990 -0.8425±0.6961 0.1698±0.2058 0.2568±0.1054 0.1664 0.1206 0.7116 0.3480 0.2654 0.9271 
SLC16A1 rs7169 0.8682 0.7746 -0.0569±0.4925 0.2786±0.1701 0.2087±0.1147 0.5208 0.6007 0.7360 0.7960 0.8593 0.9390 
SLC16A1 rs9429505 0.8413 0.7166 0.2559±0.1861 0.1372±0.1366 0.3257±0.1742 0.6086 0.7838 0.4012 0.8649 0.9592 0.6773 




Supplemental Table P.24 cont’d 
  P-value Least Square Means by genotype group GLM P-value Tukey adj. P-value 
Gene SNP Model SNP 1 2 3 1v2 1v3 2v3 1v2 1v3 2v3 
SLC16A3 rs4550503 0.9136 0.8922 0.2525±0.1356 0.2152±0.1401 0.0801±0.3236 0.8483 0.6240 0.7064 0.9799 0.8755 0.9244 
SLC16A3 rs4789698 0.1821 0.0658 0.0342±0.1317 0.3040±0.1376 0.7894±0.3111 0.1581 0.0293 0.1575 0.3336 0.0742 0.3325 
SLC16A4 rs12062656 0.0354 0.0087 0.6898±0.6699 -0.3022±0.1924 0.3728±0.1045 0.1558 0.6415 0.0032 0.3296 0.8869 0.0089 
SLC5A8 rs1709189 0.3827 0.1826 0.2978±0.1074 0.0880±0.1813 -0.6417±0.5641 0.3209 0.1046 0.2206 0.5802 0.2348 0.4370 
SLC5A8 rs7309172 0.8160 0.6675 0.3029±0.1420 0.1969±0.1418 0.0567±0.2388 0.5979 0.3722 0.6156 0.8573 0.6498 0.8698 
SLC5A8 rs844016 0.7958 0.6314 0.0775±0.1803 0.2614±0.1222 0.3048±0.2255 0.4003 0.4324 0.8659 0.6763 0.7112 0.9843 
TLR4 rs4986790 0.4188 0.2087 0.2740±0.0966 -0.2953±0.3088 0.0427±0.9808 0.0821 0.8150 0.7431 0.1897 0.9701 0.9422 





Supplemental Table P.25 Individual Genetic Associations between candidate SNPs and BMIZ in NHB (dominant and recessive) 
  Dominant Model Recessive Model 
  P-value LS Means P-value LS Means 
Gene SNP Model SNP Tukey adj. 0 1 Model SNP 
Tukey 
adj. 0 1 
ANGPLT4 rs1044250 0.5898 0.2788 0.2788 0.3050±0.1199 0.0884±0.1453 0.7601 0.5103 0.5103 0.2337±0.0963 -0.0026±0.3504 
ANGPTL4 rs2278236 0.7056 0.4214 0.4214 0.0806±0.2008 0.2575±0.1034 0.6956 0.4067 0.4067 0.1736±0.1070 0.3537±0.1798 
ANGPTL4 rs7255436 0.844 0.9218 0.9218 0.2137±0.1473 0.2235±0.1242 0.6343 0.3455 0.3455 0.1859±0.1002 0.4599±0.2668 
ANGPTL3 rs10889337 0.6267 0.3199 0.3199 0.3861±0.1852 0.1670±0.1056 0.7984 0.609 0.609 0.2554±0.1097 0.1331±0.1752 
CD36 rs10499859 0.6306 0.3242 0.3242 0.4908±0.2823 0.1884±0.0972 0.8539 0.8543 0.8543 0.2416±0.1275 0.1969±0.1349 
CD36 rs3173798 0.2417 0.0648 0.0648 0.1091±0.1082 0.4859±0.1666 0.7616 0.5205 0.5205 0.2132±0.0929 0.6692±0.6998 
FFAR2 rs2074056 0.8481 0.8101 0.8101 0.1910±0.1354 0.2460±0.1258 0.5393 0.2363 0.2363 0.2554±0.0964 -0.1112±0.1956 
GHRL rs27647 0.5878 0.3264 0.3264 0.2975±0.1187 0.1149±0.1499 0.807 0.8838 0.8838 0.2249±0.0936 0.3335±0.6961 
IL6 rs1554606 0.161 0.0367 0.0367 -0.0368±0.1488 0.3703±0.1136 0.7441 0.4861 0.4861 0.1941±0.0992 0.3847±0.2465 
LEP rs11761556 0.8594 0.9186 0.9186 0.2059±0.2849 0.2222±0.0976 0.3801 0.1288 0.1288 0.0519±0.1399 0.3459±0.1206 
LEP rs1349419 0.7884 0.5821 0.5821 0.3280±0.3288 0.2115±0.0960 0.8073 0.6349 0.6349 0.1507±0.1580 0.2572±0.1143 
LEPR rs1137101 0.865 0.9673 0.9673 0.2162±0.1843 0.2176±0.1083 0.8348 0.7219 0.7219 0.2359±0.1092 0.1679±0.1777 
LPL rs12678919 0.7475 0.4924 0.4924 0.1807±0.1072 0.3347±0.1822 0.8618 0.9827 0.9827 0.2202±0.0932 0.2409±0..6978 
LPL rs13702 0.8618 0.9802 0.9802 0.2080±0.1912 0.2243±0.1054 0.861 0.9487 0.9487 0.2159±0.1051 0.2363±0.1930 
LPL rs328 0.7292 0.4596 0.4596 0.1848±0.1031 0.3613±0.2044 0.8106 0.6455 0.6455 0.2242±0.0926 -0.2337±0.9858 
NFkB rs230531 0.859 0.9114 0.9114 0.2132±0.1050 0.2458±0.1968 0.8374 0.7496 0.7496 0.2256±0.0938 0.0493±0.5748 
NPY rs16145 0.7346 0.6448 0.6448 0.1581±0.1516 0.2405±0.1185 0.774 0.8235 0.8235 0.1990±0.1019 0.2621±0.2320 
NPY rs2189495 0.8613 0.9586 0.9586 0.2171±0.1751 0.2218±0.1087 0.8246 0.6942 0.6942 0.2372±0.1027 0.1510±0.2095 
NPY2R rs1047214 0.5988 0.2906 0.2906 0.2795±0.1082 0.0688±0.1734 0.8477 0.8076 0.8076 0.2242±0.0937 0.0903±0.5678 
NPY2R rs13120088 0.4341 0.1604 0.1604 -0.0902±0.2397 0.2731±0.0989 0.5787 0.2711 0.2711 0.1421±0.1144 0.3641±0.1551 
NPY2R rs2880415 0.0911 0.0173 0.0173 0.3952±0.1163 -0.0395±0.1418 0.8428 0.7778 0.7778 0.2280±0.0968 0.1386±0.3315 
PPARG rs12639162 0.797 0.6051 0.6051 0.1792±0.1182 0.2865±0.1498 0.8615 0.9667 0.9667 0.2212±0.0948 0.2075±0.4041 
PPARG rs2279525 0.7589 0.515 0.515 0.1264±0.1582 0.2715±0.1155 0.8566 0.8808 0.8808 0.2261±0.1023 0.1955±0.2178 
PYY rs2070592 0.6568 0.4662 0.4662 0.2973±0.1597 0.1703±0.1131 0.2036 0.0617 0.0617 0.1334±0.1001 0.5938±0.2193 
PYY rs228771 0.754 0.5051 0.5051 0.2601±0.1058 0.0845±0.1980 0.3733 0.1251 0.1251 0.2380±0.0921 -0.8450±0.6933 




Supplemental Table P.25 cont’d 
  Dominant Model Recessive Model 
  P-value LS Means P-value LS Means 
Gene SNP Model SNP Tukey adj. 0 1 Model SNP 
Tukey 
adj. 0 1 
SLC16A1 rs9429505 0.8541 0.8569 0.8569 0.2546±0.1858 0.2094±0.1062 0.7534 0.5039 0.5039 0.1788±0.1096 0.3240±0.1736 
SLC16A3 rs3176827 0.7426 0.7587 0.7587 0.2242±0.1167 0.2686±0.1472 0.7359 0.7266 0.7266 0.2327±0.0941 0.3708±0.3655 
SLC16A3 rs4550503 0.8438 0.784 0.784 0.2525±0.1351 0.1926±0.1262 0.8111 0.647 0.647 0.2345±0.0971 0.0784±0.3220 
SLC16A3 rs4789698 0.2505 0.0682 0.0682 0.7812±0.3125 0.1632±0.0959 0.223 0.0577 0.0577 0.3843±0.1261 0.0405±0.1323 
SLC16A4 rs12062656 0.0399 0.0062 0.0062 0.3721±0.1050 -0.2300±0.1866 0.7353 0.4701 0.4701 0.2114±0.0930 0.7259±0.6940 
SLC5A8 rs1709189 0.4437 0.1664 0.1664 0.2978±0.1077 0.0200±0.1730 0.3712 0.124 0.124 0.2434±0.0926 -0.6415±0.5641 
SLC5A8 rs7309172 0.7368 0.4728 0.4728 0.3029±0.1415 0.1601±0.1212 0.7181 0.4411 0.4411 0.2498±0.1001 0.0561±0.2380 
SLC5A8 rs844016 0.826 0.6997 0.6997 0.3051±0.2252 0.2036±0.1011 0.6454 0.3412 0.3412 0.2713±0.1070 0.0775±0.1795 
TLR4 rs4986790 0.2817 0.0810 0.0810 0.2742±0.0962 -0.2648±0.2934 0.8538 0.8534 0.8534 0.2222±0.0928 0.0481±0.9901 





Supplemental Table P.26 Individual Genetic Associations between candidate SNPs and WAZ in NHB (genotypic model) 
  P-value Least Square Means by genotype group GLM P-value Tukey adj. P-value 
Gene SNP Model SNP 1 2 3 1v2 1v3 2v3 1v2 1v3 2v3 
ANGPLT4 rs1044250 0.1324 0.8567 0.4208±0.1407 0.2783±0.1869 0.3468±0.4094 0.5437 0.8647 0.8791 0.8154 0.9841 0.9873 
ANGPTL4 rs2278236 0.1073 0.6826 0.4533±0.2099 0.3959±0.1475 0.1950±0.2343 0.8235 0.4118 0.4694 0.9728 0.6891 0.7487 
ANGPTL4 rs7255436 0.1321 0.5589 0.3622±0.1713 0.2611±0.1625 0.6489±0.3116 0.6717 0.4218 0.2712 0.9053 0.6999 0.5124 
ANGPTL3 rs10889337 0.1291 0.8614 0.2960±0.2046 0.4362±0.1579 0.3246±0.2169 0.5924 0.9239 0.6772 0.8533 0.9950 0.9085 
CD36 rs10499859 0.0117 0.0493 0.4492±0.1532 0.1249±0.1620 0.9810±0.3221 0.1499 0.1394 0.0192 0.3191 0.3002 0.0500 
CD36 rs3173798 0.0633 0.3561 1.0801±0.8106 0.5573±0.2012 0.2778±0.1271 0.5317 0.3299 0.2423 0.8054 0.5919 0.4702 
FFAR2 rs2074056 0.0513 0.2764 0.2705±0.1563 0.5484±0.1604 0.0141±0.3431 0.2175 0.4964 0.1614 0.4321 0.7742 0.3394 
GHRL rs27647 0.1126 0.6547 0.4488±0.8131 0.2367±0.1798 0.4398±0.1391 0.7991 0.9913 0.3765 0.9647 0.9999 0.6491 
IL6 rs1554606 0.0654 0.3704 0.2822±0.1757 0.5119±0.1518 0.0898±0.2857 0.3245 0.5670 0.1944 0.5849 0.8341 0.3950 
LEP rs11761556 0.0767 0.4503 0.1708±0.3299 0.2168±0.1881 0.4904±0.1413 0.9036 0.3758 0.2472 0.9919 0.6482 0.4775 
LEP rs1349419 0.056 0.3073 0.4924±0.1320 0.1534±0.2083 0.0664±0.3796 0.1745 0.2905 0.8412 0.3618 0.5396 0.9780 
LEPR rs1137101 0.1308 0.8436 0.2660±0.2150 0.2894±0.1587 0.4271±0.2074 0.6459 0.5926 0.8851 0.8897 0.8534 0.9885 
LPL rs12678919 0.1146 0.7408 0.3257±0.1251 0.5179±0.2204 0.1514±0.8122 0.4513 0.8324 0.6643 0.7307 0.9755 0.9010 
LPL rs13702 0.0392 0.2005 0.0153±0.2198 0.4531±0.1450 0.5311±0.2219 0.1000 0.0999 0.7695 0.2257 0.2255 0.9536 
LPL rs328 0.0895 0.5447 0.3189±0.1200 0.5968±0.2433 -0.1773±1.1453 0.3080 0.6671 0.5100 0.5633 0.9026 0.7865 
NFkB rs230531 0.1157 0.7504 0.2811±0.6695 0.5354±0.2440 0.3294±0.1223 0.7179 0.9437 0.4437 0.9303 0.9972 0.7299 
NPY rs16145 0.0236 0.1493 -0.0974±0.2665 0.5015±0.1585 0.3860±0.1741 0.0560 0.1318 0.6254 0.1348 0.2862 0.8764 
NPY rs2189495 0.0399 0.2050 -0.0074±0.2413 0.4881±0.1461 0.4034±0.2016 0.0816 0.1939 0.7342 0.1887 0.3942 0.9382 
NPY2R rs1047214 0.0593 0.3291 -0.3016±0.6565 0.1961±0.2119 0.4550±0.1257 0.4728 0.2605 0.2951 0.7520 0.4970 0.5459 
NPY2R rs13120088 0.1053 0.6664 0.1922±0.2812 0.3379±0.1522 0.4854±0.1814 0.6495 0.3815 0.5367 0.8919 0.6549 0.8096 
NPY2R rs2880415 0.0381 0.1936 0.5187±0.1372 0.1918±0.1888 -0.0287±0.3816 0.1627 0.1809 0.6094 0.3417 0.3726 0.8655 
PPARG rs12639162 0.1378 0.9362 0.3929±0.1381 0.3171±0.1895 0.4191±0.4716 0.7494 0.9574 0.8421 0.9451 0.9984 0.9783 
PPARG rs2279525 0.1338 0.9012 0.4410±0.2540 0.3966±0.1598 0.2948±0.1849 0.8828 0.6440 0.6819 0.9880 0.8885 0.9112 
PYY rs2070592 0.0587 0.4591 0.4385±0.1855 0.2360±0.1540 0.5761±0.2585 0.4050 0.6635 0.2641 0.6815 0.9005 0.5023 
PYY rs228771 0.0643 0.363 -0.6803±0.8102 0.2460±0.2396 0.4249±0.1227 0.2759 0.1794 0.5139 0.5191 0.3702 0.7900 
SLC16A1 rs7169 0.1416 0.9695 0.5075±0.5733 0.3419±0.1980 0.3739±0.1335 0.7853 0.8210 0.8945 0.9597 0.9721 0.9903 




Supplemental Table P.26 cont’d 
  P-value Least Square Means by genotype group GLM P-value Tukey adj. P-value 
Gene SNP Model SNP 1 2 3 1v2 1v3 2v3 1v2 1v3 2v3 
SLC16A3 rs3176827 0.1336 0.8834 0.3902±0.1402 0.3069±0.1927 0.5480±0.4392 0.7279 0.7332 0.6153 0.9352 0.9377 0.8696 
SLC16A3 rs4550503 0.1126 0.7249 0.3115±0.1574 0.4595±0.1626 0.2179±0.3754 0.5142 0.8187 0.5617 0.7902 0.9713 0.8300 
SLC16A3 rs4789698 0.0211 0.0969 0.2319±0.1536 0.3609±0.1604 1.1099±0.3627 0.5612 0.0297 0.0622 0.8296 0.0752 0.1482 
SLC16A4 rs12062656 0.1159 0.7517 0.5644±0.8103 0.2242±0.2328 0.4095±0.1264 0.6861 0.8508 0.4949 0.9136 0.9806 0.7728 
SLC5A8 rs1709189 0.1142 0.7379 0.3428±0.1264 0.4816±0.2133 -0.0006±0.6637 0.5761 0.6122 0.4905 0.8412 0.8674 0.7687 
SLC5A8 rs7309172 0.0371 0.1877 0.3189±0.1632 0.5523±0.1630 -0.0075±0.2745 0.3134 0.3090 0.0823 0.5705 0.5646 0.1920 
SLC5A8 rs844016 0.1138 0.7348 0.2684±0.2098 0.3668±0.1422 0.5335±0.2624 0.6984 0.4312 0.5775 0.9203 0.7100 0.8422 
TLR4 rs4986790 0.0461 0.243 0.4268±0.1124 -0.2073±0.3594 0.3496±1.1413 0.0958 0.9465 0.6425 0.2175 0.9975 0.8876 





Supplemental Table P.27 Individual Genetic Associations between candidate SNPs and WAZ in NHB (dominant and recessive) 
  Dominant Model Recessive Model 
  P-value LS Means P-value LS Means 
Gene SNP Model SNP Tukey adj. 0 1 Model SNP 
Tukey 
adj. 0 1 
ANGPLT4 rs1044250 0.0693 0.5875 0.5875 0.4208±0.1400 0.2900±0.1697 0.0789 0.9530 0.9530 0.3693±0.1122 0.3482±0.4082 
ANGPTL4 rs2278236 0.0551 0.3928 0.3928 0.1947±0.2333 0.4149±0.1202 0.0698 0.6532 0.6532 0.3389±0.1246 0.4541±0.2094 
ANGPTL4 rs7255436 0.1151 0.9681 0.9681 0.3609±0.1715 0.3435±0.1446 0.0733 0.3126 0.3126 0.3091±0.1166 0.6494±0.3104 
ANGPTL3 rs10889337 0.0741 0.7939 0.7939 0.3238±0.2162 0.3835±0.1233 0.0722 0.7224 0.7224 0.3977±0.1276 0.2969±0.2038 
CD36 rs10499859 0.0132 0.0499 0.0499 0.9827±0.3238 0.2960±0.1115 0.0595 0.4546 0.4546 0.2972±0.1479 0.4492±0.1564 
CD36 rs3173798 0.0358 0.1953 0.1953 0.2775±0.1267 0.5866±0.1952 0.0544 0.3838 0.3838 0.3574±0.1078 1.0754±0.8120 
FFAR2 rs2074056 0.0576 0.4278 0.4278 0.2723±0.1570 0.4523±0.1458 0.0453 0.2811 0.2811 0.4059±0.1121 0.0172±0.3439 
GHRL rs27647 0.0589 0.375 0.375 0.4400±0.1385 0.2463±0.1750 0.0833 0.9151 0.9151 0.3634±0.1092 0.4563±0.8122 
IL6 rs1554606 0.0663 0.5741 0.5741 0.2826±0.1763 0.4192±0.1346 0.0462 0.2900 0.2900 0.4138±0.1150 0.0901±0.2856 
LEP rs11761556 0.0677 0.6038 0.6038 0.1736±0.3304 0.3918±0.1132 0.0371 0.2058 0.2058 0.2056±0.1632 0.4904±0.1407 
LEP rs1349419 0.0605 0.4703 0.4703 0.0644±0.3811 0.3944±0.1113 0.0263 0.1250 0.1250 0.1333±0.1818 0.4928±0.1314 
LEPR rs1137101 0.0682 0.5651 0.5651 0.2662±0.2140 0.4033±0.1258 0.0758 0.7609 0.7609 0.3458±0.1270 0.4260±0.2066 
LPL rs12678919 0.0635 0.5196 0.5196 0.3258±0.1247 0.4926±0.2118 0.0739 0.7842 0.7842 0.3728±0.1083 0.1524±0.8106 
LPL rs13702 0.0183 0.0763 0.0763 0.0146±0.2189 0.4765±0.1207 0.0567 0.4144 0.4144 0.3199±0.1217 0.5347±0.2236 
LPL rs328 0.0536 0.3739 0.3739 0.3196±0.1197 0.5632±0.2373 0.0692 0.6374 0.6374 0.3733±0.1076 -0.1722±1.1455 
NFkB rs230531 0.0627 0.5065 0.5065 0.3286±0.1218 0.5090±0.2283 0.0756 0.8778 0.8778 0.3717±0.1091 0.2770±0.6682 
NPY rs16145 0.0575 0.8751 0.8751 0.3868±0.1763 0.3450±0.1379 0.0115 0.0601 0.0601 0.4492±0.1166 -0.0974±0.2655 
NPY rs2189495 0.0753 0.8587 0.8587 0.4039±0.2035 0.3555±0.1263 0.0192 0.0812 0.0812 0.4589±0.1178 -0.0074±0.2404 
NPY2R rs1047214 0.0353 0.1909 0.1909 0.4546±0.1254 0.1486±0.2009 0.0470 0.2987 0.2987 0.3878±0.1083 -0.3035±0.6568 
NPY2R rs13120088 0.0617 0.4888 0.4888 0.1913±0.2804 0.3990±0.1157 0.0587 0.4426 0.4426 0.3049±0.1333 0.4862±0.1807 
NPY2R rs2880415 0.0193 0.082 0.082 0.5180±0.1368 0.1471±0.1667 0.0435 0.2629 0.2629 0.4060±0.1119 -0.0384±0.3832 
PPARG rs12639162 0.0734 0.7624 0.7624 0.3923±0.1345 0.3316±0.1743 0.0761 0.9240 0.9240 0.3664±0.1101 0.4161±0.4696 
PPARG rs2279525 0.0703 0.6663 0.6663 0.2946±0.1841 0.4092±0.1344 0.0736 0.7701 0.7701 0.3529±0.1189 0.4406±0.2531 
PYY rs2070592 0.0491 0.5905 0.5905 0.4341±0.1857 0.3261±0.1316 0.0397 0.3847 0.3847 0.3188±0.1178 0.5708±0.2581 
PYY rs228771 0.053 0.3665 0.3665 0.4279±0.1228 0.1706±0.2297 0.0355 0.1925 0.1925 0.3862±0.1073 -0.6853±0.8081 




Supplemental Table P.27 cont’d 
  Dominant Model Recessive Model 
  P-value LS Means P-value LS Means 
Gene SNP Model SNP Tukey adj. 0 1 Model SNP 
Tukey 
adj. 0 1 
SLC16A1 rs9429505 0.0764 0.9664 0.9664 0.3814±0.2160 0.3649±0.1235 0.0309 0.1574 0.1574 0.2696±0.1264 0.6155±0.2003 
SLC16A3 rs3176827 0.0769 0.8826 0.8826 0.3905±0.1397 0.3454±0.1762 0.0722 0.6868 0.6868 0.3613±0.1126 0.5493±0.4374 
SLC16A3 rs4550503 0.0671 0.5890 0.5890 0.3115±0.1569 0.4190±0.1466 0.0712 0.6900 0.6900 0.3830±0.1129 0.2249±0.3743 
SLC16A3 rs4789698 0.0106 0.0379 0.0379 1.1060±0.3615 0.2935±0.1110 0.0418 0.2474 0.2474 0.4847±0.1480 0.2416±0.1552 
SLC16A4 rs12062656 0.0636 0.5225 0.5225 0.4093±0.1259 0.2489±0.2237 0.0743 0.8035 0.8035 0.3652±0.1083 0.5743±0.8082 
SLC5A8 rs1709189 0.0719 0.7124 0.7124 0.3428±0.1261 0.4366±0.2027 0.0662 0.5705 0.5705 0.3787±0.1086 -0.0007±0.6617 
SLC5A8 rs7309172 0.0702 0.6622 0.6622 0.3188±0.1648 0.4057±0.1411 0.0280 0.1368 0.1368 0.4357±0.1154 -0.0061±.0.2745 
SLC5A8 rs844016 0.0626 0.5044 0.5044 0.5337±0.2614 0.3359±0.1173 0.0657 0.5610 0.5610 0.4046±0.1247 0.2682±0.2091 
TLR4 rs4986790 0.0232 0.1049 0.1049 0.4272±0.1120 -0.1571±0.3416 0.0764 0.9839 0.9839 0.3691±0.1079 0.3556±1.1507 





Supplemental Table P.28 Individual Genetic Associations between candidate SNPs and HAZ in NHB (genotypic model) 
  P-value Least Square Means by genotype group GLM P-value Tukey adj. P-value 
Gene SNP Model SNP 1 2 3 1v2 1v3 2v3 1v2 1v3 2v3 
ANGPLT4 rs1044250 0.3595 0.9724 0.4296±0.1545 0.3846±0.2052 0.4991±0.4495 0.8610 0.8840 0.8167 0.9832 0.9883 0.9707 
ANGPTL4 rs2278236 0.3063 0.7764 0.4219±0.2305 0.4755±0.1620 0.2619±0.2573 0.8496 0.6431 0.4838 0.9803 0.8879 0.7624 
ANGPTL4 rs7255436 0.4764 0.8716 0.4146±0.1881 0.3376±0.1784 0.5376±0.3421 0.7688 0.7532 0.6045 0.9533 0.9467 0.8620 
ANGPTL3 rs10889337 0.2303 0.5250 0.3877±0.2234 0.5422±0.1724 0.2100±0.2369 0.5889 0.5871 0.2577 0.8507 0.8494 0.4931 
CD36 rs10499859 0.0216 0.0286 0.5531±0.1672 0.0997±0.1767 1.0714±0.3515 0.0659 0.1863 0.0150 0.1560 0.3817 0.0395 
CD36 rs3173798 0.2945 0.7351 1.0968±0.8953 0.4440±0.2222 0.3906±0.1403 0.4797 0.4371 0.8392 0.7586 0.7161 0.9774 
FFAR2 rs2074056 0.236 0.5428 0.3117±0.1725 0.5643±0.1771 0.2445±0.3788 0.3095 0.8716 0.4464 0.5652 0.9856 0.7257 
GHRL rs27647 0.391 0.8826 0.2806±0.8923 0.3354±0.1973 0.4532±0.1527 0.9522 0.8493 0.6398 0.9980 0.9802 0.8859 
IL6 rs1554606 0.1179 0.2201 0.5127±0.1919 0.4875±0.1658 -0.0890±0.3120 0.9213 0.1029 0.1053 0.9946 0.2314 0.2360 
LEP rs11761556 0.3088 0.7853 0.1820±0.3639 0.4049±0.2075 0.4666±0.1559 0.5948 0.4743 0.8123 0.8550 0.7534 0.9693 
LEP rs1349419 0.1037 0.1875 0.5577±0.1443 0.2310±0.2276 -0.1337±0.4149 0.2307 0.1176 0.4426 0.4526 0.2598 0.7218 
LEPR rs1137101 0.2256 0.5091 0.2383±0.2346 0.4023±1731 0.6190±0.2263 0.5756 0.2474 0.4472 0.8408 0.4779 0.7265 
LPL rs12678919 0.3344 0.8791 0.4159±0.1375 0.4524±0.2422 -0.0201±0.8925 0.8964 0.6302 0.6107 0.9907 0.8796 0.8664 
LPL rs13702 0.0445 0.0668 -0.0623±0.2389 0.5157±0.1576 0.6728±0.2411 0.0464 0.0317 0.5873 0.1134 0.0799 0.8496 
LPL rs328 0.3375 0.8905 0.4030±0.1322 0.4940±0.2681 -0.0663±1.2622 0.7614 0.7120 0.6650 0.9502 0.9273 0.9014 
NFkB rs230531 0.2692 0.6492 0.3909±0.7334 0.6432±0.2673 0.3612±0.1340 0.7473 0.9684 0.3480 0.9441 0.9991 0.6146 
NPY rs16145 0.0291 0.0487 -0.2453±0.2899 0.5626±0.1724 0.5162±0.1895 0.0183 0.0300 0.8567 0.0478 0.0759 0.9821 
NPY rs2189495 0.0858 0.1481 -0.0430±0.2639 0.5563±0.1597 0.4710±0.2204 0.0544 0.1375 0.7545 0.1311 0.2967 0.9473 
NPY2R rs1047214 0.1648 0.3377 -0.4561±0.7201 0.2784±0.2325 0.4986±0.1379 0.3346 0.1958 0.4163 0.5978 0.3974 0.6939 
NPY2R rs13120088 0.3609 0.9808 0.4219±0.3096 0.3931±0.1676 0.4488±0.1997 0.9350 0.9418 0.8321 0.9963 0.9970 0.9754 
NPY2R rs2880415 0.1801 0.3790 0.4883±0.1514 0.4277±0.2082 -0.1360±0.4209 0.8137 0.1666 0.2376 0.9697 0.3484 0.4632 
PPARG rs12639162 0.2854 0.7036 0.4871±0.1511 0.2754±0.2074 0.4961±0.5159 0.4153 0.9866 0.6953 0.6929 0.9998 0.9176 
PPARG rs2279525 0.3398 0.8992 0.5354±0.2787 0.3898±0.1753 0.3912±0.2029 0.6597 0.6776 0.9959 0.8982 0.9088 1.0000 
PYY rs2070592 0.3166 0.9859 0.4299±0.2055 0.4125±0.1706 0.3767±0.2864 0.9484 0.8793 0.9153 0.9977 0.9873 0.9938 
PYY rs228771 0.2497 0.5856 -0.2694±0.8929 0.2610±0.2640 0.4744±0.1352 0.5706 0.4111 0.4789 0.8369 0.6883 0.7586 
SLC16A1 rs7169 0.274 0.6651 0.9041±0.6266 0.3148±0.2165 0.4379±0.1459 0.3756 0.4703 0.6410 0.6480 0.7495 0.8866 




Supplemental Table P.28 cont’d 
  P-value Least Square Means by genotype group GLM P-value Tukey adj. P-value 
Gene SNP Model SNP 1 2 3 1v2 1v3 2v3 1v2 1v3 2v3 
SLC16A3 rs3176827 0.3506 0.8615 0.4293±0.1535 0.3320±0.2109 0.6034±0.4807 0.7106 0.7311 0.6054 0.9266 0.9367 0.8626 
SLC16A3 rs4550503 0.2131 0.4732 0.2735±0.1719 0.5723±0.1776 0.3913±0.4102 0.2290 0.7916 0.6904 0.4500 0.9621 0.9159 
SLC16A3 rs4789698 0.1361 0.2641 0.4035±0.1700 0.2998±0.1776 1.0296±0.4015 0.6732 0.1588 0.1002 0.9062 0.3348 0.2262 
SLC16A4 rs12062656 0.2407 0.5575 0.1840±0.8861 0.6603±0.2545 0.3464±0.1382 0.6050 0.8569 0.2912 0.8624 0.9822 0.5405 
SLC5A8 rs1709189 0.1422 0.2794 0.3007±0.1374 0.7323±0.2318 0.5821±0.7215 0.1115 0.7023 0.8431 0.2482 0.9223 0.9785 
SLC5A8 rs7309172 0.0631 0.1018 0.2747±0.1780 0.6909±0.1777 0.0431±0.2993 0.1006 0.5072 0.0661 0.2270 0.7840 0.1565 
SLC5A8 rs844016 0.3269 0.8510 0.4077±0.2304 0.3773±0.1562 0.5667±0.2882 0.9130 0.6671 0.5644 0.9934 0.9026 0.8321 
TLR4 rs4986790 0.2945 0.7349 0.4451±0.1245 0.1212±0.3981 0.5546±1.2644 0.4403 0.9315 0.7443 0.7195 0.9959 0.9428 





Supplemental Table P.29 Individual Genetic Associations between candidate SNPs and HAZ in NHB (dominant and recessive) 
  Dominant Model Recessive Model 
  P-value LS Means P-value LS Means 
Gene SNP Model SNP Tukey adj. 0 1 Model SNP 
Tukey 
adj. 0 1 
ANGPLT4 rs1044250 0.228 0.9325 0.9325 0.4297±0.1538 0.4042±0.1863 0.2255 0.8564 0.8564 0.4133±0.1229 0.4996±0.1175 
ANGPTL4 rs2278236 0.187 0.4944 0.4944 0.2621±0.2561 0.4578±0.1320 0.228 0.9835 0.9835 0.4149±0.1368 0.4228±0.2300 
ANGPTL4 rs7255436 0.3529 0.9024 0.9024 0.4139±0.1874 0.3801±0.1580 0.3278 0.6568 0.6568 0.3741±0.1280 0.5380±0.3407 
ANGPTL3 rs10889337 0.1468 0.3103 0.3103 0.2092±0.2361 0.4841±0.1346 0.2268 0.9080 0.9080 0.4276±0.1401 0.3903±0.2237 
CD36 rs10499859 0.045 0.0549 0.0549 1.07381±0.3554 0.3389±0.1224 0.135 0.2689 0.2689 0.2952±0.1617 0.5530±0.1710 
CD36 rs3173798 0.2171 0.7332 0.7332 0.3902±0.1400 0.4806±0.2157 0.1781 0.4459 0.4459 0.4058±0.1183 1.0959±0.8914 
FFAR2 rs2074056 0.173 0.4205 0.4205 0.3128±0.1722 0.5068±0.1600 0.2075 0.6370 0.6370 0.4347±0.1235 0.2474±0.3788 
GHRL rs27647 0.248 0.6190 0.6190 0.4532±0.1520 0.3329±0.1921 0.2727 0.8889 0.8889 0.4089±0.1195 0.2849±0.8891 
IL6 rs1554606 0.1907 0.5161 0.5161 0.5132±0.1934 0.3609±0.1477 0.0607 0.0820 0.0820 0.4983±0.1250 0.0890±0.3106 
LEP rs11761556 0.1901 0.5123 0.5123 0.1826±0.3623 0.4443±0.1241 0.2081 0.6415 0.6415 0.3505±0.1802 0.4663±0.1553 
LEP rs1349419 0.0988 0.1645 0.1645 -0.1357±0.4516 0.4632±0.1214 0.0376 0.1008 0.1008 0.1466±0.1992 0.5590±0.1440 
LEPR rs1137101 0.1622 0.3698 0.3698 0.2392±0.2341 0.4822±0.1376 0.1472 0.3105 0.3105 0.3444±0.1386 0.6177±0.2256 
LPL rs12678919 0.2281 0.9985 0.9985 0.4160±0.1370 0.4197±0.2328 0.2056 0.6207 0.6207 0.4248±0.1187 -0.0199±0.8885 
LPL rs13702 0.0231 0.0233 0.0233 -0.0636±0.2381 0.5628±0.1313 0.1234 0.2323 0.2323 0.3399±0.1330 0.6775±0.2444 
LPL rs328 0.2236 0.8285 0.8285 0.4035±0.1374 0.4698±0.2612 0.2144 0.7024 0.7024 0.4208±0.1181 -0.0646±1.2570 
NFkB rs230531 0.1647 0.3825 0.3825 0.3604±0.1334 0.6135±0.2500 0.2278 0.9605 0.9605 0.4179±0.1197 0.3853±0.7330 
NPY rs16145 0.1617 0.5106 0.5106 0.5172±0.1936 0.3516±0.1514 0.0129 0.0141 0.0141 0.5416±0.1267 -0.2453±0.2886 
NPY rs2189495 0.2208 0.7814 0.7814 0.4716±0.2231 0.3959±0.1385 0.0442 0.0535 0.0535 0.5270±0.1288 -0.0430±0.2628 
NPY2R rs1047214 0.1336 0.2644 0.2644 0.4981±0.1379 0.2082±0.2208 0.1195 0.2206 0.2206 0.4415±0.1186 -0.4578±0.7190 
NPY2R rs13120088 0.228 0.9908 0.9908 0.4215±0.3082 0.4161±0.1272 0.2248 0.8544 0.8544 0.3996±0.1466 0.4486±0.1988 
NPY2R rs2880415 0.1812 0.4620 0.4620 0.4866±0.1516 0.3132±0.1849 0.1008 0.1696 0.1696 0.4674±0.1223 -0.1378±0.4190 
PPARG rs12639162 0.1805 0.4585 0.4585 0.4859±0.1505 0.3068±0.1907 0.2262 0.8907 0.8907 0.4131±0.1208 0.4878±0.5150 
PPARG rs2279525 0.2263 0.8935 0.8935 0.3906±0.2021 0.4312±0.1476 0.2084 0.6447 0.6447 0.3904±0.1303 0.5354±0.2774 
PYY rs2070592 0.1921 0.8932 0.8932 0.4304±0.2045 0.4030±0.1449 0.1919 0.8866 0.8866 0.4196±0.1301 0.3763±0.2850 
PYY rs228771 0.1655 0.3860 0.3860 0.4761±0.1348 0.2178±0.2521 0.1763 0.4368 0.4368 0.4283±0.1183 -0.2754±0.8908 




Supplemental Table P.29 cont’d 
  Dominant Model Recessive Model 
  P-value LS Means P-value LS Means 
Gene SNP Model SNP Tukey adj. 0 1 Model SNP 
Tukey 
adj. 0 1 
SLC16A1 rs9429505 0.2276 0.943 0.943 0.4041±0.2369 0.4211±0.1355 0.1034 0.1763 0.1763 0.3137±0.1388 0.6733±0.2199 
SLC16A3 rs3176827 0.2414 0.841 0.841 0.4295±0.1529 0.3754±0.1929 0.2282 0.6768 0.6768 0.3955±0.1233 0.6050±0.4788 
SLC16A3 rs4550503 0.1283 0.2474 0.2474 0.2735±0.1713 0.5420±0.1600 0.228 0.977 0.977 0.4180±0.1239 0.4055±0.4109 
SLC16A3 rs4789698 0.0767 0.1136 0.1136 1.0327±0.4000 0.3539±0.1228 0.2279 0.9638 0.9638 0.4205±0.1633 0.4130±0.1713 
SLC16A4 rs12062656 0.1548 0.3409 0.3409 0.3467±0.1378 0.6256±0.2448 0.2204 0.7759 0.7759 0.4214±0.1187 0.1673±0.8865 
SLC5A8 rs1709189 0.076 0.1122 0.1122 0.3007±0.1368 0.7183±0.2198 0.2232 0.821 0.821 0.4125±0.1192 0.5817±0.7266 
SLC5A8 rs7309172 0.1421 0.2933 0.2933 0.2746±0.1800 0.5212±0.1541 0.1061 0.1832 0.1832 0.4831±0.1269 0.0454±0.3017 
SLC5A8 rs844016 0.1996 0.575 0.575 0.5668±0.2869 0.3869±0.1288 0.2277 0.9546 0.9546 0.4203±0.1369 0.4075±0.2297 
TLR4 rs4986790 0.1833 0.4737 0.4737 0.4453±0.1240 0.1603±0.3782 0.2269 0.9141 0.9141 0.4156±0.1183 0.5577±1.2621 








Supplemental Figure P.1 Heat Maps of SNP-SNP interactions for BMIZ by pathway in NHW and NHB cohorts 
NHW Pathway 1 
Gene ANGPTL4 ANGPTL3 PPARG LPL CD36 
ANGPTL4 
  0.9112 0.8128 0.6037 0.0562 0.4835 0.9817 0.0099 0.3565 0.2772 0.1912 0.8839 0.3741 
   0.7998 0.6002 0.0583 0.4626 0.9785 0.0092 0.3528 0.2734 0.1786 0.8729 0.363 
    0.6176 0.049 0.3048 0.9251 0.0001 0.5245 0.4888 0.164 0.6162 0.2342 
ANGPTL3      0.0043 0.1535 0.3697 0.0121 0.2152 0.1724 0.2026 0.5152 0.111 
PPARG 
      0.0255 0.2893 0.0002 0.0054 0.0058 0.0258 0.1748 0.0294 
       0.8325 0.0086 0.2008 0.1922 0.2503 0.5179 0.3145 
        0.0233 0.6025 0.4861 0.5769 0.9721 0.2679 
LPL 
         0.0236 0.0218 0.006 0.0605 0.0056 
          0.2802 0.0949 0.2124 0.1441 
           0.0873 0.2274 0.127 
CD36 
            0.534 0.0547 
             0.2692 
              
ANGPTL4 
  NA 0.6614 0.6379 0.1361 0.2037 0.9129 0.1216 0.1783 0.1385 0.1258 0.4945 0.5239 
   0.5948 0.6294 0.133 0.1832 0.8906 0.1104 0.1736 0.1342 0.1115 0.4634 0.4912 
    0.8995 0.1828 0.1598 0.9457 0.0032 0.8009 0.8164 0.2148 0.3313 0.6138 
ANGPTL3      0.0222 0.1591 0.353 0.5774 0.5738 0.446 0.7947 0.5164 0.9817 
PPARG 
      0.0552 0.9671 0.1166 0.033 0.043 0.3238 0.5695 0.5163 
       0.8498 0.2266 0.1287 0.1546 0.4268 0.2407 0.7831 
        0.3795 0.7944 0.6677 0.8985 0.8962 0.3503 
LPL 
         0.8945 0.9448 0.7403 0.8429 0.648 
          NA 0.1576 0.0697 0.6822 
           0.1796 0.1006 0.7325 
CD36 
            0.8381 0.0901 
             0.7298 
                          




Supplemental Figure P.1 (cont.) 
NHB Pathway 1 
Gene ANGPTL4 ANGPTL3 PPARG LPL CD36 
ANGPTL4 
 0.9019 0.9308 0.8814 0.9729 0.7336 0.9893 0.9068 0.9407 0.6807 0.6937 
  0.8826 0.9628 0.9659 0.5043 0.9578 0.8741 0.7342 0.9391 0.7079 
   0.5957 0.9606 0.2291 0.8571 0.591 0.6485 0.4512 0.6615 
ANGPTL3     0.8837 0.9646 0.9027 0.7076 0.9517 0.7436 0.8032 
PPARG      0.9959 0.9766 0.8751 0.6787 0.9489 0.5513 
      0.9928 0.2819 0.5478 0.7223 0.7942 
LPL 
       0.9522 0.9731 0.6797 0.7715 
        0.9186 0.8561 0.5945 
         0.8335 0.6839 
CD36           0.2192 
           
ANGPTL4 
 0.8625 0.6678 0.6947 0.9236 0.3399 0.9349 0.7178 0.7661 0.3749 0.7697 
  0.95 0.959 0.9056 0.1462 0.7535 0.5147 0.2759 0.8846 0.6878 
   0.2796 0.9193 0.0405 0.512 0.1984 0.2139 0.1798 0.7916 
ANGPTL3     0.5792 0.9183 0.5735 0.279 0.8367 0.4463 0.9617 
PPARG      0.9916 0.7273 0.3893 0.1727 0.7931 0.3475 
      0.9257 0.0282 0.1000 0.3379 0.8296 
LPL 
       0.5279 0.6291 0.2326 0.7298 
        NA 0.5717 0.903 
         0.4024 0.6736 
CD36           0.0931 






Supplemental Figure P.1 (cont.) 
NHW Pathway 2 
Gene FFAR1 FFAR2 FFAR3 PYY GHRL NPY NPY2R LEP LEPR BDNF 
FFAR1   0.5253 0.9837 0.3402 0.9118 0.7372 0.7798 0.5307 0.9517 0.9313 0.9081 0.4659 0.9112 0.5198 0.8849 0.8685 0.922 0.294 0.041     0.8852 0.1896 0.9639 0.3416 0.642 0.0621 0.8033 0.3874 0.5184 0.8937 0.5312 0.8718 0.5564 0.0753 0.1685 0.2133 0.8361 
FFAR2      0.7301 0.5344 0.9079 0.7718 0.822 0.9842 0.9858 0.9796 0.6951 0.8207 0.8407 0.9111 0.9343 0.9823 0.2782 0.78 
FFAR3       0.6731 0.8039 0.4956 0.7637 0.7294 0.2041 0.2055 0.6907 0.1813 0.7146 0.7218 0.9603 0.9159 0.6188 0.6532 
PYY 
       0.9371 0.5995 0.6003 0.8239 0.8586 0.7706 0.7191 0.9607 0.6898 0.2666 0.8185 0.666 0.8544 0.9537 
        0.1545 0.9181 0.9706 0.9015 0.8014 0.9314 0.6957 0.9125 0.9516 0.9682 0.9709 0.9651 0.9397 
         0.1989 0.6724 0.3191 0.419 0.1734 0.468 0.187 0.767 0.6993 0.7103 0.6711 0.246 
GHRL           0.7942 0.8728 0.8788 0.2521 0.3455 0.1639 0.7223 0.8385 0.7883 0.5442 0.6493            0.9554 0.9277 0.5445 0.9723 0.5208 0.8902 0.7576 0.7761 0.9717 0.5821 
NPY             0.2659 0.583 0.8824 0.3256 0.9595 0.6701 0.739 0.9737 0.9701              0.6554 0.8911 0.381 0.8827 0.7214 0.5334 0.9065 0.9325 
NPY2R 
              0.4006 0.1107 0.925 0.498 0.4665 0.7589 0.8357 
               0.3713 0.8658 0.9294 0.9405 0.9736 0.3398 
                0.7736 0.2591 0.1943 0.7242 0.8277 
LEP 
                 0.304 0.775 0.8297 0.9339 
                  0.3174 0.4277 0.8083 
                   0.8366 0.9504 
LEPR                     0.7426 
BDNF                      
FFAR1   0.1616 0.9415 0.0574 0.6534 0.2593 0.8698 0.1562 0.5699 0.6652 0.6667 0.2428 0.7153 0.288 0.522 0.5346 0.5792 0.0421 0.0026     0.7278 0.0668 0.9285 0.076 0.7111 0.0072 0.4275 0.0927 0.1665 0.9493 0.2471 0.9712 0.2394 0.0065 0.0262 0.0379 0.8344 
FFAR2      0.4212 0.1482 0.5166 0.7747 0.4874 0.8432 0.9 0.925 0.4754 0.4565 0.7679 0.6133 0.6795 0.844 0.0428 0.4464 
FFAR3       0.3805 0.564 0.32 0.6454 0.3832 0.0368 0.038 0.742 0.0372 0.8024 0.5676 0.9583 0.8146 0.3466 0.6222 
PYY 
       0.7265 0.8712 0.2584 0.3664 0.4982 0.4048 0.6194 0.8905 0.6101 0.0445 0.451 0.2299 0.566 0.9584 
        0.0414 0.7334 0.7033 0.5493 0.4178 0.9676 0.2885 0.9025 0.7753 0.8298 0.7781 0.8479 0.8711 
         0.0718 0.4066 0.11 0.2088 0.1086 0.3444 0.1103 0.8074 0.6536 0.5738 0.7489 0.0944 
GHRL           0.3241 0.6204 0.7195 0.0908 0.0983 0.052 0.4761 0.5671 0.4208 0.2145 0.4182            0.6004 0.6038 0.24 0.9257 0.2136 0.5126 0.204 0.1859 0.8505 0.1504 
NPY             NA 0.3358 0.5848 0.1203 0.7999 0.2367 0.2655 0.8842 0.9785              0.4583 0.6895 0.1887 0.6201 0.3349 0.1419 0.7128 0.9394 
NPY2R 
              0.2047 NA 0.8189 0.2308 0.2077 0.6563 0.9741 
               0.1903 0.506 0.7562 0.7257 0.9634 0.1029 
                0.4914 0.0811 0.0439 0.5495 0.9266 
LEP 
                 0.0765 0.3017 0.4716 0.8463 
                  0.1053 0.0988 0.608 
                   0.4447 0.8902 
LEPR                     0.4931 






Supplemental Figure P.1 (cont.) 
NHB Pathway 2 
Gene FFAR1 FFAR2 FFAR3 PYY GHRL NPY NPY2R LEP LEPR 
FFAR1  0.7457 0.8020 0.1469 0.1638 0.5648 0.9008 0.8781 0.8923 0.1347 0.2462 0.4018 0.7393 0.4964 
FFAR2   0.7383 0.6375 0.0624 0.2994 0.6934 0.8612 0.7761 0.3829 0.1788 0.3378 0.8703 0.8545 
FFAR3    0.5239 0.2423 0.8042 0.7866 0.8956 0.0354 0.514 0.0494 0.4977 0.8853 0.9316 
PYY 
    0.3168 0.3200 0.3505 0.546 0.7048 0.1959 0.3184 0.6445 0.84 0.7222 
     0.1277 0.4592 0.6489 0.3655 0.1192 0.1349 0.4384 0.5722 0.2412 
GHRL       0.3164 0.5009 0.1277 0.249 0.1533 0.2126 0.5891 0.3112 
NPY 
       0.7949 0.9709 0.9029 0.6786 0.5546 0.8161 0.7985 
        0.4666 0.7236 0.197 0.5585 0.8625 0.7849 
NPY2R 
         0.5857 0.3233 0.6712 0.9776 0.944 
          0.3208 0.7834 0.928 0.6524 
           0.2311 0.6199 0.1613 
LEP 
            0.7865 0.2413 
             0.7789 
LEPR               
FFAR1  0.9138 0.9808 0.0504 0.2229 0.1949 0.7461 0.7063 0.9472 0.0379 0.4883 0.2378 0.4587 0.1758 
FFAR2   0.8499 0.6529 0.1101 0.0855 0.3436 0.8668 0.6024 0.2397 0.332 0.2196 0.7545 0.5942 
FFAR3    0.5447 0.3086 0.8861 0.516 0.9269 0.0014 0.4269 0.0756 0.3714 0.9138 0.9483 
PYY 
    0.5935 0.0749 0.0706 0.1823 0.6017 0.0701 0.5749 0.7539 0.8217 0.3896 
     0.1131 0.5681 0.8997 0.7681 0.2179 0.7897 0.9402 0.947 0.1953 
GHRL       0.0461 0.1165 0.0579 0.0744 0.1033 0.0656 0.1664 0.0392 
NPY 
       0.4848 0.8276 0.2828 0.5501 0.6672 0.9734 0.2804 
        0.0908 0.5003 0.1349 0.4566 0.5094 0.2951 
NPY2R 
         0.2828 0.5501 0.6672 0.9734 0.6673 
          0.4672 0.963 0.9681 0.4195 
           0.7857 0.9121 0.1076 
LEP 
            0.8413 0.0688 
             0.3228 





Supplemental Figure P.1 (cont.) 
NHW Pathway 3 
Gene SLC16A4 SLC16A1 SLC5A8 SLC16A3 SLC11A1 SLC1A2 
SLC16A4   
0.8069 0.7195 0.4448 0.9407 0.6619 0.9173 0.757 0.558 0.5435 0.9119 
    0.4577 0.6043 0.9235 0.2768 0.407 0.3094 0.7018 0.0717 0.5237 
SLC16A1      
0.3707 0.7942 0.2392 0.8638 0.5989 0.5094 0.5476 0.8967 
      0.5000 0.1305 0.7053 0.4683 0.2776 0.0916 0.5838 
SLC5A8 
       0.4527 0.6041 0.705 0.8006 0.4118 0.9492 
        0.538 0.4243 0.1018 0.2429 0.541 
         0.864 0.3806 0.2102 0.9526 
SLC16A3           
0.6101 0.328 0.6057 
           0.3592 0.7722 
SLC11A1             0.3785 
SLC1A2              
SLC16A4   
0.3102 0.5183 0.4252 0.8717 0.9037 0.9049 0.5911 0.5649 0.5649 0.5732 
    0.1987 0.7976 0.8357 0.1973 0.1647 0.0863 0.8846 0.0300 0.0877 
SLC16A1      
0.5223 0.741 0.2542 0.9312 0.5384 0.6428 0.7723 0.8453 
      0.6567 0.2158 0.9551 0.742 0.776 0.1455 0.6264 
SLC5A8 
       0.8601 0.8247 0.6319 0.9909 0.4582 0.8602 
        0.5816 0.662 0.1911 0.6077 0.5677 
         0.9968 0.5032 0.2251 0.9662 
SLC16A3           
0.6419 0.3678 0.3195 
           0.7374 0.8749 
SLC11A1             0.3152 






Supplemental Figure P.1 (cont.) 
NHB Pathway 3 
Gene SLC16A4 SLC16A1 SLC5A8 SLC16A3 SLC1A2 
SLC16A4   0.0274 0.7067 0.7635 0.4414 0.8616 0.8691 0.3188 0.7018 0.6043 
    0.2271 0.1762 0.0662 0.2273 0.1568 0.0258 0.2744 0.113 
SLC16A1      0.9368 0.2799 0.4997 0.9915 0.6761 0.6529 0.9686 
      0.6794 0.8515 0.9241 0.585 0.9364 0.9603 
SLC5A8 
       0.4279 0.2389 0.2095 0.5608 0.5056 
        0.9917 0.2237 0.5166 0.7827 
         0.4356 0.9515 0.7865 
SLC16A3           0.431 0.068 
           0.3875 
SLC1A2             
SLC16A4 
  0.1199 0.3946 0.7819 0.4432 0.8819 0.9053 0.6866 0.6532 0.3155 
    0.7323 0.7273 0.6077 0.8988 0.817 0.3831 0.8453 0.6326 
SLC16A1      0.7798 0.0665 0.1076 0.9776 0.9515 0.1902 0.8906 
      0.8733 0.519 0.6927 0.8129 0.6374 0.8032 
SLC5A8 
       0.3451 0.0653 0.6923 0.5019 0.3482 
        0.9805 0.1712 0.1404 0.324 
         0.5232 0.8305 0.3289 
SLC16A3 
          0.7354 0.0199 
           0.0585 





Supplemental Figure P.1 (cont.) 
NHW Pathway 4 
Gene TLR4 NFkB TNFA IL6 
TLR4 
  0.9187 0.9035 0.9211 0.5652 
    0.8355 0.9279 0.7841 
NFkB      0.5397 0.623 
TNFA       0.6529 
IL6           
TLR4 
  0.6342 0.8795 0.9063 0.3737 
    0.7334 0.9621 0.9308 
NFkB      0.4018 0.7031 
TNFA       0.6769 
IL6           
 
NHB Pathway 4 
Gene TLR4 IL6 NFkB TNFA 
TLR4   0.2752 0.8274 0.6137 
IL6     0.6174 0.4585 
NFkB      0.9958 
TNFA       
TLR4   0.3946 0.8492 0.3606 
IL6     0.6337 0.3822 
NFkB      0.9063 























Abbreviations: PCA: principal component analysis, ALLSKP: all STRONG Kids Program cohort, NHW+NHB: combined non-Hispanic white and non-
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